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Articular cartilage is susceptible to age-related diseases, such as osteoarthritis (OA). OA is the 
most common degenerative joint disorder and it affects millions. It presents with degradation 
of articular cartilage which leads to loss of joint mobility and function, accompanied by 
chronic pain. The molecular landscape underlying OA pathogenesis is complex and includes 
several genetic and epigenetic mechanisms. It is hypothesised that there are distinct 
molecular mechanisms that drive cartilage ageing and disease. MicroRNAs (miRNAs or miRs) 
are gene expression regulators that act post-transcriptionally and control tissue homeostasis 
in response to environmental and intracellular changes. This thesis established differentially 
expressed (DE) miRNAs between cartilage from young [age ± standard deviation 
(SD)=23.8±3.8] patients undergoing anterior cruciate ligament (ACL) surgery and OA intact 
and lesioned cartilage from old (age±SD=62.6±7.3) patients undergoing total knee 
replacement (TKA) by using microarray analysis. Differential expression of selected miRNAs 
was further assessed in an extended cohort of human young ACL and old OA cartilage samples 
by quantitative Polymerase Chain Reaction (qPCR), and the response of these miRNAs was 
characterised in an in vitro OA inflammatory cell model by treating chondrocytes with human 
recombinant interleukin-1 beta (IL-1β) for different time points (6h, 24h and 5 days). Potential 
mRNA targets of specific miRNAs were selected by utilising online target prediction tools and 
miRNA-mRNA interactions were experimentally investigated by undertaking gain and loss of 
function approaches in human primary OA chondrocytes, coupled with transcriptomic and 
proteomic detection methods, such as qPCR and Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS). Moreover, this thesis investigated the effect of ageing without OA 
involvement on miRNA expression by using small RNA Sequencing (RNA-Seq) between young 
(age mean±SD=4±1 years) and old (age mean±SD=17.4±1.9 years) healthy equine 
chondrocytes.  
miRNAs have attracted a lot of scientific interest in the last few years. In this thesis, the use 
of microarray analysis allowed the identification of several DE miRNAs between young ACL 
cartilage and old OA human cartilage. Bioinformatics analysis indicated the involvement of DE 
miRNAs in ageing and OA-related mechanisms and revealed a distinct set of molecular 
viii 
 
pathways involved in disease progression, including inflammation and mechanical stress. 
qPCR validation of selected miRNAs, such as miR-361-5p, -379-5p, -107 and -143-3p in an 
extended cohort of human cartilage samples confirmed microarray findings. Furthermore, 
investigation of these miRNAs in an in vitro inflammatory environment revealed a time-
dependent catabolic effect of inflammation on the expression of the selected miRNAs, which 
differed per timepoint, level of dysregulation and miRNA species. While no differences were 
observed in miRNA expression between IL-1β-treated and control chondrocytes at the 6h 
timepoint, miR-361-5p and miR-107 showed decreased expression in IL-1β-treated cells after 
24h, which further decreased after 5 days of treatment. miR-379-5p showed no difference at 
the 24h timepoint but had the largest decrease in IL-1β-treated cells after 5 days of treatment. 
Interestingly, miR-143-3p showed increased expression in IL-1β-treated cells at the 24h 
timepoint, but its expression was decreased after 5 days of IL-1β treatment.  
Gain and loss of function approaches supported a role for miR-107 and miR-143-3p in 
important pathways relevant to OA. qPCR analysis suggested the involvement of miR-107 in 
the Wingless-Related Integration Site (WNT) and Indian Hedgehog (IHH) signalling pathways, 
through the targeting of WNT4 and IHH, respectively, in human primary OA chondrocytes 
treated with miR-107 mimics and inhibitors and in human ACL and OA cartilage tissues. LC-
MS/MS in human primary chondrocytes treated with miR-143-3p mimics and inhibitors 
indicated a role for miR-143-3p in stress response and suggested a link between miR-143-3p 
and Eukaryotic Translation Initiation Factor (EIF) 2 signalling. In addition, results suggested 
the targeting of Transforming Growth Factor Beta Receptor (TGFBR) 1 by miR-379-5p in 
human OA chondrocytes, however this interaction was not validated in human cartilage 
tissues. Also, there were no specific interactions identified between miR-361-5p and the 
target genes that were selected for validation. Finally, small RNA-Seq in young and old healthy 
equine chondrocytes identified a well-defined profile of DE miRNAs in chondrocyte ageing, 
including miR-143-3p. 
This thesis identified a large set of DE miRNAs involved in cartilage biology and OA and 
supported the implication of specific miRNAs in important cellular mechanisms that regulate 
chondrocyte proliferation, hypertrophy and protein translation. In addition, it has set the 
ground for future research on the role of miRNAs in cartilage and chondrocyte homeostasis 
















Articular cartilage is a specialised type of connective tissue found in diarthrodial joints and 
covers the end of bones, protecting them from friction and load bearing. It is devoid of blood 
vessels and nerves and has a limited intrinsic healing capacity. Alteration in articular cartilage 
begin to accumulate with age, predisposing the tissue to age-related diseases such as 
osteoarthritis (OA). OA is the most common musculoskeletal disorder and a major cause of 
disability in older individuals. According to the World Health Organisation, 10-15% of people 
over 60 years have some degree of OA and this percentage is expected to increase as the 
ageing population increases (Wittenauer et al., 2013). It is estimated that by 2050, 130 million 
people will suffer from OA worldwide, of which 40 million will be severely affected 
(Wittenauer et al., 2013). In the UK this is also reflected on the economic burden, as 
musculoskeletal diseases have the highest rate of medical consultation (Wittenauer et al., 
2013).  
OA commonly affects the knee and hip joints, and primarily presents with articular cartilage 
degeneration that leads to impaired joint movement and increased frailty. Other symptoms 
include subchondral bone remodelling, osteophyte formation and joint inflammation (Martel-
Pelletier et al., 2016). Many risk factors have been identified, such as genetics and obesity, 
however age is the most common (Loeser et al., 2016). Although OA is not the direct result of 
ageing, it is believed that age-related changes in the joint make articular cartilage susceptible 
to OA (Loeser et al., 2016). Moreover, there is an imbalance between anabolic and catabolic 
processes in OA, but the molecular mechanisms that drive disease pathogenesis still remain 
elusive.   
MicroRNAs (miRNAs/miRs) are a class of short [~22 nucleotides (nt)], endogenous, non-
coding RNA molecules which act at the post-transcriptional level to regulate gene expression 
(Li et al., 2015). They function by targeting complementary sequences in messenger RNAs 
(mRNAs) which leads to translational repression and/or mRNA degradation (Iwakawa et al., 
2015). It is estimated that miRNAs bind 1/3 of human genes and are involved in many different 
physiological processes, including cartilage ageing and metabolism (Li et al., 2015, Ukai et al., 
2012). Indeed, miRNAs play an important role in maintaining normal cartilage physiology (Li 
et al., 2015, Miyaki et al., 2010), but have also been implicated in the pathogenesis of OA 
(Miyaki et al., 2012, Nugent, 2016, Yu et al., 2015). Many studies have reported differentially 




al., 2010, Chen et al., 2016a, Wu et al., 2017, Zhang et al., 2017), highlighting their potential 
value as therapeutic targets and disease biomarkers.  
This thesis hypothesises that alterations in miRNA expression in ageing cartilage result in gene 
expression dysregulation and hence altered chondrocyte phenotype contributing to OA. To 
test this, I set the following objectives:  
1. Establish DE miRNAs between young intact and old OA human knee cartilage using 
microarrays to investigate miRNAs that change with ageing and OA. 
2. Investigate selected miRNAs in an in vitro OA inflammatory model. 
3. Characterise selected target genes of a set of DE miRNAs based on their predicted function 
in cartilage homeostasis and investigate the role of physiologically relevant miRNA:target 
interactions through miRNA gain- and loss-of-function approaches, quantitative polymerase 
chain reaction (qPCR) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
4. Establish DE miRNAs between young healthy and old healthy equine chondrocytes using 
small RNA sequencing (RNA-Seq).  
 
1.1 General information about articular cartilage 
Cartilage is a highly specialised connective tissue found in different anatomical positions 
within the human body. It consists of chondrocytes, the only cell type present in the tissue, 
and the extracellular matrix (ECM). Dependent on ECM composition, three different types of 
cartilage exist: hyaline, elastic and fibrous cartilage (Krishnan et al., 2018). Hyaline cartilage is 
the most common type in humans and it is found in the ribs, nose, trachea as well as in the 
articulating surfaces of diarthrodial joints, in which case it is called articular cartilage (Krishnan 
et al., 2018).  
Articular cartilage is a type of tissue that does not contain blood vessels and nerves and 
receives nutrients via synovial fluid and to a lesser degree via subchondral bone (Wang et al., 
2013). The main function of articular cartilage is to support joint movement by providing a 
smooth gliding surface between bones, to facilitate load bearing and load transferring 




Three distinct zones make up the full thickness of articular cartilage; the superficial or 
tangential zone, the middle or transitional zone and the deep zone, all of which have different 
chondrocyte and ECM organisation (Sophia Fox et al., 2009) (Figure 1.1). The superficial zone 
is the thinnest of the three zones and makes up approximately 10-20% of articular cartilage 
thickness. This zone protects the deeper layers and is responsible for the tensile and 
stretching-resistant properties of articular cartilage. The middle zone makes up 40-60% of 
cartilage thickness and provides the first line of resistance to compressive forces. Finally, the 
deep zone makes up around 30% of tissue thickness and shows the greatest resistance to 
compressive forces (Sophia Fox et al., 2009). A layer of calcified cartilage is found beneath the 












Figure 1.1: Zonal organisation of articular cartilage. The three main zones of articular 
cartilage: superficial, middle and deep zone, are characterised by different chondrocyte 
organisation and ECM composition and are responsible for the tensile and force-resistant 
abilities of the tissue. A layer of calcified cartilage acts as an anchor between articular cartilage 
and subchondral bone. Figure adapted from (Bohaček et al., 2015) with permission from the 
journal (the contents of PERIODICUM BIOLOGORUM may be reproduced without permission 









Chondrocytes are the only cell type present in articular cartilage and make up approximately 
5% of cartilage total volume (Rahmati et al., 2017). Their number, shape and size differ 
dependent on which of the three main zones the cells are located in. Chondrocytes in the 
superficial zone are flatter and smaller, in the middle zone are rounder with a random 
orientation, whereas in the deep zone are larger and organised in columns perpendicular to 
the articular surface (Sophia Fox et al., 2009, Goldring, 2012). Chondrocytes are sparsely 
distributed in cartilage and they do not form cell to cell interactions. Mature chondrocytes in 
adults show very little proliferative capacity and remain in a steady phase which resembles 
the resting chondrocytes of the growth plate during development (Correa et al., 2017). This 
results to the very limited healing capacity of articular cartilage (Sophia Fox et al., 2009).  
Mature chondrocytes are quiescent, fully differentiated cells that are responsible for 
maintaining the synthesis of ECM components such as collagens, proteoglycans, 
glycoproteins and other non-collagenous molecules (Singh et al., 2018). These molecules have 
a low turnover and chondrocytes are responsible for maintaining the balance between 
anabolic and catabolic processes, thus maintaining the integrity of the tissue.  
 
1.2.2 The extracellular matrix (ECM) 
 
The ECM makes up approximately the remaining 95% of articular cartilage volume and 
consists of 80% water and 20% solid components (Camarero-Espinosa et al., 2016). The solid 
component of the ECM consists of different types of proteins, such as collagens, 
proteoglycans and other non-collagenous proteins (Camarero-Espinosa et al., 2016). The 
composition of the ECM varies between the different zones of articular cartilage (Armiento 
et al., 2018). In addition to the differences observed between zones, the ECM shows a 
radial/regional organisation as well. Single or grouped chondrocytes are surrounded by a 




surrounded cell constitutes a chondron. Chondrons are surrounded by the territorial matrix 
and the region between chondrons is called the interterritorial matrix (Armiento et al., 2018, 
















Figure 1.2: The regional organization of the ECM of articular cartilage. Three different 
regions have been described in the ECM: the pericellular matrix, the territorial matrix and the 





Collagens are the main proteins that make up the solid component of the ECM in articular 
cartilage (approximately 50-75% of the solid component) (Camarero-Espinosa et al., 2016). 
Chondrocytes secrete premature forms of collagens called procollagens. Procollagens are 




found throughout articular cartilage (Camarero-Espinosa et al., 2016). These collagen fibrils 
are linked in a specific way and form an extensive meshwork which is responsible for many of 
the load-bearing and tensile properties of the tissue (Eyre, 2002). There are different types of 
ECM collagen, such as collagen type II, III, VI, IX, X and XI (Eyre, 2002). The abundance and 
localisation of each type is different (Table 1.1).  
 
Table 1.1: Distribution of different types of collagen in articular cartilage and their 
percentage of total collagen content. Table compiled with information from (Camarero-
Espinosa et al., 2016, Eyre et al., 2006, Luo et al., 2017, Wu et al., 2010). 
Collagen type % of total collagen 
content 
Distribution 
Collagen II 90-95 Throughout the tissue 
Collagen IX 1 Throughout the tissue, 
associated with type II 
(cross-linking) 
Collagen XI 3 Throughout the tissue, 
associated with type II 
(cross-linking) 
Collagen VI <1 Concentrated in the 
pericellular matrix 






Collagen type II is the most abundant type of collagen in articular cartilage and accounts for 
approximately 90-95% of the total collagen content in the adult tissue (Camarero-Espinosa et 
al., 2016, Eyre et al., 2006). Transmission electron microscopy reveals a specific pattern in the 
three cartilage zones (Eyre et al., 2006). In the superficial zone, collagen fibrils tend to be 
thinner and aligned parallel to cartilage surface. In the middle zone, collagen fibrils are thicker 
and more randomly distributed, whereas in the deep zone fibrils seem to obtain an 
orthogonal orientation perpendicular to cartilage surface (Eyre, 2002, Eyre et al., 2006). A 
similar pattern is seen within the regional organisation of the ECM, with thinner collagen 
fibrils closer to the pericellular matrix and thicker fibrils closer to the interterritorial matrix 
(Eyre, 2004, Eyre et al., 2006).  
Collagen type IX and XI are two other collagen types important for the assembly of the 
collagen meshwork in articular cartilage. Even though they account for a small percentage of 
the total collagen content in the adult tissue (about 1% and 3%, respectively) (Camarero-
Espinosa et al., 2016), they form a heteropolymer along with collagen type II which is essential 
for the formation of the basic cartilage structure (Eyre et al., 2006). Specifically, collagen type 
IX cross-links with collagen type II and other collagen type IX fibrils forming the heteromeric 
fibrils observed in articular cartilage (Eyre et al., 2006, Luo et al., 2017). Collagen type XI fibrils 
cross-link mainly to each other but also to collagen type II fibrils and they regulate cartilage 
formation by constraining the lateral growth of collagen type II network (Eyre, 2002, Luo et 




Proteoglycans account for about 10% to 15% of cartilage dry weight (Camarero-Espinosa et 
al., 2016, Vynios, 2014). As their name suggests, proteoglycans consist of a core protein and 
Collagen III 0.5-10 Throughout the tissue, 




one or more polysaccharide branches which are called glycosaminoglycans (GAGs). GAGs are 
linear polysaccharides, with the most common being chondroitin sulphate, keratan sulphate, 
dermatan sulphate and hyaluronan (Camarero-Espinosa et al., 2016). GAGs, except for 
hyaluronan, have a negative charge and are responsible for the osmotic pressure generated 
within cartilage and contribute significantly to the compressive and load bearing ability of the 
tissue (Knudson et al., 2001, Sophia Fox et al., 2009). Based on their GAG content, composition 
and properties, proteoglycans are divided into several families (Vynios, 2014). Each  contains 
different members but the most important and well-studied proteoglycans are aggrecan, 
decorin and biglycan (Vynios, 2014). 
Aggrecan is the largest and most abundant proteoglycan in articular cartilage (Sophia Fox et 
al., 2009). Its core protein consists of three globular domains (G1, G2 and G3) and three 
interglobular domains. Chondroitin sulphate and keratan sulphate are the two types of GAGs 
found on aggrecan, and they bind the core protein on the interglobular domain between G2 
and G3 (Knudson et al., 2001). Aggrecan strongly binds hyaluronan through a link protein. 
More than 100 aggrecan molecules bind a single string of hyaluronan to form aggregates 
(Dudhia, 2005) which contribute significantly to the load-bearing function of articular 
cartilage.  
Decorin and biglycan belong to the family of small leucine-rich proteoglycans. The family 
derives its name from the leucine-rich motif found in adjacent domains in the protein 
(Roughley, 2006). Decorin has one chain of dermatan sulphate, whereas biglycan has two 
(Roughley, 2006, Sophia Fox et al., 2009). In contrast to aggrecan, decorin and biglycan do not 
form aggregates. Instead, they are linked to the collagen meshwork by achieving a ‘horse-
shoe’ confirmation which interacts with individual collagen fibrils (Roughley, 2006). This helps 
fibril formation, development and interaction in the ECM. Moreover, decorin, biglycan, and 
other proteoglycans from this family, can bind to proteins which are produced intracellularly 
but are secreted in the ECM. These include fibronectin, elastin, growth factors such as 
transforming growth factor beta (TGF-β), as well as cytokines such as tumour necrosis factor 
alpha (TNF-α). In this way, these proteoglycans sequester proteins that play an important role 
in cartilage metabolism and make these secreted signalling factors available to chondrocytes 






Figure 1.3: Schematic representation of the ECM of articular cartilage. Chondrocytes in 
articular cartilage are embedded in a thick ECM, made up mainly by different types of 
collagens and proteoglycans. The organisation of the matrix is responsible for many 
properties of the tissue. Original diagram compiled with information from (Eyre et al., 2006, 
Knudson et al., 2001). 
 
  
1.3 Chondrogenesis and cartilage formation 
Chondrogenesis is an important process during skeletal development which results in the 
formation of cartilage intermediate (or cartilage anlagen) and long bone through 
endochondral ossification (Goldring et al., 2006). During the first weeks of gestation, 
mesenchymal stem cells (MSCs) from the mesoderm start forming the limb buds by 
undergoing mitosis and forming cell condensates (Camarero-Espinosa et al., 2016). Cell 
condensation is the result of cell to cell and cell-matrix interactions. TGF-β is one of the first  
signalling pathways activated in MSC condensates and leads to the expression of fibronectin 
which, then, regulates the expression of neural cell adhesion molecule (NCAM), a protein 




condensates undergo differentiation into chondroprogenitor cells which form the cartilage 
anlagen. During this process, cells lose their elongated MSC-like appearance and become 
rounder, resembling chondrocytes (Burdan et al., 2009). These chondroprogenitor cells 
switch off expression of condensation markers and start expressing early cartilage-related 
proteins, such as collagen type II, IX and XI (Goldring, 2012).  
A transcription factor essential for chondrogenesis is sex determining region Y-box 
transcription factor (SOX) 9. SOX9 is a master regulator of chondrogenesis, expressed not only 
during embryogenesis but also in adult articular cartilage (Song et al., 2020). During 
embryogenesis it is expressed as early as MSC condensate formation and differentiation into 
chondroprogenitor cells (Hallett et al., 2019, Song et al., 2020). Its expression is regulated 
through the bone morphogenetic protein (BMP) signalling pathway and it interacts with two 
other SOX members, SOX5 and SOX6, to form the so-called ‘SOX trio’. SOX trio activates the 
expression of collagen type II, XI and aggrecan in the differentiated chondroprogenitor cells 
(Hallett et al., 2019).  
At the centre of the cartilage anlagen the growth plate is formed which consists of four 
different chondrocyte layers (Lefebvre et al., 2005). In the outer layer, there are resting 
chondrocytes which produce large amounts of ECM components (Camarero-Espinosa et al., 
2016). The next layer is the proliferating zone which undergoes hypertrophy, adding to the 
third layer of the growth plate, the transformation zone (Burdan et al., 2009, Lefebvre et al., 
2005). The final layer is the degeneration zone where the terminally differentiated 
hypertrophic chondrocytes undergo apoptosis accompanied by cartilage matrix calcification, 
blood cell invasion (angiogenesis) and, finally, ossification (Goldring et al., 2006) (Figure 1.4).  
The molecular pathways associated with growth plate formation and bone development are 
complex. One of the key transcription factors essential for chondrocyte maturation, 
endochondral ossification and bone formation is RUNX family transcription factor 2 (RUNX2). 
RUNX2 is expressed in resting and proliferative chondrocytes at low levels, but its expression 
is increased in prehypertrophic chondrocytes (Komori, 2018, Nishimura et al., 2018). RUNX2 
induces the expression of Indian hedgehog (IHH) in prehypertrophic chondrocytes. IHH has 
an array of roles in cartilage and bone development (Nishimura et al., 2018), such as inducing 
the expression of parathyroid hormone-related protein (PTHrP) in the zone of resting and 




chondrocytes in the proliferating stage (Melrose et al., 2016). However, IHH can also act in a 
PTHrP-independent manner and studies have shown that, in addition, it can promote 
chondrocyte maturation and matrix calcification (Amano et al., 2008, Nishimura et al., 2018).  
 
Figure 1.4: Chondrocyte differentiation and growth plate formation during embryonic 
development of long bones. A schematic representation of the sequential stages of 
chondrocyte differentiation during long bone development is depicted here. The cartilage 
anlagen is surrounded by a chondrogenic structure called the perichondrium. Following blood 
vessel invasion, osteoblasts arrive at the site to form new bone (bone collar and periosteum). 







In addition to IHH, RUNX2 regulates the expression of other target proteins, including collagen 
type X in hypertrophic chondrocytes and matrix metallopeptidase (MMP) 13  and vascular 
endothelial growth factor A (VEGFA) in terminally differentiated chondrocytes (Komori, 
2020). Collagen type X is a well-recognised marker of chondrocyte hypertrophy and it is 
believed that the matrix formed by collagen type X provides support during cartilage 
degradation and is easily replaced by bone (Shen, 2005).  Moreover, collagen type X binds to 
specific matrix vesicles which rapidly uptake Ca2+, suggesting that this type of collagen plays 
a role in calcification and matrix mineralisation during endochondral ossification (Shen, 2005). 
Furthermore, MMP13 is responsible for the breakdown of the ECM by cleaving collagen type 
II in the layer of terminally differentiated chondrocytes (Malemud, 2006). VEGFA drives blood 
vessel invasion and vascularisation of the forming bone (Vadalà et al., 2018). Figure 1.5 
summarises the basic molecular signalling pathways during growth plate development.  
Articular cartilage forms at the end of long bones, however the events that lead to its 
formation, maturation and permanent status are less clear. It is believed that articular 
cartilage is formed from flat, densely packed MSCs which appear at each site of joint 
formation in the cartilage anlagen. These MSCs are called the ‘interzone’ and they are de-
differentiated chondrocytes from the chondrocyte anlagen (Decker et al., 2015). Postnatally, 
articular cartilage undergoes growth and re-modeling to form mature cartilage. Again, the 
events responsible for the maturation of the tissue and its zonal organisation are not clear. 
Studies have shown the presence of i) slow-proliferating, stem-like cells within the superficial 
zone, and ii) rapidly-dividing cells in the middle and upper layers of the deep zone (Hayes et 
al., 2001, Hunziker et al., 2007). The stem cells in the superficial zone have a dual role; by 
dividing they contribute to the lateral growth of articular cartilage, and also provide daughter 
cells to the rapidly-dividing middle and deep zone which, in turn, are responsible for the 






Figure 1.5: Simplified overview of the molecular signalling pathways in the growth plate 
during endochondral ossification. During embryonic development, a growth plate is formed 
in each side of the long bones and consists of different layers of chondrocytes, each with its 
own organisation and specific molecular signals involved. A complex network of proteins, 
including ligands, transcription factors and structural proteins, acts in each layer to regulate 
growth plate elongation and bone formation. Growth plate development is a highly 
specialised process and the signalling pathways involved need to be tightly regulated in each 




1.4 Ageing and articular cartilage 
Ageing can be defined as the accumulation of changes in the biological, psychological and 
social aspect of an organism and is a life-long process (Kalache, 1999). Biological ageing refers 
to the accumulation of damage at the molecular and cellular level that impacts the well-being 
of an organism. Ageing can influence the function of all organs in an organism and, therefore, 
it can have an adverse effect on proper articular cartilage and joint function and, in turn, can 
predispose individuals to an increased risk for developing joint diseases and pathologies 
(Rahmati et al., 2017). This is evident from that fact that ageing is the leading risk factor for 
developing OA (Loeser et al., 2016). Changes with ageing in articular cartilage have been 
observed at the molecular, cellular and extracellular level and these are discussed below.  
 
1.4.1 Ageing-related changes in the ECM of articular cartilage 
 
Articular cartilage has a limited healing capacity and a very slow turnover. Aged cartilage 
exhibits reduced synthesis of anabolic markers and ECM components (Mobasheri et al., 
2015), but also the quality of the ECM itself decreases.  Collagen type II has a half-life of more 
than 100 years (Loeser et al., 2016). However, non-enzymatic cross-linking of collagen type II 
is observed with increasing age (Loeser et al., 2016). Collagen cross-linking results in the 
accumulation of advanced glycation end-products which occur as the result of non-enzymatic 
glycation of proteins, and specifically when reducing sugars, such as glycose and fructose, 
react with lysine or arginine (Loeser, 2010). This extensive cross-linking impacts the 
mechanical properties of the tissue, making articular cartilage stiffer and more brittle, and 
leads to focal defects which accumulate with age (Loeser, 2010). Moreover, these advanced 
glycation end-products result in bigger collagen fibres which reduces collagen elasticity, 
making the tissue more susceptible to damage (Rahmati et al., 2017). A Magnetic Resonance 
Imaging (MRI) study between young (20-30 years) and old (50-78 years) individuals with no 
OA or other knee-related defects, showed thinning of knee femoral articular cartilage in the 




deformation of cartilage in the old group, which supports that the tissue becomes more brittle 
with increasing age (Hudelmaier et al., 2001).  
Figure 1.6: Increasing proteolytic cleavage of aggrecan with ageing. Aggrecan molecules 
within ECM undergo increasing trimming with ageing. (A) One hyaluronan filament can be 
bound by many aggrecan molecules. (B) The first events of proteolytic cleavage take place at 
the G3 domain (1) and the link protein (2). (C) With increasing ageing, aggrecan is further 
trimmed at the chondroitin sulphate chain, which results in aggrecan molecules with different 
lengths of chondroitin sulphate chains (3, 4). (D) Final cleavage events lead to free G1 and link 
protein domains which remain in the ECM or are diffused in synovial fluid (5). Figure modified 




Ageing also impacts the proteoglycan content in articular cartilage. The size of the aggregates 
formed by aggrecan decreases with ageing, caused by changes in the length of keratan and 
chondroitin sulphates (Rahmati et al., 2017). Studies have shown that there is an increase in 
the length of keratan sulphate chains and a decrease in the length of chondroitin sulphates 
with age (Dudhia, 2005). This results in changes in the structure and sulphate-content of the 
aggregates, thus limiting the functional properties of the tissue (Loeser, 2010). In addition, 
proteolytic cleavage from both ends of the aggrecan molecules have been observed with 
ageing (Dudhia, 2005) (Figure 1.6). The trimming usually starts at the C-terminal of the G3 
domain and the N-terminal of the link protein and they are the first events of proteolytic 
cleavage of aggrecan. Then, with increasing age, the trimming continues to the chondroitin 
sulphate region which can result in a heterogeneous mixture of aggrecan molecules of 
different length. Following from this, the interglobular domain is cleaved and the chondroitin 
sulphate chains are diffused in the synovial fluid and, finally, as the trimming continues, there 
are just G1 domains left attached in hyaluronan filaments or free G1 domains in the ECM 
(Dudhia, 2005). This is supported by studies that have shown that the free G1 molecules are 
more abundant in aged normal cartilage compared to link protein molecules which seem to 
be cleaved early in life (Wells et al., 2003). These events change the composition of the 
aggregates and interfere with the ability of the tissue to maintain its functionality. The thinner 
appearance of aged human cartilage compared to young cartilage can also be explained by 
the limited amount of water held withing the aggregates of the ECM due to the structural and 
functional changes in aggrecan (Loeser, 2010).  
 
1.4.2 Age-related chondrocyte senescence, inflammation and oxidative stress  
 
A cell is characterised as senescent when it stops proliferating and enters a growth arrest 
phase with altered metabolism (Rahmati et al., 2017). Senescence is considered a hallmark of 
ageing, and aged or diseased chondrocytes may display features of senescence, termed 
chondrosenescence (Mobasheri et al., 2015). One of the mechanisms which can lead to 
senescence is telomere shortening through repetitive cell proliferation, referred to as 
replicative senescence (Rahmati et al., 2017). However, chondrocytes are long-lived cells that 




explanatory mechanism of chondrosenescence in articular cartilage (Loeser, 2010). Instead, 
chondrosenescence can also be caused by other events, such as trauma, DNA damage and 
oxidative stress (Rahmati et al., 2017). DNA damage accumulates with ageing especially in 
chondrocytes which divide very slowly, leading to changes in gene expression and 
predisposing them to disease (Loeser et al., 2016, Rose et al., 2012).  
Oxidative stress is another major contributor of age-related cell damage that could lead to 
senescence in chondrocytes. Oxidative stress is caused by the accumulation of free reactive 
oxygen species (ROS) which are produced during mitochondrial respiration and can damage 
DNA and proteins, resulting in altered cellular function (Sacitharan et al., 2016). ROS 
production is linked to mitochondrial function which worsens with ageing, causing an 
imbalance between the production of these damaging agents and the antioxidant 
mechanisms of the cell (Loeser et al., 2016). Increased levels of different ROS groups have 
been identified in aged articular chondrocytes of different species, including superoxide 
derivatives in rat (Jallali et al., 2005) and nitrotyrosine in human and monkey (Loeser et al., 
2002). In addition, decreased levels of antioxidants have been found in aged 
cartilage/chondrocytes. Specifically, the activity of superoxide dismutase 2 (SOD2), a protein 
which metabolises ROS, was decreased in cartilage from old rats compared to young (Fu et 
al., 2016), and Sod2 knockout mice exhibited cartilage degeneration and increased superoxide 
production compared to control (Koike et al., 2015). ROS also acts by oxidising antioxidant 
proteins in chondrocytes, interfering with their antioxidant activity, such as in the 
hyperoxidation of the peroxiredoxin enzyme family, which was increased in chondrocytes 
from older humans compared to young (Collins et al., 2016).  
Once senescence is established in a cell, this results in more phenotypic changes that could 
have a detrimental effect on cell homeostasis. A characteristic of ageing linked to senescence 
is the systemic low-grade inflammation, termed inflammageing (Franceschi et al., 2000). 
Production of pro-inflammatory cytokines, such as IL-1β and interleukin 6 (IL-6), increase with 
ageing and are linked to age-related diseases of the musculoskeletal system such as OA 
(Loeser, 2010). Inflammation is considered a feature of aged senescent chondrocytes which 
seem to acquire the so-called ‘senescence-associated secretory phenotype’ (SASP). SASP is 




enzymes, such as MMP13, and therefore aged senescent chondrocytes with SASP may 
contribute to the development of disease (Li et al., 2017, Loeser, 2010, Loeser et al., 2016).  
Moreover, aged senescent chondrocytes are characterised by altered responses to growth 
factors and other stimuli. Studies have shown that chondrocytes isolated from old healthy 
human cartilage have a reduced response when treated with insulin growth factor 1 (IGF-1) 
and BMP-7 (also known as osteogenic protein-1) compared to chondrocytes isolated from 
young donors (Loeser et al., 2014). Both IGF-1 and BMP-7 exert an anabolic effect on cartilage, 
resulting in proteoglycan synthesis. Old chondrocytes had reduced proteoglycan synthesis 
due to reduced sensitivity to these two growth factors. In the same study, oxidative stress-
induced chondrocytes showed less proteoglycan synthesis due to the inhibition of IGF-1 
signalling, providing further evidence on the link between age, senescence and altered 
cellular signalling (Loeser et al., 2014).  
 
1.4.3 Age-related chondrocyte autophagy and apoptosis 
 
Autophagy is an essential mechanism which acts to maintain cell homeostasis during nutrient 
supply shortage and energy/metabolism stress by removing and recycling defective or 
unnecessary organelles or proteins of the cell, thus promoting cell survival (Li et al., 2017, 
Rahmati et al., 2017). Increased autophagy is associated with longevity, and several studies 
have reported a decreased autophagic activity and autophagy-promoting proteins in aged 
chondrocytes and cartilage. Caramés et al (2015) reported reduced autophagic vesicles in the 
knee joints of old mice compared to young, and concluded that the expression of key 
autophagic proteins, such as autophagy related 5 (ATG5) and microtubule-associated protein 
1 light chain 3 (LC3), was decreased with age (Caramés et al., 2015). In an earlier study, the 
same group demonstrated decreased levels of three key proteins that drive autophagy, Unc-
51-like kinase 1 (ULK1), Beclin1 and LC3, in cartilage and chondrocytes from old human donors 
compared to young (Caramés et al., 2010). In another study, Petursson et al (2013) 
demonstrated that the expression of another autophagy-related protein, 5' AMP-activated 
protein kinase (AMPK), was decreased in the joints of old mice compared to young (Petursson 




Drosophila melanogaster led to increased autophagy and longevity (Ulgherait et al., 2014), 
thus providing further evidence on the link between autophagy and age.  
In addition, an important mechanism associated with ageing and autophagy is the 
mechanistic target of rapamycin kinase (mTOR) signalling pathway. mTOR regulates cellular 
growth and metabolism in response to nutrient intake reduction. Inhibition or deletion of the 
gene that codes for mTOR leads to increased lifespan in many organisms, including mammals 
(Johnson et al., 2013). Autophagy is a target of mTOR signalling, supported by the fact that 
autophagy declines with ageing while mTOR signalling increases. AMPK promotes autophagy 
by activating ULK1 directly and mTOR disrupts the interaction between these two proteins 
(Kim et al., 2011). Deletion of the mTOR gene in cartilage resulted in i) increased expression 
of the autophagy markers ATG5, ULK1, LC3 and AMPK, ii) increased expression of collagen 
type II and aggrecan, iii) decreased expression of catabolic markers, such as MMP13 and iv) 
protection of mouse joints from induced OA (Zhang et al., 2015b).  
Apoptosis, also called programmed cell death, is the regulated process of cell death during 
embryonic development (Mobasheri et al., 2015). However, it is now clear that apoptosis is a 
characteristic of various age-related diseases, including OA. The link between apoptosis and 
cartilage ageing is unclear. There seems to be a reduction in the number of chondrocytes with 
ageing, however the effect of ageing on chondrocyte number and density is still debatable. 
An older study from Vignon et al (1976) reported a 40% decrease in total chondrocyte number 
and cell density in the femoral head of donors ranging from 20 up to 90 years old, with the 
superficial zone showing the most profound decrease among the ECM zones  (Vignon et al., 
1976). However, another study in human knee cartilage, did not detect significant apoptosis 
in aged cartilage samples (Aigner et al., 2001). This does not seem to be the case for other 
species, as there was significant apoptosis detected in the joints of old mice and rats 
compared to young controls (Adams et al., 1998), highlighting potential species differences. 
Although the level of apoptosis in aged cartilage is unclear, a potential mechanism through 
which age could promote apoptosis in chondrocytes is through the high mobility group box 2 
(HMGB2). HMGB2 is expressed only in the superficial zone and its expression decreases with 
ageing in humans and mice (Taniguchi et al., 2009). Mice lacking Hmgb2 had decreased 
cellularity and increased apoptosis in the superficial zone, suggesting Hmgb2 plays an 




2009). An age-related decrease in the levels of HMGB2 could contribute to increased 
apoptosis in the superficial zone justifying, in part, the chondrocyte loss and fibrillation 
observed in the superficial zone of old healthy donors with no history of OA. Nonetheless, 
further research is needed to elucidate the effect of ageing on chondrocyte apoptosis. Table 
1.2 summarises the age-related changes observed in articular cartilage and the ways these 
changes contribute to OA. 
 
Table 1.2. Summary of age-related changes in articular cartilage and their contribution to 
OA. Table compiled with information from (Loeser, 2010). 
Changes with ageing Contribution to OA 
Formation of end glycation products Non-enzymatic collagen cross linking resulting in 
stiffer and more brittle ECM 
Trimming of aggrecan molecules  Loss of water content and decreased ECM 
resiliency and tensile strength  
Chondrosenescence with cells exhibiting the 
senescent secretory phenotype  
Increased cytokine and MMP production that 
stimulates matrix degradation 
Oxidative stress/damage Increased susceptibility to cell death and reduced 
matrix synthesis 
Decreased growth factor responsiveness Reduced matrix synthesis and repair 
Decreased chondrocyte autophagy Reduced cell survival and energy stress response 








 1.5 Osteoarthritis 
 
1.5.1 Definition, epidemiology and management of osteoarthritis  
 
Osteoarthritis (OA) is the most common joint disease and type of arthritis. It can affect any 
joint but the most commonly affected are the knee, the hip, the hand, the foot and the spine. 
The information given in this section will primarily focus on knee OA, which is the main joint 
discussed in this thesis. OA is one of the leading causes of disability and millions are affected 
worldwide; approximately 250 million people are suffering from knee OA alone (O'Neill et al., 
2018). Even though the major clinical feature is cartilage loss, it is now accepted that OA is a 
disease of the whole joint and several joint tissues, such as bone, synovium, ligaments and 
muscles, are also affected (Martel-Pelletier et al., 2016).  
OA is usually diagnosed based on radiographic findings. The radiographic criteria commonly 
used to diagnose OA are based on the Kellgren-Lawrence (KL) grading system (Kellgren et al., 
1957). According to this, there are five grades of OA severity based on x-ray findings: grade 0 
(normal), grade 1 (doubtful), grade 2 (minimal), grade 3 (moderate) and grade 4 (severe). This 
grading system is based on the presence or absence of various morphological features in a 
joint, such as formation of osteophytes (small bony projections), narrowing of the joint space, 
sclerosis of subchondral bone and altered shape of the bone ends (Kellgren et al., 1957) 
(Figure 1.7).  
Moreover, OA can be divided into different subclasses based on the underlying cause (primary 
and secondary OA), and whether there are symptoms present or not (symptomatic and 
asymptomatic OA). It is called primary (or idiopathic) OA when there is not an identifiable 
underlying cause but instead it develops as the result of several risk factors. In contrast, it is 
characterised as secondary when it develops as the result of a specific underlying cause, such 
as joint trauma, joint defect during birth, joint surgery and others (Martel-Pelletier et al., 
2016). Symptomatic OA is characterised by radiographic findings and the presence of 
symptoms, such as pain, joint stiffness, loss of joint function and movement, which have a 
significant impact on the quality of life for patients. However, up to 50% of OA cases show 




asymptomatic or structural or radiographic OA (Hannan et al., 2000, Martel-Pelletier et al., 
2016).  
 
Figure 1.7: Kellgren and Lawrence (KL) grading system. The KL scoring system assesses OA 
severity based on radiographic findings. According to it, there are five different grades of OA 
severity and each grade is characterised by a set of radiographic findings based on changes in 
the morphology and shape of the joint, such as osteophytes (black arrows), joint space 
narrowing (white arrows) and sclerosis (red arrows). Figure modified with permission from 




The prevalence of OA differs among different populations. However, for both asymptomatic 
and symptomatic OA, the prevalence increases with age, and especially in women (Figure 
1.8). It is clear that management and treatment for OA are a significant economic burden, 
and the costs in developed countries are estimated to be between 1% and 2.5% of the gross 
domestic product (Hiligsmann et al., 2013).  
 
 
Figure 1.8: Percentage of knee and hip OA prevalence according to age and sex. Knee and 
hip OA prevalence increases with ageing for both men and women. A steep increase is 
observed after the age of 40 for both sexes and especially for women. Data comes from a 
Dutch population sample. Data was reported by (Oliveria et al., 1995). Figure modified with 






Early management of knee OA usually begins by educating patients and proposing lifestyle 
modifications. These may include weight loss, the use of knee braces or walking assisting 
devices and muscle strengthening (Gress et al., 2020). If symptoms persist, patients can be 
administered drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), to relieve pain. 
In cases where patients are not responding to NSAIDs treatment, they can be treated with 
injectable corticosteroids to alleviate symptoms (Gress et al., 2020). Corticosteroids act by 
suppressing inflammation, thus decreasing swelling of the joint. However, due to side effects, 
injections should not be administered too often and other treatment options should be 
considered. 
Surgical intervention for end-stage OA patients who are unresponsive to drug treatment and 
experience advanced symptoms is another option. There are different surgical treatments for 
OA and the correct type of surgery depends on patient and disease characteristics (Gress et 
al., 2020). So far, the most successful model of surgery for treating end-stage knee OA is TKA, 
also known as total knee/joint replacement. The procedure involves the dissection and 
exposure of the knee joint, removal of femoral condyles and tibial plateau and finally fitting 
and cementing of the prosthetic part (Gress et al., 2020). A study that compared OA patients 
who received TKA to patients receiving non-surgical treatment (physiotherapy, weight-
management, exercise and pain medication), found that TKA significantly reduced pain and 
improved quality of life for patients, but was associated with more adverse events compared 
to the non-surgical group (Skou et al., 2015). As with most surgeries, patient selection is 
critical to achieve maximum patient satisfaction and the best possible outcome. Predictive 
factors include number of affected joints and presence of comorbidities, as patients with 
more than one troublesome joints and comorbidities are more likely to have a less 
satisfactory TKA outcome (Hawker et al., 2013). In a previous study, approximately 10% to 
34% of patients who had a knee TKA still reported long-term pain (Beswick et al., 2012). In 
fact, a percentage of patients who undergo TKA will need a second operation as they need 
adjustments and revisions to their initial arthroplasty (Gress et al., 2020).  
TKA is an invasive operation and a heavy economic burden for the health system, despite 
being the best option for end-stage OA at the moment. In the last few years, research has 
focused on alternative surgical interventions for OA. One of them is autologous chondrocyte 




the joint, in order to delay OA progression and potentially reverse the disease (Gress et al., 
2020). Unfortunately, the results so far have been discouraging as studies have not 
demonstrated significant improvement in the groups that underwent chondrocyte 
implantation and several of the patients required TKA to manage the disease progression 
(Knutsen et al., 2016).  
 
1.5.2 Risk factors for osteoarthritis development  
 
There are many risk factors associated with the initiation and progression of OA. Usually these 
can be divided into two categories: systemic or person-level and mechanical or joint-level 
(Martel-Pelletier et al., 2016, O'Neill et al., 2018). Systemic risk factors are age, genetics, sex, 
ethnicity, whereas mechanical risk factors include joint structure, occupation, joint trauma 
and physical activity. However, it is not always possible to categorise risk factors as certain of 
them, such as body mass index (BMI), could fall in both categories. Some of these risk factors 
are analysed further below, except for ageing which has already been discussed extensively.  
The role of genetics in the development of OA is still not completely understood. Studies have 
shown that the contribution of genetics in OA is approximately 50%, but this contribution is 
polygenic (O'Neill et al., 2018). This means that there is not a single genetic locus responsible 
for OA, but, instead, there are multiple genetic loci, each contributing minorly to the 
development of the disease. Genome-wide association studies have identified several such 
loci, which include variants associated with genes and pathways important for cartilage 
biology, such as TGF-β and (Wingless-related integration site) WNT signalling pathway, 
mitogen-activated protein kinase (MAPK) signalling pathway, growth/differentiation factor 5 
(GDF5), iodothyronine deiodinase 2 (DIO2), asporin (ASPN) genes and others (Martel-Pelletier 
et al., 2016, Valdes et al., 2011, Zengini et al., 2018). Even though the contribution of each 
locus in OA development is only small/moderate, they still provide useful information 
regarding the involvement of specific genes in OA susceptibility and biomarker discovery.  
BMI/obesity is another strong risk factor for OA development, especially in the knee. 
Overweight (BMI >25 kg/ m2) and obese (BMI >30kg/m2) patients have an increased likelihood 




Similarly, loss of weight results in decreased likelihood for developing knee OA (Felson et al., 
1992). This is partially due to the excessive strain put on the knee joint from increased weight.  
Altered biomechanics is a significant risk factor for developing OA and an abnormal joint 
structure can increase the risk significantly. Abnormal alignment in the knee joint increases 
the risk for both OA initiation and progression (Sharma et al., 2010). In fact, based on the type 
of deformity, the medial or the lateral knee condyle can be affected (Sharma et al., 2010).  
The relationship between mechanical loading and OA is of great importance. Physical activity 
is crucial for healthy cartilage and joint development in children, and there seems to be an 
excessive cartilage volume loss in adults who remain immobilised for a long time due to injury 
(Martel-Pelletier et al., 2016). Normal mechanical loading is also crucial for chondrocyte 
homeostasis and development, as it promotes growth factor stimulation and matrix synthesis 
(Sanchez-Adams et al., 2014). However, the effect of mechanical load on chondrocytes and 
the ECM depends on different factors such as degree of strain, frequency and duration, 
among others. There is a range within which mechanical load is beneficial to cartilage and too 
little or too much stress could jeopardise joint function and lead to decreased matrix synthesis 
and catabolic responses (Sanchez-Adams et al., 2014) (Figure 1.9). This is also evident from 
studies regarding the effect of physical activity on knee OA risk. In a related study, light and 
moderate exercise did not increase the risk for knee OA, whereas heavy exercise (>4h per 
day) increased the risk for knee radiographic OA significantly (McAlindon et al., 1999). In 
addition, the underlying health of the joint plays a role. In subjects with established knee OA, 
physical exercise increased the risk for joint replacement surgery (Wang et al., 2011), whereas 
physical activity had a beneficial effect on healthy subjects with no history of knee disease 





Figure 1.9: Effect of mechanical loading on chondrocyte function and ECM physiology. The effect of mechanical loading on cartilage depends 
on the degree of strain, duration, frequency and loading history. Chondrocytes need physiologic loading in a dynamic manner which stimulates 
growth factor production and synthesis of matrix components. Too little loading in a static manner, or too much loading in a frequent manner 
will lead to an inflammatory response, cell death and catabolism. An acute mechanical load beyond the bearing capacity of cartilage will lead to 




Trauma to the joint is another risk factor associated with OA, which, in this case, is called post-
traumatic OA (PTOA). PTOA is a distinctive type of OA which usually differs from age-related 
OA and it accounts for approximately 12% of symptomatic OA cases (O'Neill et al., 2018). The 
mechanism behind PTOA is usually excessive loading and strain on the joint during injury 
and/or changes in the structure of the joint tissues (O'Neill et al., 2018). An example of joint 
trauma is ACL rupture. ACL rupture usually occurs in younger individuals who participate in 
high-activity sports. Patients with ACL rupture have a higher chance of developing PTOA in 
the long term, even after ACL reconstruction surgery (Ajuied et al., 2014). In an ACL patient 
cohort, about 34% of patients showed K&L grade I radiological changes 10 years after injury, 
and 31.5% had grade II radiological changes. Only 14% did not have any radiographical 
changes (grade 0) 10 years after ACL injury (Ajuied et al., 2014).  
 
1.5.3 Macroscopic changes in knee osteoarthritic cartilage  
 
OA is a disease of the whole joint. However, articular cartilage is one of the main joint tissues 
affected. At an early stage of the disease, there is swelling of the ECM caused by increased 
water content in the articular cartilage of the femoral condyles and tibia plateau. This results 
in superficial fibrillation of the articular surface and the presence of small cracks in the 
superficial zone (Goldring et al., 2016). Typically, as the disease progresses, there is increased 
loss of cartilage from the surface towards the deeper zones which leads to the formation of 
lesions and fissures that extend in the deeper layers (Goldring et al., 2016). In end-stage OA, 
there is complete loss of cartilage and exposure of the underlying subchondral bone, either 
from the whole condyle/plateau or parts of these (Goldring et al., 2016).  
In 1961, Outerbridge published a classification scoring system to macroscopically describe 
cartilage lesions (Outerbridge, 1961). Even though this scoring system was initially used to 
describe lesions in chondromalacia patellae, it has since been used to describe and classify 
macroscopic/gross changes in knee cartilage or other joints too (Curl et al., 1997). This 
classification is based on direct visualisation of articular cartilage through an open joint or 
arthroscopy and is mainly used among clinicians to classify group patients for research, guide 




The Outerbridge scoring system is described in Table 1.3 and examples of different-grade 
knee cartilage according to the Outerbridge system are seen in Figure 1.10.  
 




Figure 1.10: Different grades of gross damage in knee cartilage according to the Outerbridge 
scoring system. The Outerbridge scoring system consists of four different grades, based on 
gross changes in articular cartilage. Knee femoral cartilage is depicted here and the changes 
are marked with black arrows. Grade I is characterised by swelling of the tissue. Grade II and 
III by fragmentation, fissuring and lesions of different sizes. Grade IV represents full erosion 
of cartilage down to the subchondral bone. Original figure, courtesy of the author. 
Grade Pathology 
I Softening and swelling of articular cartilage 
II Fragmentation and fissuring of articular cartilage affecting an area of 
less than 0.5 inches 
III Fragmentation and fissuring of articular cartilage affecting an area of 
greater than 0.5 inches 




1.5.4 Microscopic/histological changes in knee osteoarthritic cartilage 
 
Histology is one of the main tools used to visualise microscopic changes in the ECM and 
chondrocytes of OA cartilage. Simple staining techniques, such as haematoxylin and eosin 
(H&E) or safranin O/fast green (S-O/FG), are widely used in cartilage research to assess OA 
lesions. H&E stains the chondrocyte nuclei blue-purple and the ECM pink, whereas S-O/FG 
stains the proteoglycan and GAG content red and in the absence of these, the tissue is stained 
light blue (Schmitz et al., 2010). H&E staining of healthy knee cartilage shows the zonal 
organisation of the tissue and chondrocyte distribution. The surface of the tissue, along the 
superficial zone, is a smooth line that does not contain cracks (Figure 1.11A). Normal cartilage 
stained with S-O/FG appears red due to the high proteoglycan content (Figure 1.11B). In early 
OA there is fibrillation of the superficial zone, small cracks start to appear on the surface and 
chondrocytes begin to proliferate as a response to cartilage breakdown (Goldring et al., 2016, 
Pritzker et al., 2006) (Figure 1.11C). There is also small loss of proteoglycans and GAGs (Figure 
1.11D). As OA progresses, there is extended cartilage breakdown and cracks extend vertically 
into the deeper zones to form fissures (Pritzker et al., 2006). Chondrocytes shift into a 
hypertrophic phenotype and are mostly organised into clusters. (Goldring et al., 2016) (Figure 
1.11E). There is increased chondrocyte apoptosis observed at this stage and most of the 
proteoglycan content is missing from the superficial and middle zones (Figure 1.11F). End-
stage OA is characterised by erosion of cartilage to the bone, as a significant percentage of 
the ECM has been degraded by this point. Only the deep zone remains focally, and in some 
areas, there is exposure of the underlying bone (Figure 1.11G). S-O/FG staining reveals almost 
complete loss of proteoglycan and GAG content (Figure 1.11H).  
Figure 1.11: Histological assessment of OA cartilage stages. A, C, E and G: H&E staining of 
normal, early, moderate and end-stage OA cartilage. B, D, F and H: S-O/FG staining of normal, 
early, moderate and end-stage OA cartilage. Main changes include loss of ECM and 
proteoglycan content, fissure formation, chondrocyte clustering and apoptosis. Figures 
1.11A, B, C, D, F, G and H modified with permission from (Pritzker et al., 2006, Shen et al., 
2016, Sulzbacher, 2013) (License Number: 4987840685333, 4987841293921 and 








Histological evaluation of OA cartilage provides useful information on disease stage. It is 
widely used in research to stratify patients and, as with macroscopic classification, there are 
different scoring systems for assessing cartilage changes at microscopic level. Two of the most 
widely used are the Mankin histological-histochemical grading system (HHGS) (Mankin et al., 
1971) and the Osteoarthritis Research Society International (OARSI) histopathology scoring 
system (Pritzker et al., 2006).  
The Mankin HHGS was developed by Mankin et al in 1971 for scoring hip OA but has since 
been applied to other joints too. This system assesses features such as structure of cartilage, 
relative number of cells, S-O/FG staining or loss of it, as well as tidemark integrity (Table 1.4). 
Each feature is assigned a grade based on severity and the final score is calculated. Minimum 
score is 0 and denotes normal cartilage and maximum score is 14 and denotes end-stage OA 
cartilage. This system is still widely used but has received criticism over its capability to 
distinguish between mild and moderate OA stages (Ostergaard et al., 1999). 
 
Table 1.4: Mankin’s histological-histochemical grading system. Pannus refers to the invasion 
of fibrous granulated tissue in hyaline articular cartilage, a common finding in OA patients 
(Shibakawa et al., 2003). Table copied with permission from (Pearson et al., 2011). (License 
Number: 4987850693987).  
 Grade 
I. Structure  
a. Normal 0 
b. Surface irregularities 1 
c. Pannus and surface irregularities 2 
d. Clefts to middle zone 3 
e. Clefts to deep zone 4 
f. Clefts to calcified zone 5 
g. Complete disorganisation 6 
  
II. Cells  
a. Normal 0 
b. Diffuse hypercellularity 1 
c. Cloning 2 
d. Hypocellularity 3 
  
III. Safranin-O staining  
a. Normal  0 









The OARSI histopathology scoring system is a more recent grading system that was developed 
in 2006. This system utilises grades and stages in order to provide a more comprehensive and 
standard manner for scoring articular cartilage lesions. In this system, there are six grades 
which represent depth of the lesion (Table 1.5) and four stages which represent the 
percentage of articular surface that is affected (Table 1.6). Multiplying grade score by stage 
score gives the final score, which ranges between 0 and 24 (Pritzker et al., 2006). The OARSI 
scoring system provides more detailed information about histopathology of OA cartilage 
compared to previous scoring systems and it is fairly easy to use. However, as with every 
scoring system, there are limitations. As it has been noted by others, it is quite difficult to 
generate sections from the whole articular cartilage surface for stage assessment (Moskowitz, 
2006). This holds true for human samples especially, where usually a small block of tissue is 
collected.  
 
Table 1.5: The OARSI histopathology scoring system: the grade assessment (depth 
progression of cartilage lesion). Table copied with permission from (Pritzker et al., 2006) 
(License Number: 4987840685333). 
Grade (key feature) Associated criteria (tissue reaction) 
Grade 0: surface intact, 
cartilage morphology intact 
Matrix: normal architecture 
Cells: intact, appropriate orientation 
c. Moderate reduction 2 
d. Severe reduction 3 
e. No dye noted 4 
  
IV. Tidemark integrity  
a. Intact 0 




Grade 1: surface intact Matrix: superficial zone intact, oedema and/or superficial 
fibrillation (abrasion), focal superficial matrix condensation. 
Cells: death, proliferation (clusters), hypertrophy, superficial 
zone. Reaction must be more than superficial fibrillation only 
Grade 2: surface discontinuity As above 
+Matrix discontinuity at superficial zone (deep fibrillation) 
±Cationic stain matrix depletion (Safranin O or Toluidine 
Blue) upper 1/3 of cartilage. 
±Focal perichondronal increased stain (mid zone). 
±Disorientation of chondron columns. 
Cells: death, proliferation (clusters), hypertrophy 
Grade 3: vertical fissures 
(clefts) 
As above 
Matrix vertical fissures into mid zone, branched fissures. 
±Cationic stain depletion (Safranin O or Toluidine Blue) into 
lower 2/3 of cartilage (deep zone) 
±New collagen formation (polarized light microscopy, Picro 
Sirius Red stain) 
Cells: death, regeneration (clusters), hypertrophy, cartilage 
domains adjacent to fissures 
Grade 4: erosion Cartilage matrix loss: delamination of superficial layer, mid 
layer cyst formation. Excavation: matrix loss superficial layer 
and mid zone 
Grade 5: denudation Surface: sclerotic bone or reparative tissue including 
fibrocartilage within denuded surface. Microfracture with 




Grade 6: deformation Bone remodelling (more than osteophyte formation only). 
Includes: microfracture with fibrocartilaginous and osseous 
repair extending above the previous surface. 
 
Table 1.6: The OARSI histopathology scoring system: the stage assessment (percentage of 
articular cartilage surface affected). Table copied with permission from (Pritzker et al., 2006) 
(License Number: 4987840685333).  
 
 
1.5.5 Molecular changes in osteoarthritic cartilage  
 
In healthy articular cartilage there is a balance between anabolism and catabolism, as the 
action of matrix-synthesising factors counteracts that of matrix-degrading enzymes. In early 
OA there is an increase in catabolic factors which leads to ECM degradation. The tissue reacts 
by synthesising increased amounts of ECM components in an attempt to repair tissue 
damage. However, the tissue is unable to cope with the extended damage and the balance 
soon shifts in favour of catabolism leading to further cartilage destruction (Goldring et al., 
2016). The molecular landscape of OA is very complex and still not completely understood. 
Years of research have highlighted the implication of several molecular pathways in the 
pathogenesis of OA; the TGF-β pathway, the WNT/beta-Catenin pathway, the 
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mTOR pathway, the Notch pathway 
Stage % Involvement (surface, area, volume) 
Stage 0 No OA activity seen 
Stage 1 <10% 
Stage 2 10-25% 
Stage 3 25-50% 




and the Sirtuin-1 (SIRT1) and AMPK pathway (He et al., 2020). The interplay of these pathways 
is extremely complex and beyond the scope of this review. Instead, focus will be given to the 
role of inflammation and the function of specific transcription factors which are of specific 
interest in cartilage and OA.  
Inflammation of the joint is an important component of OA pathogenesis. Both ageing and 
mechanical stress on the joint are characterised by low-grade inflammation and the release 
of proinflammatory cytokines such as IL-1β, IL-6 and TNF-α, which predispose cartilage to OA 
(He et al., 2020). These are produced by chondrocytes and other cell types in the joint, such 
as synoviocytes, osteoblasts and mononuclear cells, and they have a numerous of 
downstream effects in cell signalling and gene expression by eliciting an inflammatory 
response and contributing to the catabolic effects observed in OA cartilage (Chow et al., 
2020).  
IL-1β is the most researched cytokine in OA and cartilage degradation. It plays a role in various 
cellular functions, including cell proliferation and apoptosis, and it is elevated in cartilage, 
synovium and synovial fluid from OA patients (Chow et al., 2020). Its significance in OA is 
realised by the plethora of its downstream effects in chondrocytes (Figure 1.12). IL-1β reduces 
the synthesis of ECM components, such as collagen type II and aggrecan (Chow et al., 2020). 
Moreover, it induces the expression of other proinflammatory cytokines, such as IL-6 and 
TNF-α (Chow et al., 2020, Wojdasiewicz et al., 2014). This leads to activation of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), which   promotes the 
expression of matrix-degrading enzymes, such as MMP3 and MMP13, contributing further to 
cartilage degradation (Chow et al., 2020, Wojdasiewicz et al., 2014). It stimulates the 
expression of A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) 4 
protein, also known as aggrecanase for its ability to cleave aggrecan (Wojdasiewicz et al., 
2014). IL-1β also promotes the production of ROS, such as nitric oxide (NO), contributing to 
the senescence and DNA damage evident in OA chondrocytes (Rose et al., 2012). In addition, 
IL-1β induces the expression of cyclooxygenase 2 (COX-2), which, in turn, enhances the 
expression of prostaglandin 2 (PGE2) leading to decreased synthesis of ECM components and 
loss of chondrocyte proliferative capacity (Chow et al., 2020). Such is the effect of IL-1β in 
chondrocytes, that it is routinely used in chondrocyte cultures to mimic an in vitro OA 





Figure 1.12: Functions of IL-1β in OA cartilage. IL-1β is one of the main proinflammatory cytokines with several different functions in OA cartilage. It has an 
inhibitory effect on anabolic factors and ECM synthesis, while it promotes cartilage degradation via increased synthesis of matrix-degrading enzymes. It 
functions alongside other proinflammatory cytokines of the IL and TNF family to exert their catabolic effect on OA chondrocytes. Figure redrawn with 





Transcription factors play significant roles in cartilage development and chondrogenesis and 
they are also implicated in OA pathogenesis. SOX9, which is the master regulator in cartilage 
development, is upregulated in early OA which leads to increased synthesis of ECM 
components such as collagen type II and aggrecan (Zhang et al., 2015a). This increased 
expression is probably an attempt of the tissue to compensate for the cartilage loss during 
the early disease stages. As OA develops further, expression of SOX9 decreases along with 
collagen type II and aggrecan (Zhang et al., 2015a). Moreover, a usual feature of OA cartilage 
is hypertrophy of chondrocytes and apoptosis which closely resembles the process of 
endochondral ossification during long bone development. RUNX2 is a pivotal transcription 
factor during this process and it has also been linked to molecular changes seen in OA. RUNX2 
expression is increased in OA cartilage and it was shown that this increased expression was 
positively correlated with OA grading (Zhong et al., 2016). RUNX2 can induce the expression 
of matrix-degrading enzymes and collagen type X contributing to chondrocyte hypertrophy 
and osteophyte formation (Neefjes et al., 2020, Nishimura et al., 2020). CCAAT enhancer 
binding protein beta (C/EBPβ), a transcriptional partner of RUNX2, is also implicated in OA 
and it is believed to act along RUNX2 to bind the MMP13 gene to induce its expression 
(Nishimura et al., 2020). Hypoxia-inducible factor (HIF) 2α is another transcription factor that 
can bind elements on the MMP3, MMP13, collagen type X alpha 1 chain (COL10A1) and 
VEGFA gene promoters and induce their expression in OA (Goldring et al., 2016). In addition, 
HIF2α can also act as an upstream regulator of C/EBPβ and contribute to cartilage degradation 




1.6.1 MicroRNA general remarks and biogenesis  
 
Cellular function is highly determined by the information that lies within the genome of an 
organism. From the simplest life forms to the most complex organisms, genes play the most 
crucial role in development. Some genes are transcribed into RNA, and RNA is translated into 




involved in all stages of life cycle. However, for some genes, the process of gene expression 
stops at the RNA level and the end-product is RNA and not protein. These RNA molecules are 
called non-coding RNAs because they do not code for proteins. Instead, they have other 
regulatory or structural roles in the cell. Dependent on their sequence length, non-coding 
RNAs are divided into long coding RNAs (lncRNAs), which are longer than 200nt, and small 
non-coding RNAs (sncRNAs), which are shorter than 200nt. There are different types of 
sncRNAs, including miRNAs, small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), 
transfer RNAs (tRNAs), piwi-interacting RNAs (piRNAs) and others. Among these, miRNAs are 
the most researched sncRNAs in development and disease.  
miRNAs are short in length, between 17 and 25nt long, with an average length of 22nt. They 
are epigenetic, post-transcriptional regulators of gene expression and they function by 
targeting complementary sequences in mRNA targets leading to translational repression 
and/or mRNA decay (Matsuyama et al., 2019). The first miRNA was discovered in 
Caenorhabditis elegans and was transcribed by gene lin-4 (Lee et al., 1993). Since then, 
multiple miRNAs have been discovered in plants and animals, and some miRNAs have been 
found in protists and viruses (Ha et al., 2014). Specifically, in humans, there is an estimate of 
2300 true miRNAs (Alles et al., 2019).  
miRNA genes are located throughout the genome. In humans, most of the miRNAs are 
transcribed by genes located within regions of other non-coding genes or within introns of 
coding genes. However, some miRNAs are located within exons of other genes (Ha et al., 
2014). Moreover, miRNA genes can be organised individually in a locus (monocistronic), or in 
clusters (polycistronic) (Matsuyama et al., 2019). Biogenesis of canonical miRNAs involves 
several steps (Figure 1.13). miRNAs are transcribed into long primary miRNA (pri-miRNA) 
transcripts, by RNA polymerase II. Pri-miRNAs are approximately 33bp double-strand stems 
with hairpin structures which undergo cleavage by the microprocessor complex in the nucleus 
(Matsuyama et al., 2019). The microprocessor complex consists of two proteins, DROSHA, an 
RNase III endoribonucleolytic enzyme, and DiGeorge critical region 8 (DGCR8), which is a 
double-strand RNA-binding protein. DGCR8 positions the pri-miRNAs in such way, so that 
DROSHA cleaves the molecule at a specific site, 11bp away from the base of the hairpin 




~70nt stem-loop that has a 3’ overhang. Pre-miRNAs exit the nucleus and are exported to the 
cytoplasm via exportin-5.  
 
Figure 1.13. miRNA biogenesis. miRNA biogenesis is a multi-step process where the initial 
long miRNA transcript is cleaved sequentially to form the mature miRNA. The process begins 
in the nucleus and is finalised in the cytoplasm and includes several different proteins. The 
mature miRNA is incorporated into the RISC complex to exert its function on the mRNA target. 
Figure copied with permission from (Matsuyama et al., 2019) (No special permission is 
required to reuse all or part of article published by MDPI, including figures and tables). 
 
In the cytoplasm, pre-miRNAs are cleaved further by another endoribonucleolytic enzyme 
with RNase III activity, DICER (Yates et al., 2013). After cleavage, there is a ~22nt RNA duplex 
left with 3’ overhangs at both ends. This RNA duplex is loaded into an Argonaute (Ago) protein 
to form the RNA-induced silencing complex (RISC). From the two strands of the RNA duplex, 
the one complementary to the mRNA target (called the guide strand) is selected, whereas the 
other strand (called the passenger strand) is quickly discarded and degraded (Matsuyama et 
al., 2019, Yates et al., 2013). The guide RNA strand that remains, is the mature miRNA. 
Depending on the mRNA target, both strands of the RNA duplex within the RISC complex have 




from the 5’ arm of the RNA duplex is annotated with the suffix -5p, whereas the one that 
arises from the 3’ arm is annotated with the suffix -3p (Matsuyama et al., 2019).  
 
1.6.2 MicroRNA and mRNA pairing: microRNA function 
 
miRNAs have emerged as potent gene regulators. They act at the post-transcriptional level by 
binding their mRNA targets at the 3’ untranslated region (UTR). Complementarity between 
the mature miRNA and mRNA differs and is based on miRNA/mRNA sequence and species. In 
plants the mature miRNA usually has perfect complementarity to the mRNA target sequence. 
In contrast to plants, in animals there is usually partial pairing between the miRNA and the 
mRNA target (Dexheimer et al., 2020). Nucleotides 2 to 7 or 2 to 8 relative to 5’ end of the 
mature miRNA are called the ‘seed’ region and are the most important for miRNA/mRNA 
pairing. Even though in animals there may not be perfect complementarity between the 
entire miRNA sequence and the mRNA target, the seed sequence is usually perfectly 
complementary to the mRNA sequence. If there is a mismatch between the seed region and 
the mRNA target, then this is compensated by near-perfect complementarity between the 3’ 
end of the miRNA and the mRNA sequence (Huang et al., 2010) (Figure 1.14). Because miRNA-
mRNA pairing is primarily dependent on the 7 or 8 nucleotides of the seed region, this means 
that a single miRNA can bind different mRNA targets, given the short length of the seed 
region. Moreover, the 3’ UTR of a single mRNA can be bound be many different miRNAs at 





Figure 1.14: The three main types of miRNA and mRNA pairing in animals. A. The 5’ 
dominant canonical type: There is perfect or near perfect complementarity between the 
miRNA/mRNA duplex with a mismatch (bulge) in the middle of the duplex. B. The 5’ dominant 
seed only type: There is perfect complementarity between the seed region of the miRNA and 
the mRNA but several mismatches closer to 3’ end. C. The 3’ compensatory type: There is a 
mismatch between the seed region of the miRNA and the mRNA target which is compensated 
by perfect complementarity at the 3’ end of the miRNA. Figure copied with permission from 
(Huang et al., 2010) (License Number: 4987860749835).  
 
Perfect or near perfect complementarity between the miRNA and the mRNA in plants leads 
to mRNA cleavage by Ago of the RISC complex due to its 5’ to 3’ exonuclease activity (Iwakawa 
et al., 2015). However, in animals, due to only partial complementarity the mode of action is 
different. There are two proposed modes of miRNA-induced silencing of gene expression in 
animals: translational repression and mRNA decay (Dexheimer et al., 2020). The relative 
contribution of each mechanism is still unclear. At first, it was believed that silencing was 
achieved by translational repression without any effect on the mRNA level. However, this 
could not account for the extensive transcriptomic changes seen in some studies when miRNA 




where a miRNA could induce moderate silencing of its targets by affecting protein levels 
through translational repression and only the targets that were highly repressed showed 
reduction at mRNA level too. In addition, polysome analysis concluded that changes at the 
protein level were only modest and that mRNA level changes were more profound. However, 
these studies did not take into account different transcript isoforms and their contribution to 
gene expression and protein synthesis. When accounted for these isoforms, changes at 
protein levels became more apparent. Thus, it is clear that neither the mechanism of 
translational repression nor that of mRNA decay alone can explain all the available data 
(Cloonan, 2015). It is generally accepted that these two mechanisms work together to induce 
gene silencing and they are closely linked. Current data suggests that translational repression 
precedes mRNA decay and occurs in a rapid manner but has a modest effect, followed by 
mRNA decay which comes later and has a more substantial role in gene silencing (Dexheimer 
et al., 2020, Iwakawa et al., 2015). However, this also depends on the cell type, developmental 
stage, miRNA-RISC context, as well as position and number of miRNA binding sites (Dexheimer 
et al., 2020, Iwakawa et al., 2015).  
The mechanisms through which miRNAs induce gene silencing through translational 
repression and mRNA decay are also under investigation. In both proposed models, a protein 
called Gawky or GW182 in Drosophila melanogaster, and its human ortholog, trinucleotide 
repeat containing adaptor 6 (TNRC6), is a key protein in miRNA-induced gene silencing 
(Iwakawa et al., 2015). In mRNA decay, GW182 acts as a recruiter protein by recruiting two 
deadenylase complexes to the mRNA target, the Carbon Catabolite Repression-Negative On 
TATA-less (CCR4-NOT) complex and the Poly(A)-binding protein-dependent poly(A) 
ribonuclease (PAN)2-PAN3 complex (Iwakawa et al., 2015). These two complexes function by 
inducing shortening of the poly(A) tail resulting in mRNA destabilisation. Destabilised mRNAs 
are subjected to oligouridylation by terminal uridylyl transferase (TUT) 4/7 and are targeted 
for degradation (Iwakawa et al., 2015). mRNA decay is further promoted by decapping of the 
5’ end of the mRNA target by decapping activators, such as DEAD-box helicase 6 (DDX6), 
which are recruited onto the CCR4-NOT complex (Iwakawa et al., 2015).  
Translational repression probably occurs at the initiation step and three mechanisms have 
been proposed as to how this is accomplished: i) GW182-mediated poly(A) binding protein 




dissociation of eukaryotic translation initiation factor (eIF) 4A  from the cap-binding complex 
eIF4F (Iwakawa et al., 2015). GW182 directly interacts with PABP and promotes its 
dissociation from the poly(A) tail, thus disrupting mRNA translation (Iwakawa et al., 2015). 
Moreover, GW182 can recruit translational repressors to the mRNA target, such as eIF4E-
Transporter (4E-T), which is recruited to the CCR4-NOT complex through DDX6 and represses 
translation. This highlights how closely linked mRNA decay and translational repression are, 
since both modes of silencing share common mechanisms. The last mechanism through which 
translational repression is achieved, is through dissociation of eIF4A from the eIF4F cap-
binding complex. EIF4A functions by recruiting the ribosome to the mRNA target and 
dissociation of eIF4A promotes translational repression of the mRNA target.  
Figure 1.15 illustrates the two proposed models of mRNA decay and translational repression 






Figure 1.15: miRNA-induced gene silencing is mediated through mRNA decay and 
translational repression. mRNA decay is mediated through deadenylation of the mRNA target 
through GW182 protein in Drosophila, and TNRC6 in humans, which recruits the CCR4-NOT 
and PAN2-PAN3 complexes for poly(A) tail removal. Translational repression occurs through 
three mechanisms: dissociation of PABP, recruitment of translational repressors such as 4E-T 
and DDX6 (which is also a de-capping activator promoting mRNA decay) and dissociation of 
eIF4A, a factor which assists in ribosomal recruitment (43S preinitiation complex (43S PIC)). 
The first two mechanisms of translational repression are also mediated via GW182/TNRC6, 
whereas the last one via an independent manner. Both mRNA decay and translational 
repression work together to achieve miRNA-induced gene silencing. Figure modified with 





1.6.3. MicroRNA databases, nomenclature and target prediction tools 
 
miRNAs have attracted a lot of attention since their discovery in Caenorhabditis elegans in 
1993 (Lee et al., 1993). It is estimated that approximately 60% of protein-coding transcripts 
in human are subjected to miRNA regulation, which highlights their biological significance 
(Dexheimer et al., 2020). Moreover, miRNAs seem to be quite conserved among different taxa 
of organisms (Dexheimer et al., 2020). This holds true, especially for the seed region which is 
the most conserved site in the miRNA sequence. Apart from the seed region, some miRNAs 
show conservation in their entire sequence across a large evolutionary distance. For example, 
miRNA let-7 is exactly the same from worms to humans, which highlights the significance of 
not just the seed sequence, but of the entire let-7 sequence across evolution (Pasquinelli et 
al., 2000). Therefore, it comes as no surprise that research on miRNAs has increased 
substantially in the last few years due to their role in gene expression regulation. 
Subsequently, the number of annotated miRNAs in different species has also increased. To 
account for the growing number of novel miRNAs and the need of researchers to have a 
common point of reference for miRNA-related information, the miRBase database was 
created (Griffiths-Jones et al., 2006, Kozomara et al., 2019). miRBase contains information on 
miRNA annotation, sequence and genomic location of pre-miRNAs and mature miRNAs from 
hundreds of organisms. The user has access to both mature miRNA forms (5p and 3p) that 
arise from the same stem-loop hairpin sequence. Furthermore, the data can be downloaded 
and the database provides links to open-access research papers that are relevant to the 
miRNA of interest. The newest released version is miRBase 22.1 (up until the writing of this 
section) and contains information for 271 organisms, 38589 pre-miRNAs and 48860 mature 
miRNAs (Kozomara et al., 2019, Shaker et al., 2020).  
Moreover, miRBase offers information on miRNA nomenclature. Mature miRNAs are named 
by using the prefix ‘miR’, followed by a hyphen (-) and the number of the miRNA, followed by 
a hyphen and ‘5p’ or ‘3p’ (if known), depending on whether the mature miRNA comes from 
the 5p or the 3p arm of the pre-miRNA. A three-letter code at the beginning of the mature 
miRNA name can be used to denote the species. For example, hsa-miR-221-5p, is the Homo 
sapiens mature miRNA 221 that arises from the 5p arm of the pre-miRNA 221. The pre-




(Ambros et al., 2003). miRNAs that have the same seed region but differ in other parts of the 
miRNA sequence constitute a miRNA family (Dexheimer et al., 2020). These miRNAs arise 
from gene duplication events and the members are usually named by using the same number. 
A letter after the number is used to distinguish between members of a miRNA family, for 
example, hsa-miR-30a-5p and hsa-miR-30b-5p. An exception to the above nomenclature rules 
is miRNA family let-7. miRNA let-7 was first discovered in Caenorhabditis elegans and retains 
the same name in other species too, without prefix ‘miR’.  
miRNAs target mRNAs based primarily on complementarity. Elucidating the role of miRNAs 
requires extensive knowledge of their mRNA targets via which they exert their function. The 
first step is understanding which mRNAs are targeted by miRNAs. To this direction, several 
online target prediction tools have been developed. These include: TargetScan (Agarwal et 
al., 2015), miRWalk (Dweep et al., 2015), miRmap (Vejnar et al., 2012), miRDB (Chen et al., 
2020), miRTar (Hsu et al., 2011) and several others (Huang et al., 2010, Shaker et al., 2020). 
These tools use a specific set of criteria to make predictions. The main criteria for predicting 
miRNA-mRNA interactions are usually three: i) miRNA-mRNA sequence complementarity, ii) 
amount of free energy of miRNA-mRNA duplex and iii) how conserved the miRNA-mRNA 
interaction is (Huang et al., 2010). The first criterion has been discussed above. On the free 
energy criterion, the lower the free energy an RNA-RNA duplex has, the more stable it is, and 
this is taken into account when predicting miRNA targets. In addition, the more conserved 
the binding interaction is, the higher the possibility it represents a true interaction (Huang et 
al., 2010). Each tool has a different interface, gives the user different options to choose from 
and presents results in its own characteristic way. Therefore, each tool comes with its own 
advantages and disadvantages and, even though they have contributed significantly to miRNA 
target validation, it is worth noting that they also produce many false positives, at a rate that 
ranges between 20 and 50% (Cloonan, 2015). This constitutes experimental validation of a 
predicted miRNA target a necessity in miRNA research (Shaker et al., 2020).  
In addition to the online predicting tools, there are also online databases which list 
experimentally validated targets of miRNAs, such as DIANA-TarBase (Karagkouni et al., 2018) 
and miRTarBase (Chou et al., 2018). These databases also list the experimental approach via 




ontology and others. Finally, databases on miRNA expression, function, networks and disease 
pathways have also been developed in the last few years (Shaker et al., 2020).  
 
1.6.4 miRNAs in cartilage development and homeostasis 
 
miRNA research has shown that these molecules play important roles in organism 
development and disease. Their expression and function are regulated in a temporal and 
spatial manner by several different ways and dysregulation of their normal function can 
disrupt homeostasis and contribute to disease (Ha et al., 2014, Matsuyama et al., 2019). 
miRNAs play an important role in the skeletal system and specifically cartilage and bone 
development. Chondrocyte-specific deletion of DICER in the growth plate of mice reduced the 
number of proliferating chondrocytes, increased hypertrophic chondrocytes and led to severe 
skeletal defects and premature death (Kobayashi et al., 2008). DICER is a key protein for 
miRNA biogenesis, thus ablation of the gene that encodes for it leads to dysfunctional miRNA 
biogenesis. In the previous study, DICER-deficient chondrocytes demonstrated very low levels 
of miRNA expression compared to control (Kobayashi et al., 2008). 
One of the most important miRNAs in cartilage is miR-140, as it has multiple roles in 
maintaining chondrocyte homeostasis. miR-140 expression is regulated by SOX9, the master 
transcription regulator of chondrogenesis (Miyaki et al., 2010), but it was reported that miR-
140 can also regulate SOX9 expression, indicating a reciprocal regulation between miR-140 
and SOX9. Decreased miR-140 expression correlated with decreased SOX9 and aggrecan 
levels and it was found that this was mediated through targeting of RAS like proto-oncogene 
A (RALA) (Karlsen et al., 2014). Moreover, miR-140 inhibited chondrocyte hypertrophy and 
promoted chondrocyte proliferation through inhibiting histone deacetylase (HDAC) 4 in 
mouse embryos, providing further evidence on the role of miR-140 in cartilage development. 
This was also supported by a study in which mice that overexpressed miR-140 displayed 
resistance to antigen-induced arthritis (Miyaki et al., 2010). In the same study, mice lacking 
miR-140 expression showed mild skeletal abnormalities and were more prone to spontaneous 
OA (Miyaki et al., 2010). These results were attributed to miR-140 targeting ADAMTS5, a 
















Figure 1.16. Example of miRNA regulation in chondrogenesis. Chondrogenesis and 
chondrocyte homeostasis are regulated by several miRNAs. Some of these promote 
chondrocyte proliferation and cartilage formation exerting an anabolic effect, whereas other 
exert a catabolic effect when needed. Many miRNAs have been reported to have a role in this 
process by targeting genes and pathways important for chondrocyte proliferation and 
apoptosis. Abbreviations: Platelet derived growth factor receptor alpha (PDGFRα), Insulin-like 
growth factor binding protein (IGFBP), Aspartyl aminopeptidase (DNPEP), Sp1 transcription 
factor (SP1), Cartilage oligomeric matrix protein (COMP), Collagen type II alpha 1 chain 
(COL2A1), Collagen type IX alpha 2 chain (COL9A2), Aggrecan (ACAN). Figure copied with 
permission from (Asahara, 2016) (This is an Open Access article distributed under the terms 
of the Creative Commons Attribution Non-Commercial License which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium, provided the original 






miR-140 is not the only miRNA that has a role in cartilage development. miR-23b was shown 
to promote differentiation of human MSCs into chondrocytes and, thus, promote 
chondrogenesis, by targeting protein kinase A (PKA) (Ham et al., 2012). miR-488 and miR-21 
were also reported to be positive regulators of chondrogenesis by targeting different genes 
(Liu et al., 2018, Song et al., 2013). Other in vitro studies have also revealed the positive 
regulation of chondrogenesis by more miRNAs, such as miR-199a, miR-130b, miR-152, miR-
28, miR-26b, miR-455 (Asahara, 2016). However, as discussed earlier, chondrogenesis and 
endochondral ossification is a tightly regulated process, with stages of chondrocyte 
proliferation and chondrocyte hypertrophy and apoptosis. Therefore, miRNAs can also have 
a negative effect on cartilage development. miR-145 reduced levels of collagen type II and 
aggrecan and increased levels of RUNX2 and MMP13 in human articular chondrocytes by 
directly targeting SOX9 (Martinez-Sanchez et al., 2012). In addition, miR-29a had a negative 
effect on differentiation of human MSCs into chondrocytes by targeting forkhead box O3 A 
(FOXO3A) and repressing the expression of cartilage-specific markers (Guérit et al., 2014). It 
is, therefore, inferred that chondrogenesis is under the control of both transcriptional and 
epigenetic regulation through various transcription factors and signalling pathways, but also 
via the numerous miRNAs that regulate such pathways, suggesting an even more complex 
landscape in cartilage development (Figure 1.16).  
 
1.6.5 miRNAs in cartilage ageing 
 
Ageing is the main risk factor for OA. Several cellular pathways are altered with ageing 
predisposing to disease. miRNA expression is also altered with ageing in many tissues 
including the musculoskeletal system (Weilner et al., 2015). While there are numerous 
published articles on miRNAs and OA, there are very few studies on miRNAs and ageing 
cartilage or chondrocytes without the effect of OA. Ukai et al (2012), by using microarrays, 
compared miRNA expression between chondrocytes isolated from the fingers of infants 
diagnosed with polydactylism (average age: 13 months) and normal, non-load bearing 
articular cartilage from young patients undergoing ACL reconstruction (average age: 22.3 




and decreased expression of miR-320c in the ACL group compared to the infant group. By 
overexpressing miR-199a-3p and miR-193b in chondrocytes, they detected reduced 
expression of COL2A1, ACAN and SOX9 compared to control, whereas the opposite occurred 
when inhibiting the expression of these two miRNAs in chondrocytes. Furthermore, when 
they overexpressed miR-320c, the group reported reduced expression of ADAMTS5, whereas 
the opposite was shown when they inhibited miR-320c (Ukai et al., 2012). The group 
concluded that miR-199a-3p and miR-193b are potentially involved in chondrocyte 
senescence, and miR-320c in chondrogenesis. 
In addition, Peffers et al (2013) by using RNA-Seq between young (4 years) and old (>15 years) 
normal cartilage samples from the metacarpophalangeal joints of horses, detected 
significantly higher expression of miR-21 in the old group, proposing that this miRNA could 
potentially be involved in cartilage ageing (Peffers et al., 2013).  
 
1.6.6 miRNAs in OA cartilage 
 
In many tissues, miRNAs play important roles in maintaining homeostasis. Therefore, 
dysfunctional miRNA network could contribute to disease and, vice versa, disease could lead 
to dysfunctional miRNA network. There is a significant amount of research on the role of 
miRNAs in OA (Jeffries, 2019, Reynard et al., 2020). Dozens of miRNAs have been implicated 
in OA, either having a protective or a destructive role in cartilage (Table 1.7), and usually 
linked to important cellular processes, such as inflammation, autophagy and senescence 
(Endisha et al., 2018). Genome and proteome-wide analyses, such as RNASeq/small RNASeq, 
microarrays and LC-MS/MS, have made it possible to analyse for thousands of miRNAs and 
target genes at the same time, contributing to the exponentially increasing evidence in this 
field. miR-92a-3p was reported to be downregulated in human OA cartilage and in cells 
treated with IL-1β, leading to increased expression of its target genes: ADAMTS4, ADAMTS5 
and HDAC2 (Endisha et al., 2018). Moreover, miR-502-5p, which protects cartilage by 
targeting TNF receptor-associated factor (TRAF) 2 and inhibiting NF-κB signalling, is also 
downregulated in human OA cartilage, leading to increase NF-κB signalling and expression of 
matrix-degrading enzymes (Zhang et al., 2016). miR-98 and miR-34a promoted apoptosis and 




inducible (iNOS), respectively (Endisha et al., 2018). However, in some cases, studies have 
reported controversial results regarding specific miRNAs. In one study, miR-145 was 
downregulated in human OA cartilage and TNF-α-treated rat chondrocytes (Hu et al., 2017b), 
whereas in another study, the same miRNA was upregulated in human OA cartilage and IL-
1β-treated chondrocytes (Yang et al., 2014). These differences could be due to study designs, 
experimental approach and donor variability. 
 
Table 1.7: List of miRNAs implicated in OA. Table compiled with information from (Endisha 











































































The clinical value of miRNAs in OA lies within their use as prognostic or disease-monitoring 
biomarkers and their potential use as therapeutic agents. miRNAs are stable, sensitive to 
disease changes and easy to detect in body fluids, thus making them suitable candidates for 
disease biomarkers by using non interventional approaches (Bottani et al., 2020). Indeed, 
there is great need to discover miRNAs that could be used to discriminate between healthy 
subjects and OA patients, but also between different stages of OA, as symptoms are usually 
diagnosed after cartilage has been affected beyond repair (Endisha et al., 2018). Several 
studies have tested the potential use of circulating cell-free miRNAs as biomarkers in synovial 
fluid and serum/plasma. By using microarrays, a study found that seven miRNAs (miR-23a-3p, 
24-3p, 27a-3p, 27b-3p, 29c-3p, 34a-5p and 186-5p) were DE in synovial fluid from patients 
with early-stage OA (KL score I/II) compared to late-stage OA (KL score III/IV) (Li et al., 2016). 
In the same study, miR-378-5p was detected in late-stage OA samples only, providing 
evidence of a potential miRNA biomarker in differentiating OA stages and disease 
progression. Moreover, miRNAs can be packed in extracellular vesicles, called exosomes, 
which are produced by one cell type and can travel to target cells to elicit a specific response. 
Withrow et al (2016) found that the miRNA content of synovial fluid exosomes was different 
in patients with OA compared to age-matched normal controls and some miRNAs were DE 
between the two groups (Withrow et al., 2016). Interestingly, some miRNAs may be possible 
to distinguish between different diseases that affect the musculoskeletal system. For 
example, miR-16, miR-146a, miR-155 and miR-223 were significantly higher in synovial fluid 
from rheumatoid arthritis patients compared to OA patients (Murata et al., 2010).  
Studies in serum/plasma have also shed light on the potential use of circulating miRNAs as 
biomarkers. Ntoumou et al (2017) used a microarray platform to assess circulating miRNAs in 
the serum of OA patients and controls and identified 279 DE miRNAs. Among these, miR-140 
was identified as significantly downregulated in OA patients in accordance with previous 
reports from cartilage tissue (Ntoumou et al., 2017). In a similar study between OA patients 




miRNAs were predicted to target genes important for cartilage metabolism (Borgonio Cuadra 
et al., 2014). Furthermore, miRNAs could be used for monitoring disease severity. In another 
microarray study by Kong et al (2017), plasma circulating miRNAs miR-19b-3p, miR-122-5p 
and miR-486-5p were independent risk factors for OA and miR-19b-3p and miR-486-5p were 
positively correlated to disease severity (Kong et al., 2017). However, no common circulating 
miRNAs were discovered between all the above studies. Five miRNAs (miR-122, miR-885, miR-
140, miR-93 and miR-663a) were common in two of the studies, which might offer some 
direction on future experiments regarding the use of circulating miRNAs as OA biomarkers 
(Swingler et al., 2019).  
Finally, miRNAs could be used in OA therapeutics, either by using overexpression or inhibiting 
agents, dependent on the action of the miRNA. These can be delivered directly into the joint 
via intra-articular injections or via lentiviral vectors (Swingler et al., 2019). One potential 
problem is the uptake of the construct by cartilage. Even though there have been successful 
trials of delivery in mouse and rat joints, it is still doubtful whether these can be applied to 
man (Swingler et al., 2019). An alternative way is the use of exosomes for miRNA delivery. 
Indeed, they have been successful studies in which exosomes produced by MSCs treated with 
overexpressing or inhibiting miRNA agents were delivered and taken up by chondrocytes in 
mouse and rat models (Mao et al., 2018, Tao et al., 2017). Yet, it is still a long way before 























2-Mercaptoethanol  Sigma-Aldrich, Dorset, UK 
Acetic acid  Fisher Scientific, Loughborough, UK 
Acid alcohol  Leica Biosystems, Milton Keynes, UK 
Acid-phenol:chloroform  Sigma-Aldrich, Dorset, UK 
Affymetrix FlashTag™ Biotin HSR RNA Labeling Kit  ThermoFisher Scientific, Paisley, UK 
Alcoholic eosin  Leica Biosystems, Milton Keynes, UK 
Ammonium Bicarbonate  Sigma-Aldrich, Dorset, UK 
Amphotericin B/fungizone  Gibco/ThermoFisher Scientific, Paisley, UK 
Benzonase nuclease  Biocompare, San Francisco, USA 
Cap-Clip Acid Pyrophosphatase  Cellscript, Madison, USA 
Chloroform  Sigma-Aldrich, Dorset, UK 
Collagenase type 2 Worthington  Biochemicals, Danehill, UK 
cOmplete™ ULTRA, EDTA-free, tablet of protease 
inhibitor cocktail  
Roche Life Science, Penzberg, Germany 
 
Coomassie Brilliant Blue R-250 Destaining Solution  Bio-Rad, Watford, UK 
Coomassie Brilliant Blue R-250 Staining Solution  Bio-Rad, Watford, UK 
Dithiothreitol  Sigma-Aldrich, Dorset, UK 
DNase I  Qiagen, Manchester, UK 
Dulbecco’s phosphate buffered saline  Sigma-Aldrich, Dorset, UK 
Dulbecco's Modified Eagle Medium  ThermoFisher Scientific, Paisley, UK 
Ethanol  Fisher Scientific, Loughborough, UK 
Ethanol-molecular biology grade  Fisher Scientific, Loughborough, UK 
Fast-green solution  Sigma-Aldrich, Dorset, UK 
Foetal bovine serum  Gibco/ThermoFisher Scientific, Paisley, UK 
GlycoBlue™ Coprecipitant  Invitrogen by ThermoFisher Scientific, 
Paisley, UK 




HiPerFect Transfection Reagent  Qiagen, Manchester, UK 
Recombinant Human IL-1 beta R&D Systems, Abingdon, UK 
Iodoacetamide  Sigma-Aldrich, Dorset, UK 
Isopropanol  Sigma-Aldrich, Dorset, UK 
Kapa Library Quantification Kit  Roche Life Science, Penzberg, Germany UK 
L-glutamine  Gibco/ThermoFisher Scientific, Paisley, UK 
miRNeasy Mini Kit  Qiagen, Manchester, UK 
mirVana™ miRNA Isolation Kit with phenol  Ambion by Life Technologies, Paisley, UK 
miScript II RT Kit  Qiagen, Manchester, UK 
miScript SYBR® Green PCR Kit  Qiagen, Manchester, UK 
M-MLV reverse transcriptase  Promega, Southampton, UK 
M-MLV 5X Reaction Buffer  Promega, Southampton, UK 
NEBNext® Small RNA Library Prep Set for 
Illumina®/Multiplex Compatible  
New England Biolabs, Herts, UK 
 
Novex™ Sharp Pre-stained Protein Standard ladder  ThermoFisher Scientific, Paisley, UK 
Novex™ Tris-Glycine SDS Sample Buffer  ThermoFisher Scientific, Paisley, UK 
NuPAGE® MES Running Buffer  ThermoFisher Scientific, Paisley, UK 
NuPAGE™ 4% to 12% (w/v), Bis-Tris gel  ThermoFisher Scientific, Paisley, UK 
PBS containing 0.1% (w/v) Bovine Serum Albumin  R&D Systems, Abingdon, UK 
PCR Nucleotide Mix  Promega, Southampton, UK 
Penicillin-streptomycin  Gibco/ThermoFisher Scientific, Paisley, UK 
Pierce Silver Stain Kit  ThermoFisher Scientific, Paisley, UK 
Pierce™ 660nm Protein Assay  ThermoFisher Scientific, Paisley, UK 
Pierce™ Water, LC-MS Grade  ThermoFisher Scientific, Paisley, UK 
Pre-diluted BSA protein assay standards  ThermoFisher Scientific, Paisley, UK 
QIAquick PCR Purification Kit  Qiagen, Manchester, UK 
Qubit® dsDNA HS Assay Kit  ThermoFisher Scientific, Paisley, UK 




Random Primers  Promega, Southampton, UK 
RNaseZAP  Sigma-Aldrich, Dorset, UK 
RNasin(R) Plus RNase Inhibitor  Promega, Southampton, UK 
Safranin-O  Sigma-Aldrich, Dorset, UK 
Trifluoroacetic acid  Sigma-Aldrich, Dorset, UK 
TRIzol reagent  Ambion by Life Technologies, Paisley, UK 
Trypsin/Lys-C Mix, Mass Spec Grade  Promega, Southampton, UK 
Trypsin-Ethylenediaminetetraacetic acid  Sigma-Aldrich, Dorset, UK 
Xylene  Fisher Scientific, Loughborough, UK 
 
Instrument/Consumables Manufacturer 
96-well PCR plate  StarLab, Milton Keynes, UK 
Affymetrix GeneChip scanner 3000 7G  ThermoFisher Scientific, Paisley, UK 
Affymetrix GeneChip® miRNA 4.0 Arrays  ThermoFisher Scientific, Paisley, UK 
Affymetrix hybridisation oven 645  ThermoFisher Scientific, Paisley, UK 
Agilent 2100 Bioanalyser RNA Pico chips  Agilent, Stockport, UK 
Cell strainer  Fisher Scientific, Loughborough, UK 
ChemiDoc XRS+ Gel Imaging System  Bio-Rad, Watford, UK 
DNA high sensitivity Bioanalyzer chip  Agilent, Stockport, UK 
FLUOstar Omega Microplate Reader  BMG LABTECH, Aylesbury, UK 
GeneChip Fluidics station 450  ThermoFisher Scientific, Paisley, UK 
Haemocytometer  Hawksley, Sussex, UK 
Illumina MiSEq platform  Illumina, Cambridge, UK 
Leica CV5030 Fully Automated Glass Coverslipper  Leica Biosystems, Milton Keynes 
Leica ST5020 Multistainer  Leica Biosystems, Milton Keynes, UK 
LightCycler® 480 Instrument II  Roche Life Science, Penzberg, Germany 
LightCycler® 96 Instrument  Roche Life Science, Penzberg, Germany 




Mikro-dismembrator S  Sartorius, Melsungen, Germany 
Nanodrop 2000 Spectrophotometer  ThermoFisher Scientific, Paisley, UK 
Pippin Prep instrument  Sage Science, Beverly, USA 
Soniprep 150 ultrasonic disintegrator  MSE, East Sussex, UK 
T75/T175 flask  Greiner Bio-One, Stonehouse, UK 
 
2.1 Collection of human knee cartilage 
Human knee OA cartilage was collected from the femoral condyles of patients undergoing 
TKA and processed the same day. Human OA cartilage for microarray analysis in Chapter 3 
and subsequent validation with qPCR in Chapter 4, was collected by Tim Welting’s laboratory 
group at Maastricht University, Netherlands following ethical approval (Maastricht University 
Medical Centre approval IDs: MEC 08-4-028 and 14-4-038). Two cartilage samples were 
collected per patient: one sample from an intact area of femoral cartilage, and one sample 
from a lesioned area of femoral cartilage (Figure 2.1). Specifically, the medial and lateral 
femoral condyles were placed in saline and kept on ice until transferred in the laboratory. 
Then femoral condyles were placed in a class II laminar flow hood and transferred to petri 
dishes. Scalpels, cleaned with RNaseZAP (Sigma-Aldrich, Dorset, UK) to inactivate RNases, 
were used to collect cartilage from an intact area and a lesioned area. Excised cartilage tissue 


















2.2 Collection of intact/healthy knee cartilage from non-OA donors 
In the current thesis, three groups of human intact/healthy knee cartilage were collected: 
i) Young cartilage from patients undergoing ACL reconstruction, to include in 
microarray analysis in Chapter 3. Cartilage was collected from the area of the 
intercondylar notch (Figure 2.2) as a by-product of the procedure. Tissue was 
collected, snap-frozen and stored at -80°C by Tim Welting’s laboratory group at 
Maastricht University, Netherlands, following ethical approval (Maastricht 
University Medical Centre approval IDs: MEC 08-4-028 and 14-4-038). Samples 
were shipped to the Institute of Life Course and Medical Sciences, University of 
Liverpool, UK and further processed by the author. This group will be referred to 
throughout the thesis as Young intact cartilage.  
ii) Young cartilage from cadavers with no history of OA or knee disease. Samples were 
purchased from Proteogenex, USA and were collected from the lateral and medial 
femoral condyles of young non-OA cadavers with an unrelated cause of death. 
Therefore, ethical approval was not needed. This group was used for qPCR analysis 
Figure 2.1: Example of intact and lesioned human knee OA cartilage. Cartilage biopsies were collected from 
intact (red circle) and lesioned areas (black circle) of knee femoral condyles from end-stage OA patients, after 
surgery. Full thickness cartilage was collected (for lesioned cartilage, full thickness was collected when 





in Chapter 4 and will be referred to throughout the thesis as Young healthy 
cartilage. 
iii) Old cartilage from cadavers with no history of OA or knee disease. Samples were 
purchased from Proteogenex, USA and were collected from the lateral and medial 
femoral condyles of old non-OA cadavers with an unrelated cause of death. 
Therefore, ethical approval was not needed. This group was used for qPCR analysis 



















Figure 2.2: The intercondylar notch. The intercondylar notch in the human knee joint is 





2.3 Macroscopic scoring of human knee osteoarthritic cartilage 
Medial and lateral femoral condyles from human knee OA joints were scored macroscopically 
using the Outerbridge scoring system (Table 2.1) (Outerbridge, 1961). Samples were scored 
by two independent scorers at two different time points. Scorer agreement was calculated 
using Cohen's weighted kappa coefficient (Cohen, 1960), available here: (StatsToDo, 2020).  
 
Table 2.1: The Outerbridge scoring system. 
 
2.4 Paraffin embedding of human knee OA cartilage 
Paraffin embedding of human, intact and lesioned, knee OA cartilage was performed by Tim 
Welting’s laboratory group at Maastricht University, Netherlands. Paraffin blocks were 
shipped to the Institute of Life Course and Medical Sciences, University of Liverpool, UK and 
further processed by the author.  
 
2.5 Sectioning of human knee cartilage 
Sectioning of human knee cartilage (OA and healthy) was undertaken as follows: 
Grade Pathology 
0 Normal 
I Softening and swelling of articular cartilage 
II Fragmentation and fissuring of articular cartilage affecting an area of 
less than 0.5 inches 
III Fragmentation and fissuring of articular cartilage affecting an area of 
greater than 0.5 inches 




A) For histological analysis of knee OA cartilage, paraffin-embedded human knee OA 
cartilage, blocks were cooled at 4°C for 30min. Blocks were sectioned at 4μm using a 
Leica RM 2235 microtome (Leica Biosystems, Milton Keynes, UK). Sections were left 
to float on a water-bath for 2-3min to smooth out any wrinkles and then placed on 
microscope slides (ThermoFisher Scientific, Paisley, UK). Sections were left to dry on a 
warm surface for 15min and then at 37°C overnight. Once dried, sections were kept 
at room temperature.  
B) For histological analysis of young and old healthy human knee cartilage from cadavers, 
samples were cryosectioned using a Leica CM1520 cryostat (Leica Biosystems, Milton 
Keynes, UK). Temperature inside the cryostat was set to -20°C and tissue samples were 
kept frozen on dry-ice. Tissue was mounted on a cryostat chuck using tissue freezing 
medium (Leica Biosystems, Milton Keynes, UK). Tissue was sectioned at 10μm and 
sections were placed on microscope slides. Slides were either stained immediately or 
kept at -80°C for a short amount of time until staining. 
 
2.6 Haematoxylin and eosin staining 
Paraffin embedded sections of human knee OA cartilage were stained with H&E using the 
Leica ST5020 Multistainer (Leica Biosystems, Milton Keynes, UK) in conjunction with the Leica 
CV5030 Fully Automated Glass Coverslipper (Leica Biosystems, Milton Keynes, UK). 
Specifically, sections were placed at 37°C for 30min prior to staining to warm the wax around 
the section. Then, sections were placed in the following solutions for dewaxing: 
- 5min in xylene (x2) (Fisher Scientific, Loughborough, UK) 
- 5min in 100% (v/v) ethanol (Fisher Scientific, Loughborough, UK) 
- 5min in 90% (v/v) ethanol  
- 5min in 70% (v/v) ethanol  
After dewaxing, sections were washed with water for 10sec and then placed in Harris 
haematoxylin (Leica Biosystems, Milton Keynes, UK) for 7min. Excess of haematoxylin was 
washed away by placing the sections in water for 10sec and then in 1% (v/v) acid alcohol 




water for 5min and counter stained with alcoholic eosin (Leica Biosystems, Milton Keynes, 
UK) for 10min. Excess eosin was washed away with water for 10min and then sections were 
dehydrated by placing them in the following solutions: 
- 1min in 96% (v/v) ethanol (x2) 
- 1min in 100% (v/v) ethanol (x2) 
- 1min in xylene (v/v) (x2) 
Sections were covered with coverslips and left to dry in the fume hood overnight.  
Cryosections of young and old healthy knee cartilage from cadavers were stained with H&E 
following the same process, except for the dewaxing steps. Cryosections were placed straight 
in ethanol instead of xylene. Aibek Smagul, PhD Student, University of Liverpool, sectioned 
and stained young healthy cartilage samples.  
 
2.7 Safranin-O and fast-green staining 
Paraffin embedded sections of human knee OA cartilage were stained with Saf-O/FG using 
the Leica ST5020 Multistainer (Leica Biosystems, Milton Keynes, UK) in conjunction with the 
Leica CV5030 Fully Automated Glass Coverslipper (Leica Biosystems, Milton Keynes, UK). As 
with H&E staining, sections were placed at 37°C for 30min prior to staining to warm the wax 
around the section. Then, sections were placed in the following solutions for dewaxing: 
- 10min in xylene (x2)  
- 2min in 100% (v/v) ethanol  
- 2min in 90% (v/v) ethanol  
- 2min in 70% (v/v) ethanol  
After dewaxing, sections were placed in Harris haematoxylin for 30sec and then washed with 
water for 5min. Sections were stained with 0.2% (w/v) fast-green solution (Sigma-Aldrich, 
Dorset, UK) for 10min and then placed in 1% (v/v) acetic acid (Fisher Scientific, Loughborough, 
UK) for 20sec (x2). Sections were washed shortly with water for 10sec and then stained with 
0.5% (w/v) safranin-O solution (Sigma-Aldrich, Dorset, UK) for 2min. Sections were 




- 20 sec in 70% (v/v) ethanol 
- 2 min in 90% (v/v) ethanol 
- 2 min in 100% (v/v) ethanol 
- 3 min in xylene 
Sections were covered with coverslips and left to dry in the fume hood overnight.  
 
2.8 Histological scoring of human knee OA cartilage  
Human knee OA cartilage sections from intact and lesioned areas, stained with H&E and Saf-
O/FG, were scored using two scoring systems for comparison: the Mankin HHGS (Mankin et 
al., 1971) (Table 2.2) and the OARSI scoring system (Pearson et al., 2011) (Table 2.3). Sections 
were viewed using a Nikon Eclipse 80i microscope (Nikon, UK).  
Table 2.2: The Mankin HHGS was used to score human knee OA cartilage sections. Adapted 
from (Mankin et al., 1971).   
 Grade 
I. Structure  
h. Normal 0 
i. Surface irregularities 1 
j. Pannus and surface irregularities 2 
k. Clefts to middle zone 3 
l. Clefts to deep zone 4 
  
II. Cells  
e. Normal 0 
f. Diffuse hypercellularity 1 
g. Cloning 2 
h. Hypocellularity 3 
  
III. Safranin-O staining  
f. Normal  0 
g. Slight reduction 1 
h. Moderate reduction 2 
i. Severe reduction 3 






Table 2.3: The OARSI scoring system that was used to score stained human knee OA 
cartilage sections. Adapted from (Pearson et al., 2011).  
Grade (key feature) Associated criteria (tissue reaction) 
Grade 0: surface intact, 
cartilage morphology 
intact 
Matrix: normal architecture 
Cells: intact, appropriate orientation 
Grade 1: surface intact Matrix: superficial zone intact, oedema and/or superficial 
fibrillation (abrasion), focal superficial matrix condensation. 
Cells: death, proliferation (clusters), hypertrophy, superficial 
zone. Reaction must be more than superficial fibrillation 
only. 
Grade 2: surface 
discontinuity 
As above 
+Matrix discontinuity at superficial zone (deep fibrillation) 
±Cationic stain matrix depletion (Safranin-O) upper 1/3 of 
cartilage. 
±Focal perichondronal increased stain (mid zone). 
±Disorientation of chondron columns. 
Cells: death, proliferation (clusters), hypertrophy. 
Grade 3: vertical fissures 
(clefts) 
As above 
Matrix vertical fissures into mid zone, branched fissures. 
±Cationic stain depletion (Safranin-O) into lower 2/3 of 
cartilage (deep zone). 
Cells: death, regeneration (clusters), hypertrophy, cartilage 




Grade 4: erosion Cartilage matrix loss: delamination of superficial layer, mid 
layer cyst formation. Excavation: matrix loss superficial layer 
and mid zone. 
 
Cartilage samples collected as in Section 2.1 did not include the calcified zone or subchondral 
bone. Therefore, the Mankin HHGS scoring system used here did not include parameters ‘I.f’, 
‘I.g’, ‘IV.a’ and ‘IV.b’ as described in Table 1.4 of Chapter 1. Maximum score was 11. Similarly, 
the OARSI scoring system used here did not include grade 5 and 6, as described in Table 1.5 
of Chapter 1, since these refer to changes in the subchondral bone. Moreover, the OARSI 
scoring system used here did not include stage assessment, as this would require stained 
sections from the whole articular surface of femoral condyles which was not possible. 
Therefore, maximum score was 4. Sections were scored by two independent scorers, in two 
different time points. Scorer agreement was calculated using Cohen's weighted kappa 
coefficient (Cohen, 1960), available here: (StatsToDo, 2020) 
 
2.9 Isolation of human primary chondrocytes from articular cartilage  
For isolation of human primary OA chondrocytes, human OA cartilage was collected by the 
Liverpool Musculoskeletal Biobank, following Sponsorship Approval (Sponsor Ref: 
UoL001398) and Clatterbridge Hospital, Wirral following ethical approval (IRAS ID 242434; 
Main Investigator: Dr Simon Tew, Senior Lecturer, University of Liverpool). Isolation of human 
primary chondrocytes from cartilage tissue was carried out under sterile conditions in a class 
II laminar flow hood and all items were sprayed with 70% (v/v) ethanol prior to use to 
maintain sterility. Once tissue was transferred to the laboratory, it was placed in a sterile 
hood. A sterile scalpel was used to excise pieces of cartilage from the femoral condyles and 
remove the subchondral bone. To remove debris and blood, excised cartilage tissue was 
washed twice with sterile complete media consisting of Dulbecco's Modified Eagle Medium 
(DMEM) (ThermoFisher Scientific, Paisley, UK), with the following composition: 
- low glucose (1g/L) 




- 1% (v/v) L-glutamine 
- phenol-red (15mg/L) 
and supplemented with: 
- 10% (v/v) foetal bovine serum (FBS) (Gibco/ThermoFisher Scientific, Paisley, UK) 
- 1% (v/v) penicillin-streptomycin (P/S) (Gibco/ThermoFisher Scientific, Paisley, UK) 
- 0.2% (v/v) amphotericin B/fungizone (F/Z) (Gibco/ThermoFisher Scientific, Paisley, UK) 
Cartilage was cut into 2-3mm pieces and transferred in a 50mL falcon of complete media 
supplemented with 0.08% (w/v) collagenase type 2 (Worthington Biochemicals, Danehill, UK). 
The falcon was placed in a shaking incubator at 37°C overnight for tissue digestion and 
chondrocyte extraction from the ECM. Next day, the solution was passed through a 70μm 
sterile cell strainer (Fisher Scientific, Loughborough, UK) to remove undigested cartilage 
pieces. The solution was centrifuged at 1400 rounds per minute (rpm), at room temperature 
for 4min. Isolated chondrocytes were pelleted and supernatant removed. Chondrocytes were 
resuspended and washed in 5mL complete media and spun down as before. Supernatant was 
removed and chondrocytes were resuspended in 12mL complete media and transferred to a 
T75 flask (Greiner Bio-One, Stonehouse, UK) to attach. Flask was placed in a tissue culture 
incubator at 37°C, supplied with 20% (v/v) O2 and 5% (v/v) CO2.  
 
2.10 Isolation of healthy equine primary chondrocytes from cartilage tissue 
Healthy primary chondrocytes were isolated from the metacarpophalangeal joints of non-
Thoroughbred horses. The Animal (Scientific procedures) Act 1986, Schedule 2, does not 
define collection from these sources as scientific procedures. Ethical approval was therefore 
not required. Horses euthanised for other reasons were collected from the abattoir. Horse 
legs were cleaned and sprayed with 70% (v/v) ethanol. An incision was made across the leg 
using a scalpel to remove the skin around the joint. Then, the metacarpophalangeal joint 
cavity was opened using a sterile scalpel and the joint was inspected macroscopically for 
lesions and signs of cartilage degradation. Only healthy joints were selected and full thickness 
cartilage was excised and transferred to a laminar flow hood. Chondrocytes were isolated 




Chondrocytes in T175 flasks were placed in a tissue culture incubator at 37°C, supplied with 
20% (v/v) O2 and 5% (v/v) CO2. 
 
2.11 Human and equine chondrocyte culture and passaging 
After chondrocyte isolation, human and equine chondrocytes were placed in T75/T175 flasks 
to proliferate. Complete media was changed twice a week until chondrocytes reached 90% 
confluence. To collect or passage chondrocytes, media was removed and cells were washed 
twice with 5mL 1x Dulbecco’s phosphate buffered saline (DPBS) (Sigma-Aldrich, Dorset, UK). 
DPBS was removed and 5mL of 1x trypsin-Ethylenediaminetetraacetic acid (EDTA) (Sigma-
Aldrich, Dorset, UK) was added to the cells. Cells were placed at 37°C for 3min to detach from 
plastic and trypsin-EDTA was deactivated by adding 5mL of complete media. Cells were 
collected and centrifuged at 1400rpm for 4min. Supernatant was removed and cell pellet was 
resuspended in 5mL of complete media. Cells were counted with a haemocytometer 
(Hawksley, Sussex, UK) and cell number was calculated by using the formula below: 
total cell number: number of cells counted in four corner squares / 4 x 103 x initial volume 
Cells were either collected and lysed or seeded in well plates in appropriate density according 
to the experimental procedure downstream. Chondrocytes up to passage 1 were used for all 
experiments. 
2.12 Homogenisation of human knee cartilage tissue  
Due to its extensive ECM, human knee cartilage tissue needs to be ground before isolation of 
nucleic acids and especially RNA. Disruption and grinding of cartilage tissue were carried out 
using a mikro-dismembrator S (Sartorius, Melsungen, Germany). Approximately 100mg of 
tissue were used per sample. Prior to the procedure, the metallic flasks and grinding balls of 
the dismembrator were cleaned with RNaseZAP and autoclaved. On the day of the procedure, 
samples were cut into 2-3mm small pieces and kept in 1.5mL tubes and snap frozen in liquid 
nitrogen. Metallic flasks and grinding balls were also snap frozen in liquid nitrogen to maintain 
low temperature during grinding. By working fast, one sample at a time was placed in a clean 




dismembrator and cartilage tissue was grinded into powder at 2000rpm for 1min. 
Appropriate lysis buffer was added in the cartilage powder and transferred in a 1.5mL tube 
and kept on ice if RNA extraction was carried out on the same day, or stored at -80°C.  
 
2.13 Total RNA extraction from human knee cartilage tissue and 
human/equine chondrocytes 
For this thesis, total RNA, containing sncRNAs, was extracted in three different ways 
dependent on the downstream application. The mirVana™ miRNA Isolation Kit with phenol 
(Ambion by Life Technologies, Paisley, UK) was used for extracting total RNA from human 
knee articular cartilage for microarray analysis and subsequent qPCR validation in Chapter 3. 
The miRNeasy Mini Kit (Qiagen, Manchester, UK) was used for extraction of total RNA from 
equine primary chondrocytes for small RNA-Seq and subsequent qPCR validation in Chapter 
6. Finally, extraction of total RNA from samples that would be used for standard analysis, such 
as qPCR analysis in human articular cartilage and human primary chondrocytes in Chapter 4 
and 5, was carried out with the commonly used acid guanidinium thiocyanate-phenol-
chloroform method (Chomczynski et al., 1987), using TRIzol reagent (Ambion by Life 
Technologies, Paisley, UK) for cell lysis. DNase treatment was not performed except for RNA 
extraction from equine primary chondrocytes as it was required for the downstream small 
RNA-Seq experiment. In our experience, genomic DNA carry over is minimal and does not 
interfere with downstream analysis. Moreover, total RNA extraction from cartilage tissue 
does not produce high concentrations of RNA and during DNase treatment some amount of 
RNA is lost. Therefore, DNase treatment was omitted from all other RNA extraction methods 
as it could compromise the amount of total RNA isolated. Each method is analysed further 
below. 
 
2.13.1 Total RNA extraction from human knee articular cartilage tissue using the 
mirVana™ miRNA Isolation Kit with phenol  
 
Total RNA, intended for microarray analysis, was extracted from human knee articular 




protocol (Ambion, 2011), with minor modifications. Prior to RNA extraction, solutions ‘Wash 
solution 1’ and ‘Wash solution 2/3’ were prepared by adding 21mL and 40mL of 100% (v/v) 
molecular biology-grade ethanol (Fisher Scientific, Loughborough, UK). Human knee articular 
cartilage was ground into powder as described in Section 2.12. Then: 
- 1mL of Lysis/Binding Buffer was added to the powder and collected in 1.5mL tubes. 
Lysate was vortexed for 5min to aid tissue disruption.  
- 100μL of miRNA Homogenate Additive was added to the lysate and left at room 
temperature for 10min. Lysate was then vortexed and centrifuged at 13,000rpm at 
room temperature for 10min. Supernatant was collected in a fresh tube and cartilage 
powder at the bottom of the tube was discarded to avoid contamination of the 
supernatant.  
- An equal volume of acid-phenol:chloroform (Sigma-Aldrich, Dorset, UK) was added to 
the supernatant and sample was vortexed for 1min and centrifuged at 13,000rpm at 
room temperature for 5min to separate the aqueous and organic phases. The aqueous 
phase was transferred to a fresh tube without disturbing the organic phase.  
- 1.25x volumes of 100% (v/v) molecular biology-grade ethanol (room temperature) 
was added to the aqueous phase. Up to 700μL of sample was then transferred onto a 
filter cartridge placed in a collection tube and centrifuged at room temperature at 
10,000rpm for 15sec. Total RNA was captured on the filter cartridge and the flow-
through was discarded.  
- 700μL of Wash solution 1 was applied to the filter cartridge and centrifuged at 
10,000rpm for 10sec. Flow-through was discarded and 500μL of wash solution 2/3 was 
added and spun down at 10,000rpm for 10sec. This step was repeated with extra 
500μL of wash solution 2/3. Flow through was discarded. 
- Filter cartridge in the collection tube was centrifuged at 10,000rpm for 1min to 
remove any fluid left. Then, the filter cartridge was placed in a new collection tube.  
- 70μL of nuclease-free water, pre-heated at 95°C, was added onto the filter cartridge 
and sample was centrifuged at 13,000rpm for 1min to elute total RNA. Eluate with 
total RNA was kept on ice and the filter cartridge was placed in a new collection tube 
(Note: Elution buffer provided with the kit was avoided as it could potentially interfere 




- An extra 70μL of pre-heated nuclease-free water was added onto the filter cartridge 
and centrifuged as before to collect a second elution, for maximum total RNA 
recovery. 
- RNA concentration and purity were measured using a Nanodrop 2000 
Spectrophotometer (ThermoFisher Scientific, Paisley, UK). RNA was stored at -80°C.  
 
2.13.2 Total RNA extraction from equine primary chondrocytes using the miRNeasy Mini 
Kit 
 
Total RNA, intended for small RNA-Seq analysis, was extracted from equine primary 
chondrocytes using the miRNeasy Mini Kit, according to the manufacturer’s protocol (Qiagen, 
2020). Equine cells growing in T175 flasks were trypsinised and collected in complete media 
as described in Section 2.11. Cells were centrifuged at 1,400rpm at room temperature for 
4min and media was removed. 5mL of 1x DPBS was added to wash and resuspend the pellet 
and then cells were pelleted again as above. DPBS was removed and total RNA was extracted 
using the miRNeasy Mini Kit, including a DNase I (Qiagen, Manchester, UK) digestion step. 
Specifically, before starting the procedure, 2x and 4x volumes of 100% (v/v) molecular 
biology-grade ethanol was added to buffer RWT and buffer RPE, respectively. Lyophilised 
DNase I was dissolved in 550µl of RNase-free water and mixed gently by flicking the vial. Then: 
- 1mL of Qiazol Lysis Reagent was added to the cells. Sample was vortexed for 2min to 
lyse the cells. Lysate was placed at room temperature for 5min. 
- 200μL of chloroform (Sigma-Aldrich, Dorset, UK), was added to the lysate. Lysate was 
shaken vigorously for 15sec to achieve thorough mixing. Sample was left at room 
temperature for 2-3min until an aqueous phase appeared on top.  
- The sample was centrifuged at 13,000rpm at 4°C for 20min for complete phase 
separation. The upper/aqueous phase was transferred with caution to a new tube to 
avoid transferring any of the interphase.  
- 1.5x volumes of 100% (v/v) molecular biology-grade ethanol was added to the 
aqueous phase and pipetted up and down to mix thoroughly.  
- An RNeasy Mini spin column was placed in a 2mL collection tube and up to 700μL of 




temperature for 15sec and flow-through was discarded. This step was repeated for 
the remaining of the sample.  
- 350μL of buffer RWT was pipetted onto the RNeasy Mini spin column and centrifuged 
at 13,000rpm at room temperature for 15sec to wash the RNA on the filter of the 
column. Flow-through was discarded.  
- 10μL of DNase I was added to 70μL of buffer RDD and mixed gently by flicking the 
tube. The 80μL of this mix was pipetted directly on the centre of the column and the 
sample was placed at room temperature for 15min for DNA digestion. 
- 350μL of buffer RWT was pipetted onto the column and centrifuged at 13,000rpm at 
room temperature for 15sec. Flow-through was discarded. 
- 500μL of buffer RPE was added onto the RNeasy Mini spin column and the sample was 
centrifuged at 13,000rpm at room temperature for 15sec. Flow-through was 
discarded. This step was repeated with an extra of 500μL of buffer RPE and the sample 
was spun at 13,000rpm at room temperature for 2min. Flow-through was discarded.  
- The RNeasy Mini spin column was placed in another collection tube and spun at 
13,000rpm at room temperature for 1min to dry the filter and remove any remaining 
liquid.  
- The RNeasy Mini spin column was placed in a 1.5mL tube and 30μL of RNase-free 
water was added directly onto the column. The column was centrifuged at 13,000rpm 
at room temperature for 1min to elute the RNA.  
- The RNeasy Mini spin column was placed in a second 1.5mL tube. Additional 30μL of 
RNase-free water was added directly onto the column and the column was centrifuged 
as above to elute the remaining of the RNA.  
- RNA concentration and purity were measured using a Nanodrop 2000 
Spectrophotometer. RNA was stored at -80°C.  
 
2.13.3 Total RNA extraction from human knee articular cartilage and human primary 
chondrocytes using the guanidinium thiocyanate-phenol-chloroform method (TRIzol) 
 
Total RNA, intended for qPCR analysis, was isolated from human knee articular cartilage and 




cartilage tissue was homogenised as described in Section 2.12. For chondrocytes growing in 
well-plates, media was removed and cells washed twice with 1x DPBS. DPBS was then 
discarded and cells lysed. Specifically, for tissue and cells: 
- 1mL of TRIzol was added to 100mg of homogenised human cartilage tissue (powder). 
For human chondrocytes, the amount of TRIzol dependent on the number of cells. 
Chondrocytes growing in 12-well and 24-well plates were lysed in 700μL and 500μL of 
TRIzol, respectively. 
- The sample was lysed by vortexing for 2min. Specifically for tissue, after vortexing, the 
sample was placed on a rotator and rotated at medium speed at room temperature 
for 10min to aid lysis. Then, the sample was centrifuged at 13,000rpm at 4°C for 5min 
to pellet any non-lysed powder. Supernatant was transferred to a new 1.5mL tube and 
passed ten times through a 21-gauge needle to aid lysis and breakdown of 
proteoglycans.  
- 200μL of chloroform (or less, dependent on amount of TRIzol added, 
TRIZol:chloroform 5:1) was added to the lysate and shaken vigorously to mix. The 
sample was left at room temperature for 2-3min until the aqueous phase appeared 
on top.  
- The sample was then centrifuged at 13,000rpm at 4°C for 20min for phase separation. 
The aqueous phase was transferred to a new 1.5mL tube. 
- 2μL of GlycoBlue™ Coprecipitant (Invitrogen by ThermoFisher Scientific, Paisley, UK) 
was added to the aqueous phase and mixed.  
- An equal amount of isopropanol (Sigma-Aldrich, Dorset, UK) was added and the tube 
was inverted ten times to mix. The sample was left on ice for 30min to precipitate total 
RNA.  
- The sample was centrifuged at 13,000rpm at 4°C for 20min to pellet RNA. Supernatant 
was discarded.  
- The pelleted RNA was washed with 1mL of 75% (v/v) ice-cold molecular biology-grade 
ethanol. The sample was centrifuged at 13,000rpm at 4°C for 5min. Most of the 
ethanol was discarded by decanting. To remove any ethanol left, the sample was pulse 
spun and the excess of ethanol was pipetted out of the tube. The sample was left on 




- The RNA pellet was dissolved in 15μL of nuclease-free water. 
- RNA concentration and purity were measured using a Nanodrop 2000 
Spectrophotometer. RNA was stored at -80°C. 
 
2.14 Microarray analysis for detection of differentially expressed miRNAs 
Differential miRNA expression analysis in cartilage samples was undertaken by appropriate 
personnel at the Centre for Genomic Research (CGR) at the University of Liverpool, using the 
Affymetrix GeneChip® miRNA 4.0 Arrays (ThermoFisher Scientific, Paisley, UK). Arrays assayed 
for all mature miRNAs in miRBase Release 20 and contained probes for 2578 human mature 
miRNAs and 2025 human precursor miRNAs (Affymetrix, 2016). Quantity and quality of RNA 
submitted to CGR was assessed using the Agilent 2100 Bioanalyser RNA Pico chips (Agilent, 
Stockport, UK). 500ng of total RNA was used as the initial input and speed-vac was undertaken 
to reduce the volume to 8μL per sample. Then, the Affymetrix FlashTag™ Biotin HSR RNA 
Labeling Kit (ThermoFisher Scientific, Paisley, UK) was used to prepare samples for 
hybridisation according to manufacturer’s instructions (Affymetrix, 2012). Specifically, small 
RNAs, including miRNAs, were polyadenylated and then ligated to biotin-labelled 3DNA® 
dendrimers for robust signal detection (Figure 2.3). Each labelled sample was mixed with the 
hybridisation cocktail and then injected into an Affymetrix GeneChip miRNA 4.0 array. Arrays 
were place in the Affymetrix hybridisation oven 645 (ThermoFisher Scientific, Paisley, UK) and 
incubated at 48°C at 60rpm for 17.5h. After hybridisation, the hybridisation cocktail was 
extracted from each array and the arrays were washed using the Affymetrix Hybridisation 
wash and stain kit on the GeneChip Fluidics station 450 (ThermoFisher Scientific, Paisley, UK) 
using fluidics script FS450_0002, and scanned using the Affymetrix GeneChip scanner 3000 









Figure 2.3: The Affymetrix FlashTag™ Biotin HSR RNA Labeling protocol. miRNAs were 
polyadenylated by poly(A) polymerase. Then, biotin-labelled 3DNA® dendrimers were ligated 
to the polyadenylated miRNAs by T4 DNA Ligase through a bridge oligonucleotide. Labelled 
polyadenylated miRNAs were hybridised onto the Affymetrix GeneChip miRNA 4.0 arrays and 
signal detection was achieved through the Streptavidin-PE system. Abbreviations: 





2.15 Small RNA-Seq analysis for detection of differentially expressed miRNAs 
Differential expression analysis in equine chondrocytes was undertaken by appropriate 
personnel at CGR using the Illumina MiSEq platform (Illumina, Cambridge, UK). Prior to 
sequencing, cDNA library preparation was carried out using the NEBNext® Small RNA Library 
Prep Set for Illumina®/Multiplex Compatible (New England Biolabs, Herts, UK) according to 
the manufacturer’s protocol (NewEngland-Biolabs, 2020) (Figure 2.4). In short, total RNA was 
ligated to a 3´ SR Adaptor and then subjected to Cap-Clip Acid Pyrophosphatase treatment 
(Cellscript, Madison, USA) to remove some 5’ cap structures found on some snRNAs. Then, 
total RNA was ligated to a 5´ SR Adaptor and cDNA synthesis through a reverse transcription 
primer was performed, followed by PCR Amplification and the addition of barcodes to the 
amplicons. PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, 
Manchester, UK) and quantity of the recovered cDNA was checked with the Qubit® dsDNA HS 
Assay Kit (ThermoFisher Scientific, Paisley, UK). Quality check of the libraries was undertaken 
on a DNA high sensitivity Bioanalyzer chip (Agilent, Stockport, UK) and size selection for small 
RNAs (0-280bp) was undertaken with the Pippin Prep instrument using the 3% (w/v) agarose, 
dye-free gel with internal standards (Sage Science, Beverly, USA). The quantity and quality of 
the final pool was assessed by Qubit and Bioanalyzer as before, and subsequently by qPCR 
using the Kapa Library Quantification Kit (Roche Life Science, Penzberg, Germany), run on a 
LightCycler® 480 Instrument II (Roche Life Science, Penzberg, Germany). Briefly, a 20μL qPCR 
reaction (performed in triplicate for each pooled library) was prepared on ice with 12μL SYBR 
Green I Master Mix and 4μL of diluted pooled cDNA (dilutions: 1:1000 to 1:100,000 depending 
on the initial concentration determined by the Qubit® dsDNA HS Assay Kit). Following 
calculation using the qPCR data, 5μL of the final pool was denatured for 5min at room 
temperature using 5μL of freshly diluted 0.1N NaOH and the reaction was subsequently 
terminated by the addition of the HT1 Hybridization Buffer. The final loading concentration 
of 10.5pM was reached by adding the required HT1 buffer volume. The libraries were 





















Figure 2.4: The Multiplex Small RNA Library Prep Workflow for Illumina. Figure copied with 




2.16 Poly(A) cDNA synthesis for miRNA quantification 
Using total RNA as the starting material, miRNAs and specific snRNAs and snoRNAs were 
converted into poly(A) cDNA for miRNA quantification using the miScript II RT Kit (Qiagen, 
Manchester, UK) (Qiagen, 2011b). SncRNAs lack a poly(A) tail and the miScript system 
facilitates both the addition of poly(A) tails and reverse transcription into cDNA (Figure 2.5). 
This system uses an oligo-dT primer that binds the poly(A) tail. A universal tag attached to the 
oligo-dT primer enabled the use of a universal reverse primer for miRNA qualification, 
irrespective of the miRNA sequence.  
Per sample, 200ng of total RNA was converted into poly(A) cDNA. This was mixed with 4μL of 
5x miScript HiSpec Buffer, 2μL of 10x Nucleics Mix and 1μL of miScript Reverse Transcriptase 
Mix. The reaction was brought to a final volume of 20μL with the addition of nuclease-free 
water. The tube was mixed gently and pulse spun. The mixture was incubated at 37°C for 
60min for poly(A) cDNA synthesis and then at 95°C for 5min for reverse transcriptase 






Figure 2.5: Overview of the miScript system for poly(A) cDNA synthesis and miRNA 





2.17 cDNA synthesis for mRNA quantification 
Total RNA was reverse transcribed into cDNA for mRNA quantification using the M-MLV 
reverse transcriptase (Promega, Southampton, UK) (Promega, 2016). 500ng of total RNA was 
converted into cDNA. This was mixed with 0.5μL of random primers (Promega, Southampton, 
UK) and with nuclease-free water up to final volume of 18.3μL. This was incubated at 70°C for 
5min to dissociate secondary RNA structures. Then, the mixture was mixed with 5μL of M-
MLV 5X Reaction Buffer (Promega, Southampton, UK), 0.6μL of 25mM PCR Nucleotide Mix 
(Promega, Southampton, UK), 0.6μL of RNasin(R) Plus RNase Inhibitor (Promega, 
Southampton, UK) and 0.5μL M-MLV Reverse Transcriptase, up to final volume of 25μL. The 
final mixture was mixed well and incubated at 37°C for 60min for reverse transcription. 
Reverse transcriptase was inactivated at 93°C for 5min and cDNA stored at -20°C.  
 
2.18 qPCR for miRNA quantification 
miRNA amplification by qPCR was carried out using the miScript SYBR® Green PCR Kit (Qiagen, 
Manchester, UK) (Qiagen, 2011a). This system offers the use of a miRNA-specific forward 
primer, whereas the reverse primer is a universal primer that can be used for quantification 
of any miRNA, using poly(A) cDNA prepared with the miScript II RT Kit as starting material. 
Poly(A) cDNA was diluted with nuclease-free water to a working concentration of 1ng/μL. 
Then, in a 96-Well Semi-Skirted PCR Plate (StarLab, Milton Keynes, UK), the following were 
added per well: 5μL of diluted poly(A) cDNA (5ng per reaction), 7.5μL of QuantiTect SYBR 
Green PCR Master Mix, 1μL of miRNA-specific forward primer (final concentration in reaction: 
330nM), 1μL of miScript Universal Reverse Primer (final concentration in reaction: 330nM) 
and 0.5μl of nuclease-free water. Final volume was 15μL per reaction. Each reaction was run 
in duplicate or triplicate. miRNA amplification was undertaken by a LightCycler® 96 
Instrument (Roche Life Science, Penzberg, Germany) under the following cycling conditions: 
- 1 cycle of: 95°C for 15min, for HotStarTaq DNA Polymerase activation 
- 45 cycles of: 94°C for 15sec, for double strand dissociation 
          55°C for 30sec, for primer annealing 




- Melting curve: 95°C for 10sec  
                           65°C for 60sec 
                           97°C for 1sec (acquisition mode: continuous) 
miRNA expression was calculated using the 2-ΔCT method (Livak et al., 2001), relative to 
appropriate reference genes.  
 
2.19 qPCR for mRNA quantification 
mRNA amplification by qPCR was carried out using the QuantiTect SYBR Green PCR Master 
Mix (Qiagen, Manchester, UK). Primers were either designed by the author or OriGene 
(OriGene, Herford, Germany) and synthesised by Eurogentec (Seraing, Belgium), or designed 
and synthesised by Primerdesign (Chandler's Ford, UK). When possible, primers were 
designed to be exon spanning (Table 2.6). 
cDNA was diluted with nuclease-free water at a working concentration of 2.5ng/μL. 
Eurogentec forward and reverse primers were mixed and diluted at a working concentration 
of 20μM per primer. Primerdesign primers were resuspended as a primer mix at a working 
concentration of 6μM. In a 96-Well Semi-Skirted PCR Plate, the following were added per well: 
4μL of diluted cDNA (10ng per reaction), 5μL of QuantiTect SYBR Green PCR Master Mix, 0.2μL 
of Eurogentec primer mix (final concentration in reaction: 400nM) or 0.67μL of Primerdesign 
primer mix (final concentration in reaction: 400nM). Nuclease-free water was added up to 
10μL final volume per reaction. Each reaction was set up in duplicate or triplicate. mRNA 
amplification was carried out by a LightCycler® 96 Instrument under the following cycling 
conditions: 
- 1 cycle of: 95°C for 15min, for HotStarTaq DNA Polymerase activation 
- 45 cycles of: 94°C for 15sec, for double strand dissociation 
          55°C for 30sec, for primer annealing 
          70°C for 30sec, for strand elongation  
- Melting curve: 95°C for 10sec  
                           65°C for 60sec 




mRNA expression was calculated using the 2-ΔCT method (Livak et al., 2001), relative to the 
appropriate reference genes. 
 
2.20 Primer efficiency calculation 
Primer efficiency for protein-coding genes was calculated by qPCR by using serial dilutions of 
cDNA from human primary chondrocytes. The following serial dilutions of template cDNA 
were used (Table 2.4): 
 
Table 2.4: Serial dilutions of cDNA used for primer efficiency calculation. 
Template cDNA amount (ng) Dilution to starting cDNA amount Log10(template cDNA amount) 
40 1:1 1.602059991 [log10(40)] 
20 1:2 1.301029996 [log10(20)] 
10 1:4 1 [log10(10)] 
5 1:8 0.698970004 [log10(5)] 
2.5 1:16 0.397940009 [log10(2.5)] 
1.25 1:32 0.096910013 [log10(1.25)] 
0.625 1:64 -0.204119983 [log10(0.625)] 
0.3125 1:128 -0.505149978 [log10(0.3125)] 
 
For each primer pair, qPCR reactions were set up in triplicate per dilution and carried out as 
described in Section 2.19. Primer concentration was kept at 400nM in all dilutions. The 
average of CT values for each dilution was plotted against log10(template cDNA amount) in 
Excel (Microsoft, Reading, UK) and the slope of the graph was calculated. Primer efficiency 
was calculated using the formula (Ginzinger, 2002): 








2.21 List of sncRNA and mRNA primers 
Table 2.5: Primers used for sncRNA quantification 
Type Name Sequence/Qiagen ID Species 
snoRNA SNORD68 Proprietary to Qiagen/MS00033712 Human 
miRNA miR-6786-5p Proprietary to Qiagen/MS00046928 Human 
miRNA miR-107 Proprietary to Qiagen/MS00031255 Human 
miRNA miR-143-3p Proprietary to Qiagen/MS00003514 Human/Equine 
miRNA miR-379-5p Proprietary to Qiagen/MS00009653 Human 
miRNA miR-361-5p Proprietary to Qiagen/MS00004032 Human 
miRNA miR-20a-5p Proprietary to Qiagen/MS00003199 Human 
miRNA miR-6087 Proprietary to Qiagen/MS00045402 Human 
miRNA miR-1915-3p Proprietary to Qiagen/MS00044604 Human 
miRNA miR-140-5p Proprietary to Qiagen/MS00003500 Human 
miRNA miR-155-5p Proprietary to Qiagen/MS00031486 Human 
miRNA miR-132-3p Proprietary to Qiagen/MS00003458 Human 
miRNA miR-122 Proprietary to Qiagen/MS00003416 Human/Equine 
miRNA miR-145 Proprietary to Qiagen/MS00003528 Human/Equine 
miRNA miR-148a Proprietary to Qiagen/MS00003556 Human/Equine 
miRNA miR-181b Proprietary to Qiagen/MS00006699 Human/Equine 
snRNA U6 Proprietary to Qiagen/MS00033740 Human/Equine 






Table 2.6: Primers used for mRNA quantification. Abbreviations:  Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), Ribosomal protein L13a (RPL13A), Ribosomal protein 
lateral stalk subunit P0 (RPLP0), Ribosomal protein L3 (RPL3), Ribosomal protein L4 (RPL4), 
ATP synthase F1 subunit alpha (ATP5F1A), Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein epsilon (YWHAE), Ras homolog family member A (RHOA), 
Transforming growth factor beta receptor (TGFBR) 1, Fibroblast growth factor (FGF) 2, 
Interferon regulatory factor (IRF) 1, Calmodulin (CALM) 3, Small mothers against 
decapentaplegic (SMAD) 9. N/A: primer efficiency not calculated. 




































































































































































R: TAGCATCTCGGCTGGACTTCGA  
 
2.22 Treatment of human primary chondrocytes with IL-1β 
Lyophilised recombinant human IL-1β (R&D Systems, Abingdon, UK) was reconstituted in 
sterile PBS containing 0.1% (w/v) Bovine Serum Albumin (BSA) (R&D Systems, Abingdon, UK) 
according to manufacturer’s recommendations. Human primary OA chondrocytes were 
extracted from knee femoral cartilage and cultured in T75 flasks as described in Section 2.9. 
Cells were trypsinised as described in Section 2.11 and seeded in 12-well plates at a seeding 
density of 30,000cell/cm2. Cells were seeded in complete media and left to attach and 
proliferate in a tissue culture incubator at 37°C, supplied with 20% (v/v) O2 and 5% (v/v) CO2 
overnight. Next day, complete media was removed and replaced with DMEM supplemented 
with 1% (v/v) P/S and 0.2% (v/v) F/Z. No FBS was added to the culture media. Chondrocytes 




supplemented with 10ng/mL IL-1β (R&D Systems, Abingdon, UK) or PBS/BSA as control. 
Treated cells and control were then lysed in TRIzol.  
IL-1β treatment of human primary chondrocytes from non-OA donors undergoing autologous 
cartilage transplantation after trauma/sport injury, was undertaken by Dr Caron Marjolein, 
Assistant Professor, Maastricht UMC+, Netherlands, following ethical approval (ID MEC 08‐4‐
028). The same process was followed. cDNA from these cells was shipped to the Institute of 
Life Course and Medical Sciences, University of Liverpool, UK and further processed by the 
author. 
 
2.23 Overexpression and knockdown of miRNAs in IL-1β induced human 
primary chondrocytes 
miRNA mimics and inhibitors (Qiagen, Manchester, UK) were used to overexpress and 
knockdown the expression of four miRNAs in IL-1β induced human primary chondrocytes: 
hsa-miR-107, hsa-miR-379-5p, hsa-miR-361-5p and hsa-miR-143-3p. Two commercially 
available systems by Qiagen were used to undertake these experiments. For hsa-miR-107, -
379-5p, -361-5p the miScript mimics, inhibitors and controls were used. For hsa-miR-143-3p, 
the miRCURY LNA mimic, inhibitor and controls were used. These are summarised in Table 
2.7 below. 
Table 2.7: List of miRNA mimics, inhibitors and controls used in this thesis.  































































Negative Control miRCURY 





miRCURY LNA miRNA 






Chondrocytes were extracted from the femoral condyles of OA patients undergoing TKA 
according to Section 2.9 and cultured as described in Section 2.11. Cells were seeded in well-




hsa-miR-107, -379-5p, -361-5p, chondrocytes were seeded in 24-well plates for qPCR analysis. 
For experiments concerning hsa-miR-143-3p, chondrocytes were seeded in 6-well plates for 
LC-MS/MS. Cells were left to attach and proliferate overnight. Next day, chondrocytes were 
treated with the respective mimic, inhibitor or control. The HiPerFect Transfection Reagent 
(Qiagen, Manchester, UK) was used for delivery into the cell. Specifically, working under 
sterile conditions, the appropriate volume of mimic, mimic negative control, inhibitor and 
inhibitor negative control was added in sterile 1.5mL tubes, one tube per condition per 
miRNA. The appropriate volume of HiPerFect Transfection Reagent was added to each tube. 
The volume of the transfection reagent was dependent on the size of the well. For 24-well 
plates, 3μL were added per tube, whereas for a 6-well plate, 12μL were added per tube. The 
volume was brought to a final volume of 100μL by adding DMEM media without FBS, P/S, F/Z 
and phenol red, but supplemented with 1% (v/v) L-glutamine (Gibco/ThermoFisher Scientific, 
Paisley, UK). Tubes were vortexed, spun down briefly and left at room temperature for 20min 
for constructs to form.  
In the meantime, complete media was removed from chondrocytes in well plates and cells 
were washed twice with DMEM supplemented only with 1% (v/v) L-glutamine. For 24-well 
plates, 300μL of DMEM, supplemented with 1% (v/v) L-glutamine and 10ng/mL IL-1β, was 
added to each treatment well, whereas for 6-well plates, 900μL of the same media was added. 
After 20min, 100μL of each construct/treatment was added drop-wise to the respective well. 
For a 24-well plate, final volume was 400μL, whereas for a 6-well plate, final volume was 1mL. 
Chondrocytes were treated for 48h and then lysed either in TRIzol for qPCR analysis or as 
described in Section 2.24 for LC-MS/MS analysis.  
 
2.24 Collection and lysis of human primary chondrocytes for LC-MS/MS 
analysis 
Prior to chondrocyte collection, a fresh 2x protease inhibitor cocktail solution and a fresh 
50mM Ammonium Bicarbonate (AmBic) (Sigma-Aldrich, Dorset, UK) solution were prepared. 
For the 2x protease inhibitor cocktail, one cOmplete™ ULTRA, EDTA-free, tablet of protease 
inhibitor cocktail (Roche Life Science, Penzberg, Germany) was dissolved in 5mL of Pierce™ 




AmBic was dissolved in 10mL of Pierce™ Water, LC-MS Grade. Equal volume of each solution 
was mixed to prepare a 25mM AmBic solution supplemented with 1x protease inhibitor 
cocktail and stored on ice.  
For chondrocyte collection, media was removed and cells were washed with 1xDPBS. DPBS 
was removed and 200μL of 25mM AmBic supplemented with 1x protease inhibitor cocktail 
was added per well. Cells were scrapped off the well surface using a cell scrapper and 
collected in tubes. 7.5units of benzonase nuclease (Biocompare, San Francisco, USA) was 
added per sample and mixed slightly to release histones from DNA. Cells were lysed by 
sonication with a Soniprep 150 ultrasonic disintegrator (MSE, East Sussex, UK). Cells were 
sonicated on ice, in three rounds of 30sec each, with 1min and 15sec rest between each 
round. Volume was adjusted to 200μL by adding 25mM AmBic supplemented with 1x 
protease inhibitor cocktail. 20μL per sample was taken for protein quantification and 10μL 
was taken for protein quality analysis. The remaining lysate was stored at -80°C for LC-MS/MS 
analysis.   
 
2.25 Pierce™ 660nm Protein Assay for protein quantification 
Prior to LC-MS/MS, protein amount in each sample was quantified using the Pierce™ 660nm 
Protein Assay (ThermoFisher Scientific, Paisley, UK). For protein standard preparation, two 
pre-diluted BSA protein assay standards (ThermoFisher Scientific, Paisley, UK) of known 
concentration, 2000μg/mL and 1000μg/mL, were serially diluted in 25mM AmBic 
supplemented with 1x protease inhibitor cocktail, according to Table 2.8. 
 
Table 2.8: Protein standard preparation for Pierce™ 660nm Protein Assay.  
Known concentration of pre-
made standard (μg/mL) 
Volume of pre-diluted 
BSA protein assay 
standard (μL) 
Volume of 25mM 
AmBic/1x protein 
inhibitor cocktail (μL) 
Standard - final 
concentration (μg/mL) 




2000 25 25 1000 
1000 37.5 12.5 750 
1000 25 25 500 
1000 12.5 37.5 250 
1000 5 35 125 
1000 2.5 47.5 50 
- - 50 0 (Blank) 
 
10μL of standards, blank and unknown samples was loaded in duplicate onto a Costar® 96-
well plate (Corning, Flintshire, UK). 150μL of the Protein Assay Reagent was added to each 
well. The plate was covered and mixed on a plate shaker at medium speed for 1min, incubated 
at room temperature for 5min and then absorbance was measured at 600nm using a 
FLUOstar Omega Microplate Reader (BMG LABTECH, Aylesbury, UK).  
For protein quantification, absorbance of the blank was deducted from standards and 
unknown samples and a standard curve was designed in Excel by plotting the corrected 
absorbance of the standards against their concentration. Using the standard curve, the 
protein concentration and total protein amount were calculated for the unknown samples.  
 
2.26 SDS-PAGE for protein quality assessment 
Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins derived from chondrocyte lysates and prepare gel for silver staining or 
Coomassie Brilliant Blue staining. 7.5μL of 2x Novex™ Tris-Glycine SDS Sample Buffer 
(ThermoFisher Scientific, Paisley, UK), supplemented with 8% (v/v) of 2-Mercaptoethanol 
(Sigma-Aldrich, Dorset, UK), was added to 7.5μL of sample (2μg of protein). Samples were 
mixed and heated at 100°C for 10min to denature proteins. Samples were placed immediately 
on ice. A NuPAGE™ 4% to 12% (w/v), Bis-Tris gel (ThermoFisher Scientific, Paisley, UK) was 




Buffer (ThermoFisher Scientific, Paisley, UK) (diluted from the 20x stock in ultrapure water). 
Samples were loaded onto the gel alongside 6μL of the Novex™ Sharp Pre-stained Protein 
Standard ladder (ThermoFisher Scientific, Paisley, UK). The gel was run at 80V for 10min and 
then 100V for the remaining time of electrophoresis.  
 
2.27 Silver staining of polyacrylamide gels 
Silver staining is a sensitive method which allows visualisation of protein bands on a 
polyacrylamide gel. The Pierce Silver Stain Kit (ThermoFisher Scientific, Paisley, UK) was used 
to assess quality and molecular weight distribution of proteins run on polyacrylamide gels 
according to manufacturer’s instructions (ThermoFisherScientific, 2016). Prior to staining, the 
following solutions were prepared in advance: 
- Fixing solution [60% (v/v) water:30% (v/v) ethanol:10% (v/v) acetic acid] 
- 10% (v/v) ethanol 
- Stop solution (5% (v/v) acetic acid) 
Then gel was stained as follows: 
- The gel was washed twice in ultrapure water for 5min each.  
- Then, the gel was fixed in fixing solution in two consecutive rounds, for 15min each.  
- After fixing, the gel was washed twice in 10% (v/v) ethanol for 5min each and washed 
twice in ultrapure water for 5min each.  
- Sensitiser working solution was prepared by mixing 1 part of Silver Stain Sensitizer 
with 500 parts ultrapure water. The gel was incubated in the sensitiser working 
solution for exactly 1min and then washed twice in ultrapure water for 1min each.  
- Stain Working Solution was prepared by mixing 1 part of Silver Stain Enhancer with 50 
parts Silver Stain. The gel was incubated in Stain Working Solution for 30min.  
- Developer working solution was prepared by mixing 1 part of Silver Stain Enhancer 
with 50 parts Silver Stain Developer. 
- After incubating the gel in Stain Working Solution, the gel was washed twice in 




- Then, Developer Working Solution was added onto the gel and incubated for 
approximately 2min until protein bands appeared. 
- Immediately after 2min, Developer Working Solution was removed and the gel was 
washed in stop solution for 20sec. The first round of stop solution was replaced by an 
extra round of stop solution and the gel was incubated in that for 10min.  
The gel was visualised using the ChemiDoc XRS+ Gel Imaging System (Bio-Rad, Watford, 
UK). 
 
2.28 Protein sample preparation for LC-MS/MS 
Prior to LC-MS/MS, fresh 25mM and 50mM AmBic solutions were prepared and the total 
protein amount in each sample was measured as described in Section 2.25. For normalisation 
purposes, the same amount of protein in the same starting volume was used for all samples. 
In this protocol, 160μL was used as the starting volume for all samples. The sample with the 
lowest total protein amount, based on the Pierce™ 660nm protein assay, was the reference 
sample. The amount of protein contained in 160μL of the reference sample was selected as 
the amount of protein that would be used for LC-MS/MS for every sample. Thus, per sample, 
this amount of protein was transferred in protein LoBind tubes (Eppendorf, Stevenage, UK) 
and volume was brought to 160μL by adding 25mM AmBic. Samples were randomised for 
processing. Then: 
- 10μL of 1% (w/v) RapiGest SF Surfactant (Waters, Herts, UK) (freshly prepared in 
25mM AmBic) was added to each sample. The samples were vortexed briefly and 
incubated at 80°C for 10min, with a quick vortex at the 5min timepoint. The samples 
were then pulse spun to collect all liquid at the bottom of the tube. 
- 11.1mg of Dithiothreitol (DTT) (Sigma-Aldrich, Dorset, UK) was dissolved in 1mL of 
25mM AmBic to prepare a 11.1mg/mL solution. 10μL of this solution was added to 
each sample (final DTT concentration 4mM) and the samples were vortexed briefly. 
Then, the samples were incubated at 60°C for 10min, with a quick vortex at the 5min 





- After cooling down, 46mg of iodoacetamide (IAA) (Sigma-Aldrich, Dorset, UK) was 
dissolved in 1mL of 25mM AmBic and solution was kept in the dark. 10μL of IAA was 
added in all samples and the samples were incubated in the dark, at room 
temperature for 30min.   
- To prevent overalkylation, 9.4μL of the 11.1mg/mL DTT solution was added in each 
sample (final DTT concentration 7mM). Samples were vortexed briefly. 
- For protein digestion, Trypsin/Lys-C Mix, Mass Spec Grade (Promega, Southampton, 
UK), provided as powder, was reconstituted in 50μL of resuspension buffer (provided 
in the pack) and 50μL of 50mM AmBic. 10μL of Trypsin/Lys-C Mix was added to every 
sample and then samples were placed in a rotating incubator at 37°C for 2h, at 
medium speed. After 2h, samples were pulse spun to collect all liquid and an extra 
10μL of Trypsin/Lys-C Mix was added to each sample. The samples were placed in a 
rotating incubator at 37°C, overnight, to achieve complete protein digestion.  
- Next day, the samples were pulse spun to collect digest at the bottom of the tube. 1μL 
of Trifluoroacetic acid (TFA) (Sigma-Aldrich, Dorset, UK) was added per sample and 
then samples were vortexed briefly and pulse spun. Acidity of the samples was 
confirmed with pH paper (Camlab, Cambridge, UK) and then the samples were 
incubated at 37°C for 45 min. 
- After incubation, samples were centrifuged at 13,000g at 4°C for 15min to remove all 
insolubles. Supernatant was transferred to new tubes and the samples were spun 
again at 13,000g at 4°C for 15min. Supernatant was transferred in new tubes and 
checked that no precipitate was present in any of the samples. Aliquots containing 
1μg of digested protein were taken to confirm digestion on an SDS-PAGE gel with 
Coomassie Brilliant Blue staining. 
 
2.29 Coomassie Brilliant Blue staining of polyacrylamide gels 
To confirm full digestion of proteins, 1μg of digested protein samples was run on an SDS-
polyacrylamide gel as described in Section 2.26. After electrophoresis, gel was washed 3x 
times with ultrapure water for 5min each. The gel was stained with Coomassie Brilliant Blue 




destained in Coomassie Brilliant Blue R-250 Destaining Solution (Bio-Rad, Watford, UK) in 4x 
washes for 30min each with gentle agitation. The gel was visualised using the ChemiDoc XRS+ 
Gel Imaging System.  
 
2.30 LC-MS/MS workflow  
Digested proteins, extracted from human primary chondrocytes treated with miRNA mimic, 
inhibitor, or control, were subjected to LC-MS/MS and run on a 90min gradient with a 30min 
run of blanks between samples. The procedure was carried out by appropriate personnel at 
the Centre for Proteome Research (CPR) at the University of Liverpool, as described in (Timur 
et al., 2020). 500ng of digest per sample was used for LC-MS/MS. Analysis was undertaken 
using a QExactive HF quadrupole-Orbitrap mass spectrometer (ThermoFisher Scientific, 
Paisley, UK) coupled to an UltiMate™ 3000 RSLCnano liquid chromatographer (ThermoFisher 
Scientific, Paisley, UK). The samples were loaded onto a trap column (Acclaim PepMap 100 
C18, 75μm × 2cm, 3μm packing material, 100Å) for 7 min at a flow rate of 12 μL/min, using 
0.1% (v/v) TFA in acetonitrile/water [2/98 (v/v)] as the loading buffer. The trap column was 
set in-line with an analytical column (EASY-Spray PepMap RSLC C18, 75μm × 50cm, 2μm 
packing material, 100Å). The peptides were eluted using a linear gradient of 96.2% A:3.8% B 
to 50% A:50% B over 90min at a flow rate of 300 nL/min, where A is 0.1% (v/v) formic acid 
and B is 0.1% (v/v) formic acid in water/acetonitrile [80/20 (v/v)]. This was followed by a 
washing step at 1% A:99% B for 5min. Then column was re-equilibrated to starting conditions. 
The column was kept at 40°C and the effluent was introduced into the nano-electrospray 
ionisation source set in positive ion mode. The mass spectrometer was set to data-dependent 
acquisition mode with survey scans between mass-to-charge ratio (m/z) 350–2000, acquired 
at a mass resolution of 60,000 (full width at half maximum) at m/z 200. The maximum 
injection time was 100msec, and the automatic gain control was set to 3e6. The 12 most 
intense precursor ions with charges states of between 2+ and 5+ were selected for MS/MS 
with an isolation window of 2 m/z units. The maximum injection time was 100ms, and the 
automatic gain control was set to 1e5. Fragmentation of the peptides was by higher-energy 




mass/charge values to prevent repeated fragmentation of the same peptide was used with 
an exclusion time of 20sec.  
 
2.31 Bioinformatic analysis of microarray experiment 
Microarray analysis was performed as described in Section 2.14. Bioinformatic analysis was 
performed by appropriate personnel at CGR who produced the following report: After 
scanning the arrays, Affymetrix array .CEL files were generated using the Affymetrix GeneChip 
Command Console Software. Data was pre-processed using Robust Microarray data Analysis 
(RMA) to obtain normalised small RNA expression data. Model-based analysis of small RNA 
expression was applied to data pre-processed with RMA which generated normalised 
expression values presented on a log2 scale. Data quality was assessed by measuring small 
RNA expression distribution. Two statistical tools were used for data variation assessment. 
The first was a heatmap of correlation coefficients among arrays and the second was the 
Principal Component Analysis (PCA) (Abdi et al., 2010). The random variation of the data was 
formulated following a normal distribution, and the model was linear, taking the mean of 
each group as a model parameter. Therefore, the number of parameters was equal to the 
number of sample groups.  
The log2 Fold Change (logFC) was computed from model fitting results and tested using t-tests 
to get associated p-values. P-values were adjusted for multiple testing using the False 
Discovery Rate (FDR) approach (Benjamini et al., 1995). Significantly differentially expressed 
miRNAs were defined as those with FDR-adjusted p-value < 5%. All the processes were 
performed in R environment using limma package (Smyth, 2005).  
 
2.32 Bioinformatic analysis of small RNA-Seq experiment  
Small RNA-Seq analysis was performed as described in Section 2.15. Bioinformatic analysis 
was performed by appropriate personnel at CGR who produced the following report: Initial 
processing and quality assessment of the sequence data was performed using an in-house 




indexed reads were performed by CASAVA version 1.8.2 (Illumina, Cambridge, UK) to produce 
the sequence data for the samples, in fastq format. The raw fastq files were trimmed to 
remove Illumina adapter sequences using Cutadapt version 1.2.1 (Martin, 2011). The option 
“-O 3” was set so that the 3' end of any reads which matched the adapter sequence over at 
least 3bp could be trimmed off. The reads were further trimmed to remove low quality bases, 
using Sickle version 1.200 with a minimum window quality score of 20. After trimming, reads 
shorter than 20bp were removed. If both reads from a pair passed this filter, each was 
included in the R1 (forward reads) or R2 (reverse reads) file. If only one of a read pair passed 
this filter, it was included in the R0 (unpaired reads) file. 
The genome reference sequence and annotations used for alignment were downloaded from 
NCBI. The link for the DNA reference sequence is: 
ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/002/863/925/GCF_002863925.1_EquCab3.0/G
CF_002863925.1_EquCab3.0_genomic.fna.gz  
The link of the annotation GFF is: 
ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/002/863/925/GCF_002863925.1_EquCab3.0/G
CF_002863925.1_EquCab3.0_genomic.gff.gz  
Annotation information of gene features are also linked to other databases: 
ftp://ftp.ebi.ac.uk/pub/databases/Rfam/14.0/  
ftp://mirbase.org/pub/mirbase/CURRENT/genomes/eca.gff3 
Alignment of reads was carried out using the above genome references. TopHat version 2.1.0 
(Kim et al., 2013) was used as the alignment tool with the option “-g 1”, which instructs the 
software to report the best hits, or randomly select one if there are more than 1 hits that are 
equally best. Reads aligning to the reference genome sequences were counted according to 
the gene features that they mapped to, as defined in the GFF files, using HTSeq-count version 
0.6.1p1 (Anders et al., 2010). The features whose biotype belonged to the gene categories, 
such as miRNA, were extracted to generate a categorised gene reads-count table. Differential 
gene expression analysis for the genes was applied to the read count data and conducted in 
R environment, using the EdgeR package (Robinson et al., 2010). Assessment of variation in 




correlation heatmaps and PCA plots of the 1st and 2nd components using the log10 count data 
from all libraries.  
For differential expression analysis, the random variations in the data were formulated 
following negative binomial distributions. The data model is a Generalised Linear Model with 
as many parameters, as the number of the groups compared. Normalisation factors were 
calculated to correct for differences in library size among samples, which could otherwise 
cause bias in differential expression analysis. The default method “TMM” in EdgeR was 
applied, with default parameters. The common, trended (dispersion-mean relationship) and 
gene-wise dispersion parameters were estimated. Gene-wise dispersion was used for 
significance testing. The Generalised Linear Model was parametrized using the count data and 
then used to obtain the logFC values for each required comparison. The estimated logFC were 
tested in EdgeR using a likelihood ratio test. P-values associated with logFC were adjusted for 
multiple testing using the FDR approach (Benjamini et al., 1995). Significantly DE miRNAs were 
defined as those with FDR-adjusted p-value < 5%.  
 
2.33 Bioinformatic analysis of LC-MS/MS experiment  
Bioinformatic analysis of LC-MS/MS data was performed by appropriate personnel at CPR, as 
described in (Timur et al., 2020). For label-free quantification, the raw files of the acquired 
spectra were aligned by the Progenesis QI for proteomics software (Waters, Manchester, UK), 
which peak picks for quantification by peptide ion abundance. One reference sample was 
selected and the retention times of the other samples were aligned. The top five spectra for 
each feature were exported from Progenesis QI and used for peptide identification with our 
local Mascot server (Version 2.6.2) searching against the Unihuman Reviewed database, 
containing 22,640 protein sequences. Search parameters were adjusted to mass tolerance of 
10ppm, fragment mass tolerance of 0.01Da, one missed cleavage allowed, with 
carbamidomethyl cysteine as a fixed modification and methionine, proline, lysine oxidation 
as variable modifications. For statistical analysis, proteins that had at least two unique 
peptides were selected. To assessed differences between mimic and control mimic, and 




Stats R package (Version 4.0.2). P values were adjusted for multiple testing. Differences at 
FDR-adjusted p<0.05 were considered significant. 
 
2.34 Primer design 
For primer design, the Primer-Blast tool was used (Ye et al., 2012). The accession number or 
FASTA sequence of the gene of interest was pulled from NCBI Gene (2004) and inserted into 
the ‘PCR template’ field of Primer-Blast. Product size was adjusted between 70bp and 200bp 
and, when possible, the option for the primers to span an exon-exon junction was selected. 
From the primer pairs proposed by Primer-Blast, the pairs that did not have unintended 
targets were selected for further assessment. In some cases, proposed primer pairs were 
edited slightly with the addition or removal of flanking nucleotides from the sequence 
retrieved from NCBI Gene to create more suitable pairs. The selected primer pair was 
subjected to further quality control which included the use of the New England Biolabs ‘Tm 
Calculator’ tool (2020b), adjusted for Hot Start Taq and Hot Start Taq DNA Polymerase 2X 
Master Mix, to calculate primer Tm. In general, most primers were designed approximately at 
a similar Tm, between 58°C -60°C, which allowed the use of multiple primer pairs during qPCR 
amplification. Furthermore, the potential generation of primer dimers or self-dimers was 
assessed with the ThermoFisher Scientific ‘Multiple Primer Analyzer’ tool (2020a), with primer 
concentration adjusted at 400nM. Primer pairs that were not predicted to generate primer 
dimers or self-dimers were selected.  
 
2.35 miRNA target prediction tools 
For prediction of miRNA targets, four online prediction tools were used: TargetScan (Agarwal 
et al., 2015), miRmap (Vejnar et al., 2012), miRTar (Hsu et al., 2011) and miRWalk (Dweep et 
al., 2015). In TargetScan, the name of the miRNA of interest was inserted in the appropriate 
field, setting ‘human’ as species. The results tab provided a list of all predicted target genes 
along with a total score starting from the most probable interaction. In miRmap, human was 
selected as species, and the miRNA of interested was inserted in the ‘miRNA’ field. In case of 




the relationship between the miRNA and the gene of interest was assessed and reported 
through a scoring system. In miRTar, in the ‘Prediction’ tab, either the ‘Single miRNA to single 
gene’ mode or the ‘Single miRNA to multiple genes’ mode was selected. The mature miRNA 
sequence in FASTA format and the gene symbol(s) were inserted in the appropriate fields. 
The ‘miRNA Target Regions’ option was set on ‘3’ UTR’. This tool provided results on an 
‘interaction-no interaction’ basis without providing a probability score. Finally, in miRwalk, 
the ‘predicted target module’ was selected and from the dropdown menu, the ‘MicroRNA-
gene Targets’ option was selected. In step 1, human was selected as species, ‘miRBase’ was 
the chosen database and the identifier was set to MIMATid. The name of the mature miRNA 
was written in the provided space. In step 2, the following default options were selected: 
‘miRNA’, ‘similar seeds’, ‘miR family’, ‘alignment’, ‘Host gene’ and ‘family alignment’. In step 
3, ‘3’ UTR’ and ‘minimum seed length=7’ were selected. miRWalk users have the option of 
viewing miRNA-gene interactions as predicted by miRWalk alone, or interactions predicted 
by miRwalk in combination with other online tools. For the second option the following tools 
were selected: ‘miRWalk’ and ‘RNA22’ and ‘miRanda’ and TargetScan. With this option, only 
the miRNA-gene interactions which were common among the selected tool were displayed.  
Genes predicted as miRNAs targets from at least two of the above four online tools were 
selected for further experimental validation.  
  
2.36 Ingenuity Pathway Analysis of miRNA-gene interactions 
Ingenuity Pathway Analysis (IPA) (Qiagen, Manchester, UK) was used for miRNA target 
prediction and pathway analysis and interaction. IPA was utilised for the three main 
experiments in this thesis: A) microarray analysis in Chapter 3, B) proteomic analysis in 
Chapter 5 and C) small RNA-Seq analysis in Chapter 6. 
A) Experimentally obtained DE miRNAs and their calculated logFC were inserted in an Excel 
spreadsheet and uploaded into IPA. For prediction of target genes, the ‘analyze/filter dataset’ 
option was selected, followed by the ‘microRNA target filter’ option. IPA generated a list of 




addition to the default columns, the following columns were added in order to filter the 
results:  
- Tissue/cells: ‘Cartilage’ and ‘Chondrocytes’  
- Disease: ‘Connective Tissue Disorders’ and ‘Skeletal and Muscular Disorders’  
- Species: ‘Human’  
Confidence was set to ‘High (predicted)’. Results with predicted mRNAs were saved and 
downloaded onto an Excel file. Then, predicted mRNAs were re-uploaded into IPA as new 
dataset and a Core Analysis was run to identify pathways, diseases, functions and upstream 
regulators specific to the predicted target genes. Filters in Core Analysis were set to default.  
B) For proteomic analysis, the list of identified proteins with their p values and expression 
ratio from each comparison; mimic vs control mimic and inhibitor vs control inhibitor, was 
uploaded in IPA. Filters were set to default and p value cut-off was set to 0.05.  Core analysis 
was run for each list of proteins.  
C) For the small RNA-Seq experiment, the list of DE miRNAs in equine chondrocytes was paired 
to a list of experimentally obtained DE mRNAs in equine cartilage, generated in a previous 
project by our group (Peffers et al., 2013). To achieve this, the list of DE miRNAs and their 
logFC values were uploaded on IPA as described previously. The ‘analyze/filter dataset’ and 
‘microRNA target filter’ options were selected. In the table generated, the ‘Add/Replace 
mRNA dataset’ was selected and a list with DE mRNAs from our previous project, along with 
their logFC values, was uploaded. The ‘Expression Pairing’ option was selected so that DE 
miRNAs were paired to DE mRNA targets, but only if the direction of expression was opposite 
(upregulation of miRNA-downregulation of mRNA and vice versa). mRNAs that passed this 
filter were re-uploaded on IPA and a ‘Core Analysis’ was carried out for disease, pathway and 
network analysis.  
 
2.37 Enrichr analysis of predicted target genes 
To confirm results generated by IPA, lists of all highly predicted mRNA targets from IPA were 




analysis and further pathway identification. Results were listed based on ‘Pathway’, 
‘Ontologies’ and ‘Disease/Drugs’ information.  
 
2.38 ToppGene Suite, REVIGO and Cytoscape analysis for gene network 
generation and visualisation 
To generate and visualise gene networks, datasets of predicted mRNAs were uploaded on 
ToppGene Suite (Chen et al., 2009). This generated a list of gene ontology (GO) terms for 
biological processes, and each GO term was assigned an FDR value. Go terms with FDR were 
uploaded onto REVIGO (Supek et al., 2011) and interactive graphs and tree maps were 
generated. To better visualise the gene networks generated by REVIGO, these were 
downloaded and then uploaded on Cytoscape (Shannon et al., 2003). Within cytoscape, 
networks were filtered by ‘value’ and gene interactions were visualised. 
 
2.39 STRING analysis for identification of protein-protein interactions 
To identify protein-protein interactions, STRING analysis was undertaken (Szklarczyk et al., 
2019). The ‘Multiple proteins’ option was selected and protein lists were uploaded on STRING. 
Organism was set to ‘Homo sapiens’. Network type was set to ‘full STRING network’ and 
meaning of network edges was set to ‘evidence’. Minimum required interaction score was set 
to ‘highest confidence (0.900)’.   
 
2.40 Selection of reference genes for qPCR data normalisation 
RefFinder (Xie et al., 2012) is a free  online tool used to select the best reference genes for 
qPCR data normalisation between different sample groups. It integrates four different 
programs: geNorm (Vandesompele et al., 2002), Normfinder (Andersen et al., 2004), 
BestKeeper (Pfaffl et al., 2004), and the comparative Delta-CT method (Silver et al., 2006), to 
rank the best reference genes for the samples of interest. CT values of the candidate genes 
were obtained after qPCR analysis in the sample groups of interest. These CT values were 




reference gene based on each of the four programmes used, but also a comprehensive 
ranking that takes into account all four programmes together. 
 
2.41. Principal Component Analysis using MetaboAnalyst 
For LC-MS/MS and small RNA-Seq experiments, data variation was assessed by PCA plots 
generated with MetaboAnalyst 5.0 (Chong et al., 2019). Data type was set to ‘Concentrations’ 
and data were uploaded on MetaboAnalyst. Data were log transformed using ‘Log 
transformation’ option on MetaboAnalyst and submitted for analysis. 2D PCA plot were 
generated using the ‘Principal Component Analysis (PCA)’ function and selecting for 2D Scores 
plots.  
 
2.42 Statistical Analysis  
Statistical analysis was undertaken in GraphPad Prism version 8.0.1 for Windows and 
normality of data was assessed using the Shapiro-Wilk normality test. For radiographic, 
macroscopic and histological scoring of human cartilage samples, as well as for qPCR 
quantification of miRNAs and mRNAs in human and equine cartilage tissues, the Mann-
Whitney test was used as data did not follow the Gaussian distribution and groups were 
independent. For qPCR quantification of miRNAs and mRNAs in human primary cells treated 
with IL-1β, miRNA mimics/inhibitors or control, paired t-tests were undertaken between 
treated and control groups. Paired t-test was chosen as, for every donor, cells were extracted 
and cultured in the same flask and were only split in different wells during the time of 










Chapter 3: MicroRNA profiling 
in young intact, old OA intact 
and old OA lesioned human 








Cartilage biology and OA research have advanced considerably in the last decade due to 
technological improvements in the field of transcriptomics. ‘Whole transcriptome’ 
techniques, such as microarrays and RNA-Seq, have facilitated a shift from interrogating 
specific areas of the genome to investigating the global transcriptomic profile of chondrocytes 
and cartilage, in response to homeostatic changes and disease (Chen et al., 2018, Korostynski 
et al., 2018, Li et al., 2019b, Rai et al., 2020). This, in combination with the development of 
specific software and bioinformatic tools to process, filter and analyse the ‘big data’ 
generated by such experiments, have added significantly to our knowledge regarding 
cartilage biology and OA, away from the simple ‘wear and tear’ model.  
Moreover, scientific advancements in the field have redefined the interrogation of different 
molecules in cartilage biology and disease, including miRNAs. There is growing interest in the 
role of miRNAs in OA and their potential use as biomarkers and therapeutic agents. The 
number of miRNAs involved in OA pathogenesis has increased substantially in the last few 
years, and this is, in part, due to the use of ‘whole genome’ technologies. Microarrays are a 
simple and cost-effective way of measuring expression of thousands of miRNAs in different 
samples at the same time. Miyaki et al (2009) used microarrays to detect DE miRNAs between 
human primary chondrocytes and human MSCs and identified miR-140 as a novel player in 
human chondrocyte differentiation and OA development (Miyaki et al., 2009). In a similar 
study, Swingler et al (2012) identified a set of miRNAs involved in chondrogenesis and their 
potential role in OA, such as miR-455 which was shown to regulate TGF-β signalling by 
suppressing the SMAD2/3 pathway (Swingler et al., 2012).  
Furthermore, Díaz-Prado et al (2012) used microarray analysis to identify DE miRNAs in 3-D 
cultured chondrocytes, isolated from old healthy and old OA human cartilage tissue. Amongst 
these, miR-483-5p was upregulated in OA chondrocytes, whereas miR-149-3p, -582-3p, -
1227, -634, -576-5p and -641 were downregulated in OA chondrocytes (Díaz-Prado et al., 
2012). Microarrays have also been used to identify circulating miRNAs in serum from OA 
patients (Beyer et al., 2015) and in synovial fluid from early and late-stage OA patients (Li et 




Moreover, ageing is the most prominent risk factor for developing OA. It is believed that age-
related effects predispose cartilage to OA development through the accumulation of changes 
in ECM composition and signalling pathways (Loeser et al., 2016). There is very little research 
that has addressed the role of miRNAs in cartilage ageing without the effect of OA, mainly 
due to the difficulty of obtaining relatively healthy cartilage samples from young and old 
donors. Ukai et al (2012) compared the expression of miRNAs between cartilage samples 
collected from infants with polydactylism and cartilage collected from young ACL donors and 
identified three DE miRNAs: miR-199a-3p, -193b and -320c (Ukai et al., 2012). Peffers et al 
(2013) detected significantly higher expression of miR-21 in the metacarpophalangeal joints 
of old horses compared to young suggesting that this miRNA could potentially have a role in 
cartilage ageing (Peffers et al., 2013). Given the lack of data, more research is needed in 
identifying potential miRNA candidates with a role in cartilage ageing. 
 
3.2 Study aim and rationale 
OA is a heterogeneous disease and the molecular landscape that underlines it, is complex. 
There are several risk factors which influence the development and progression of OA, and 
ageing is the most prominent. Moreover, clinical presentation of cartilage degeneration varies 
between patients even within the same joint, with some areas being more affected than 
others. Up to the start of this project (September 2016), there was a limited number of studies 
on the effect of ageing on miRNA expression in human knee OA cartilage tissue. In addition, 
to the best of our knowledge, there were not any studies on the expression of miRNAs 
between areas of different cartilage degeneration within the same knee joint. Therefore, the 
aim of this study was to identify DE miRNAs between young intact, old OA intact and old OA 
lesioned human knee cartilage using microarray analysis.  
 
3.3 Experimental design 
The experimental procedures, pertinent to this chapter, are described briefly below. For full 
details on the experimental procedures, please refer to Chapter 2. Appropriate references are 




3.3.1 Human knee cartilage specimens 
 
To identify DE miRNAs in ageing and OA, three, all male, human knee cartilage groups were 
used:  
i) Young intact cartilage from patients undergoing ACL reconstruction (n=9, 
age±SD=23.8±3.8). Samples were collected from the area of the intercondylar 
notch, as described in Section 2.2. 
ii) Old OA intact cartilage from patients undergoing TKA (n=10, age±SD=62.6±7.3). 
Intact OA cartilage samples were collected from a relatively intact area of the 
femoral condyles of OA patients, as described in section 2.1. 
iii) Old OA lesioned cartilage from patients undergoing TKA (n=10, age±SD=62.6±7.3). 
Lesioned OA cartilage samples were collected from a lesioned area of the femoral 
condyles of OA patients, as described in section 2.1.  
 
The femoral condyles of OA patients were assessed radiographically prior to TKA, and 
macroscopically on the day of TKA. Old OA intact and lesioned cartilage samples were 
collected on the day of TKA. For every patient, a note was made regarding which condyle, 
lateral or medial, intact and lesioned cartilage was sampled from. Moreover, each intact and 
lesioned cartilage sample collected was divided into two pieces. One piece was used for 
histological assessment, and the other piece was used for RNA extraction and microarray 
analysis. Therefore, from each OA patient, four cartilage pieces were collected: two pieces 
from an intact area (histology+microarray analysis) and two pieces from a lesioned area 
(histology+microarray analysis). One cartilage piece was collected from the young intact 
group for microarray analysis, as the piece was not of sufficient size to be used for histology 
too. 
 
3.3.2 Kellgren-Lawrence grading of human knee OA cartilage samples 
 
The lateral and medial femoral condyles of the OA patients (which the old OA intact and 
lesioned cartilage samples were collected from) were radiographically assessed using the KL 




severity, as described in Section 1.5.1 and further explained in Figure 1.7. Statistical analysis 
for KL scores between lateral and medial condyles was undertaken using the Mann-Whitney 
test in GraphPad Prism version 8.0.1 for Windows (GraphPad, 2018). P values<0.05 were 
considered significant.  
 
3.3.3 Macroscopic assessment of human knee OA cartilage samples 
 
The area of the femoral condyles, from which the old OA intact and lesioned cartilage samples 
were collected from, were macroscopically scored using the Outerbridge scoring system, as 
described in Section 2.3. Scoring was undertaken by two independent scorers, at two 
different time points per scorer as described in Section 2.3. For scorer agreement, Scorer A-
1st time was compared to Scorer B-1st time, and Scorer A-2nd time to Scorer B-2nd time. For 
agreement calculation, averages were not used to avoid decimal numbers which are 
incompatible with the online tool used to calculate scorer agreement. For statistical analysis, 
the average score of intact and lesioned cartilage samples was compared using the Mann-
Whitney test in GraphPad Prism version 8.0.1 for Windows. P values<0.05 were considered 
significant. 
 
3.3.4 Histologic assessment of human knee OA cartilage samples 
 
Histology assessment was undertaken for the old OA intact and lesioned cartilage samples 
collected. Samples were paraffin embedded and sectioned as described in Sections 2.4 and 
2.5A. Sections were stained with H&E and Saf-O/FG as described in sections 2.6 and 2.7. 
Sections were scored using the Mankin HHGS and the OARSI scoring system as described in 
Section 2.8. Scoring was undertaken by two independent scorers, in two different time points 
per scorer, and scorer agreement was calculated as described in Section 2.8. Scorer 
agreement was calculated as described above in Section 3.3.3. This was undertaken for both 






3.3.5 RNA extraction from human cartilage samples for microarray analysis 
 
Young intact, old OA intact and lesioned human cartilage tissue was homogenised as 
described in Section 2.12. For microarray analysis, RNA was extracted using the mirVana™ 
miRNA Isolation Kit with phenol, as described in Section 2.13.1.  
 
3.3.6 Microarray analysis between young intact, old OA intact and old OA lesioned human 
knee cartilage samples 
 
DE miRNAs between young intact, old OA intact and old OA lesioned human knee cartilage 
samples were identified using the Affymetrix GeneChip® miRNA 4.0 Arrays, as described in 
Section 2.14. Bioinformatic and statistical analyses of the microarray experiment were 
undertaken as described in Section 2.31.  
 
3.3.7 Target gene prediction and identification of miRNA/mRNA-related biological 
pathways 
 
Target prediction of DE miRNAs identified by microarray analysis in cartilage samples was 
undertaken using IPA as described in Section 2.36. Biological pathways where DE miRNAs 
might be involved in were identified by the ‘Core Analysis’ feature in IPA, as described in 
Section 2.36 and Enrichr analysis as described in Section 2.37. GO terms were generated and 












3.4.1 Kellgren-Lawrence grading of human knee OA femoral condyles 
 
The lateral and medial femoral condyles of the OA patients, recruited for microarray analysis, 
were assigned a KL score according to radiographic findings. Scores for each patient are listed 
in Table 3.1. KL score of the medial condyles was significantly higher to that of the lateral 
condyles (p=0.03) (Figure 3.1). Further analysis showed that for all patients, intact cartilage 
was collected from the lateral condyle, whereas lesioned cartilage was collected from the 
medial condyle Table 3.1.  
 
Table 3.1: KL score of each femoral condyle of the OA patients recruited for microarray 
analysis. N/A: KL score was not available for these samples (patient 1 and 4). 
OA Patient Condyle KL Score Type of sample collected 
1 Lateral N/A Intact 
Medial N/A Lesioned 
2 Lateral 2 Intact 
Medial 4 Lesioned 
3 Lateral 1 Intact 
Medial 2 Lesioned 
4 Lateral N/A Intact 
Medial N/A Lesioned 
5 Lateral 1 Intact 
Medial 3 Lesioned 
6 Lateral 1 Intact 




7 Lateral 3 Intact 
Medial 3 Lesioned 
8 Lateral 3 Intact 
Medial 3 Lesioned 
9 Lateral 2 Intact 
Medial 2 Lesioned 
10 Lateral 2 Intact 











Figure 3.1: Scatter plot of KL score between lateral and medial condyles of the OA patients, 
recruited for microarray analysis. The lateral and medial femoral condyles from knee OA 
patients (n=8) were assessed radiographically and scored using the KL scoring system. 
Statistical analysis was undertaken using a Mann-Whitney test in GraphPad Prism (Version 




























3.4.2 Outerbridge grading of human knee OA femoral condyles  
 
To assess tissue integrity macroscopically, intact and lesioned human knee cartilage samples 
from OA patients (Figure 3.2) were graded using the Outerbridge scoring system by two 
independent scorers, scored twice by each scorer. Results for each scorer are listed in Table 
3.2. Inter-scorer agreement is listed in Table 3.3. On average, for both scorers, intact samples 
were scored significantly lower compared to lesioned samples (p=0.002) (Figure 3.3).  
Figure 3.2: Examples of intact and lesioned cartilage samples collected from knee OA 
patients. A cartilage biopsy from intact and lesioned areas of the femoral condyles of OA 
patients was collected for histology and microarray analysis. For all ten patients, intact 
samples came from the lateral condyle and lesioned from the medial. I: intact, L: lesioned. 





Table 3.2: Outerbridge score for intact and lesioned OA cartilage collected from the knee 
joints of 10 OA patients. N/A: Outerbridge score was not available for patient 4. 
Patient Sample 
Scorer A Scorer B 
Average±SD 
1st Time 2nd Time 1st Time 2nd Time 
1 
Intact 0 0 0 0 0±0 
Lesioned 2 2 2 2 2±0 
2 
Intact 2 2 1 2 1.75±0.5 
Lesioned 4 4 4 4 4±0 
3 
Intact 0 0 0 0 0±0 
Lesioned 3 3 3 4 3.25±0.5 
4 
Intact N/A N/A N/A N/A N/A 
Lesioned N/A N/A N/A N/A N/A 
5 
Intact 1 1 0 1 0.75±0.5 
Lesioned 2 2 2 2 2±0 
6 
Intact 1 2 2 2 1.75±0.5 
Lesioned 2 3 4 4 3.25±1 
7 
Intact 0 0 0 0 0±0 
Lesioned 1 1 0 1 0.75±0.5 
8 
Intact 1 2 1 1 1.25±0.5 
Lesioned 4 4 4 4 4±0 
9 
Intact 0 1 0 0 0.25±0.5 
Lesioned 1 1 1 1 1±0 




Lesioned 2 2 1 2 1.75±0.5 
 
Table 3.3: Inter-scorer agreement between the two independent scorers – macroscopic 
assessment. <0.00: poor, 0.00-0.20: slight, 0.20-0.40: fair, 0.41-0.60: moderate, 0.61-0.80: 
Good, >0.80: Very Good. 
 Outerbridge Score 
 1st time 2nd time 
Inter-scorer agreement 0.70 0.85 
Standard Error 0.10 0.07 
95% Confidence Intervals 0.51 to 0.89 0.73 to 0.98 








Figure 3.3: Scatter plot of Outerbridge scores of intact and lesioned OA cartilage samples. 
Intact and lesioned cartilage tissue was collected from the lateral and medial femoral 
condyles of knee OA patients (n=9) after surgery for end-stage OA. Condyles were scored by 
two independent scorers using the Outerbridge scoring system. For each sample, the score 
represents the average score of two independent scorers, who each scored the samples 
twice. Statistical analysis was undertaken using a Mann-Whitney test in GraphPad Prism 





3.4.3 Histological scoring of old OA intact and lesioned human knee cartilage 
 
To assess tissue integrity histologically, intact and lesioned human knee cartilage samples 
from OA patients were sectioned and stained with H&E and Saf-O/FG (Figure 3.4). Sections 
were graded using the Mankin HHGS and the OARSI scoring system by two independent 
scorers, scored twice by each scorer. Results for each scorer are listed in Table 3.4 for the 
Mankin HHGS, and Table 3.5 for the OARSI scoring system. Inter-scorer agreement is listed in 
Table 3.6.  
For the Mankin HHGS: for patients: 3, 5, 7 and 8, the average score of intact samples was 
lower compared to that of lesioned samples, for two patients (patients 6 and 10), the average 
score of intact samples was equal to that of lesioned samples, and for one patient (patient 9), 
the score of the intact sample was higher than that of the lesioned sample. On average, for 
both scorers, intact samples were scored lower compared to lesioned samples (p=0.12) 
(Figure 3.5A).  
When using the OARSI scoring system: for patients 3, 5, 7 and 8, the average score of intact 
samples was lower compared to that of lesioned samples, whereas for three patients 
(patients 6, 9 and 10) the average score of intact samples was higher than that of the lesioned 
samples. On average from both scorers, intact samples were scored lower compared to 






Figure 3.4: Examples of intact and lesioned cartilage samples stained with H&E and Saf-
O/FG. Intact and lesioned OA cartilage samples were paraffin embedded, sectioned and 
stained with H&E (left side) and Saf-O/FG (right side) for histologic assessment. Red box 
depicts sections of intact and lesioned cartilage from one patient, and yellow box from 





Table 3.4: Mankin HHGS for intact and lesioned OA cartilage collected from the knee joints 
of 10 OA patients. N/A: Paraffin blocks for these samples were not available. 
Patient Sample 
Scorer A Scorer B 
Average±SD 
1st Time 2nd Time 1st Time 2nd Time 
1 Intact N/A N/A N/A N/A N/A 
Lesioned N/A N/A N/A N/A N/A 
2 Intact 4 4 3 3 3.5±0.5 
Lesioned N/A N/A N/A N/A N/A 
3 Intact 1 1 2 2 1.5±0.5 
Lesioned 5 4 8 7 6±1.6 
4 Intact N/A N/A N/A N/A N/A 
Lesioned N/A N/A N/A N/A N/A 
5 Intact 1 2 2 1 1.5±0.5 
Lesioned 7 7 8 6 7±0.7 
6 Intact 3 3 4 4 3.5±0.5 
Lesioned 3 4 4 3 3.5±0.5 
7 Intact 4 4 4 5 4.25±0.4 
Lesioned 7 7 7 7 7±0 
8 Intact 5 5 3 5 4.5±0.9 
Lesioned 9 9 8 9 8.75±0.4 
9 Intact 5 2 4 2 3.25±1.3 
Lesioned 1 2 2 2 1.75±0.4 




Lesioned 2 2 1 1 1.5±0.5 
 
 
Table 3.5: OARSI scoring system for intact and lesioned OA cartilage collected from the knee 
joints of 10 OA patients. N/A: Paraffin blocks for these samples were not available.  
Patient Sample 
Scorer A Scorer B 
Average±SD 
1st Time 2nd Time 1st Time 2nd Time 
1 Intact N/A N/A N/A N/A N/A 
Lesioned N/A N/A N/A N/A N/A 
2 Intact 2 2 1 1 1.5±0.6 
Lesioned N/A N/A N/A N/A N/A 
3 Intact 0 0 1 1 0.5±0.6 
Lesioned 3 2 3 3 2.75±0.5 
4 Intact N/A N/A N/A N/A N/A 
Lesioned N/A N/A N/A N/A N/A 
5 Intact 1 1 1 0 0.75±0.5 
Lesioned 3 2 3 3 2.75±0.5 
6 Intact 1 1 2 2 1.5±0.6 
Lesioned 0 2 1 1 1±0.8 
7 Intact 1 2 1 2 1.5±0.6 
Lesioned 4 4 2 3 3.25±1 
8 Intact 2 2 1 2 1.75±0.5 




9 Intact 1 1 1 1 1±0 
Lesioned 1 1 0 1 0.75±0.5 
10 Intact 1 1 1 1 1±0 





Table 3.6: Inter-scorer agreement for the two independent scorers. <0.00: poor, 0.00-0.20: 
slight, 0.20-0.40: fair, 0.41-0.60: moderate, 0.61-0.80: Good, >0.80: Very Good. 
 Mankin HHGS OARSI grading system 
 1st time 2nd time 1st time 2nd time 
Inter-scorer agreement 0.64 0.66 0.47 0.44 
Standard Error 0.07 0.08 0.14 0.12 
95% Confidence Intervals 0.50 to 0.77 0.51 to 0.82 0.20 to 0.75 0.22 to 0.67 















Figure 3.5: Scatter plot of score of intact and lesioned OA cartilage samples. Intact (n=8) and 
lesioned (n=7) OA cartilage samples were stained with H&E and Saf-O/FG and scored using 
the A) Mankin HHGS and B) OARSI grading system. For each sample, the score represents the 
average score of two independent scorers, who each scored the sections twice. Statistical 
analysis was undertaken using a Mann-Whitney test in GraphPad Prism (Version 8.0.1). Data 
are represented as mean±SD. P values<0.05 were considered significant.   
 
3.4.4 Microarray analysis overview 
 
Data quality was assessed by measuring small RNA expression in nine young intact, 10 old OA 
intact and 10 old OA lesioned samples. Log2 small RNA expression distribution (Figure 3.6A) 
and probability density curves (Figure 3.6B) for all samples, revealed that there was no 
notable systematic expression bias between samples and there were no outliers. Assessment 
of dispersion of expression values across arrays for each miRNA, identified differences in 




amongst samples showed that samples in the young group correlated closer to each other 
and there was no significant biological variation within the group. In contrast, samples in OA 
intact and OA lesioned groups were more variable and biological variation was stronger within 










Figure 3.6: Microarray data quality assessment from young intact, old OA intact and 
lesioned cartilage samples. A) Boxplot and B) density curve of miRNA log-transformed 
expression distribution generated young intact, old OA intact and lesioned cartilage samples. 




Figure 3.7: Heatmap of sample correlation coefficients. Correlation coefficients following 
microarray analysis between young intact, old OA intact and lesioned cartilage samples were 
computed using log-transformed expression values of detected miRNAs. Colour gradient from 
blue to red denotes transition from low to high correlation coefficients. Heatmap generated 






2-D PCA plot of the second and third components of log-transformed miRNA abundance 
showed that young intact cartilage samples clustered together in one group and were 
separated from OA intact and OA lesioned groups (Figure 3.8). OA intact samples were 
scattered in a wide range and could be divided into two separate subgroups: OA-Intact-1 
(samples OA-I-1, OA-I-2, OA-I-3 and OA-I-5) and OA-Intact-2 (samples OA-I-4, OA-I-6, OA-I-7, 
OA-I-8, OA-I-9 and OA-I-10).  
 
Figure 3.8: 2-D PCA plot of the second and third components of miRNA abundance in young 
intact, old OA intact and old OA lesioned samples. Clustering of young intact (Y), old OA 
intact (OA-I) and lesioned (OA-L) cartilage samples based on miRNA expression, following 
microarray analysis. Green: Young intact, magenta: old OA-Intact-1, red: old OA-Intact-2, 
black: old OA-Lesioned. Numbers (1 to 9 for young intact and 1 to 10 for old OA 




OA lesioned samples were also scattered, but the degree of variation was not as high as in 
the OA intact group. Therefore, OA lesioned samples could be clustered into three similar 
subgroups or remain in one major group. Clustering of OA lesioned samples into three 
subgroups would complicate further analysis and comparison to the rest of the groups. 
Therefore, the decision to cluster all OA lesioned samples in one group was made.  
To investigate possible reasons for the old OA intact group splitting into two subgroups, I 
analysed patient data that were available: age, KL score, Outerbridge score, Mankin score and 
OARSI score (Table 3.7). Analysis showed that there is a statistically significant 10-year 
difference between OA-Intact-1 and OA-Intact-2 groups, with patients in OA-Intact-1 being 
younger than patients in OA-Intact-2 (Figure 3.9A). Although intact and lesioned samples 
were obtained from the same OA patients, there is little separation in the lesioned group 
based on age differences, and lesioned samples were grouped together. Moreover, it was 
observed that samples in Intact-group1 had a lower KL, Outerbridge, Mankin and OARSI score 
compared to OA-Intact-2, but differences were not significant (Figure 3.9 B-E).  
 
 
Table 3.7: Characteristics and comparison of OA-Intact-1 and OA-Intact-2 samples. For each 
characteristic, the average±SD is shown. Statistical analysis undertaken using the Mann-
Whitney test. P values are indicated. 
 OA-Intact-1 OA-Intact-2 OA-Intact-1 VS OA-Intact-2 
(p-value) 
Age  56±3.5 67±4.6 0.01 
KL score  1.33±0.58 2.20±0.84 0.23 
Outerbridge score 0.63±0.83 0.70±0.76 0.74 
Mankin score 2.17±1.15 3.40±1.18 0.30 
















Figure 3.9: Comparison of OA-Intact-1 and OA-Intact-2 cartilage samples. OA-Intact-1 (n=3-
4) and OA-Intact-2 (n=5-6) samples were compared to each other based on the following 
characteristics: age of donors, KL score, Outerbridge score, Mankin HHGS score and OARSI 
score. Statistical analysis was undertaken using a Mann-Whitney test in GraphPad Prism 
(Version 8.0.1). Data are represented as mean±SD. P values<0.05 were considered significant. 
**: p<0.01. Outerbridge, Mankin HHGS and OARSI scores represent the average score of two 




3.4.5 Differentially expressed miRNAs in young intact, old OA intact and old OA lesioned 
human cartilage 
 
To identify DE miRNAs, the following comparisons were investigated:  
- Old OA lesioned vs Young (OA-Lesioned vs Y) 
- Old OA intact subgroup 1 vs Young (OA-Intact-1 vs Y)  
- Old OA intact subgroup 2 vs Young (OA-Intact-2 vs Y) 
- Old OA lesioned vs OA intact subgroup 1 (OA-Lesioned vs OA-Intact-1)  
- Old OA lesioned vs OA intact subgroup 2 (OA-Lesioned vs OA-Intact-2) 
- OA intact subgroup 1 vs OA intact subgroup 2 (OA-Intact-1 vs OA-Intact-2) 
 
In the above comparisons, the first group mentioned is the group of interest and the second 
group is the reference group. For this thesis, changes in miRNA expression 
(increased/decreased expression) refer to changes of miRNA expression in the group of 
interest compared to the reference group.  
A list of DE miRNAs was identified for each of the above comparisons and differential 
expression was reported as logFC (Figure 3.10). Significantly DE miRNAs were defined as those 
with FDR-adjusted p-value < 5%, as described in Section 2.31. Table 3.8 summarises the total 





Figure 3.10: Visual identification of significantly DE miRNAs in human cartilage samples, 
detected by microarray analysis. Volcano plots were used to contrast statistical significance 
[-log10(p-value)] to magnitude of differential expression (logFC) of miRNAs identified in six 
comparisons. Red dots represent individual miRNAs which are significantly differentially 
expressed. The further away from 0 on x axis, the higher the level of differential expression 
(either positive or negative) for an individual miRNA. The higher an individual miRNA scores 
on the y axis, the more statistically significant its differential expression is. Thus, red dots in 
the upper left and right corner of each volcano plot represent miRNAs with the highest degree 
of statistically significant differential expression.  Plots generated in R. Intact-1: OA intact 




Table 3.8.: Number of significantly DE miRNAs in human cartilage samples. Significant DE 
miRNAs are defined as those with FDR-adjusted p-value<5%. 
 
 OA-Lesioned vs Y  OA-Intact-1 vs Y  OA-Intact-2 vs Y 
No of DE miRNAs with higher 
expression in the group of interest 
20 69 19 
No of DE miRNAs with lower expression 
in the group of interest 
298 408 313 
Total 318 477 332 
 




 OA-Intact-1 vs OA-
Intact-2 
No of DE miRNAs with higher 
expression in the group of interest 
90 3 30 
No of DE miRNAs with lower expression 
in the group of interest 
33 9 85 
Total 123 12 115 
 
The full list of significantly DE miRNAs for every comparison is in Appendix to Chapter 3. 
Analysis showed that the list of significantly DE miRNAs was similar in the following three 
comparisons: OA-Lesioned vs Y, OA-Intact-1 vs Y and OA-Intact-2 vs Y, indicating that OA 
intact and OA lesioned cartilage samples were more similar to each other than to the young 
cartilage samples. Of the old OA groups, OA-Lesioned and OA-Intact-2 were more similar to 
each other and less similar when compared to OA-Intact-1 group. Since the list of DE miRNAs 
was similar for the first three comparisons, I selected these for analysis in IPA. MicroRNA 
Target filter analysis generated a list of experimentally validated and highly predicted mRNA 




high (>10,000). For core analysis, there is a cut off of 8,000 genes. To meet this requirement 
and redefine the number of predicted mRNAs appropriate filters for cartilage and OA were 
selected. As expected, the list of mRNA targets was highly similar for all three comparisons 
and included transcription factors, cytokines and ligands, receptors and ECM components.  
Figure 3.11: Top canonical pathways of validated and predicted mRNA targets of DE miRNAs in human 
cartilage samples. Core analysis of highly predicted mRNA targets of DE miRNAs in OA-Lesioned vs Y, OA-Intact-
1 vs Y and OA-Intact-2 vs Y, revealed the most important pathways that these mRNAs are involved in. Pathways 
were ranked based on level of significance [-log(p-value)], dependent on the number of mRNAs involved in each 
pathway. The figure depicts biological pathways generated from validated and predicted mRNA targets of the 
DE miRNAs identified in the OA-Lesioned vs Y comparison. DE miRNAs in OA-Intact-1 vs Y and OA-Intact-2 vs Y 






Figure 3.12: The osteoarthritis pathway generated by IPA based on predicted target genes 
of DE miRNAs. Osteoarthritis pathway was one of the top canonical pathways associated with 
the predicted target genes of DE miRNAs. Predicted target genes were involved in several OA-
related mechanisms and were linked to ageing, injury, physical exercise and obesity. Figure 




IPA Core Analysis generated similar results for the three comparisons. Specifically, predicted 
mRNA targets of DE miRNAs were involved in significant canonical pathways, including 
osteoarthritis pathway [-log(p-value)=50.04], hepatic fibrosis [-log(p-value)=39.46], role of 
osteoblasts and chondrocytes in rheumatoid arthritis [-log(p-value)=36.67], IL-17 signalling [-
log(p-value)=19.86], HIF1α signalling [-log(p-value)=18.89] and others (Figure 3.11) (Figure 
3.12). Top diseases and disorders associated with these mRNAs are listed in Table 3.9, and 
top molecular and cellular functions are listed in Table 3.10. Moreover, IPA generated a list 
of potential upstream regulators of the predicted target genes. Amongst these, there were 
molecules involved in inflammation, such as IL-1β (p= 1.92x10-66) and TNF-α (p=5.33x10-62), 
as well as cell signalling, such as TGF-β (p=2.11x10-55). IPA report is in Appendix to Chapter 3. 
Table 3.9: Top diseases and disorders associated with predicted targets genes of DE 
miRNAs.  
Name p-value range Number of target genes 
involved 
Cancer  1.11x10-22 – 4.69x10-63 188 
Organismal Injury and 
Abnormalities  
1.69x10-22 –  4.69x10-63 212 
Cardiovascular Disease  5.46x10-23 – 1.51x10-56 139 
Inflammatory Response  2.28x10-22 – 7.97x10-50 155 
Connective Tissue Disorders  8.87x10-23 – 2.96x10-48 147 
 
Table 3.10: Top molecular and cellular functions associated with predicted mRNA targets of 
DE miRNAs. 
Name p-value range Number of mRNAs involved 
Cellular Movement  9.40x10-23 – 5.42x10-72 157 




Cellular Growth and 
Proliferation  
2.13x10-22 – 3.33x10-64 178 
Cell Death and Survival  1.69x10-22 – 3.33x10-60 162 
Cell-To-Cell Signalling and 
Interaction  
1.81x10-22 – 3.98x10-56 141 
 
To investigate further the potential pathways that the DE miRNAs and their predicted target 
genes are associated with, the Enrichr online tool was used. Analysis showed that predicted 
mRNAs of DE miRNAs from OA-Lesioned vs Y, OA-Intact-1 vs Y and OA-Intact-2 vs Y were 
involved in pathways such as inflammatory response, cytokine production, cytokine response, 
regulation of apoptosis and regulation of cell proliferation amongst others. To create pathway 
interactions, gene ontology terms were generated with ToppGene Suite and redefined with 









Figure 3.13: Pathway interaction analysis of predicted targets of DE miRNAs from 
comparisons OA-Intact-1 vs Young Intact and OA-Intact-2 vs Young Intact. Predicted target 
genes of DE miRNAs from comparisons A) OA-Intact-1 vs Young Intact and B) OA-Intact-2 vs 
Young Intact were uploaded on ToppGene Suite which generated a list of GO terms. GO terms 
were pasted in REVIGO for selection of key biological pathways. Biological pathways were 
visualised with Cytoscape Version 3.8.2, which generated the figures. Pathways of interest 







After identifying biological pathways from the first three comparisons (OA-Lesioned vs Y, OA-
Intact-1 vs Y and OA-Intact-2 vs Y), I sought to identify pathways relevant to the other three 
comparisons that were generated by microarray analysis: OA-Lesioned vs OA-Intact-1, OA-
Lesioned vs OA-Intact-2 and OA-Intact-1 vs OA-Intact-2. Enrichr analysis was undertaken to 
investigate the biological processes that the predicted targets of DE miRNAs from these three 
comparisons were involved in. Analysis revealed that these were involved in pathways such 
as regulation of ion transport, actin and cytoskeleton regulation, MAPK cascade, Ras 
signalling, regulation of apoptosis, neuronal signalling, synaptic transmission, response to 











Figure 3.14: Pathway interactions of predicted gene targets of DE miRNAs from comparison 
OA-Lesioned vs OA-Intact-1 and OA-Intact-1 vs OA-Intact-2. Predicted targets of DE miRNAs 
from comparisons A) OA-Lesioned vs OA-Intact-1 and B) OA-Intact-1 vs OA-Intact-2 were 
uploaded on ToppGene Suite which generated a list of GO terms. GO terms were pasted in 
REVIGO for selection of key biological pathways. Biological pathways were visualised with 












OA is the most common joint disease that affects millions of people worldwide and especially 
the elderly population. It is considered a whole joint disease with several joint tissues 
affected. Amongst them, cartilage is, by far, the most researched tissue in OA. Ageing is the 
most prevalent risk factor for OA and it is thought that cartilage changes that accumulate with 
increasing ageing contribute to OA. An evolving area in cartilage ageing and OA that has 
attracted scientific interest is epigenetic alterations and, specifically, changes in miRNA 
expression. Scientific and technical advancements have enabled the interrogation of the 
whole miRNAome in tissue homeostasis and disease. In this project, I undertook a microarray 
analysis approach to detect changes in miRNA expression between young intact, old OA intact 
and old OA lesioned cartilage and investigate how differentially expressed miRNAs could 
contribute to cartilage ageing and disease.  
Old OA intact and lesioned cartilage samples were collected from patients undergoing TKA. 
Prior to surgery, lateral and medial condyles were assessed radiographically and scored, 
based on the KL grading system. Analysis showed that, per patient, OA intact samples were 
collected from the lateral condyle and OA lesioned samples from the medial condyle. 
Moreover, it was shown that lateral condyles were graded significantly lower than medial 
condyles (p=0.03). This is to be expected as the medial is the most weight-bearing condyle 
between the two and usually more affected than the lateral (Pelletier et al., 2007). 
Macroscopic scoring using the Outerbridge grading system confirmed that the lateral 
condyles were less damaged than the medial condyles, per patient. To avoid scorer bias, two 
independent scorers graded the sections in two different time points. Results showed that 
there was a good level of agreement between the scorers and analysis was reproducible.  
Histologic assessment and scoring using the Mankin HHGS and the OARSI grading system 
generally confirmed radiographic and macroscopic assessments. For all but two patients, 
intact samples were graded lower than lesioned samples with the Mankin HHGS, although 
the difference between these scores was small. For patient 9, the intact sample was scored 
higher than the lesioned sample (average 3.5 compared to 1.75) and for patient 10, intact 
sample had the same score as the lesioned sample (average 1.5 for both), in contrast to KL 




lesioned. One possible explanation for this, is that biopsies taken from specific parts of the 
condyles were not representative of the joint as a whole (Moskowitz, 2006). This could explain 
partially why results for the Mankin HHGS did not reach statistical significance (p=0.12). This 
also applies to the OARSI scoring system (p=0.26). The OARSI scoring system utilises not only 
the depth of the lesion (grade) but also the extent of damage in the articular surface (stage) 
to assess OA severity. However, this implies that sections be prepared from the whole condyle 
which was not possible for this project. Moreover, the OARSI system assesses bone 
deformation and remodelling (Pritzker et al., 2006) which was beyond the scope of this 
project. Therefore, partial use of the parameters outlined for each scoring system could lead 
to skewed or biased results. However, this does not undermine the use of histology, or 
suggests that KL and macroscopic scoring systems are better at assessing OA severity. This is 
because KL and Outerbridge scoring systems take into account specific criteria and the grades 
assigned have a limited range (from 0 to 4) and cannot distinguish between samples that are 
similar and only differ slightly. For such samples histologic assessment is more reliable in 
identifying underlying tissue differences, as long as different parts of the joint are assessed. 
Although there was a good agreement between radiographic, macroscopic and histologic 
assessment for most patients in our study, it is preferred, when possible, to utilize different 
scoring approaches for better assessment of tissue integrity and OA severity. Moreover, 
another point that should be taken into account is donor variability. Even though for the same 
patient, intact samples are generally graded lower than lesioned samples, this might not be 
the case when comparing different patients to each other, as the intact sample from one 
patient could have the same or slightly higher score than the lesioned sample of another 
patient. All samples came from end-stage OA patients following TKA, however, this does not 
mean that lateral and medial condyles from different patients have the same degree of 
cartilage damage. As OA is a heterogeneous disease, there are many factors, apart from 
cartilage loss, that could affect a patient’s decision to have TKA, including pain in the joint, 
level of discomfort, degree of disability and interference with everyday activities (Skou et al., 
2015). In our data set, this is also evident from the error bars in the scatter plots for the 
Mankin and OARSI scores (Figure 3.5), which implies some degree of patient variability, even 
though our data suggests that the general trend is that intact samples had lower scores than 




For microarray analysis, three different groups were used: young intact cartilage from 
patients undergoing ACL reconstruction, old OA intact and lesioned cartilage from patients 
undergoing TKA (collected from the same OA patients). This project aimed to identify DE 
miRNAs in ageing and diseased cartilage, hence the use of young intact samples. An important 
note here is the suitability of cartilage from young ACL patients as the control/reference 
group. Rupture of the cruciate ligament is a known risk factor for developing PTOA as the 
rupture destabilises the knee joint if left untreated or in some cases even after reconstruction 
(Ajuied et al., 2014). In a follow up study, about 34% of patients who had ACL surgery showed 
signs of slight joint degeneration (KL=1) and approximately 30% showed moderate 
degeneration (KL=2), ten years after surgery. Perhaps, changes in the joint following ACL 
injury that lead to OA might not appear until years after rupture. In this project, all young 
samples were collected from patients who had reconstruction weeks to a few months after 
injury and therefore this time frame may not have been enough for changes to be established 
in cartilage. Moreover, young cartilage was collected from the intercondylar notch, an area 
which is not heavily affected by OA. MRI longitudinal studies in weight-bearing knee areas of 
OA patients showed that the most cartilage volume loss over a period of 24 months was 
observed in the medial condyle, followed by the lateral condyle and the area less affected 
was that of the intercondylar notch (Pelletier et al., 2007). In our study, young cartilage from 
the notch was inspected for any pathological changes during collection and intact tissue was 
collected. Histologic assessment would have provided more details about to tissue integrity 
of young intact cartilage samples and their suitability to be used as the control group in our 
microarray analysis. However, that was not possible due to the small amount of cartilage 
tissue collected from these young ACL patients, which was enough for RNA extraction only 
and did not allow its use for histologic assessment as well.  
Following microarray analysis, the 2-D PCA plot generated showed a wide distribution of 
samples. Even though young intact samples clustered tighter together, old OA samples 
clustered more widely. Old OA lesioned samples did not cluster as tight as young samples but 
could still be considered as one group. However, old OA intact samples clustered in two 
distinctive subgroups: OA-Intact-1 and OA-Intact-2. This could be due to the 10-year age 
difference (OA-Intact-1: 56±3.5 years, OA-Intact-2: 67±4.6 years) or tissue integrity of the 




Outerbridge, Mankin and OARSI scores compared to OA-Intact-2 group (Table 3.7) even 
though differences between the two groups were not significant. Therefore, the separation 
of the OA intact group observed in our microarray data could be the result of different OA 
severity amongst the samples of the group. In our experience, this was not generally 
unexpected. In a previous microarray study published by our group, I compared the 
expression of miRNAs between a smaller number of young cartilage samples from ACL donors 
and old OA intact cartilage from TKA donors (Balaskas et al., 2017). Analysis showed that old 
OA intact cartilage samples were separated in three different clusters based on OA severity, 
defined by KL radiographic assessment. Results from our previous study and this study 
suggest the accumulation of biological variation in miRNA expression with ageing and OA. 
Furthermore, as already discussed, OA is a heterogeneous disease characterised by different 
phenotypes, risk factors and clinical symptoms amongst patients (Roman-Blas et al., 2020). 
Therefore, subgrouping might indicate underlying molecular differences. 
Several DE miRNAs were identified in each comparison. First, I compared the old OA intact 
group to the young group and the old OA lesioned group to the young group, as this was the 
primary focus of the project. Most of DE miRNAs identified in these comparisons had lower 
expression in the old OA groups compared to the young intact group. This was in accordance 
with our previous study in cartilage, discussed previously (Balaskas et al., 2017). In fact, the 
list of DE miRNAs was similar in all three comparisons (OA-Lesioned vs Y, OA-Intact-1 vs Y and 
OA-Intact-2 vs Y). This indicated that, as expected, old OA groups were more similar to each 
other than to young samples. This was also apparent by the number of DE miRNAs between 
all comparisons, as there were more DE miRNAs when old OA groups were compared to the 
young intact group than to each other. This is expected as there are more biological factors 
that could drive miRNA differences when comparing the young group to the old OA groups. 
These include mainly ageing and OA. Apart from the fact that disease is one of the major 
differences between young ACL and old OA donors in our data set, there was also an 
approximate 40-year age difference between young donors and old OA donors. In contrast, 
old OA intact and lesioned cartilage was collected from the same OA donors and therefore 
ageing was not a critical factor driving miRNA expression when the old OA groups were 
compared to each other. Therefore, it is expected that the number of DE miRNAs would be 




fact, most dysregulation was observed in the OA-Intact-1 vs Y comparison, based on the 
number of DE miRNAs. Predicted gene targets of DE miRNAs from these three comparisons 
revealed that these are involved in cartilage and OA-related pathways including 
inflammation, cytokine production, secretion and signalling all of which are linked to cartilage 
ageing and OA (Chow et al., 2020, Sokolove et al., 2013, Wojdasiewicz et al., 2014).  
Following initial analysis, old OA groups were compared to each other. Of the three OA 
groups, OA-Intact-2 and OA-Lesioned groups were more similar to each other than to OA-
Intact-1 group, also evident by the number of DE miRNAs between these comparisons (Table 
3.8).  When comparing OA-Intact-1 group to OA-Lesioned and OA-Intact-2, there were 123 
and 115 DE miRNAs, respectively, in contrast to OA-Lesioned vs OA-Intact-2 comparison, 
where there were only 12 DE miRNAs. This could be due to the differences between OA-
Intact-1 and 2 groups mentioned previously. Samples in OA-Intact-1 were graded lower (less 
severe OA) compared to samples in OA-Intact-2 and OA-Lesioned groups. Tissue integrity was 
more compromised in OA-Intact-2 group, thus more similar to the OA-Lesioned group. By 
looking at the biological processes and the predicted targets of DE miRNAs from each of these 
comparisons, it was found that DE miRNAs in OA-Lesioned vs OA-Intact-1 and OA-Intact-1 vs 
OA-Intact-2, were involved in regulation of cell proliferation, actin and cytoskeleton 
organisation, chemokine signalling, ion transport, responses to wounding, apoptosis and 
neurotransmitter transport. This is in agreement with the results reported by Soul et al (2018), 
where they compared gene expression between old OA intact cartilage samples and age-
matched non-OA cartilage samples (Soul et al., 2018). In this study, old OA intact samples 
were clustered into two sub-groups: Group A and Group B. As in our study, Group A had lower 
Mankin Score and age mean compared to Group B and Group B included genes related to 
mechanotransduction, actin and cytoskeleton regulation and ion transport. Comparison of 
these two subgroups revealed DE genes involved in oxidative stress, immune responses, 
chemokine signalling, apoptosis, calcium and ion regulation (Soul et al., 2018), which are 
similar to our study when I compared OA-Intact-1 to OA-Intact-2. In fact, our study showed 
that there was a shift in the biological pathways/molecular mechanisms, when comparing 
young samples to old OA groups and when comparing old OA groups amongst each other. 
When old OA groups were compared to the young group, inflammation and cytokine-related 




other, inflammation-related pathways were not the prominent pathways identified. This may 
suggest that after inflammation is established in the joint, there are not major changes in the 
levels of inflammatory cytokines that are released as OA progresses. This is in agreement with 
other studies where they failed to identify major changes in inflammatory genes between 
intact and lesioned OA samples (Dunn et al., 2016).  
Pathways identified when comparing old OA groups to each other, such as cell morphology, 
cell proliferation, apoptosis, ion transport, wound healing, blood circulation and neuron-
related pathways, highlight the biological processes that take place during OA progression. 
These include changes in tissue integrity as cartilage breaks down and chondrocytes become 
hypertrophic and apoptotic. The wound healing pathway identified in the analysis is closely 
linked to transition from intact to lesioned cartilage. As the process of cartilage break down 
begins, there is a tissue reaction to compensate for the loss of ECM (Goldring et al., 2016). 
The results reported here indicate that such alterations in tissue morphology and wound 
healing are also reflected on the cartilage miRNAome. Of note is the identification of 
cation/ion-transport related pathways when the old OA groups were compared, and 
especially when the OA-Lesioned group was compared to the OA-Intact-1 group. 
Chondrocytes have a defined channelome which responds to mechanical and physical stimuli 
(Mobasheri et al., 2019). Our analysis revealed, intact samples came from the lateral condyle 
and lesioned samples from the medial condyle. During OA, the medial condyle is subjected to 
higher mechanical pressures compared to the lateral condyle. This could affect ion channel 
responsiveness between the two areas of cartilage, leading to altered ion and biomechanical-
related pathways between areas of high and low loading. When Dunn et al (2016) compared 
gene expression between intact and lesioned areas of cartilage, they identified DE genes 
involved in, amongst others, mechanical loading and stimuli. The fact that predicted target 
genes of DE miRNAs identified in OA-Lesioned vs OA-Intact-1 were also involved in 
mechanotransduction, confirms the important function of miRNAs in several aspects of 
cartilage biology and homeostasis.  
Finally, two other biological processes that were identified as significant when comparing old 
OA intact and lesioned groups were blood circulation and neuronal signalling. Cartilage is 
devoid of blood vessels and neurons. However, in advanced stages of OA, when significant 




vessels penetrate calcified cartilage (Mapp et al., 2012). Blood invasion is also accompanied 
by innervation in areas of the joint that normally do not have any sensory neurons, leading to 
increased pain in the joint (Mapp et al., 2012). At first, pain is nociceptive occurring when the 
joint moves. However, as OA progresses, pain can be present even during resting phases or 
during the night and this coincides with greater cartilage damage (Schaible, 2012). Even 
though there is not a direct correlation between radiographic findings and pain, it was 
reported that OA patients with higher KL score have more incidents of pain and this was linked 
to more loss of cartilage damage in the medial condyle (Eckstein et al., 2011). This is 
consistent with our analysis, as the comparison between OA-Intact-1 and OA-Lesioned 
samples, where the biggest differences in scoring/cartilage loss were observed, identified DE 
miRNAs that could be involved in neuronal/pain-related pathways, further cementing the role 
of miRNAs in cartilage homeostasis and different stages of disease and highlighting the 
interplay between different tissues in the joint and their contribution to OA.  
 
3.6 Conclusion 
Microarray analysis between young intact, old OA intact and old OA lesioned human knee 
cartilage samples identified a distinctive profile of DE miRNAs in ageing and OA cartilage of 
different damage stages. Analysis suggested that there are several disease mechanisms that 
can contribute to OA and within these mechanisms, miRNAs play an important role from 
initiation to disease progression. This highlights that gene regulation in cartilage is a multi-
layered process and is indicative of the complex molecular landscape that underlies cartilage 
damage and OA. In the next chapters, I validated a selected set of DE miRNAs from our 












Chapter 4: Validation of miRNA profiling in 
young intact, old OA intact and old OA 
lesioned human cartilage and investigation 








There has been a significant increase in the number of publications regarding miRNAs and OA 
in the last decade. MiRNAs have been linked to important biological pathways in cartilage and 
OA such as inflammation, hypertrophy, apoptosis and mechanotransduction (Chen et al., 
2016b, Gu et al., 2021, Hecht et al., 2019, Liao et al., 2020). Inflammation is one of the most 
prominent changes that characterise ageing and OA cartilage. Aged senescent chondrocytes 
exhibit a secretory phenotype by producing higher levels of pro-inflammatory cytokines, 
leading to the establishment of low-grade inflammation in the joint, called inflammageing 
(Loeser, 2010). Inflammageing, together with other factors, such as injury and mechanical 
stress, contributes to the development of OA and of a more severe inflammatory response. 
This leads to extended changes in the joint and contributes to cell apoptosis and cartilage loss 
(He et al., 2020).  
Inflammation of the OA joint is evident, not only in the tissue level, but at a molecular level. 
A key part of this inflammatory response is IL-1β, a pro-inflammatory cytokine which has 
major roles in OA-related molecular pathways (for more detailed information please refer to 
Chapter 1, Figure 1.12). IL-1β affects expression of important cartilage and ECM components, 
such as collagens, aggrecan, MMPs and ADAMTSs, but also promotes the expression of other 
pro-inflammatory cytokines, such as TNF-α and IL-6 (Chow et al., 2020). Moreover, 
inflammation, and IL-1β specifically, affect the expression of several miRNAs and their target 
genes. In vitro experiments using IL-1β-treated primary chondrocytes have shed light on the 
role of IL-1β in miRNA expression (Papanagnou et al., 2016). These experimental conditions 
mimic an OA inflammatory environment and provide the opportunity to investigate OA-
related gene responses and disease mechanisms in vitro. Of significant use are microarray 
studies which compare miRNA expression in IL-1β treated chondrocytes compared to control, 
as they provide the opportunity to investigate several miRNA changes in response to IL-1β. 
One such study, from Akhtar et al (2010,) identified 44 DE miRNAs (2 upregulated and 42 
downregulated) in OA chondrocytes treated with 5ng/ml or 10ng/ml IL-1β for 6h (Akhtar et 
al., 2010). In a similar study, Rasheed et al (2016) identified one upregulated and 35 
downregulated miRNAs in OA chondrocytes treated with 5ng/ml IL-1β for 24h, including 
several miRNAs from the let-7 family (Rasheed et al., 2016). Therefore, this experimental 




4.2 Study aim and rationale 
Microarray analysis in Chapter 3 identified DE miRNAs between young intact, old OA intact 
and old OA lesioned cartilage collected from knee joints of young patients undergoing ACL 
reconstruction, and old OA patients undergoing TKA. In this chapter, qPCR validation of 
selected miRNAs was carried out in: 
i) the same cartilage samples used in the microarrays (dependent cohort) 
ii) an additional cohort of young intact, old OA intact and old OA lesioned cartilage 
samples (independent cohort) 
iii) young healthy and old healthy cartilage samples from cadavers 
 
Moreover, in Chapter 3, IPA analysis of DE miRNAs from comparisons OA-Intact vs Young, and 
OA-Lesioned vs Young identified inflammatory response and cytokine signalling amongst the 
main pathways that these miRNAs are involved in. Furthermore, IL-1β was identified as an 
upstream regulators of these DE miRNAs and their predicted targets. Therefore, to further 
investigate the expression of selected miRNAs in an OA in vitro inflammatory model, primary 
OA chondrocytes were treated with human IL-1β for different time points.  
 
4.3 Experimental design 
The experimental procedures, pertinent to this chapter, are described briefly below. For full 
details on the experimental procedures, please refer to Chapter 2. Appropriate references are 
provided throughout the text.  
 
4.3.1 Selection of specific DE miRNAs for follow up studies following microarray analysis 
 
For validation of microarray results by qPCR, specific DE miRNAs were selected for follow up 
studies. As described in Chapter 3, the list of DE miRNAs in comparisons OA-Lesioned vs Y, 




three comparisons as I was interested in including all three major cartilage groups (young, old 
OA intact and lesioned). Specific DE miRNAs were selected based on the following criteria: 
- only mature miRNA forms were selected for further validation 
 
- fold change, as I chose those with logFC <-3 or >3 in all three comparisons 
 
- known and predicted importance in cartilage biology, based on the available 
literature and known/predicted target genes generated by target prediction tools 
as described in Section 2.35. 
Additionally, miRNAs that belonged to families with very similar sequences, such as miRNAs 
of the let-7 family and miRNA isoforms (miRNAs denoted with -a, -b, -c and so on) were 
excluded from further follow up, as qPCR technology may not be sufficient to conclusively 
distinguish between these. Finally, other candidates were selected for qPCR validation, based 
on known function in cartilage biology from the available literature. 
 In addition, miRNAs with no/limited data regarding their function in cartilage were also 
selected for qPCR validation. These miRNAs were investigated further in young healthy and 
old healthy cartilage samples from cadavers, and primary chondrocytes treated with IL-1β.  
 
4.3.2 Human knee cartilage specimens used for qPCR validation of microarray results 
 
Validation of microarray results was carried out by qPCR in the same samples that were used 
for microarray analysis (dependent cohort), as well as in an independent cohort of cartilage 
samples also from male donors. Patient characteristics for the dependent cohort can be found 
in Chapter 3, Section 3.3.1. For the independent cohort, the following samples were used: 
i) Young intact cartilage from patients undergoing ACL reconstruction (n=8, 
age±SD=21±6.5). Samples were collected from the area of the intercondylar notch, 





ii) Old OA intact cartilage from patients undergoing TKA (n=7, age±SD=62.1±3.7). 
Intact OA cartilage samples were collected from the most grossly intact area of the 
femoral condyles of OA patients, as described in Section 2.1. 
 
iii) Old OA lesioned cartilage from patients undergoing TKA (n=7, age±SD=62.1±3.7). 
Lesioned OA cartilage samples were collected from a lesioned area of the femoral 
condyles of OA patients, as described in Section 2.1.  
 
4.3.3 Young healthy and old healthy human knee cartilage specimens for the investigation 
of ageing in selected miRNAs 
 
Microarray analysis identified DE miRNAs between young intact and old OA intact and 
lesioned cartilage samples from knee joints of young patients undergoing ACL reconstruction 
and old OA patients undergoing TKA. There were two main variables driving the differential 
expression between these groups: ageing and OA. To further clarify whether ageing alone 
could affect the expression of selected miRNAs, young healthy and old healthy human knee 
cartilage samples were collected from male cadavers with no history of knee pain and disease 
and an unrelated cause of death (ProteoGenex, Inglewood, USA). These samples were 
macroscopically normal. Specifically, the following samples were used: 
i) Young healthy cartilage from cadavers (n=5, age±SD=32±3.7). Samples were 
collected from the knee femoral lateral and medial condyles.  
ii) Old healthy cartilage from cadavers (n=5, age±SD=62±6.6). Samples were 
collected from the knee femoral lateral and medial condyles.   
Further characteristics of these donors are listed in Table 4.1 below. 
 
Table 4.1: Characteristics of young healthy and old healthy cartilage donors. 
Donor Age BMI Comorbidities 




Young-Healthy -2 35 24.8 N/A 
Young-Healthy -3 32 29.6 Hypertension, chronic tonsillitis, impaired glucose tolerance 
Young-Healthy -4 26 25.3 N/A 
Young-Healthy -5 35 24.7 N/A 
Old-Healthy-1 70 24.9 Gastric ulcer perforation, peritonitis 
Old-Healthy-2 67 26.1 
Coronary artery disease, atherosclerosis, hypertension, 
pelvic vein thrombosis, cardiosclerosis, prostatitis 
Old-Healthy-3 56 25.7 
Coronary artery disease, atherosclerosis, hypertension, 
history of cholecystectomy 
Old-Healthy-4 63 25.9 
Hypertension, atherosclerosis, myocardial hypertrophy, 
impaired glucose tolerance, coronary artery disease 
Old-Healthy-5 55 24.2 




4.3.4 Histologic assessment of young healthy and old healthy cartilage samples  
 
To confirm that young healthy and old healthy cartilage samples collected from cadavers had 
no pathologic perturbations, histologic assessment with H&E staining was undertaken to 
examine tissue integrity. Samples were cryosectioned as described in Section 2.5B and then 
stained with H&E as described in Section 2.6. Tissue sections were examined under the 
microscope for pathological perturbations. 
 
4.3.5 Treatment of human primary chondrocytes with human recombinant IL-1β  
 
To investigate the effect of IL-1β on the expression of selected miRNAs, primary articular 




transplantation after trauma/sport injury, and OA donors undergoing TKA (n=2 per group), as 
described in Section 2.22. Donor details are as below: 
i) Non-OA primary chondrocytes from autologous cartilage repair donors (n=2, 
age±SD=48±5.7, 1 male/1 female) 
ii) OA primary chondrocytes from OA patients (n=2, age±SD=64.5±4.9, 1 male/1 
female) 
Due to the limited number of non-OA donors available, and to optimise treatment time 
points, OA chondrocytes from one donor were treated for 6h and 24h. Based on these results 
further treatments in more donors were undertaken for 24h and 5 days (n=5 OA donors). 
Furthermore, to investigate the extent of the inflammatory response in chondrocytes in vitro, 
the effect of IL-1β on the following cartilage and OA-related markers was measured: COL2A1, 
ACAN, MMP13 and ADAMTS4, after 24h and 5-day treatments.  
 
4.3.6 Total RNA extraction from human cartilage samples and primary chondrocytes for 
qPCR validation  
 
For the dependent cohort of microarray analysis, total RNA was extracted as described in 
Section 2.13.1. This consisted of total RNA that was not used for microarray analysis.  
For the independent cohort, additional samples of young intact, old OA intact and lesioned 
human cartilage tissue were homogenised as described in Section 2.12. Total RNA was 
extracted using the mirVana™ miRNA Isolation Kit with phenol, as described in Section 2.13.1. 
For the young healthy and old healthy cartilage samples, plus the human primary 
chondrocytes, total RNA was extracted as described in Section 2.13.3. Total RNA was 
extracted using the guanidinium thiocyanate-phenol-chloroform method (TRIzol). 
 
4.3.7 Poly(A) cDNA synthesis for miRNA quantification 
 
Poly(A) cDNA for miRNA quantification by qPCR was synthesised from total RNA as described 




4.3.8 cDNA synthesis for mRNA quantification 
 
cDNA synthesis for mRNA quantification by qPCR was synthesised from total RNA as described 
in Section 2.17.  
 
4.3.9 qPCR for miRNA and mRNA quantification  
 
miRNA and mRNA quantification by qPCR was undertaken as described in Section 2.18 and 
2.19, respectively. Statistical analysis was undertaken in GraphPad Prism version 8.0.1 for 
Windows and normality of data was assessed using the Shapiro-Wilk normality test. For 
miRNA quantification in human cartilage tissue, statistical significance was calculated using 
the Mann-Whitney test, as data did not follow the Gaussian distribution. For miRNA and 
mRNA quantification in IL-1β treated and control human primary chondrocytes, statistical 
significance was calculated using a two-tailed paired t-test, as data followed the Gaussian 
distribution.  P values<0.05 were considered significant. 
 
4.3.10 Selection of endogenous reference genes for qPCR data normalisation 
 
For qPCR validation of microarray analysis, five potential reference genes were selected for 
testing. Two of them, RNU6 and SNORD61, were widely used in the literature for miRNA 
normalisation, and three of them, miR-1915-3p, miR-6786-5p and miR-6087, were selected 
from the microarray results as having high and stable expression in all samples (mean log 
expression >10 and SD <0.5). For IL-1β treatment, three potential reference genes were 
selected for testing: SNORD68, miR-6786-5p and RNU6. Selection of the appropriate 









4.4.1 Selection of specific DE miRNAs from microarray analysis 
 
For selection of DE miRNAs from microarray analysis, I focused on three comparisons: OA-
Lesioned vs Y, OA-Intact-1 vs Y and OA-Intact-2 vs Y. After applying filters of logFC <-3 and >3, 
the list of DE miRNAs was reduced to 66 DE mature miRNAs, of which all had lower expression 
in the old OA groups compared to young (logFC<-3). There were no common mature miRNAs 
with logFC>3 in these three comparisons. The only comparison that contained mature 
miRNAs with logFC>3 was the OA-Intact-1 vs Y comparison and therefore no miRNAs with 
logFC>3 were selected for validation. 
To further reduce the number of mature DE miRNAs, miRNAs with high sequence similarity, 
such as miRNAs of the let-7 family, and miRNA isoforms were excluded from further analysis. 
This way the list was reduced to 35 DE mature miRNAs (Table 4.2).  
 
Table 4.2: Important DE mature miRNAs in young intact, old OA intact and old OA lesioned 
cartilage.  
 LogFC 
miRNA OA-Lesioned vs Y OA-Intact-1 vs Y OA-Intact-2 vs Y 
hsa-miR-107 -4.65 -8.97 -3.40 
hsa-miR-1231 -3.07 -4.16 -3.26 
hsa-miR-126-3p -7.36 -7.86 -7.07 
hsa-miR-127-3p -4.01 -6.54 -3.75 
hsa-miR-132-3p -4.02 -5.14 -4.70 
hsa-miR-139-5p -4.31 -4.14 -4.30 
hsa-miR-140-5p -5.11 -6.99 -3.82 
hsa-miR-143-3p -7.35 -7.75 -7.36 
hsa-miR-145-5p -7.20 -8.85 -8.35 




hsa-miR-155-5p -4.77 -6.25 -4.51 
hsa-miR-16-5p -6.62 -9.25 -5.11 
hsa-miR-17-5p -4.42 -5.96 -5.11 
hsa-miR-185-5p -3.59 -5.84 -4.10 
hsa-miR-195-5p -7.30 -9.55 -4.90 
hsa-miR-21-5p -3.20 -3.22 -3.07 
hsa-miR-221-3p -4.23 -6.69 -4.38 
hsa-miR-222-3p -4.80 -7.43 -3.80 
hsa-miR-25-3p -3.96 -4.56 -4.39 
hsa-miR-28-3p -3.35 -4.32 -4.10 
hsa-miR-28-5p -4.14 -4.10 -4.31 
hsa-miR-342-3p -4.40 -6.99 -4.13 
hsa-miR-361-5p -4.20 -7.54 -4.04 
hsa-miR-379-5p -4.50 -4.58 -4.77 
hsa-miR-382-5p -4.16 -4.98 -4.72 
hsa-miR-409-3p -3.92 -4.61 -3.90 
hsa-miR-432-5p -4.58 -5.11 -4.72 
hsa-miR-4417 -3.30 -4.97 -4.88 
hsa-miR-4485 -3.20 -4.08 -3.06 
hsa-miR-455-5p -3.62 -4.69 -4.18 
hsa-miR-532-5p -3.17 -4.06 -3.71 
hsa-miR-6807-5p -3.17 -3.58 -3.56 
hsa-miR-6824-5p -3.01 -3.53 -3.31 
hsa-miR-8071 -3.61 -4.15 -4.17 
hsa-miR-93-5p -3.89 -5.66 -4.91 
 
To narrow down further the number of DE miRNAs for validation I searched the available 
literature and investigated the predicted target genes or pathways that these miRNAs were 
involved in (predicted targets are analysed further in Chapter 5). Based on this criteria, I 




candidate miRNAs with limited or no data regarding their role in cartilage and OA. The final 
list of miRNAs for qPCR validation is in Table 4.3.  
 
Table 4.3: Final list of DE mature miRNAs for qPCR validation in young intact, old OA intact 
and old OA lesioned cartilage 
miRNA Previously reported in cartilage-OA/novel candidate 
miR-140-5p Previously reported (Karlsen et al., 2014, Miyaki et al., 
2009, Miyaki et al., 2010, Swingler et al., 2012) 
miR-155-5p Previously reported (Xu et al., 2015) 
miR-143-3p novel candidate 
miR-107 novel candidate 
miR-379-5p novel candidate 
miR-361-5p novel candidate 
miR-132-3p novel candidate 
 
 
4.4.2 Selection of reference genes for qPCR data normalisation 
 
Appropriate reference gene was selected using RefFinder (Xie et al., 2012). RefFinder utilises 
four different tools for reference gene selection and one comprehensive ranking, based on all 
four tools. Results are shown in Figure 4.1. miR-6786-5p was selected as the reference gene 
for miRNA data normalisation in the dependent and independent cohort for qPCR validation 































Figure 4.1: Selection of appropriate reference gene for qPCR validation of microarray 
analysis. RefFinder was used to select the appropriate reference gene for qPCR validation of 
microarray analysis. Five potential reference genes, SNORD61, RNU6, miR-6786-5p, miR-
1915-3p and miR-6087, were ranked by each one of RefFinder tools (A, B, C, D) and a stability 
value was generated for each potential reference gene. The lower the value, the most stable 
the gene. A comprehensive gene stability ranking (E), integrating all results, showed that miR-
6786-5p was the best reference genes out of the five. Graphs generated with RefFinder. 
 
4.4.3 qPCR validation of microarray findings in the dependent cohort 
 
To validate microarray results from Chapter 3, I carried out qPCR analysis for a selected set of 
DE miRNAs, using RNA from the same donors as in the microarrays. Selected miRNAs had 
significantly lower expression in the OA-Intact and Lesioned groups when compared to Young 
group and followed the same trend as in microarray analysis (Figure 4.2). OA-Intact-1 and -2 
groups, which were separated during microarray analysis, were grouped together in one 
cluster as both groups showed similar direction of dysregulation when compared to Young 
group. Moreover, as in microarray analysis, selected miRNAs were not significantly different 
between OA-Intact and OA-Lesioned groups and their expression was similar between the 

































Figure 4.2: qPCR validation of selected DE miRNAs in the dependent cohort. Seven miRNAs 
which were DE in microarray analysis were selected for validation with qPCR in the same 
samples. N=5-10 samples/group. Y axis represents log-transformed expression relative to 
miR-6786-5p. Statistical analysis was undertaken using a Mann Whitney test in GraphPad 
Prism (Version 8.0.1). Data are represented as mean+SD (due to the logarithmic scale on Y 
axis, negative SD values cannot be plotted). P values<0.05 were considered significant. *: 
p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001.  
 
4.4.4 qPCR validation of microarray findings in the independent cohort 
 
After validating microarray findings in the dependent cohort, I sought to investigate 
expression of DE miRNAs in an independent cohort of Young, OA-Intact and OA-Lesioned 
cartilage samples. Analysis was undertaken by qPCR. Validation in the independent cohort is 
shown in Figure 4.3. Results indicated that selected miRNAs had significantly lower expression 
in OA-intact and lesioned groups compared to Young intact group. Moreover, as with the 
dependent cohort, expression of these miRNAs in the OA-intact group was lower than in the 












Figure 4.3: qPCR validation of selected DE miRNAs in the independent cohort. Seven miRNAs 
which were DE in microarray analysis were selected for validation with qPCR in an 
independent cohort of cartilage samples. N=5-10 samples/group. Y axis represents log-
transformed expression relative to miR-6786-5p. Statistical analysis was undertaken using a 
Mann Whitney test in GraphPad Prism (Version 8.0.1). Data are represented as mean+SD (due 
to the logarithmic scale on Y axis, negative SD values cannot be plotted). P values<0.05 were 




 Table 4.3 summarises and compares findings between microarray analysis and qPCR in the 
dependent and independent cohorts. Results showed that there was good agreement 
between microarray findings and qPCR validation for both cohorts. Specifically, the direction 
of dysregulation was the same for both microarray and qPCR analyses for all seven miRNAs 
selected. In addition, LogFC of expression was similar between microarray and qPCR results 
for OA-Intact vs Y, and OA-Lesioned vs Y. The largest difference was observed for miR-140-5p 
in OA-Intact vs Y comparison. miR-140-5p had logFC= -5.09 in the microarray analysis, and 
logFC= -10.40 in qPCR validation of the dependent cohort. However, for the independent 
cohort, miR-140-5p had logFC= -5.71, which agrees with the microarray findings. A similar 
finding was observed for miR-361-5p in comparison OA-Lesioned vs Y. miR-361-5p had logFC= 
-4.20 in microarray analysis, and logFC= -2.59 in qPCR validation for the dependent cohort. 
For the independent cohort, logFC of this miRNA was -3.74.  
 
Table 4.3 Comparison of direction of dysregulation and logFC between microarray analysis 
and qPCR validation in same samples used for microarray analysis and an independent 




 (dependent cohort) 
qPCR  
(independent cohort) 
 OA-Intact vs Y OA-Intact vs Y OA-Intact vs Y 
 Direction LogFC Direction LogFC Direction LogFC 
miR-140-5p 
Lower in OA 
intact 
-5.09 
Lower in OA 
intact 
-10.40 












































 (dependent cohort) 
qPCR  
(independent cohort) 
 OA-Lesioned vs Y OA-Lesioned vs Y OA-Lesioned vs Y 
 Direction LogFC Direction LogFC Direction LogFC 
miR-140-5p 
Lower in OA 
lesioned 
-5.11 
Lower in OA 
lesioned 
-7.48 




































4.4.5 Investigation of selected miRNAs in cartilage ageing 
 
Microarray analysis and qPCR validation of selected miRNAs was carried out in young cartilage 
samples from ACL donors and old OA intact and lesioned cartilage samples from TKA patients. 
There were two main variables between these groups: ageing and OA. To investigate the 
effect of ageing on selected miRNAs without the effect of OA, further analysis was carried out 
on young healthy and old healthy human knee cartilage samples collected from the femoral 
lateral and medial condyles of male cadavers with no history of knee disease. To confirm that 
samples, and especially old ones, had no extended pathologic perturbations, cartilage was 
stained with H&E to visualise tissue integrity and any pathological perturbations. Staining 
showed that both young and old samples were quite intact with no extended pathological 
perturbations (Figure 4.4). In old samples there was some superficial fibrillation and surface 
irregularities but there was no cartilage loss or clefts extending into the lower superficial zone 
or middle zone. Therefore, samples were considered healthy with no pathological 










































































Figure 4.4: Examples of H&E staining of human young and old healthy knee cartilage. 
Cartilage samples collected from the knee femoral condyles of cadavers with no history of 
knee disease were stained with H&E to assess tissue integrity. A and B represent young 
healthy human cartilage samples. C, D, E and F represent old healthy human cartilage 
samples. For each sample shown here, there are two figures: one showing a greater area of 
the tissue (magnification 10x) and the other one showing the surface of the section in greater 
magnification (20x). Scale bars are indicated. Photographed using a Nikon Eclipse 80i 
microscope (Nikon, UK). Original figures. Figure A and B are courtesy of Aibek Smagul (used 
with his permission). Figures C-F are courtesy of the author. 
 
After histologic assessment of young and old healthy samples, expression of selected miRNAs 
from microarray analysis was measured to assess the impact of ageing. Of the seven miRNAs 
that were validated previously, four of these were selected for investigation in young healthy 
and old healthy cartilage: miR-107, miR-379-5p, miR-361-5p and miR-143-3p. This selection 
was based on novelty, as there was little or no data regarding their role in cartilage and OA. 
SNORD68 was used as the reference gene as it was more stable than miR-6786-5p that was 




subsequent qPCR validation in the dependent and independent cohorts, these four miRNAs 
had lower expression in OA intact and lesioned cartilage samples when compared to young 
cartilage samples from ACL donors. However, qPCR analysis of these four miRNAs in young 
healthy and old healthy cartilage samples, showed that there was no significant difference in 
their expression in these samples (Figure 4.5). miR-107 had higher expression in the old 










Figure 4.5: Expression of selected miRNAs in young healthy and old healthy human knee 
cartilage. Expression of four selected miRNAs was investigated with qPCR in young and old 
human healthy cartilage samples from cadavers with no history of knee disease. Y axis 
represents log-transformed expression relative to SNORD68. N=4-5 samples/group. Statistical 
analysis was undertaken using a Mann Whitney test in GraphPad Prism (Version 8.0.1). Data 




4.4.6 Investigation of selected miRNAs in an OA in vitro inflammatory model 
 
To investigate miRNA response in an OA-like inflammatory system, I undertook a number of 
approaches. Initially, I tested the effect of inflammation on chondrocytes from non-OA donors 
and compared them to OA chondrocytes from donors undergoing TKA. I first assessed the 
appropriate reference gene to be used for IL-1β treated human chondrocytes. I tested three 
reference genes: miR-6786-5p, SNORD68 and RNU6. RefFinder indicated that the best 
reference gene was SNORD68, followed closely by miR-6786-5p and then RNU6 (Figure 4.6).  
 
Figure 4.6: Selection of appropriate reference genes in human chondrocytes treated with 
IL-1β. Three reference genes were tested for stability in human chondrocytes treated with IL-
1β: SNORD68, miR-6786-5p and U6. Comprehensive gene stability for the three candidates is 
shown. Y axis represents ranking values. Graphs generated with RefFinder. 
 
Having tested for suitable reference gene and due to the limited starting material for the non-
OA group, only two miRNAs were selected during this first treatment: miR-143-3p and miR-
107. Chondrocytes from non-OA donors treated with 10ng/ml IL-1β had reduced expression 




chondrocytes treated with IL-1β for 24h showed a less clear expression profile and changes 
in miRNA expression were less prominent between the treated and control group. In fact, in 
treated non-OA chondrocytes, expression of these miRNAs reached similar levels to OA 











Figure 4.7: Before-after plot showing expression of miR-143-3p and miR-107 in IL-1β treated 
chondrocytes extracted from non-OA and OA cartilage. Non-OA and OA chondrocytes were 
treated with 10ng/ml of human recombinant IL-1β for 24h. Y axis represents log-transformed 
expression relative to SNORD68. N=2 donors/group. Each line connects the control and 




I, next, focused on further IL-1β treatment of human OA chondrocytes due to the availability 
of the cells. Given that little difference in miRNA expression was observed in the 24h time 
point, I performed an initial experiment for a shorter amount of time using primary OA 
chondrocytes from one patient to investigate whether shorter treatments were more 
appropriate. Chondrocytes were treated for 6h and 24h for comparison and RNA was 
collected and subjected to poly(A) cDNA synthesis and qPCR. I also checked chondrocyte 
morphology under the microscope to identify potential morphological changes between 
treated and control. I observed changes in cell morphology for both the 6h and 24h 
treatments. Chondrocytes in control groups had the typical fibroblastic appearance that they 
acquire in monolayer culture, with axonal projections present. In treated groups, even from 
the 6h time point, cells became rounder, their extensions became shorter and cells looked 
more apoptotic. Changes were more prominent in the 24h time point (Figure 4.8). 
Figure 4.8: OA chondrocyte morphology after treatment with IL-1β or control for 6h and 
24h. Human OA chondrocytes were treated with 10ng/ml human recombinant IL-1β or 
control for 6h and 24h. Cells were photographed at the 6h and 24h time points using a ZEISS 





qPCR analysis of cell lysates showed that selected miRNAs responded even less to the 6h 
treatment compared to the 24h treatment (Figure 4.9). None of the four selected miRNAs, 
showed any differences in their expression at the 6h time point when compared to control. 
 
 
Figure 4.9 Expression of selected miRNAs in human OA chondrocytes treated with IL-1β in 
a time course of 6h and 24h. Human OA chondrocytes from one patient were treated with 
10ng/ml of human recombinant IL-1β or control for 6h and 24h. miRNA expression is relative 





At the 24h time point, expression of miR-107 and miR-143-3p followed a similar trend to the 
previous experiment. For miR-107 there was slightly lower expression in the treated group 
compared to control, whereas expression of miR-143-3p was slightly higher compared to 
control. miR-361-5p showed the largest decrease in expression in the treated group 
compared to control, and miR-379-5p did not show any difference at the 24h time point.  
Based on the above results, I decided to further test the expression of selected miRNAs at the 
24h time point but this time include longer treatments as well, specifically treatment for 5 
days, to see if larger changes were observed. Furthermore, with this series of experiments, in 
addition to miRNA expression, I determined the expression of specific cartilage and OA 
markers, namely COL2A1, ACAN, MMP13 and ADAMTS4, in order to investigate how effective 
IL-1β treatment is in the establishment of an OA inflammatory response. Analysis showed 
that for the 24h time point, miR-107 and miR-361-5p had lower expression in the treated 
group and the difference was almost significant for the latter. Expression was almost 
significantly higher in the treated group for miR-143-3p, whereas miR-379-5p did not show 
any difference (Figure 4.10A). Analysis of cartilage markers in OA chondrocytes treated with 
IL-1β for 24h showed that COL2A1 and ACAN did not have significant changes between 
treated cells and control, although there was a slight increase in ACAN expression in the 
treated group. In contrast, MMP13 and ADAMTS4 had significantly higher expression in 








































Figure 4.10: Before-after plot showing expression of selected (A) miRNAs and (B) cartilage 
markers in human OA chondrocytes treated with IL-1β or control for 24h. Human OA 
chondrocytes were treated with 10ng/ml human recombinant IL-1β or control for 24h and 
expression of selected miRNAs and cartilage markers was measured. N=4-5 donors. Y axis 
represents log-transformed expression relative to SNORD68 for miRNAs and relative to 
GAPDH for OA markers. Statistical analysis was undertaken using a two-tailed paired t-test in 
GraphPad Prism (Version 8.0.1). P values<0.05 were considered significant. *: p<0.05. Each 
line connects the control and treated group of the same donor. 
 
Next, I sought to investigate the expression of miRNAs and cartilage markers in chondrocytes 
treated with IL-1β for 5 days. As before, I also visualised cell morphology under the 
microscope. I observed similar morphological changes as in the 24h time point, mainly 




Figure 4.11: OA chondrocyte morphology after treatment with 10ng/ml IL-1β or control for 
5 days. Human OA chondrocytes were treated with 10ng/ml human recombinant IL-1β or 
control for 5 days. Cells were photographed at the 5-day time point using a ZEISS Axio Vert.A1 
Inverted Microscope at 10x magnification. Original figure, courtesy of the author. 
 
Regarding gene expression, IL-1β treatment of OA chondrocytes for 5 days resulted in a 
miRNA expression profile that resembled that of our microarray experiment. While miR-143-
3p had higher expression in chondrocytes treated with IL-1β for 24h, its expression was 
almost significantly lower in chondrocytes treated for 5 days when compared to control. 
Therefore, there was a shift in its expression levels from the 24h time point to the 5-day time 
point. For miR-107 and miR-361-5p the trend was the same as in the 24h time point, with 
lower expression in the treated group compared to control. However, the difference between 
treated and control cells was much larger in the 5-day time point and reached statistical 
significance, whereas this did not happen in the 24h time point for these two miRNAs. miR-
379-5p showed the largest difference between the 24h and 5-day time points. There was no 
difference in expression between treated and control chondrocytes in the 24h time point for 
this miRNA (p=0.96). However, after 5 days of treatment, miR-379-5p had significantly lower 
expression in the treated group compared to control (p=0.0002). Results for the 5-day time 

















Figure 4.12: Before-after plot showing expression of selected miRNAs in human OA 
chondrocytes treated with 10ng/ml IL-1β for 5 days. Human OA chondrocytes were treated 
with 10ng/ml human recombinant IL-1β or control for 5 days and expression of selected 
miRNAs was measured. N=5 donors. Y axis represents log-transformed expression relative to 
SNORD68. Statistical analysis was undertaken using a two-tailed paired t-test in GraphPad 
Prism (Version 8.0.1). P values<0.05 were considered significant. *: p<0.05, **: p<0.01, ***: 




Following the same approach as for the 24h time point, I investigated the expression of 
selected cartilage markers in OA chondrocytes treated with IL-1β. Analysis showed that 
chondrogenic markers COL2A1 and ACAN had significantly lower expression in the treated 
group compared to control after 5 days of treatment and in contrast to the 24h time point 
where there was no significant difference between treated and control groups. Moreover 
catabolic markers MMP13 and ADAMTS4 had significantly higher expression in the treated 
groups (Figure 4.13), similar to the 24h time point. For MMP13 the difference was larger in 
the 5-day treated group compared to the 24h treated group when these were compared to 















Figure 4.13: Expression of selected miRNAs in human OA chondrocytes treated with 
10ng/ml IL-1β for 5 days. Human OA chondrocytes were treated with 10ng/ml human 
recombinant IL-1β or control for 5 days and expression of selected cartilage markers was 
measured. N=5 donors. Y axis represents log-transformed expression relative to GAPDH. 
Statistical analysis was undertaken using a two-tailed paired t-test in GraphPad Prism (Version 
8.0.1). P values<0.05 were considered significant. *: p<0.05, **: p<0.01. Each line connects 







4.5 Discussion  
In the current thesis I sought to investigate the expression of miRNAs in cartilage ageing and 
OA. To achieve this, I undertook a microarray analysis using cartilage tissue from young 
patients undergoing ACL reconstruction and old OA patients. Two areas were used from OA 
patients. A macroscopically intact area of OA cartilage and a lesioned area of OA cartilage. In 
Chapter 3 I described the results of this microarray analysis between these three main groups 
and identified DE miRNAs between young and old OA intact and lesioned cartilage. In this 
chapter I validated selected DE miRNAs by qPCR in the same samples, as well as in an 
independent cohort of cartilage tissue. Morevoer, I investigated the expression of selected 
miRNAs in young healthy and old healthy cartilage tissue. Finally, to investigate expression of 
selected miRNAs and specific cartilage markers in an in vitro OA inflammatory model, I treated 
primary chondrocytes with IL-1β for different time points. 
 
4.5.1 Validation of microarray results  
 
The first step in our analysis was to validate the microarray results from Chapter 3 using qPCR. 
For this reason I selected seven miRNAs based on logFC from the microarray results and 
known or predicted function in cartilage and OA. The selected miRNAs were: miR-140-5p, 
miR-155-5p, miR-143-3p, miR-107, miR-379-5p, miR-361-5p and miR-132-3p. I undertook 
qPCR analysis in two sample cohorts: a cohort consisting of the same samples that were used 
in our microarray analysis (dependent cohort), and an additional independent cohort of 
young and old OA intact and lesioned cartilage samples, from ACL and OA patients, 
respectively. In our microarray analysis, old OA intact samples were separated into two 
subgroups based on univariate analysis: OA-Intact-1 and 2. However, for qPCR validation I 
decided to group these samples together in one group again. This was done for the following 
reasons. First of all, I focused on the following comparisons: OA-Intact-1 vs Young, OA-Intact-
2 vs Young and OA-Lesioned vs Young. Selected miRNAs had the same direction of 
dysregulation in both OA-Intact-1 vs Young and OA-Intact-2 vs Young, therefore I decided to 
group OA-Intact-1 and 2 together into OA-Intact and compare that to the Young group. This 
would also increase power as our microarray finding showed that there was no significant 




Intact-2). Moreover, I would use an independent cohort of cartilage samples to validate our 
microarray findings with qPCR. It would not have been possible to know whether OA-intact 
samples from the independent cohort would be more similar to the OA-Intact-1 or 2 group of 
the dependent cohort, hence, for qPCR validation, I decided to have only three main groups 
for each cohort of samples: Young, OA-Intact and OA-Lesioned. 
qPCR analysis in the dependent cohort validated the microarray results for these seven 
selected miRNAs. Analysis showed that all selected miRNAs had significantly lower expression 
in the old OA-Intact and Lesioned groups when these were compared to the Young group 
from ACL donors, similar to our microarray results. Moreover, there was no significant 
difference for these selected miRNAs when old OA-Intact and Lesioned groups were 
compared to each other, in agreement with our microarray findings. Therefore, there was a 
good agreement between microarrays and qPCR.  
qPCR analysis in an additional independent cohort of cartilage samples, further validated our 
findings. Similar to the dependent cohort, all seven miRNAs had significantly lower expression 
in old OA-Intact and Lesioned groups when these were compared to the Young group. There 
was no significant difference for these miRNAs when old OA-Intact and Lesioned groups of 
the independent cohort were compared to each other This confirmed that our microarray 
findings were reproducible in a wider range of biological samples. Indeed, comparison of fold 
changes between microarray results and qPCR validation in the dependent and independent 
cohort indicated that for the selected miRNAs there was agreement not only in the direction 
of dysregulation but in the magnitude of differential expression also. This further confirmed 
the biological significance of our microarray findings and indicated that observed changes in 
miRNA expression are applicable to a larger cohort of patients. 
From the seven selected miRNAs, two of them had been studied previously in cartilage and 
OA. miR-140-5p is amongst the best studied miRNAs in cartilage homeostasis and OA. In 
agreement with our results, miR-140-5p was downregulated in OA human cartilage (Miyaki 
et al., 2009) and multiple studies have identified miR-140-5p as an important mediator of 
chondrogenesis and differentiation of MSCs into chondrocytes (Karlsen et al., 2014, Swingler 
et al., 2012). Tao et al (2017) showed that exosomes derived from MSCs overexpressing miR-
140-5p could promote knee cartilage regeneration and chondrocyte proliferation and could 




MMP13 and ADAMTS5, further validating the role of this miRNA in cartilage and OA (Miyaki 
et al., 2010). In addition, miR-155-5p is also implicated in OA. Expression of miR-155 was 
decreased in OA patients compared to control and increased in OA patients who received 
hyaluronic acid injection in the knee joint compared to those who did not (Xu et al., 2015). 
Furthermore, miR-132-3p had lower expression in the microarrays and in qPCR validation in 
the dependent and independent cohort. There were no available studies on the role of miR-
132-3p on cartilage and OA at the time of our microarray validation. However, recent studies 
have shown that this miRNA was involved in chondrogenic differentiation of rat MSCs and 
promoted proteoglycan deposition and increased expression of Sox9, Col2a1 and Acan by 
targeting Adamts5 (Zhou et al., 2018). Moreover, miR-132-3p was identified as an important 
regulator of the NF-κB pathway in ATDC5 cells treated with lipopolysaccharides (LPS) (Li et al., 
2019a). LPS is a proinflammatory agent that activates the NF-κB signalling pathway and leads 
to the release of proinflammatory cytokines. In LPS-treated ATDC5 cells, expression of miR-
132-3p was inhibited which led to increased levels of NF-κB and pro-inflammatory cytokines 
such as IL-6 and TNF-α (Li et al., 2019a). Upregulation of miR-132-3p attenuated these effects. 
The significant role of miR-132-3p in OA was further confirmed by Wang et al (2020), who 
carried out a meta-analysis of microarray expression data to generate OA dysfunctional 
modules and their transcriptional regulators (Wang et al., 2020). Amongst these, miR-132-3p 
and NF-κB were identified as important transcriptional regulators of the OA-modules 
generated and had a significant regulatory effect on OA (Wang et al., 2020). The remaining 
four miRNAs, miR-107, -379-5p, -361-5p and 143-3p were selected for further studies and 
their role in cartilage and OA will be discussed later on and in the next chapter.  
 
4.5.2 Investigation of selected miRNAs in cartilage ageing 
 
Ageing is the most common risk factor for OA. Age-related changes in cartilage can predispose 
individuals to the development of OA. In our microarray experiment and subsequent qPCR 
validation I compared young intact cartilage from ACL donors to old OA intact and lesioned 
cartilage from OA donors. In this dataset there were at least two major variables that could 
drive results: ageing and OA. To have a better understanding of how ageing can affect the 




measured by qPCR the expression of four selected miRNAs, miR-107, -379-5p, -361-5p and 
143-3p, in young healthy and old healthy cartilage tissue, collected from male cadavers 
without any known history of knee damage or OA. To confirm that tissues were indeed 
healthy, especially the old samples, I carried out H&E staining which confirmed that cartilage 
samples were mainly intact. Small perturbations, such as surface irregularities are to be 
expected in the old samples given that average age was 62±6.6 and these were not considered 
pathological changes. qPCR analysis in these samples showed that there were not any age-
related changes in the expression of these miRNAs between young and old healthy cartilage 
samples, indicating that the results I observed from the microarrays were most likely driven 
by disease rather than ageing. This is not unexpected as pathological alterations in the tissue 
are probably of greater extent compared to alterations due to ageing. Indeed, our group has 
recently carried out small RNAseq between young and old healthy human knee cartilage 
samples and none of these miRNAs were identified as DE (unpublished data). Moreover, the 
number of DE miRNAs in this ageing study was much lower compared to the number of DE 
miRNAs from our microarray study, further supporting that pathology is mostly driving results 
rather than ageing. There is very limited information in the literature on the effect of ageing 
on miRNAs in cartilage tissue without the effect of OA. To the best of our knowledge the only 
study that has investigated the effect of cartilage ageing on miRNA expression is from Ukai et 
al (2012), where they compared expression of miRNAs in cartilage from infants with 
polydactylism to cartilage collected from young ACL donors and identified three DE miRNAs 
(miR-199a-3p, -193b and -320c) (Ukai et al., 2012). Such studies are very limited in human 
cartilage given the difficulty in obtaining healthy tissue, but would shed much light on the 
effect of age on miRNA expression and help define better potential miRNA candidates in OA.  
 
4.5.3 Investigation of selected miRNAs in an in vitro OA inflammatory model 
 
Chapter 3 described the bioinformatic analysis of microarray findings using IPA to identify 
relevant biological pathways that our DE miRNAs are involved in. In comparisons OA-Intact-1 
vs Y, OA-Intact-2 vs Y and OA-Lesioned vs Y, inflammation was one of the main pathways 
identified as relevant to our dataset. Further analysis with ToppGene, Revigo and Cytoscape 




processes that our DE miRNAs are involved in. Furthermore, key pro-inflammatory cytokines, 
such as IL-1β and TNF-α, were identified by IPA as upstream regulators of our dataset. To 
investigate the effect of inflammation on our selected list of four miRNAs (miR-107, -379-5p, 
-361-5p and -143-3p), I treated human primary chondrocytes with human recombinant IL-1β. 
First, I treated non-OA chondrocytes extracted from donors undergoing autologous 
chondrocyte transplantation and OA chondrocytes extracted from patients undergoing TKA. 
There was limited number of non-OA donors available, so I was only able to interrogate two 
donors. For this part of the experiment, I also included two OA donors for direct comparison. 
There was limited amount of cDNA available for the non-OA samples so only two miRNAs 
were tested: miR-107 and miR-143-3p. Results showed that non-OA chondrocytes were more 
responsive to the treatment compared to OA chondrocytes. Both miR-107 and mi-143-3p had 
lower expression in non-OA treated cells compared to non-OA control cells. In contrast, miR-
143-3p and miR-107 showed minor changes in treated OA cells compared to control OA cells. 
This is in contrast to a study from Lee et al (2002) where they treated chondrocytes from non-
OA and OA donors with IL-1β and they concluded that OA chondrocytes responded better to 
IL-1β treatment than non-OA chondrocytes, due to the higher number of IL-1β receptors in 
OA chondrocytes (Lee et al., 2002). However, in the same study the authors concluded that 
chondrocytes become more tolerant to IL-1b with time (Lee et al., 2002). Taking into account 
that OA chondrocytes were extracted from patients with chronic OA, and therefore possibly 
subjected to an inflammatory environment for longer compared to non-OA chondrocytes 
from autologous transplantation patients, one could justify the limited response seen in OA 
chondrocytes in our study compared to non-OA chondrocytes. Moreover, a point to consider 
is the use of different markers to assess chondrocyte responsiveness. While Lee et al (2002) 
measured expression of selected gene markers, such as MMP13, NO and PGE2 to assess 
chondrocyte responsiveness, I tested the expression of specific miRNAs and therefore 
differences in the markers used with regards to their responsiveness are to be expected and 
no direct contrast can be made. Indeed, Moulin et al (2017) carried out microarray analysis in 
non-OA chondrocytes treated with 10ng/ml IL-1β for 48h and identified a list of DE miRNAs, 
including miR-140-5p (Moulin et al., 2017), which suggests that response of non-OA 
chondrocytes varies dependent on the markers that are assessed. Moreover, in our study, 
comparison of the control groups between non-OA and OA chondrocytes showed that 




levels seen in the non-OA control group compared to the OA control group. This was 
consistent with our microarray findings where both of the miRNAs had lower expression in 
the OA groups compared to the young intact group. This also suggests that chondrocytes 
retain some phenotypic characteristics after extraction from cartilage tissue, at least during 
the early passages. It is known that chondrocytes dedifferentiate following tissue extraction 
and passaging as they lose their characteristic ECM organisation and mechanical stimuli 
(Caron et al., 2012). This is accompanied by morphological changes and a shift in the 
expression of specific chondrogenic and hypertrophic markers, especially when chondrocytes 
are cultured in monolayer (Charlier et al., 2019). After treatment, expression of these two 
miRNAs was similar between non-OA and OA treated chondrocytes, mainly because non-OA 
chondrocytes responded to IL-1β treatment, whereas OA chondrocytes only had 
minor/moderate changes after 24h of treatment. This could be due to the fact that expression 
of these miRNAs in OA chondrocytes was low even in the control group and IL-1β treatment 
for 24h could not reduce expression significantly. This was also confirmed when I tested the 
expression of all four selected miRNAs in IL-1β-treated OA chondrocytes from the same donor 
for 6h and 24h. As before, I observed moderate changes in the expression of miRNAs in the 
24h time point and the changes were even smaller in the 6h time point. At the 24h time point, 
the larger change was observed for miR-361-5p and the smaller for miR-379-5p. Ji et al (2016) 
carried out a similar experiment for miR-30a in OA chondrocytes treated with 10ng/ml and 
observed larger changes in miRNA expression at the 24h time point compared to the 6h time 
point (Ji et al., 2016). Moreover, in a similar experiment, Mao et al (2017) treated OA 
chondrocytes with 10ng/ml IL-1β and observed greater changes in expression of miR-92a-3p 
after 24h of treatment compared to 6h of treatment (Mao et al., 2017).  
The above experiments prompted us to treat OA chondrocytes from more donors for longer 
periods, mainly for 5 days and compare that to the 24h time point where I observed moderate 
changes. The 6h time point was not used for further experiments. Indeed, analysis showed 
greater IL-1β response in OA chondrocytes after 5 days of treatment and miRNA expression 
profile matched that of microarray analysis. I was not able to identify any studies from the 
available literature where they checked the miRNA expression profile in OA chondrocytes 
treated with IL-1β for longer time points, as most studies have looked at shorter time points, 




Some studies have looked at the expression of specific OA markers, such as collagens and 
MMPs after treatment for longer periods. Lee et al (2002) treated OA chondrocytes with IL-
1β for up to 14 days and reported increased expression of MMP13 starting from the earlier 
time points and up to 14 days in the treated group compared to control (Lee et al., 2002).  In 
another study, Lv et al (2019) treated bovine cartilage explants for 24 days and observed 
increased collagen and GAG content loss in the treated group (Lv et al., 2019). In the same 
study, Lv et al (2019) undertook RNA sequencing to assess differential expression of extracted 
chondrocytes treated with IL-1β for 48h. It was shown that COL2A1 and ACAN had decreased 
expression and MMP13 and ADMATS4 increased expression in treated chondrocytes (Lv et 
al., 2019). Cortial et al (2006) treated bovine chondrocytes with IL-1β for 24h and 3 days and 
checked expression of specific cartilage markers for the two time points. The authors reported 
decreased expression for COL2A1 and ACAN and increased expression of MMP13 and 
ADAMTS4 for both time points. In our experiment, MMP13 and ADAMTS4 had significantly 
higher expression at both the 24h and 5-day time points. COL2A1 and ACAN did not show any 
significant changes at the 24h time point but had significant changes at the 5-day time point.  
There are limited data on the role of our selected miRNAs in chondrocyte inflammation. 
Nonetheless, there were specific trends observed for some of the miRNAs even from the 24h 
time point. miR-361-5p had lower expression in the treated group compared to control and 
this almost reached significance (p= 0.07). This trend was significant at the 5-day time point 
(p=0.0085). Therefore, this miRNA might respond to early inflammatory stimuli in 
chondrocytes. It is now accepted that inflammation is present in early stages of OA even 
before any marked changes in cartilage structure or radiographic findings (Sokolove et al., 
2013, van Dalen et al., 2016). Discovery of biomarkers in early-stage disease is of utmost 
importance. miR-361-5p was shown to be downregulated in the plasma of patients with 
chronic gouty arthritis and treatment of these patients with Chuanhutongfeng, a herb mixture 
with anti-inflammatory properties, increased levels of miR-361-5p (Wang et al., 2019b), 
suggesting an opposite relationship between inflammation and miR-361-5p levels, in 
agreement with our IL-1β experiment. Furthermore, miR-379-5p did not show any difference 
in OA chondrocytes treated with IL-1β for 24h (p=0.96), but had the largest difference at the 
5-day time point (p=0.0002). As with miR-361-5p, there is limited data on the relationship 




arsenite-treated human liver cells resulted in increased secretion of IL-1β and contributed to 
fibrosis (Li et al., 2019c). miR-107 expression was reduced in chondrocytes treated with LPS, 
an inflammatory mediator in OA, while it upregulated the expression of IL-1β. Overexpression 
of miR-107 resulted in decreased IL-1β levels in chondrocytes (Qian et al., 2021). Moreover, 
an interesting finding was that miR-143-3p showed increased expression at the 24h time 
point, which almost reached significance (p=0.06). However, treatment for 5 days resulted in 
this miRNA having lower expression in treated cells compared to control (p=0.08). Thus, there 
was a shift in its expression moving from 24h to 5 days of treatment. miR-143-3p was shown 
to have higher expression in the superficial zone of bovine cartilage compared to middle zone 
(Dunn et al., 2009, Hong et al., 2013). Expression of miR-143-3p, COL2A1 and ACAN was 
decreased in dedifferentiated chondrocytes but was restored with TGF-β1 treatment, 
indicating that miR-143-3p might play a role in cartilage homeostasis. It is known that during 
early stages of OA, there is an upregulation of chondrogenic markers as an attempt of the 
tissue to compensate for cartilage loss, but expression gradually decreases as disease 
progresses (Goldring et al., 2016). This shift in miR-143-3p expression from the 24h time point 
to the 5-day time point could potentially indicate a role for this miRNA in cartilage 
homeostasis. By looking at the expression of specific cartilage markers, such as COL2A1 and 
ACAN, starting from the 24h treatment and then up to the 5-day treatment, I also observed a 
similar pattern. This is more prominent for ACAN, which had higher expression in the treated 
group at 24h, but then its expression decreased significantly at the 5-day treatment group, 
further implying a compensation mechanism during the early stages of disease.  
Another point to take into account is the dose of IL-1β used and how closely this in vitro 
inflammatory system resembles OA. In our study I used 10ng/ml to treat OA chondrocytes for 
all time points. This concentration is one of the most used in the literature (Chang et al., 2016, 
Yang et al., 2016, Zheng et al., 2017). However, the physiological levels of IL-1β in synovial 
fluid of OA patients has been reported to be between 0.021 – 0.146 ng/mL (McNulty et al., 
2013), which is much lower than the levels used in our study and the literature. One reason 
for using higher concentration is time constraints. OA is a chronic disease progressing over 
several years. Systemic low-level inflammation is present in ageing and OA joints and 
production of pro-inflammatory cytokines by the synovium increases with ageing and in OA 




inflammatory response observed in an OA joint and in less time, higher levels or IL-1β were 
used. Moreover, an OA joint is subjected to the release of other pro-inflammatory cytokines, 
such as TNF-α and IL-6, which work synergistically to influence the inflammatory response in 
the joint. In most in vitro experiments and in our study, only IL-1β was used, therefore higher 
concentrations were selected to account for the absence of other pro-inflammatory and 
mechanically stimuli. That said, treatment of OA chondrocytes with IL-1β for these relatively 
shorter periods could resemble more acute inflammatory responses rather than the chronic 
low-level inflammation seen in OA patients. IL-1β has a short half-life of a few hours (Hazuda 
et al., 1988, Lopez-Castejon et al., 2011). In our experiment IL-1β was added in the cultures 
at day 0 and day 3 and cells were collected 24h and 5 days after day 0. In addition, while 
inflammation is one of the main features in an OA joint, and specifically during the early stage, 
other important factors have a significant effect as well. In vivo, chondrocytes are subjected 
to a sheer amount of mechanical force and are organised into zones, with different cell 
characteristics. In our IL-1β cultures, these stimuli and structure were absent and cells were 
grown in a monolayer. While IL-1β treatment induced changes in our selected miRNAs and 
specific cartilage markers, it cannot mimic the OA environment completely. Moreover, it is 
known that chondrocytes growing in monolayer cultures lose their OA and hypertrophic 
phenotype and dedifferentiate (Hong et al., 2013). Therefore, while IL-1β can be used to 
successfully induce inflammatory responses in chondrocytes, it cannot reinstate the complete 
pathological profile seen in OA and more combinatory studies would be needed for further 
interpretation of results. A more accurate approach would have been the treatment of 3-D 
cultures of healthy chondrocytes with low levels (0.05-0.1ng/ml) of IL-1β or a mixture of 
inflammatory cytokines for longer periods (weeks rather than days), where chondrocytes are 
also subjected to mechanical stress. Still, this model comes with challenges and does not fully 
represent physiological conditions.  
 
4.6 Conclusion 
qPCR analysis validated a selected list of DE miRNAs from our microarray results in the same 
samples as well as in an independent cohort of cartilage samples and confirmed 




samples did not identify any of the selected miRNAs as DE, suggesting that changes reported 
in our microarray analysis were driven mainly by disease, rather than ageing. Treatment of 
OA chondrocytes with IL-1β showed that selected miRNAs responded better to longer 
































Chapter 5: Modulation of expression of 
selected miRNAs in human primary OA 
chondrocytes and investigation of 







Over the last decade, miRNAs have become increasingly popular and a lot of research has 
been focused on elucidating their role and function. miRNAs exert their function by targeting 
complementary sequences in mRNAs, and either preventing them from being translated, or 
promoting their degradation (Dexheimer et al., 2020). miRNAs participate in all 
developmental stages by fine tuning the expression of important genes and their use as 
therapeutic targets or disease biomarkers is being realised (Bottani et al., 2020). The number 
of miRNAs implicated in cartilage and OA has steadily increased, and important cartilage and 
OA-related genes have been reported as miRNA targets (Jeffries, 2019, Reynard et al., 2020). 
Due to their short sequence length, the same miRNA can target many different mRNAs, and 
the same mRNA is targeted by many miRNAs. Several bioinformatic tools have been 
developed to predict miRNA-mRNA target interactions and provide insights into the potential 
targets of miRNAs, and therefore the potential functions of these (Huang et al., 2010). These 
tools take into account several parameters for target recognition, and amongst the most 
important is complementarity between the miRNA and the mRNA sequence. However, 
current predicting algorithms are not perfect and can generate many false positive results 
(Cloonan, 2015). Therefore, experimental validation must be undertaken for any miRNA 
target predicted by such algorithms. 
Experimental validation of miRNA targets can be undertaken using different approaches. It is 
still not clear whether miRNA-mRNA interactions result in the degradation of the mRNA 
molecule or not (Cloonan, 2015). Data suggests that both mechanisms can take place and 
work synergistically to re-define gene expression (Dexheimer et al., 2020, Iwakawa et al., 
2015). Taking this into account, to confirm miRNA targets numerous experimental 
approaches can be utilised, both at the transcriptional and protein level, using techniques 
such qPCR quantification, RNA-Seq, Western blotting, LC-MS/MS, luciferase reporter assays, 
crosslinking immunoprecipitation sequencing, and others. Confirmation of a miRNA-mRNA 







5.2 Study aim and rationale 
In Chapter 3 I undertook a microarray analysis to identify DE miRNAs between young cartilage 
from ACL donors and old OA intact and lesioned cartilage from TKA patients. In Chapter 4, a 
selected list of miRNAs that were DE between young and old OA intact/lesioned samples was 
selected for further validation. Selected miRNAs were validated by qPCR in additional 
cartilage samples and four of these; miR-361-5p, -379-5p, -107 and -143-3p, were selected 
for investigation using an in vitro OA inflammatory cell model. To investigate further the role 
and function of selected miRNAs in cartilage homeostasis and OA, I overexpressed and 
inhibited these four miRNAs in human primary OA chondrocytes using miRNA mimics and 
inhibitors. OA chondrocytes were treated in media supplemented with 10ng/ml IL-1β to 
mimic the inflammatory environment of an OA joint. Selected target genes and relevant 
biological pathways were investigated using qPCR for experiments investigating miR-361-5p, 
-379-5p and -107, and by LC-MS/MS for experiments investigating miR-143-3p. Selected 
target genes were investigated in the independent cohort of human cartilage samples that 
were used to validate microarray findings in Chapter 4.  
 
5.3 Experimental design 
The experimental procedures, pertinent to this chapter are described briefly below. For full 
details on the experimental procedures, please refer to Chapter 2. Appropriate references are 
provided throughout the text.  
 
5.3.1 Selection of predicted target genes 
 
Targets genes of selected miRNAs were predicted as described in Section 2.35. For 
experiments regarding miR-361-5p, -379-5p and -107, genes that were predicted as targets 
by at least two bioinformatic tools/databases were selected for validation. Target genes were 
selected based on their known or predicted function in cartilage and OA and novelty. Target 
genes which had previously been validated at the time of selection (as identified through 




prediction-free approach by undertaking LC-MS/MS using OA chondrocytes treated with 
mimics and inhibitors. 
 
5.3.2 Treatment of human OA chondrocytes with miRNA mimics and inhibitors 
 
Isolation of human primary chondrocytes from OA patients was undertaken as described in 
Section 2.9. Cells were grown in T75 flasks until they reached 85-90% confluence, and then 
passaged and seeded in well plates as described in Section 2.11. Donor characteristics for 
each experiment are in Table 5.1. Cells plated in well plates were treated as described in 
Section 2.23. Function of miRNA mimics and inhibitors is shown in Figure 5.1. 
 
Table 5.1: Characteristics of OA donors whose chondrocytes were used to overexpress and 
inhibit selected miRNAs.  N/A: Sample details were not available. 
miRNA Donor Age Sex 
miR-361-5p 
1 73 M 
2 61 F 
3 62 M 
4 63 F 
5 N/A F 
miR-379-5p 
1 N/A N/A 
2 85 M 
3 70 M 
4 71 M 
5 80 M 





1 75 F 
2 80 F 
3 73 M 
4 59 M 
5 51 F 
6 65 M 
7 77 M 
8 62 M 
9 78 M 
10 77 M 
11 80 M 
miR-143-3p 
1 78 M 
2 66 M 
3 81 M 
4 78 M 
5 68 F 
 
 
Figure 5.1 Function of miRNA mimics and inhibitors for modulation of miRNA expression. miRNA mimics and 
inhibitors are synthetic compounds commonly used in research for overexpression and knockdown of the miRNA 
of interest. miRNA mimics (A) ‘mimic’ the structure and sequence of the endogenous miRNA of interest resulting 
in an increased number of miRNA copies in the cell compared to control (B), thus enhancing the downstream 
effect of the miRNA on its target genes. Inhibitors (C) are compounds complementary to the miRNA of interest 
and by binding it, they prevent the miRNA from binding its mRNA targets, thus inhibiting the miRNA from 








5.3.3 Total RNA extraction from human primary OA chondrocytes for qPCR validation of 
selected target genes 
 
Total RNA was extracted from human primary OA chondrocytes treated with mimics and 
inhibitors for miR-361-5, -379-5p and -107, or control, using TRIzol as described in Section 
2.13.3.  
 
5.3.4 cDNA synthesis for miRNA and mRNA quantification 
 
Poly(A) cDNA for miRNA quantification by qPCR was synthesised from total RNA as described 
in Section 2.16. cDNA synthesis for mRNA quantification by qPCR was synthesised from total 
RNA as described in Section 2.17. 
 
5.3.5 qPCR for miRNA and mRNA quantification  
 
miRNA and mRNA quantification by qPCR was undertaken as described in Section 2.18 and 
2.19, respectively. Statistical analysis was undertaken in GraphPad Prism version 8.0.1 for 
Windows and normality of data was assessed using the Shapiro-Wilk normality test. For 
miRNA and mRNA quantification in treated and control human primary chondrocytes, 
statistical significance was calculated using a two-tailed paired t-test as data followed the 
Gaussian distribution. For mRNA quantification in human cartilage tissue, statistical 
significance was calculated using the Mann-Whitney test, as data did not follow the Gaussian 
distribution.  P values<0.05 were considered significant. 
 
5.3.6 Selection of endogenous reference genes for qPCR data normalisation 
 
For qPCR validation of target genes in cartilage tissue samples, seven potential reference 
genes were selected for testing: RPL13A, RPLP0, RPL3, ATP5F1A, RPL4, YWHAE and GAPDH. 
Potential reference genes were either selected from the literature or from an RNA-Seq project 




old normal and old OA human cartilage tissue (unpublished data). Selection of the appropriate 
reference genes for qPCR data normalisation was carried out as described in Section 2.40. 
 
5.3.7 Collection, lysis and preparation of human primary chondrocytes for LC-MS/MS 
analysis 
 
Human primary OA chondrocytes treated with mimics and inhibitors for miR-143-3p or 
control were collected and lysed for LC-MS/MS analysis as described in Section 2.24. Proteins 
in chondrocyte lysates were quantified using the Pierce™ 660nm Protein Assay as described 
in Section 2.25 and protein quality was assessed using Silver Staining as described in Sections 
2.26 and 2.27. Cell lysates were trypsin digested and prepared for LC-MS/M as described in 
Section 2.28. Complete digestion was assessed using Coomassie Brilliant Blue staining as 
described in Section 2.29. Trypsin digests were subjected to LC-MS/MS analysis as described 
in Section 2.30. Label-free quantification was undertaken using the Progenesis QI for 
proteomics software as described in Section 2.33. Briefly, the raw files of the spectra were 
aligned and peak picking was carried out by the Progenesis software for ion quantification. 
Lists of peptide ions were exported to our local Mascot server (Version 2.6.2) for peptide 
identification. Proteins that had at least two unique peptides were selected. Protein 
abundances were log10 transformed and normalised relative to a selected reference sample. 
Statistical analysis was undertaken using two-tailed paired t-tests in R (Version 4.0.2). P values 
were adjusted for multiple testing. Differences at FDR-adjusted p<0.05 were considered 
significant.  
 
5.3.8 STRING analysis for identification of protein interactions 
 
To identify protein interactions between DE proteins from LC-MS/MS, I undertook a STRING 
analysis as described in Section 2.39. Minimum required interaction score was set to highest 





5.3.9 IPA analysis for identification of miR-143-3p relevant biological pathways following 
LC-MS/MS analysis 
 
To identify relevant biological pathways that miR-143-3p is involved in, IPA was used to 
analyse the DE proteins identified by label-free quantification following LC-MS/MS of primary 
OA chondrocytes treated with mimics and inhibitors of miR-143-3p. IPA analysis was 























5.4.1 Selection of predicted targets for miR-361-5p, -379-5p and -107 
 
Predicted target genes of miR-361-5p, -379-5p and -107 were selected using bioinformatic 
tools available online. The following tools were used to predict the target genes of selected 
miRNAs: TargetScan (Agarwal et al., 2015), miRWalk (Dweep et al., 2015), miRmap (Vejnar et 
al., 2012) and miRTar (Hsu et al., 2011). TargetScan and miRwalk generated lists of all 
predicted target genes for these specific miRNAs of interest. The following target genes were 
selected for each of the three miRNAs of interest: for miR-361-5p:CALM3 and RHOA, for miR-
379-5p: TGFBR1, HDAC2 and SMAD9, and for miR-107:  WNT4, IHH, FGF2, TNF and IRF1. 
Table 5.2 summarises the predicted targets that were selected for further validation for each 
miRNA, as well as which of the four databases predicted each interaction.  
 
Table 5.2: Selected predicted targets of miR-361-5p, -379-5p and -107 by four prediction 
algorithms. 
miRNA Target TargetScan miRWalk miRmap miRTar 
miR-361-5p 
CALM3 ✓ ✓ ✓ ✓ 
RHOA ✓ ✓ ✓ x 
miR-379-5p 
TGFBR1 ✓ ✓ ✓ ✓ 
HDAC2 x ✓ ✓ ✓ 
SMAD9 x x ✓ ✓ 
miR-107 
WNT4 ✓ ✓ x ✓ 
IHH ✓ ✓ ✓ ✓ 
FGF2 ✓ ✓ ✓ ✓ 
TNF x ✓ x ✓ 




5.4.2 Expression of selected target genes in human primary OA chondrocytes treated with 
miR-361-5p mimics and inhibitors in an in vitro OA inflammatory model 
 
Human primary OA chondrocytes, cultured to passage 1, were treated with miR-361-5p mimic 
or control-mimic and miR-361-5p inhibitor or control-inhibitor, in media supplemented with 
10ng/ml IL-1β for 48h. According to the manufacturer of mimics and inhibitors, successful 
overexpression or inhibition should not be confirmed by looking at the expression of the 
miRNA itself, but at the expression of the target genes or other relevant gene markers that 
might be influenced by the miRNA (Qiagen, 2015, Qiagen, 2017). Nonetheless, for some of 
the experiments I also looked at the expression of the miRNA itself following its 
overexpression/inhibition. I also investigated the effect of transfection on predicted target 
genes or relevant cartilage markers.  
Our microarray analysis identified that miR-361-5p had a lower expression in OA intact and 
lesioned cartilage compared to young cartilage from ACL donors (Chapter 3), and also that its 
expression was lower in IL-1β treated cells compared to control (Chapter 4). Thus, I expected 
miR-361-5p to exert a positive effect on cartilage homeostasis and increase the expression of 
anabolic markers such as COL2A1 and ACAN, and decrease the expression of catabolic 
markers such as MMP13. First, I assessed the optimal concentration for the miR-361-5p mimic 
by measuring the expression of COL2A1, ACAN and MMP13 in human primary OA 
chondrocytes from the same donor treated with three different concentrations of miR-361-
5p mimic: 5nM, 10nM and 25nM. The optimum concentration would be the one that would 
exert the strongest positive effect on the anabolic markers COL2A1 and ACAN, and the 
strongest negative effect on the catabolic marker MMP13. For the inhibitor, I selected a 
concentration of 200nM based on previous experience from our colleagues and collaborators. 
Analysis showed that miR-361-5p had higher expression in all cells treated with any 
concentration of the mimic, compared to control, but all three different concentrations 
resulted in similar levels for miR-361-5p in the treated cells (Figure 5.2). COL2A1, ACAN and 
MMP13 behaved similarly in all three different concentrations and all had higher expression 
in the treated cells compared to control. Chondrocytes treated with the inhibitor had lower 
expression compared to control, whereas all selected markers had slightly higher expression 
in the inhibitor group compared to control. Since all concentrations had a similar effect on 




be used for further experiments. This was also the recommended starting concentration by 









Figure 5.2: Expression of miR-361-5p and selected cartilage markers in human OA 
chondrocytes treated with a gradient of miR-361-5p mimic or control and inhibitor or 
control. Human OA chondrocytes were treated in media supplemented with 10ng/ml IL-1β 
with miR-361-5p 5nM/10nM/25nM mimic or control-mimic and 200nM inhibitor or control-
inhibitor, for 48h. Expression of miR-361-5p and of cartilage markers is shown. N=1 donor. 
Expression is relative to SNORD68 for miR-361-5p and relative to GAPDH for cartilage 




Based on the preliminary results, I treated OA chondrocytes from additional donors with 5nM 
mimic/control-mimic and 200nM inhibitor/control-inhibitor for miR-361-5p, and measured 
the expression of miR-361-5p, of selected cartilage markers: COL2A1, ACAN, MMP13, SOX9, 
RUNX2, COL10A1, as well as the expression of two predicted target genes: CALM3 and RHOA. 
Analysis showed that expression of miR-361-5p was significantly higher in chondrocytes 
treated with mimics compared to control (p=0.006) and significantly lower in chondrocytes 
treated with the inhibitor compared to control (p=0.01). The percentage of knockdown was 
90%. However, as already mentioned this is not a clear indication that the treatments were 
successful. When I assessed the expression of predicted target genes, CALM3 and RHOA, 




Figure 5.3: Expression of miR-361-5p and its two predicted target genes in human OA 
chondrocytes treated with miR-361-5p mimic, inhibitor or control. Human OA chondrocytes 
were treated in media supplemented with 10ng/ml IL-1β with miR-361-5p 5nM mimic, 200nM 
inhibitor or control for 48h. Expression of miR-361-5p and of predicted targets is shown. N=4-
5 donors. Expression is relative to SNORD68 for miR-361-5p and relative to GAPDH for 
predicted target genes. Statistical analysis was undertaken using a two-tailed paired t-test in 
GraphPad Prism (Version 8.0.1). Data are represented as mean+SD. P values<0.05 were 





For miR-361-5p mimic and inhibitor treatments, I also looked at the expression of specific 
chondrogenic and hypertrophic cartilage markers, to investigate whether modulation of the 
miRNA expression had an effect on them. Analysis showed that most cartilage markers did 
not significantly change between mimic and control or inhibitor and control. COL2A1 and 
ACAN expression was significantly higher in the inhibitor group compared to control (p=0.04 
in both), and COL2A1 expression was higher in the mimic group compared to control but did 























Figure 5.4: Expression of selected cartilage markers in human OA chondrocytes treated with 
miR-361-5p mimic, inhibitor or control. Human OA chondrocytes were treated in media 
supplemented with 10ng/ml IL-1β with miR-361-5p 5nM mimic, 200nM inhibitor or control 
for 48h. Expression of specific chondrogenic and hypertrophic cartilage markers is shown. 
N=4-5 donors. Expression is relative to GAPDH. Statistical analysis was undertaken using a 
two-tailed paired t-test in GraphPad Prism (Version 8.0.1). Data are represented as mean+SD. 
P values<0.05 were considered significant. *: p<0.05. Control-M=control-mimic, control-
I=control-inhibitor.  
 
5.4.3 Expression of selected target genes in human primary OA chondrocytes treated with 
miR-379-5p mimics and inhibitors in an in vitro OA inflammatory model 
 
To investigate the role of miR-379-5p in cartilage and OA, the same approach was taken as 
with miR-361-5p. Human primary OA chondrocytes, were treated with miR-379-5p mimic or 
control-mimic and miR-379-5p inhibitor or control-inhibitor, in media supplemented with 
10ng/ml IL-1β for 48h. Following overexpression and inhibition, I investigated the expression 
of miR-379-5p. Additionally I investigated the effect of mimic and inhibitor on the predicted 




First, I assessed the optimum concentration for miR-379-5p mimic and inhibitor using 
chondrocytes from one donor. I used two concentrations for the mimic: 5nM (recommended 
starting concentration) and 50nM. From our miR-361-5p experiments, I observed that there 
were no significant differences between the concentrations initially tested (5nM, 10nM and 
25nM). Therefore, I utilised a higher concentration to see the effect compared to 5nM. For 
the inhibitor, 200nM was the selected concentration, as before. Additionally, I also included 
initial treatments of 50nM and 100nM for direct comparison and confirmation. Following 
treatment, I measured the relative expression of miR-379-5p, its predicted target: TGFBR1, 
and also of three cartilage markers: COL2A1, ACAN and MMP13. Results indicated that 5nM 
and 50nM mimic produced similar results and in fact the 5nM concentration led to higher 
miR-379-5p expression compared to the 50nM treatment. Both treatments led to reduced 
TGFBR1 expression and at similar levels. The effect of the mimics on cartilage markers was 
less clear. Of note was that the 50nM mimic treatment led to a larger increase in MMP13, 
compared to the 5nM mimic treatment. I selected the 5nM mimic treatment as it had the 
same effect on TGFBR1 and did not lead to an extremely high increase in MMP13 expression. 
For the inhibitor treatments, 50nM and 100nM did not have any effect on miR-379-5p 
expression, whereas 200nM treatment led to a decrease in miR-379-5p expression. The effect 
on TGFBR1 expression was the same for all concentrations with TGFBR1 having lower 
expression in all three treatments. This was opposite to what was expected. 50nM inhibitor 
treatment did not have any effect on cartilage markers, whereas 100nM and 200nM led to 
decrease COL2A1 and ACAN expression. Only the 200nM treatment led to increased MMP13 














Figure 5.5: Expression of miR-379-5p, TGFBR1 and selected cartilage markers in human OA 
chondrocytes treated with a gradient of miR-379-5p mimic/control and inhibitor/control. 
Human OA chondrocytes were treated in media supplemented with 10ng/ml IL-1β with miR-
379-5p 5nM/50nM mimic-control-mimic and 50nM/100nM/200nM inhibitor-control-
inhibitor, for 48h. Expression of miR-379-5p, predicted targets and cartilage markers is shown. 
N=1 donor. Expression is relative to SNORD68 for miR-379-5p, and relative to GAPDH for 






Based on these preliminary results, I treated OA chondrocytes from additional donors with 
5nM mimic/control-mimic and 200nM inhibitor/control-inhibitor for miR-379-5p, and 
checked the expression of miR-379-5p, of selected cartilage markers: COL2A1, ACAN, MMP13, 
as well as the expression of the predicted target genes: TGFBR1, SMAD9 and HDAC2. Results 
showed that expression of miR-379-5p was higher in chondrocytes treated with mimics 
compared to control (p=0.22), and lower in chondrocytes treated with the inhibitor compared 
to control (p=0.22), but neither reached statistical significance. However, when I looked at 
the expression of the predicted target gene, TGFBR1, there were significant changes observed 
in its expression. Specifically, expression of TGFBR1 was significantly lower in chondrocytes 
treated with the mimic (p=0.001), and significantly higher in chondrocytes treated with the 
inhibitor (p=0.02), consistent with the direction of dysregulation expected after 
overexpressing or inhibiting miR-379-5p. Predicted targets SMAD9 and HDAC2 as well as 
cartilage markers did not show any statistically significant changes between treated groups 























Figure 5.6: Expression of miR-379-5p, its predicted target gene and cartilage markers in 
human OA chondrocytes treated with miR-379-5p mimic, inhibitor or control. Human OA 
chondrocytes were treated in media supplemented with 10ng/ml IL-1β with miR-379-5p 5nM 
mimic, 200nM inhibitor or control, for 48h. Expression of miR-379-5p, predicted targets and 
cartilage markers is shown. N=5-6 donors. Expression is relative to SNORD68 for miR-379-5p 
and relative to GAPDH for protein-coding genes. Statistical analysis was undertaken using a 
two-tailed paired t-test in GraphPad Prism (Version 8.0.1). Data are represented as mean+SD. 





5.4.4 Expression of selected target genes in human primary OA chondrocytes treated with 
miR-107 mimics and inhibitors in an in vitro OA inflammatory model 
 
To investigate the role of miR-107 in cartilage and OA, I undertook a similar set of 
experiments. Human primary OA chondrocytes were treated with miR-107 mimic or control-
mimic and miR-107 inhibitor or control-inhibitor, in media supplemented with 10ng/ml IL-1β 
for 48h. Following overexpression and inhibition, I focused primarily on the expression of 
predicted target genes, WNT4, IHH, FGF2, TNF and IRF1.  
Based on results from our previous experiments, initially I used chondrocytes from two 
donors and investigated a 5nM and a 50nM concentration for the mimic treatment and 
measured the relative expression of miR-107 and two target genes: WNT4 and FGF2. Results 
showed that expression of miR-107 was higher in chondrocytes treated with either 
concentration compared to control, and reached higher levels in chondrocytes treated with 
50nM. However, when I investigated the expression of selected predicted target genes, I 
observed that WNT4 and FGF2 had an improved response to  5nM mimic treatment compared 
to 50nM. Specifically, both WNT4 and FGF2 had lower expression in chondrocytes treated 
with 5nM compared to control and higher expression in chondrocytes treated with 50nM 
mimic compared to control (Figure 5.7). Therefore, only the 5nM mimic treatment generated 
the expected results. Based on this, I selected 5nM as the concentration for follow up 















Figure 5.7: Expression of miR-107, WNT4 and FGF2 in human OA chondrocytes treated with 
a 5nM and 50nM miR-107 mimic and control. Human OA chondrocytes were treated in 
media supplemented with 10ng/ml IL-1β with miR-107 5nM or 50nM mimic or control, for 
48h. Expression of miR-107 and targets is shown. N=1-2 donors. Expression is relative to 
SNORD68 for miR-107 and relative to GAPDH for WNT4 and FGF2. Data are represented as 
mean+SD. Control-M=control-mimic, control-I=control-inhibitor.  
 
Based on these preliminary results, I treated chondrocytes from additional donors with 5nM 
mimic and 200nM inhibitor and measured the relative expression of predicted target genes: 
WNT4, IHH, FGF2, TNF and IRF1. Results demonstrated that expression of miR-107 was higher 
in chondrocytes treated with the mimic and lower in chondrocytes treated with the inhibitor. 
However, neither reached statistical significance. Moreover, chondrocytes had significantly 
lower WNT4 and IHH expression in the mimic group and significantly higher expression in the 
inhibitor group, as expected. FGF2 expression was lower in the mimic group (p=0.06) but did 
not show significant change in the inhibitor group. TNF and IRF1 did not show any significant 














































































































































Figure 5.8: Expression of miR-107 and its predicted target genes in human primary OA 
chondrocytes treated with miR-107 mimic, inhibitor or control. Human OA chondrocytes 
were treated in media supplemented with 10ng/ml IL-1β with miR-107 5nM mimic, 200nM 
inhibitor or control. Expression of miR-107 and predicted targets is shown. N=8-11 donors. 
Expression is relative to SNORD68 for miR-107, and relative to GAPDH for predicted target 
genes. Statistical analysis was undertaken using a two-tailed paired t-test in GraphPad Prism 
(Version 8.0.1). Data are represented as mean+SD. P values<0.05 were considered significant. 




5.4.5 Investigation of miRNA predicted target genes in human articular cartilage tissue  
 
Overexpression and knockdown of selected miRNAs in human primary OA chondrocytes 
offered insights on some potential target genes of these miRNAs. CALM3 and RHOA did not 
show any significant changes in chondrocytes treated with miR-361-5p mimic and inhibitor. 
TGFBR1 had significantly lower expression in chondrocytes treated with miR-379-5p mimic 
and significantly higher expression in chondrocytes treated with miR-379-5p inhibitor. 
Likewise, WNT4 and IHH had significantly lower expression in chondrocytes treated with miR-
107 mimic and significantly higher expression in chondrocytes treated with miR-107 inhibitor. 
In Chapter 3, I identified that miR-379-5p and miR-107 had significantly lower expression in 
old OA intact and lesioned cartilage tissue compared to young cartilage tissue from ACL 
donors. To investigate further whether these genes are indeed targeted by these miRNAs, I 
interrogated their expression in the independent cohort of cartilage tissue samples that were 
used to validate microarray findings in Chapter 4. First, I identified the most appropriate 
endogenous reference gene to use. I investigated the following potential reference genes: 
RPL13A, RPLP0, RPL3, ATP5F1A, RPL4, YWHAE and GAPDH. Analysis with RefFinder showed 
that the best reference gene for our cartilage tissue samples was RPL3 (Figure 5.9), and thus 










Figure 5.9: Selection of the best endogenous reference gene in human articular cartilage. 
From a list of seven potential reference genes, RefFinder identified RPL3 as the best gene to 




Results showed that TGFBR1 had lower expression in OA intact and lesioned cartilage samples 
compared to young intact cartilage from ACL donors, similar to miR-379-5p and opposite to 
what was expected (Figure 5.10). In addition, TGFBR1 had a significantly higher expression in 
OA-intact cartilage samples compared to OA-lesioned cartilage. However, as described in 
Chapter 3 and 4 there was no significant difference between OA-intact and OA-lesioned 
cartilage for miR-379-5p. Therefore, results indicated that TGFBR1 was not likely a target of 
miR-379-5p in our cartilage dataset, as they both showed the same direction of dysregulation 
between young and old OA cartilage tissues. 
 
Figure 5.10: Expression of TGFBR1 in the independent cohort of young intact and old OA 
intact and lesioned cartilage samples. Expression of miR-379-5p and TGFBR1 in young intact 
cartilage from ACL donors and old OA intact and lesioned cartilage is shown. N=6-8 donors. 
Y-axis represents log-transformed expression relative to SNORD68 for miR-379-5p, and 
relative to RPL3 for TGFBR1. Statistical analysis was undertaken using a Mann Whitney test in 
GraphPad Prism (Version 8.0.1). Data are represented as mean+SD. P values<0.05 were 





Results for WNT4 and IHH showed that these genes had significantly higher expression in old 
OA intact and lesioned cartilage tissue from OA patients compared to young intact cartilage 
from ACL donors (Figure 5.11). This is consistent with WNT4 and IHH being targets of miR-
107, since miR-107 had lower expression in old OA intact and lesioned cartilage tissue 
compared to young intact cartilage tissue. Table 5.3  summarises findings for all three miRNAs 
in OA chondrocytes and cartilage tissue. 
 
Figure 5.11: Expression of WNT4 and IHH in the independent cohort of young intact and old 
OA intact and lesioned cartilage samples. Expression of miR-107, WNT4 and IHH in young 
intact cartilage from ACL donors and old OA intact and lesioned cartilage is shown. N=5-8 
donors. Y axis represents log-transformed expression relative to SNORD68 for miR-107, and 
relative to RPL3 for WNT4 and IHH. Statistical analysis was undertaken using a Mann Whitney 
test in GraphPad Prism (Version 8.0.1). Data are represented as mean+SD. P values<0.05 were 
considered significant. *: p<0.05, **: p<0.01, ***: p<0.001.  
 
Note: I had planned to investigate the protein levels of WNT4 and IHH by Western blotting, using human primary 
chondrocytes treated with miR-107 mimic and inhibitor. However, due to the unexpected shutdown of our laboratory 
facilities in March 2020 due to COVID-19, I was unable to carry out these experiments. By the time the facilities were 
open again, the studentship that supported this project and the author of this thesis had ended, and the author had 




Table 5.3: Summary of findings of miRNA-target gene validation in human 
chondrocytes and human cartilage. Validation of miRNA-target gene interactions was 
undertaken in human primary OA chondrocytes treated with mimics, inhibitors and 
control and in human young intact cartilage from ACL donors and human OA cartilage 
from end-stage OA patients. ‘Yes/No’ denotes validated/not validated findings at 
p<0.05. N/A denotes expression measurement was not undertaken in these groups. 
 
 
5.4.6 Proteomic investigation of human primary OA chondrocytes treated with miR-143-
3p mimic and inhibitor 
 
To investigate the role of miR-143-3p in cartilage and OA, I undertook a proteomic approach, 
using LC-MS/MS and label-free quantification in human primary OA chondrocytes treated 
with 10ng/ml human recombinant IL-1β and miR-143-3p mimic, or miR-143-3p inhibitor, or 




Validated in human OA 
chondrocytes 
Validated in human young 
intact and old OA cartilage 
miR-361-5p 
RHOA No N/A 
CALM3 No N/A 
miR-379-5p 
TGFBR1 Yes No 
HDAC2 No N/A 
SMAD9 No N/A 
miR-107 
WNT4 Yes Yes 
IHH Yes Yes 
FGF2 No N/A 
TNF No N/A 




in each sample was quantified using the Pierce™ 660nm Protein Assay. To calculate protein 
concentration for each sample, a standard curve was prepared using the absorbance of 
samples with known protein concentration. The amount of protein for each unknown sample 
is listed in Table 5.4.  
Table 5.4: Amount of protein contained in chondrocyte lysates per treatment per donor. 





























To evaluate the quality and gross profile of the total protein content in chondrocyte lysates, 
prior to trypsin digestion and LC-MS/MS, all samples were subjected to SDS-PAGE using a 
NuPAGE™ 4% to 12% (w/v), Bis-Tris gel. After SDS-PAGE, the gel was  silver stained. Silver 
staining showed that quality of total protein was good for all samples. Moreover, all samples 
had protein bands in the expected range of molecular weights (10kDa-260kDa), which was a 






















Figure 5.12: Total protein detection by silver staining in chondrocyte lysates treated with 
miR-143-3p mimic, inhibitor or control. Human OA chondrocytes were treated with miR-143-
3p mimic, inhibitor or control. Cell lysates were collected 48h after treatment. 2μg of total 
protein per sample was run on a NuPAGE™ 4% to 12% (w/v), Bis-Tris gel at 100V for 90min, 
alongside a Novex™ Sharp Pre-stained Protein Standard ladder. Following electrophoresis, gel 
was silver stained and visualised using a ChemiDoc XRS+. N=5 donors per treatment. D: Donor, 
M: mimic, CM: control-mimic, I: inhibitor, CI: control-inhibitor, L: Pre-stained Protein Standard 




To investigate digestion efficiency prior to LC-MS/MS, all digests were run on a NuPAGE™ 4% 
to 12% (w/v), Bis-Tris gel. Gel was stained with Coomassie Brilliant Blue and destained in 
Coomassie Brilliant Blue Destaining Solution. Staining showed that all samples were 












Figure 5.13: Digestion quality assessment by Coomassie Brilliant Blue staining in 
chondrocyte lysates treated with miR-143-3p mimic, inhibitor or control. To confirm 
complete digestion of proteins, 1μg of digest was run on a NuPAGE™ 4% to 12% (w/v), Bis-
Tris gel at 100V for 90min, alongside a Novex™ Sharp Pre-stained Protein Standard ladder. 
Gel was stained with Coomassie Brilliant Blue for 2h and destained in Destaining Solution  for 
2h. The gel was visualised using a ChemiDoc XRS+. N=5 donors. D: Donor, M: mimic, CM: 





Digests were subjected to LC-MS/MS using a 90min gradient with 30min blanks between each 
sample. Chromatograms showed that there was good separation of ions, and of sufficient 
complexity representative of  cell lysates (Figure 5.14). 
 
 
Figure 5.14: Example of chromatograms generated following LC-MS/MS in human primary 
chondrocytes treated with miR-143-3p mimic, inhibitor or control. OA human chondrocytes 
were treated with miR-143-3p mimic, inhibitor or control for 48h. Total proteins were 
digested and 500ng of digest per sample was subjected to LC-MS/MS for identification of 
protein abundance. Samples were run on a 90min gradient. Figure depicts two basic peak ion 
chromatograms, generated by LC-MS/MS. Chromatograms plot the retention time in the 
column for each analyte against their relative abundance in the sample. Each peak represents 
the detector response for a different ion. The height of each peak represents the amount of 




A total of 2252 proteins were identified, of which 1628 were identified with two or more 
peptides. PCA plots of the 1st and 2nd component for proteins identified with two or more 
peptides showed that there were not many changes between the mimic and the control-
mimic group (Figure 5.15A), or between the inhibitor and the control-inhibitor group (Figure 
5.15B). There was no specific clustering observed between the groups and samples seemed 










Figure 5.15: PCA of the 1st and 2nd components for proteins identified with at least two 
peptides following chondrocyte lysates subjected to LC-MS/MS after treatment with miR-
143-3p mimic, inhibitor or control. Human OA chondrocytes were treated with miR-143-3p 
mimic, inhibitor or control for 48h and subjected to LC-MS/MS. Figure depicts PCA plots of 1st 
and 2nd components for proteins identified with at least two peptides in comparisons: A) 
mimic vs control-mimic and B) inhibitor vs control-inhibitor. N=5. Numbers 1-5 correspond to 
different donors. Figure produced with MetaboAnalyst 5.0. 
 
Statistical analysis following label-free quantification was carried out using two-tailed paired 




the control-inhibitor group. Paired t-test analysis identified 87 DE proteins at p<0.05 in the 
mimic/control-mimic comparison and 50 DE proteins at p<0.05 in the inhibitor/control-
inhibitor group (Appendix to Chapter 5). However, when I adjusted for multiple testing, I did 
not identify any significantly DE proteins in the two comparisons (FDR-adjusted p<0.05). 
Therefore, I continued our analysis with proteins that were DE at p<0.05. First, I sought to 
identify common DE proteins between the two comparisons, and then investigate those 
which have opposite direction of expression between the two comparisons, lower in the 
mimic vs control-mimic and higher in the inhibitor vs control-inhibitor, as this would suggest 
that these DE proteins could be potential targets of miR-143-3p. Analysis showed that there 
were no common DE proteins between the two comparisons and, therefore, I was not able 
to directly identify target genes of miR-143-3p. Nonetheless, to characterise  the sets of DE 
proteins from the two comparisons, I uploaded them on STRING, to check whether these 
proteins were interacting with each other. STRING analysis showed that for each comparison, 
most proteins were strongly interacting with each other and were forming specific networks 
(Figure 5.16A&B). Of interest is that the proteins forming these networks were ribosomal 



























Figure 5.16: STRING analysis of DE proteins identified in chondrocytes treated with miR-
143-3p mimic, inhibitor or control following LC-MS/MS. DE proteins (p<0.05) between A) 
mimic vs control-mimic group and B) inhibitor vs control-inhibitor group, were uploaded on 
STRING for protein network analysis and to identify protein-protein interactions. Filters were 
set to show both functional and physical protein associations, and highest confidence (0.900) 
was selected. Line colour indicates the type of interaction evidence. Stronger associations are 
represented by thicker lines. Figures generated with STRING. 
 
I hypothesised that the DE proteins might be part of specific pathways regulated by miR-143-
3p through targeting of genes that were not identified by LC-MS/MS. To investigate this 
hypothesis further, I uploaded the list of identified proteins for each comparison in IPA and 
carried out a ‘Core Analysis’ for each list, setting a p value cut-off at 0.05. Core Analysis 




surprisingly, for both mimic vs control-mimic and inhibitor vs control-inhibitor, the top 
canonical pathway identified was EIF2 signalling (Figure 5.17A&B). In fact, in the mimic vs 
control-mimic comparison, EIF2 signalling had a negative z score [z-score= -1, -log(p-value)= 
6.72], whereas, in the inhibitor vs control-inhibitor comparison, EIF2 signalling had a positive 
z score [z-score= 2, -log(p-value)= 7.54]. This suggests activation of EIF2 signalling in the 
inhibitor group and inhibition in the mimic group. Therefore, miR-143-3p could potentially be 
involved in translational initiation regulation either directly or indirectly via its target genes. 
Other common pathways identified by IPA between the two comparisons included: regulation 
of eIF4 and p70S6K signalling and mTOR signalling. IPA reports for both datasets are in 









Figure 5.17: Top canonical pathways linked to DE proteins from human OA chondrocytes 
treated with miR-143-3p mimic, inhibitor or control. Human OA chondrocytes were treated 
in media supplemented with 10ng/ml IL-1β with miR-143-3p mimic, inhibitor or control for 
48h. Cell lysates were collected and subjected to LC-MS/MS. Figure depicts IPA Core Analysis 
of DE proteins from chondrocytes treated with A) miR-143-3p mimic or control and B) miR-
143-3p inhibitor or control. Top canonical pathways associated with each dataset and z 
activation scores for each canonical pathways are shown. Figures generated with IPA Version 
60467501.  
 
Further to our analysis, I also checked the upstream regulators of the pathways identified in 
IPA for each comparison. In the mimic vs control-mimic comparison,  La ribonucleoprotein 1 
translational regulator (LARP1) was predicted to be an activated upstream regulator 
(activation z-score= 2.12). Other upstream regulators in this comparison include CCAAT 
enhancer binding protein alpha (CEBPA) and TNF. These were predicted to be inhibited 
(activation z-score= -2.40 and -2.17, respectively) (Figure 5.18A). 
The same analysis was undertaken in IPA for the inhibitor vs control-inhibitor comparison. 




regulator (activation score z= -2.83), opposite to what I observed in the mimic vs control-
mimic group. Furthermore, an activated upstream regulator in this comparison was MLX 
interacting protein like (MLXIPL) (activation z-score= 2.24) (Figure 5.18B). Of interest is that, 
even though there were no common DE proteins between the two comparisons, both sets of 
proteins were involved in similar pathways and IPA generated similar but opposite results for 
these sets. Moreover, according to IPA, both sets of DE proteins were involved in skeletal and 
muscular disorders (p=1.31 x 10-2 – 7.80 x 10-4) and skeletal and muscular system 













Figure 5.18: Network analysis of predicted upstream regulators of DE proteins in human OA 
chondrocytes treated with miR-143-3p mimic, inhibitor or control. IPA analysis of DE 
proteins (p<0.05) in human OA chondrocytes treated with miR-143-3p A) mimic or control-
mimic and B) inhibitor or control-inhibitor, identified  a set of predicted upstream regulators 





In this thesis I identified DE miRNAs between young intact cartilage from ACL donors and old 
OA intact and lesioned cartilage from OA patients. I selected a list of four miRNAs for follow 
up studies: miR-361-5p, -379-5p, -107 and -143-3p. To evaluate the role and function of these 
specific miRNAs in cartilage and OA, I overexpressed and knocked down their expression in 
human primary OA chondrocytes and measured the expression of selected predicted target 
genes, or of cartilage-related markers. For miRNAs miR-361-5p, -379-5p and -107, I selected 
specific target genes to investigate. I aimed at selecting genes that had not been identified 
previously as targets of our selected miRNAs, at least up to the time I selected these targets. 
Moreover, I selected genes that are or could potentially be relevant to cartilage biology and 
OA. Given that our miRNAs had significantly lower expression in OA intact and lesioned 
cartilage tissue compared to young intact cartilage from ACL donors, when possible, I selected 
genes that were reported as overexpressed in OA cartilage, so that they matched the opposite 
expression of our selected miRNAs.  
 
5.5.1 Justification of target gene selection 
 
For miR-361-5p, I selected two predicted target genes, CALM3 and RHOA. CALM3, along with 
CALM1 and CALM2, is an important gene involved in calcium transport and mechanical stimuli 
in chondrocytes, and its expression was shown to be upregulated in OA cartilage compared 
to normal cartilage (Mototani et al., 2010). RHOA is another important gene linked to cartilage 
and OA. It is involved in actin re-organization, cell maturation and apoptosis as well as in the 
remodelling of the ECM. RHOA is activated in OA cartilage and acts through the Rho 
associated coiled-coil containing protein kinase (ROCK) signalling pathway to induce 
chondrocyte hypertrophy and ECM degradation (Deng et al., 2019b). For miR-379-5p, I 
selected three predicted target genes: TGFBR1, HDAC2 and SMAD9. TGFBR1 is one of the 
receptors of TGF-β, a ligand that has major roles in cartilage development. Physiological 
loading has been shown to induce low concentrations of active TGF-β in healthy articular 
cartilage, which is necessary for cartilage homeostasis (van der Kraan, 2018). However, during 
OA, levels of TGF-β are increased and chondrocytes become exposed to higher levels of the 




development of the disease, rather than cartilage homeostasis (van der Kraan, 2018). 
Therefore, I thought to investigate further the relationship of miR-379-5p and TGFBR1. 
Following this rationale, I also included SMAD9 (also known as SMAD8) in our analysis, as 
SMADs are downstream targets of TGF-β signalling and are involved transcription regulation. 
The role of SMAD9 in cartilage seems limited compared to other SMAD proteins (Retting et 
al., 2009). Furthermore, HDAC2 is another gene involved in cartilage and OA. Studies have 
shown HDAC2 is increased in primary chondrocytes extracted from OA patients compared to 
non-OA and it can inhibit expression of ECM components, such as collagen type II and 
aggrecan (Hong et al., 2009). 
For miR-107, I selected four predicted target genes to investigate: WNT4, IHH, TNF and IRF1. 
WNT4 is a member of the WNT signalling pathway which is an important regulator of 
chondrocyte proliferation and maintenance (Wang et al., 2019c). Even though, another WNT 
family member, WNT3A, is more studied in cartilage and OA, WNT4 was also shown to be 
upregulated in hip and knee OA patients (Velasco et al., 2010). Moreover, IHH was 
upregulated in human OA articular cartilage and OA synovial fluid and induced collagen type 
X and MMP13 expression, suggesting a role for IHH in chondrocyte hypertrophy and cartilage 
degeneration in OA (Wei et al., 2012). Finally, the role of TNF and of other inflammatory 
cytokines has already been discussed in this thesis, and based on this; I chose to investigate 
whether TNF and IRF1, which is induced by TNF signalling, are targeted by miR-107.  
 
5.5.2 Evaluation of predicted targets of miR-361-6p, -379-5p and -107 
 
To evaluate whether the selected predicted target genes were targets of our three miRNAs 
of interest, I overexpressed and inhibited the expression of these miRNAs in human primary 
OA chondrocytes grown in media supplemented with 10ng/ml IL-1β for 48h. The use of IL-1β 
has been discussed more extensively in Chapter 4. As already discussed there, chondrocytes 
dedifferentiate in monolayer passaged cultures and tend to lose their phenotypic 
characteristics (Caron et al., 2012). The rationale behind the addition of IL-1β in chondrocytes 
treated with mimics or inhibitors, is to evaluate the benefit of these overexpressing or 
inhibitory agents when chondrocytes are in an inflammatory environment, and also to 




inflammatory component in early OA (Benito et al., 2005, Sokolove et al., 2013). Adding IL-1β 
treatment to OA chondrocytes treated with miRNA mimics and inhibitors is a common 
practice in the literature (Chang et al., 2016, Yuan et al., 2016, Zheng et al., 2017), and in our 
experiments all groups, mimic, inhibitor and controls, were treated with IL-1β. In addition, 
treatment time was kept to 48h, as from our IL-1β experiments in Chapter 4, I observed that 
longer treatments generated a more satisfactory response in human primary chondrocytes, 
compared to 24h. 48h is also sufficient time to observe any effects from the mimic and 
inhibitor treatments. From our experience, longer treatments for 72h and 96h did not 
produce different results (data not shown).  
Overexpression and inhibition of selected miRNAs and analysis of their predicted target genes 
showed that CALM3, RHOA, SMAD9, HDAC2, TNF and IRF1 were not validated as targets of 
using our approaches in our cell systems. This could be due to a number of reasons. First of 
all, these genes may not be actual targets of these miRNAs in chondrocytes. Even though 
these genes were predicted as targets by at least two prediction tools, these predictions could 
be false positives. Cloonan (2015) reported that the percentage of false positive predictions 
by miRNA target prediction tools ranges from 20% to 50% (Cloonan, 2015). With that said, 
RHOA was recently validated as one of miR-361-5p target genes in triple-negative breast 
cancer (Bhattacharya et al., 2020). This example points to another reason for not validating 
some of the selected target genes, and that is tissue specificity. Gene expression is a very 
tightly regulated process in eukaryotic cells and differs significantly from one cell/tissue type 
to another. Therefore, the relationship between a miRNA and its predicted targets could 
change dependent on the tissue type, developmental stage and health/disease state 
(Fiannaca et al., 2018, Sood et al., 2006). Also, it is worth mentioning that miRNAs are not the 
only regulators of gene expression. Gene expression is regulated at many different levels by 
an array of genetic and epigenetic modifiers, such as enhancers, transcription factors, DNA 
methylation, histone modifications and other classes of non-coding RNAs, which indicates the 
complex molecular landscape that underlies gene interactions. Another point to take into 
consideration is the approach taken to validate the predicted target genes from these three 
miRNAs. I used qPCR to detect expression of the miRNA of interest and of predicted target 
genes. As already mentioned, qPCR for the miRNA itself is not the recommended method to 




not consider results from miRNA quantification as confirmation of successful or unsuccessful 
overexpression/knockdown. For the overexpression experiments, even though the 
expression of the miRNA itself was increased in the mimic group by several folds compared 
to control in all three miRNAs tested, this did not guarantee that all these mimics were 
actually functional within the cells. This is also evident by the fact that using 5nM and 50nM 
mimics did not result in significant differences between the two treatments that would justify 
that the 50nM concentration should be used instead of the 5nM one. In fact, using higher 
concentrations of miRNA mimics could potentially lead to accumulation of mutated and 
unnatural passenger strands, off-target effects and saturation of the RISC complex (Jin et al., 
2015). For the knockdown experiments, qPCR should not be used to assess transfection 
efficiency. These inhibitors usually bind the miRNA of interest and prevent it from binding the 
target gene, but usually do not lead to miRNA degradation (Qiagen, 2017). From our 
experiments, I observed that miR-361-5p had significantly lower expression in the inhibitor 
group compared to control, but none of the predicted target genes expression were altered. 
Instead, even though expression of miR-379-5p and miR-107 was not significantly lower in 
the inhibitor group compared to control, TGFBR1, WNT4 and IHH had significantly higher 
expression in the inhibitor group compared to control, suggesting successful miRNA 
inhibition. This further supports that the evaluation of overexpressing and inhibitory 
experiments should be based on the expression of the target genes, rather than the miRNA 
itself. Another possible reason for the unsuccessful validation of some of the predicted target 
genes could be the experimental method used to assess this. I used qPCR to check the 
expression of the mRNA of the predicted target genes. However, changes on target genes 
may not be detectable at the mRNA level, but could be present at the protein level. This is 
because miRNA pairing does not always lead to mRNA degradation, but to translational 
repression. The contribution of each mechanism is still unclear and in certain cases one might 
be the prominent mechanism compared to the other (Cloonan, 2015). Therefore, it is possible 
that some of these target genes could show differences at the protein level. However, it was 
not possible to undertake Western blotting for all predicted targets. I had planned to 
undertake Western blot analysis for WNT4 and IHH, which were also validated by qPCR, but 
that was not possible due to the COVID-19 pandemic. Additional mechanistic experiments, 
such as proliferation or migration assays, or luciferase assays would have been useful to 




Following validation of TGFBR1, WNT4 and IHH in chondrocytes treated with mimics and 
inhibitors, I sought to investigate the expression of these predicted targets in human cartilage 
tissue. Our microarray experiment was undertaken between young intact cartilage from ACL 
donors and old OA intact and lesioned cartilage from OA patients undergoing TKA. miR-379-
5p and miR-107 had significantly lower expression in the old OA cartilage samples compared 
to young cartilage. Our results showed that WNT4 and IHH had significantly higher expression 
in old OA intact and lesioned cartilage compared to young intact cartilage, in agreement with 
previous studies (Velasco et al., 2010, Wei et al., 2012). This further confirmed that these two 
genes could represent actual targets of miR-107, since they had opposite expression to that 
of miR-107. However, our analysis showed that TGFBR1 had lower expression in old OA 
cartilage tissues compared to young cartilage tissue, following the same direction of 
dysregulation as miR-379-5p. This suggested that TGFBR1 might not represent a true target 
of miR-379-5p, at least in cartilage tissue. The fact that TGFBR1 responded to miR-379-5p 
mimic and inhibitor as I would have expected if it were a real target, could potentially indicate 
differences between cartilage tissue and cultured chondrocytes, or could be a culture artifact.  
Given the above results, it is difficult to describe the role of miR-361-5p and miR-379-5p in 
cartilage and OA. Wang et al (2019) reported that expression of miR-361-5p was upregulated 
in OA chondrocytes compared to normal chondrocytes and that it promoted chondrocyte 
apoptosis and ECM degradation (Wang et al., 2019a) . This is in contrast with our study, as 
miR-361-5p had lower expression in OA cartilage tissues. However, the experimental design 
between the two studies was different, as I used cartilage tissue and not extracted 
chondrocytes for our initial microarray analysis. Moreover, I compared OA cartilage tissues to 
young intact tissue from ACL donors, whereas Wang et al (2019) compared OA chondrocytes 
to normal chondrocytes from age-matched donors. 
Regarding miR-379-5p, there is limited data on its role in cartilage and OA. Jee et al (2018) 
reported that miR-379-5p had lower expression in the hypertrophic zone of murine growth 
plate compared to the proliferative zone and this led to increased expression of hypertrophic 
markers (Jee et al., 2018).  
miR-107 is a  well-researched miRNA. A few studies have shown that miR-107 has lower 
expression in OA cartilage tissue and chondrocytes compared to normal controls, in 




have shown that miR-107 can promote chondrocyte proliferation, and inhibition of its 
expression can lead to apoptosis. It was shown that this function of miR-107 is achieved by 
targeting genes involved in cell survival and proliferation and autophagy, such as TRAF3, 
phosphatase and tensin homolog (PTEN), and caspase 1 (CASP1). In our study, I found that 
WNT4 and IHH could be potential target genes of miR-107. WNT4 was found to be 
overexpressed in human OA hip and knee cartilage (Velasco et al., 2010), and in mice with 
induced-OA (Gu et al., 2019). In the latter study, induced-OA led to increased levels of Wnt4 
and activated the WNT signalling pathway leading to increased expression of Mmp2 and 
Mmp9 through β-catenin. In another study, inhibition of IHH signalling led to increased 
chondrocyte proliferation and reduced apoptosis and cartilage degeneration by treating cells 
with ipriflavone, a compound that inhibits IHH signalling (Guo et al., 2019). Given the 
biological pathways that WNT4 and IHH are involved in, our analyses indicate that if miR-107 
targets these genes, then it could also be involved in chondrocyte survival and proliferation. 
 
5.5.3 Investigation of miR-143-3p in cartilage and OA 
 
To investigate the role of miR-143-3p in cartilage and OA, I took a different approach 
compared to the first three miRNAs. Instead of looking at the expression of specific predicted 
target genes, I undertook LC-MS/MS analysis in lysates from chondrocytes treated with miR-
143-3p mimic, inhibitor, or control. I analysed results using two-tailed paired t-tests for 
chondrocytes treated with mimic or control mimic and inhibitor or control-inhibitor, as I was 
interested in comparing each treatment to its respective control. Analysis did not identify any 
statistically significant changes when I corrected for multiple testing, using a cut-off of FDR-
adjusted p value<0.05. This could have resulted from reduced transfection efficiency. Given 
that assaying for the miRNA itself is not a reliable approach to confirm overexpression or 
inhibition of the miRNA, it was not possible to assess the magnitude of overexpression of 
inhibition in chondrocytes treated the miR-143-3p mimics and inhibitors. Another possible 
reason could have been donor variability, as I used chondrocytes extracted from five different 
donors and this could have masked any treatment-related differences, given the small 
number of samples. This was also evident from the PCA plots, as samples clustered based on 




comparisons mimic vs control-mimic, and inhibitor vs control-inhibitor, identified DE proteins 
at p<0.05 for each comparison. Analysis showed that there were no common DE proteins 
between the two comparisons that would have pointed to specific targets of miR-143-3p. 
However, analysis of these DE proteins from each comparison with IPA indicated that both 
sets of DE proteins were involved in EIF2 signalling. In fact, IPA predicted that DE proteins 
from the mimic vs control-mimic comparison were involved in inhibition of EIF2 signalling. In 
contrast, IPA predicted that DE proteins from the inhibitor vs control-inhibitor comparison 
were involved in activation of EIF2 signalling. The potential regulation of EIF2 signalling could 
be through specific miR-143-3p target genes that were not identified by LC-MS/MS, either 
because their detection was outside of the sensitivity range of the technique, or because they 
act at an early point (a few hours after transfection), but their results can still be observed 
several hours and until collection of lysates, 48h after transfection. Either way, our results 
provided a useful insight into the potential role of miR-143-3p and its association with EIF2 
signalling.  
EIF2 signalling is involved in protein translation and protein synthesis and plays a crucial role 
in cellular response due to stress-related stimuli, such as oxidative stress, injury, and others 
(Wek, 2018). Under such stress stimuli, eIF2a is phosphorylated and this leads to its inhibition 
and to reduced global protein translation. Instead, specific genes are expressed which 
promote cellular adaptation and survival and exert an anti-apoptotic effect. In a relevant 
study, it was shown that curcumin could inhibit EIF2 signalling in oxidative stress-induced rat 
chondrocytes and alleviate OA progression and chondrocyte apoptosis (Feng et al., 2019). 
Interestingly, in a study assessing the transcriptomic differences between ovaries from young 
and middle-aged mice, the authors reported increased miR-143 expression and reduced EIF2 
signalling in middle-aged ovaries compared to young (Cuomo et al., 2018). Even though the 
authors did not discuss the potential association of miR-143 to EIF2 signalling, our results also 
suggest a potential link between miR-143-3p and EIF2. Perhaps, miR-143-3p is involved in 
cartilage homeostasis through regulating EIF2 signalling. Specifically, overexpression of miR-
143-3p could inhibit EIF2 signalling, leading to repression of global protein synthesis, but 
promoting the expression of genes that assist chondrocyte survival during stress. In contrast, 
inhibition of miR-143-3p during OA (as suggested by our microarray study), could induce EIF2 




important for cell survival, thus leading to increased apoptosis. Perhaps, this could explain 
the upregulation of miR-143-3p in chondrocytes treated with IL-1β for 24h, reported in 
Chapter 4. IL-1β-induced stress in treated chondrocytes could result in a stress response, 
which could promote increased expression of miR-143-3p. Increased expression of miR-143-
3p could, in turn, inhibit global protein translation by inhibiting EIF2 signalling, in an attempt 
of the cell to survive and adapt to the inflammatory stress. Continuous treatment with IL-1β, 
could eventually lead to inhibition of miR-143-3p, as observed by chondrocytes treated with 
IL-1β for 5 days, and subsequently to chondrocyte apoptosis. In fact, it has been suggested 
that the result of the stress response depends on the duration and intensity of the stress 
stimulus (Bevilacqua et al., 2010). During the early stages of the response, inhibition of EIF2 
signalling leads to activation of genes important for cell survival. However, with persisting 
stress stimuli, there is a shift in stress responses and eventually apoptosis is favoured over 
survival. 
Moreover, IPA identified upstream regulators of these DE proteins for each comparison. 
Amongst these, LARP1 was a common upstream regulator in both comparisons, and it was 
predicted to be activated in chondrocytes treated with the mimic, and inhibited in 
chondrocytes treated with the inhibitor. LARP1 is involved in protein translation, cell 
proliferation and cell survival and has been shown to interact with ribosomal proteins and 
also be part of the mTOR signalling pathway, suggesting a role for LARP1 in miR-143-3p 
related pathways (Berman et al., 2020). Though there are contradictory data on its role, it is 
believed that LARP1 inhibits the translation of ribosomal proteins and translation factors 
(Fonseca, Lahr, Damgaard, Alain, & Berman, 2018). However further studies are needed to 
elucidate its exact role, especially with regards to cartilage biology, as there are currently no 
data on its role in OA.  
 
5.6 Conclusion 
I was able to interrogate the role of selected miRNAs in cartilage and OA, by modulating their 
expression in human primary OA chondrocytes. Investigation of their predicted target genes 
showed that miR-107 could target WNT4 and IHH and that it could be involved in chondrocyte 




at specific target genes of miR-143-3 following LC-MS/MS, I was still able to identify pathways 
that this miRNA could be involved in, such as the EIF2 signalling pathway, and propose a link 

































Chapter 6: Investigation of miRNA 
expression in equine ageing 








Articular cartilage displays a limited repairing capacity, low chondrocyte proliferation and low 
collagen turnover (Decker, 2017). There are a number of factors affecting the homeostatic 
properties of cartilage, such as genetics and obesity. However, ageing is the leading risk factor 
that predisposes cartilage to pathological changes and OA. Although OA is not the direct result 
of ageing, it is believed that age-related changes in the joint make articular cartilage 
susceptible to OA (Loeser et al., 2016), since they affect both chondrocyte physiology and 
ECM properties (Mobasheri et al., 2015). Aged chondrocytes display increased senescence 
and higher expression of catabolic markers; features also evident in OA chondrocytes 
(Sacitharan et al., 2016). Moreover, in humans, aged knee cartilage is thinner compared to 
younger cartilage and is characterised by increased collagen crosslinking and altered 
proteoglycan content. These changes affect matrix stiffness, make cartilage susceptible to 
fractures and lower its ability to sense mechanical stimuli (Verzijl et al., 2002, Zhang et al., 
2019).  
The exact mechanisms through which age can affect cartilage health remain elusive, though 
it is believed to be a cumulative combination of many molecular pathways rather than a single 
aetiology. MiRNAs have been linked to ageing cartilage. miR-140, one of the best studied 
miRNAs in cartilage, is important for cartilage development and deletion of miR-140 in mice 
resulted in age-related OA-like changes and skeletal defects (Miyaki et al., 2010). Moreover, 
OA chondrocytes show decreased expression of miR-24, resulting in increased expression of 
the senescent marker p16INK4a, highlighting the link between OA and senescence, which is 
one of the hallmarks of ageing (Philipot et al., 2014). Ukai et al (2012) identified miRNA 
changes in chondrocytes isolated from the fingers of infants diagnosed with polydactylism 
(average age: 13 months) and normal, non-load bearing articular cartilage from young 
patients undergoing ACL reconstruction (average age: 22.3 years) (Ukai et al., 2012). They 
found elevated expression of miR-199a-3p and miR-193b, and decreased expression of miR-
320c in the ACL group compared to the infant group. Overexpression of miR-199a-3p and miR-
193b in chondrocytes resulted in reduced expression of COL2A1, ACAN and SOX9 compared 
to control, whereas the opposite occurred when they inhibited the expression of these two 
miRNAs in chondrocytes. The group concluded that miR-199a-3p and miR-193b could be 




investigate, purely, age-related changes in human cartilage without the effect of OA, given 
the difficulty in obtaining young and old healthy articular cartilage. Our group previously 
carried out RNA-Seq in cartilage tissue from the metacarpophalangeal joints of young (4 
years) and old (>15 years) horses and detected significantly higher expression of miR-21 in 
the old group, suggesting that this miRNA could potentially be involved in cartilage ageing 
(Peffers et al., 2013). There is very limited data on the effect of ageing on miRNA expression 
in cartilage and chondrocytes, without the effect of OA, therefore such studies are needed to 
elucidate age-related mechanisms that could help diagnose early-stage OA. 
 
Note: The analyses described in this chapter are included in the published research article: 
Small Non-Coding RNAome of Ageing Chondrocytes (Balaskas et al., 2020). The article is 
available in the Appendix to Chapter 6. 
  
6.2 Study aim and rationale 
In this study, I undertook small RNA-Seq to investigate the expression changes of miRNAs in 
chondrocytes isolated from healthy metacarpophalangeal joints of young and old horses. I 
used chondrocytes instead of cartilage tissue to obtain high quality RNA suitable for small 
RNA-Seq. Results were validated with qPCR using RNA from the same equine samples, as well 
as an independent cohort of young and old chondrocytes isolated from healthy 
metacarpophalangeal joints.  
 
6.3 Experimental design 
The experimental procedures, pertinent to this chapter are described briefly below. For full 
details on the experimental procedures, please refer to Chapter 2. Appropriate references are 






6.3.1 Isolation of young and old healthy equine chondrocytes  
 
For small RNA-Seq, healthy primary chondrocytes were isolated from the 
metacarpophalangeal joints of young (n = 5, age mean± SD= 4±1 years) and old (n = 5, age 
mean±SD= 17.4±1.9 years) non-Thoroughbred horses as described in Section 2.10. Joints 
were grossly inspected for pathological perturbations and only grossly normal joints were 
selected for chondrocyte isolation.  
In addition to the above samples, RNA from chondrocytes from young (n=2, age mean±SD= 
0.75±0.3 years) and old (n=6, age mean±SD; 19.3 ± 3.6 years) non-Thoroughbred horses were 
used for validation with qPCR. 
 
6.3.2 Equine chondrocyte culture, passaging and total RNA extraction 
 
Isolated chondrocytes were cultured up to 90% confluence and collected as described in 
Section 2.11. Total RNA was extracted from young and old healthy equine chondrocytes using 
the miRNeasy Mini Kit (Qiagen, Manchester, UK), as described in Section 2.13.2. 
 
6.3.3 Small RNASeq analysis for detection of differentially expressed miRNAs in young and 
old healthy equine chondrocytes 
 
To detect DE miRNAs between young and old healthy equine chondrocytes, small RNA-Seq 
was undertaken using the Illumina MiSEq platform (Illumina, Cambridge, UK), as described in 
Section 2.15. Following small RNA-Seq, sequence data were processed through a number of 
steps to obtain miRNA expression values, including base-calling, trimming of fastq files to 
remove Illumina adapter sequences and low-quality bases, read alignment, as described in 
Section 2.32. Differential expression analysis was undertaken in R environment using package 
EdgeR. The estimated logFC were tested in EdgeR using a likelihood ratio test. Significantly DE 






6.3.4 Pathway analysis of DE miRNAs between young and old equine chondrocytes 
 
In order to identify miRNA targets, bioinformatic analysis was performed by uploading DE 
miRNA data into the MicroRNA Target Filter module within IPA, along with previously 
identified DE mRNAs from our ageing equine cartilage study (Peffers et al., 2013). In IPA I 
selected miRNA-target genes based on the direction of differential expression (for example, 
if a miRNA was reduced in expression, it was only matched to mRNAs that demonstrated 
increased expression). I then identified the networks, functions, and canonical pathways of 
these miRNA-target genes, as described in Section 2.36.  
 
6.3.5 cDNA synthesis and qPCR for miRNA quantification 
 
Poly(A) cDNA for miRNA quantification using qPCR, was synthesised from total RNA as 
described in Section 2.16. miRNA quantification was undertaken as described in Section 2.18. 
Statistical analysis was undertaken in GraphPad Prism version 8.0.1 for Windows and 
normality of data was assessed using the Shapiro-Wilk normality test. For miRNA 
quantification in equine primary chondrocytes, statistical significance was calculated using 
the Mann-Whitney test, as data did not follow the Gaussian distribution. Expression levels 
were normalised to U6 (as this was stable in the small RNA-Seq data set) and calculated using 













6.4.1 Differential Expression Analysis of Small RNA-Seq Data 
 
To identify differential expression of miRNAs in ageing, small RNA-Seq between young healthy 
and old healthy equine chondrocytes was undertaken using the Illumina MiSeq platform. 
Reads mapping percentages were between 92 to 94.3%. There were 266 mature miRNAs 
identified. 
The effect of age on the expression of miRNAs was weak and the separation of young and old 
samples was not clear. The 2-D PCA plot indicated that few, but very specific changes in the 
expression of miRNAs were found, and samples from old donors were more variable than 













Figure 6.1: 2D PCA plot of the first and second components of miRNA abundance in young 
and old equine chondrocytes. PCA plot created using the logarithm-transformed data from 




A heat map of hierarchical clusters of correlations among samples depicted that the miRNA 
expression of young and old groups was not very different (Figure 6.2). Analysis showed that 
there were five DE miRNAs between young and old equine chondrocytes at FDR-adjusted 
p<0.05. Two of the DE miRNAs had significantly higher expression in the old group, whereas 




Figure 6.2: Heatmap of correlation coefficients among young and old chondrocyte samples. 
Correlation coefficients among five young and five old equine chondrocyte samples were 
computed using logarithm-transformed expression values of detected miRNAs. Colour 
gradient from blue to red denotes transition from lower to higher correlation coefficients. 




Table 6.1: Differentially expressed miRNAs in ageing chondrocytes. Log2 FC values were 
derived with young as the reference group. A positive log2 fold change equates to higher 
expression in old, whereas a negative log2 fold change equates to lower expression in old. 
Significant at FDR-adjusted p< 0.05. 








6.4.2 IPA analysis of DE miRNAs in equine chondrocyte ageing 
 
To investigate the role of the five DE miRNAs (miR-143, miR-145, miR-181b, miR-122, miR-
148a), and their potential implication in cartilage and chondrocyte ageing, I undertook further 
analysis of our dataset using IPA. Our group had previously carried out RNA-Seq between 
young and old equine cartilage tissue to identify age-related DE mRNAs (Peffers et al., 2013). 
In IPA, the five DE miRNAs were paired with the 351 DE protein coding genes from our RNA-
Seq study, to identify likely miRNA-mRNA interactions. Expression pairing was adjusted to 
show only miRNA-mRNA interactions that followed the correct pairing direction (miR increase 
and mRNA decrease or vice versa). Analysis showed that four out of five miRNAs interacted 








Table 6.2: Predicted and experimentally validated miRNA-mRNA interactions in equine 
cartilage/chondrocyte ageing. IPA analysis generated a list of experimentally validated or 
predicted (with high/moderate confidence) miRNA-mRNA interactions in 
cartilage/chondrocyte ageing. Expression pairing was set to only show pairings with opposite 
direction of expression between the miRNA and the mRNA target. Upward arrow denotes 
significantly higher expression in the old group, whereas a downward arrow denotes lower 
expression in the old group. Young group was the reference group.  
miRNA Direction mRNA Direction Confidence 
miR-122 ↑ CLSTN3 ↓ Moderate (predicted) 
miR-122 ↑ GABRA3 ↓ Moderate (predicted) 
miR-122 ↑ NCAM1 ↓ Experimentally Observed 
miR-122 ↑ RUNX2 ↓ Moderate (predicted) 
miR-122 ↑ SEMA4D ↓ High (predicted) 
miR-122 ↑ SLC52A2 ↓ High (predicted) 
miR-122 ↑ WNT11 ↓ Moderate (predicted) 
miR-143 ↓ FST ↑ Moderate (predicted) 
miR-143 ↓ KCNN3 ↑ Moderate (predicted) 
miR-143 ↓ MGARP ↑ Moderate (predicted) 
miR-148a ↑ ACSL5 ↓ Moderate (predicted) 
miR-148a ↑ AFF3 ↓ Moderate (predicted) 
miR-148a ↑ CENPF ↓ Moderate (predicted) 
miR-148a ↑ COL2A1 ↓ Moderate (predicted) 
miR-148a ↑ COL4A1 ↓ Moderate (predicted) 
miR-148a ↑ EMP1 ↓ High (predicted) 
miR-148a ↑ ETV3 ↓ Moderate (predicted) 
miR-148a ↑ FLT1 ↓ High (predicted) 
miR-148a ↑ HAS3 ↓ Moderate (predicted) 
miR-148a ↑ ITGA11 ↓ Moderate (predicted) 
miR-148a ↑ LCP2 ↓ Moderate (predicted) 
miR-148a ↑ LRP4 ↓ Moderate (predicted) 
miR-148a ↑ MMP13 ↓ Moderate (predicted) 
miR-148a ↑ NREP ↓ Moderate (predicted) 
miR-148a ↑ NRP1 ↓ High (predicted) 
miR-148a ↑ RNF144B ↓ Moderate (predicted) 
miR-148a ↑ ROBO2 ↓ Moderate (predicted) 
miR-148a ↑ SLC2A1 ↓ High (predicted) 
miR-148a ↑ ULBP1 ↓ Moderate (predicted) 
miR-181b ↓ HEY2 ↑ Moderate (predicted) 





The 31 mRNAs which interacted with our four DE miRNAs were used in IPA as network-eligible 
molecules and overlaid onto molecular networks based on information from the IPA 
database. Networks were generated based on miRNA-mRNA interactions (Figure 6.3A-D). IPA 
Core Analysis for the 31 mRNA targets identified that among the top canonical pathways were 
hepatic fibrosis (p = 1.51 × 10−3), glycoprotein 6 signalling (p = 5.67 × 10−4), and OA pathway 
(p = 2.93 × 10−3). The top diseases and cellular functions associated with this network are 



























Figure 6.3: miRNA-mRNA interactome for differentially expressed miRs in ageing. 
Significantly DE miRNAs were paired with DE mRNAs from our original RNA-Seq cartilage 
study. A) miR-122, B) miR-148a, C) miR-143 and D) miR-181b. The legend for individual 
molecules is shown. Genes in red are upregulated and green downregulated in old 
chondrocytes/cartilage compared to young, and depth of colour correlates to fold expression 
change. Figure produced in IPA using Path Designer tool. Uploaded datasets were overlaid 

































































































































































































































































































































































































Table 6.3: IPA mRNA target diseases and functions. 1st column shows A) top molecular and 
cellular functions and B) top diseases and disorders associated with predicted miRNA-mRNA 
interactions in ageing chondrocytes. 2nd column lists the level of significance for each 
network, calculated by IPA. 3rd column denotes the number of DE mRNA targets involved in 
each function/disease listed in the 1st column.  
A. Top Molecular and Cellular Functions p-Value Range 
Number of 
Molecules 
Cellular Movement 1.41 × 10−3 – 4.23 × 10−10 21 
Cell Morphology 1.37 × 10−3 – 3.52 × 10−8 16 
Cellular Development 1.42 × 10−3 – 4.94 × 10−7 24 
Cell Death and Survival 1.37 × 10−3 – 1.08 × 10−5 18 
Cell-To-Cell Signalling and Interaction 1.37 × 10−3 – 1.88 × 10−5 20 
B. Top Diseases and Disorders     
Skeletal and Muscular Disorders 1.50 × 10−3 – 1.22 × 10-9 16 
Connective Tissue Disorders 1.50 × 10−3 – 3.52 × 10-8 16 
Organismal Injury and Abnormalities 1.50 × 10−3 – 3.52 × 10-8 31 
Cancer 1.49 × 10−3 – 5.30 × 10-7 31 
Developmental Disorder 1.37 × 10−3 – 5.30 × 10-7 17 
 
 
6.4.3 Validation of DE miRNAs in young and old equine chondrocytes using qPCR 
 
To validate our findings from the small RNA-Seq experiment, I undertook qPCR analysis in an 
extended cohort of young and old equine chondrocytes. The validation cohort consisted of 
RNA samples from the same donors used in small RNA-Seq, and RNA from additional young 
and old equine chondrocyte samples. qPCR analysis showed that  miR-143, miR-145, and miR-
181b had significantly lower expression in the old group compared to young group. miR-122 
had significantly higher expression in the old group compared to young, whereas miR-148a 
did not show any significant expression differences between young and old groups (Figure 














Figure 6.5: Validation of selected miRNAs in an extended cohort of equine young and old chondrocytes. qPCR 
was used to validate DE miRNAs identified from the small RNA-Seq analysis. N= 6-10 per group. Y axis shows 
log10 expression relative to U6. V denotes DE miRNAs that were validated with qPCR. Statistical analysis was 
undertaken using a Mann Whitney test in GraphPad Prism. Data are represented as mean+SD. P values<0.05 






In Chapter 3 I undertook a microarray analysis to identify DE miRNAs between young intact 
cartilage from ACL donors and old OA intact and lesioned cartilage from TKA patients. Changes 
identified were driven by at least two major variables: ageing and OA. Even though it is likely 
that, in our study, disease-related changes could mask age-related changes, ageing is one of 
the leading risk factors contributing to OA (Lotz et al., 2012). Many studies have shown that 
ageing can affect cartilage in different ways, both at cellular and molecular level. Increased 
chondrocyte death, apoptosis, and a shift towards a catabolic profile have been observed in 
aged chondrocytes (Li et al., 2013). Additional age-related changes in articular cartilage 
include increased chondrocyte senescence (Martin et al., 2001), oxidative stress (Jallali et al., 
2005), and changes in the composition and structure of ECM (Rahmati et al., 2017). Although 
the underlying molecular causes of these changes are not completely understood, it is 
hypothesised that aged chondrocytes respond differently to various stimuli, such as growth 
factors (Hodgson et al., 2019) and demonstrate altered molecular signatures (Zhang et al., 
2019). Previously, our group undertook an RNA-Seq analysis in young and old equine cartilage 
tissue to identify DE mRNAs (Peffers et al., 2013). In this chapter, I used small RNA-Seq to 
identify alterations in miRNA expression between young and old equine chondrocytes from 
non-OA joints. The horse is a good model to study musculoskeletal ageing and disease as I 
could assess the whole joint for pathological perturbations during tissue collection. It is very 
challenging to source aged human cartilage that has no OA changes, whereas this is easily 
undertaken in equine samples. Moreover, the horse has been used as a model of OA and 
there has been significant research on equine joint anatomy and pathophysiology (Goodrich 
et al., 2006b, McIlwraith et al., 2012). 
Within our dataset, I identified two miRNAs with higher expression in the old group: miR-122 
and miR-148a, and three miRNAs with lower expression in the old group: miR-143, miR-145 
and miR-181b. Of these five miRNAs, all except miR-148a were validated in an extended 
cohort of young and old equine chondrocytes with qPCR. Studies have shown that miR-122 is 
upregulated in OA cartilage compared to normal cartilage and can induce the expression of 
catabolic markers, such as MMPs and ADAMTSs (Bai et al., 2020). In a rat bilateral ACL 
transection model, miR-122 had higher expression in joints from OA rats compared to control 




serum and plasma of patients with osteoporosis, the most common age-related bone disease 
(Mandourah et al., 2018), but was significantly upregulated in senescent human fibroblasts 
(Markopoulos et al., 2017). Interestingly, I have recently carried out small RNA-Seq in young 
and old healthy human cartilage and miR-122 was one of the miRNAs upregulated in the old 
group (unpublished data), which furthers supports a role for this miRNA in cartilage and 
chondrocyte ageing.  
Another important finding of this study is the implication of miR-143 in chondrocyte ageing. 
miR-143 was one of the miRNAs in our microarray study that was selected for further 
validation as it had significantly lower expression in old OA intact and lesioned cartilage 
compared to young intact cartilage from ACL donors. The findings here further support a role 
for this miRNA in cartilage ageing and OA. However, in Chapter 4, when I compared the 
expression of miR-143 in young and old healthy, non-OA cartilage from human cadavers, I 
failed to identify differential expression for miR-143. This could be due to species differences 
between human and equine, or sample differences between cartilage tissue and 
chondrocytes. Studies have shown that miR-143 was downregulated in muscle satellite cells 
from old mice and primary myoblasts from old humans and mice (Soriano-Arroquia et al., 
2016). In addition, circulating miR-143 was upregulated in young individuals following 
resistant exercise, but was downregulated in older individuals after resistant exercise 
(Margolis et al., 2016). In Chapter 5, when I overexpressed and knockdown miR-143 in human 
OA chondrocytes and investigated the proteomic profile of the cells, I reported a possible link 
between miR-143 and EIF2 signalling. It would be interesting to evaluate this interaction in 
ageing chondrocytes, without the effect of OA, by modulating the expression of miR-143 and 
investigating whether a similar link exists. While collection of human aged chondrocytes 
without OA is quite challenging, these experiments could be carried out in animal models, 
given that our data suggest a role for miR-143 in cartilage among difference species. 
Two other miRNAs that were validated were miR-145 and miR-181b. miR-145 belongs to the 
same cluster as miR-143 and they share similar functions (Qiu et al., 2021). There is very 
limited data on the role of this miRNA in ageing cartilage since most studies have been 
conducted using OA specimens. Specifically, miR-145 was downregulated in cartilage from old 
OA patients compared to non-OA cartilage (Liu et al., 2019a), as well as in OA rat chondrocytes 




181b in ageing. Most data on its role in musculoskeletal ageing come from muscle studies. 
miR-181b was downregulated in skeletal muscle of old rhesus monkeys compared to young 
(Mercken et al., 2013), was downregulated in myogenic progenitors of old mice compared to 
adult mice, and its overexpression promoted myogenesis (Proctor et al., 2017). 
To further investigate the potential role of the DE miRNAs identified between young and old  
equine chondrocytes, I used IPA to combine them with DE mRNAs between young and old 
cartilage from our previous equine cartilage study (Peffers et al., 2013). IPA miRNA ‘Target 
Filter and Expression Pairing’ identified 31 potential target genes. IPA core analysis of these 
genes revealed canonical pathways associated with cartilage physiology, such as role of 
chondrocytes in rheumatoid arthritis (p=2.2×10-4), OA-related pathways (p=2.93×10-3) and 
BMP signalling (p=6×10-3), all of which have been linked to ageing (Collins et al., 2018, Thielen 
et al., 2019). Of note, follistatin (FST) which was upregulated in old equine cartilage and was 
predicted by IPA as a target of the downregulated miR-143, was overexpressed in human OA 
chondrocytes compared to normal chondrocytes (Tardif et al., 2004), and in canine OA 
cartilage compared to normal cartilage (Tardif et al., 2009). In another study, FST was induced 
by telomere shortening (Liu et al., 2019b), a process closely related to ageing. Moreover, TNF 
ligand superfamily member 11 (TNFSF11), also known as receptor activator of nuclear factor 
kappa-Β ligand (RANKL), was upregulated in old equine cartilage and was identified as a 
predicted target of the downregulated miR-181b. Higher expression of TNFSF11/RANKL, 
which correlated with bone loss, was reported in old C57BL/6 mice (Cao et al., 2003), rabbits 
with chronic antigen-induced arthritis (Martínez-Calatrava et al., 2012), and in human high 
grade OA cartilage (Upton et al., 2012), suggesting that miR-181b could also be involved in 
these pathways through the targeting of TNFSF11/RANKL. 
I am aware that the effect of ageing between young and old equine chondrocytes was small 
as only five DE miRNAs were identified. I cannot rule out changes related to the use of 
chondrocytes instead of cartilage tissue. Even though chondrocytes of low passage (P0) were 
used, collagenase digestion and plating of cells could have affected their phenotype and gene 
expression. I have discussed in previous chapters of this thesis that primary chondrocytes 
dedifferentiate when in culture due to the loss of stimuli they normally receive from the ECM 
(Caron et al., 2012, Charlier et al., 2019).  The choice of chondrocytes over cartilage tissue was 




(in our hands) and heavily contaminated with proteoglycans (Ali et al., 2012), usually making 
it challenging for sequencing. With that said, with the use of chondrocytes instead of cartilage 
tissue, it is likely that I am interrogating highly specific changes that are age-dependent and 
persist even with culturing of chondrocytes. Another point that should be taken into account 
is the use of the Illumina MiSeq platform which may have contributed to the low number of 
DE miRNAs as it offers less depth coverage (12-15 million paired-end reads per run) compared 
to other systems, such as the HiSeq platform(~280 million paired-end reads per run). Finally, 
I have used a relatively small number of samples per group. Given the use of primary cells and 
the degree of variability observed, especially for the old group, the inclusion of five samples 
pre group may have contributed to the small number of differentially expressed miRNAs in 
ageing equine chondrocytes. 
 
6.6 Conclusion 
In this chapter I have investigated, using unbiased methods, the effect of ageing on the 
expression of miRNAs in equine chondrocytes. Even though the effect of ageing on equine 
chondrocytes was small, I detected five miRNAs, which are predicted to play a role in the 
development of the musculoskeletal system and in skeletal disorders. Amongst them, I 
identified miR-143, a miRNA which has been one of the main miRNAs discussed in this thesis 
for its role in cartilage and OA. Further research is needed to elucidate the role and function 
















Chapter 7: General Discussion 






7.1 General Discussion 
In this thesis, I aimed to define the miRNA signatures of ageing and OA cartilage and 
investigate the role and targetome of specific miRNAs in cartilage ageing and disease. To 
interrogate biological pathways of selected miRNAs, I undertook transcriptomic and 
proteomic analyses in human cartilage, and human and equine chondrocytes, and utilised 
bioinformatics tools and experimental approaches to explore relevant miRNA targets and 
disease-related mechanisms. The first objective of this thesis, to establish DE miRNAs in OA 
cartilage, was achieved by undertaking microarray analysis on young intact cartilage from 
donors undergoing ACL reconstruction and OA patients undergoing TKA for end-stage OA. 
The second objective, to evaluate the response of selected DE miRNAs in an in vitro OA 
inflammatory cell model, was achieved by treating human primary OA chondrocytes with 
human recombinant IL-1β for a series of time points. This thesis achieved its third objective, 
to characterise selected target genes of a set of DE miRNAs, by undertaking gain and loss of 
function approaches in human primary chondrocytes, as well as transcriptomic and proteomic 
investigation of miRNA-target interactions. Finally, this thesis achieved its fourth objective, to 
establish DE miRNAs in ageing chondrocytes, by undertaking small RNA-Seq between young 
and old healthy equine chondrocytes. The work in this thesis supports the hypothesis that 
there is aberrant miRNA expression in aged and OA cartilage and chondrocytes, which results 
in changes in gene expression and could potentially contribute to altered cellular mechanisms 
in chondrocytes.  
The starting point for this thesis was the microarray analysis between young intact cartilage 
and old OA cartilage. Young cartilage was sampled from donors undergoing ACL 
reconstruction. Time of surgery ranged from weeks to a few months after rupture. Since ACL 
is a risk factor for PTOA, I chose to refer this group as ‘Young intact’ cartilage rather than 
‘Young healthy’. Studies showed that 30% of patients who have ACL reconstruction surgery, 
show signs of cartilage degeneration, evident by KL scoring (KL=1 or 2), ten years after surgery 
(Ajuied et al., 2014). However, such alterations seem to appear years after reconstruction, 
therefore, for the purposes of the thesis, I mainly considered young intact cartilage as non-
OA. It would have been beneficial to assess these tissues histologically and confirm integrity 
of the tissue, but given the limited size of cartilage tissue collected during these surgeries, 




microarray analysis and contrast that to aged-matched OA cartilage samples. It is true that in 
Chapter 4 I used young and old healthy human knee cartilage from cadavers to look at the 
age effect of selected miRNAs. However, at the time of the microarray analysis those samples 
were not available to us to use in our microarray analysis and compare to OA tissue. 
Moreover, the limited number of these samples (n=5) would have reduced the power of the 
experiment. 
Microarray analysis between young intact, old OA intact and old OA lesioned samples 
identified significant changes (FDR-adjusted p<0.05) in the expression of multiple miRNAs 
between the contrasted groups. There were at least two variables that drove those changes: 
ageing and OA. I hypothesise that these changes were driven mainly by disease rather than 
ageing. In Chapter 4, by using qPCR, I validated our findings for a selected set of DE miRNAs 
in the samples from the microarray analysis, as well as in an additional independent cohort 
of samples. qPCR analysis validated the miRNA expression changes observed in microarray 
analysis. However, when I interrogated the expression of the same set of miRNAs in young 
and old healthy cartilage tissue from human cadavers with no history of OA and with normal 
histology, I did not observe any differences in the expression of these miRNAs. Moreover, in 
Chapter 6, I carried out small RNA-Seq between young and old equine chondrocytes from 
donors with no OA and macroscopically normal joints, and identified only five DE miRNAs 
(FDR-adjusted p<0.05) between the two groups. While a direct comparison cannot be made, 
given species differences, the use of different starting material (cartilage tissue versus 
chondrocytes), and the use of different experimental approach (qPCR versus small RNA-Seq), 
in both experiments I observed moderate miRNA expression changes with ageing. Though 
limited in number, other studies which have interrogated the expression of miRNAs in 
cartilage ageing without the effect of OA, support our findings (Ukai et al., 2012). In addition, 
our group has carried out small RNA-Seq between young and old healthy human cartilage 
from donors with no history of OA, and only a small number of miRNAs were DE at FDR-
adjusted p<0.05 (unpublished data). This is not to say that ageing does not affect cartilage 
integrity and chondrocyte homeostasis, as age is a principal risk factor for OA, but it supports 
our initial hypothesis that our microarray findings are mainly driven by OA. With that said, 
our results indicated that there was more variability in miRNA expression of old samples 




separate subgroups: OA intact 1 and 2. Old OA lesioned samples were also more variable and 
could be clustered as different subgroups. In contrast, young samples were clustered more 
tightly together. Similar trends were observed in Chapter 6, as young equine chondrocyte 
samples clustered more tightly together, whereas old equine samples showed more 
variability. Studies using monozygotic twins have reported that epigenetic variation increases 
with ageing (Talens et al., 2012). Furthermore, OA is a heterogeneous disease with a number 
of different phenotypes and endotypes, therefore, subgrouping of old OA samples was not 
unexpected (Berenbaum, 2019).  
In our microarray analysis, a high number of miRNAs were DE between young intact cartilage 
and old OA cartilage. It is quite challenging to differentiate between miRNAs that are driving 
the disease and have a causal relationship in OA, and those whose differential expression is 
the result of the disease. This would require the use of early-stage cartilage samples, which is 
difficult to obtain in humans. An alternative is the use of synovial fluid from early-stage OA 
from animal models. Recently, our group undertook small RNA-Seq in synovial fluid from 
horses with early-OA and control horses and one of the miRNAs that had significantly lower 
expression in the early-OA samples was miR-143 (Castanheira et al., 2021). miR-143-3p is one 
of the miRNAs investigated in this thesis and had significantly lower expression in human old 
OA cartilage compared to young intact and in old equine chondrocytes compared to young 
chondrocytes. The horse is a good model to study musculoskeletal ageing and disease as the 
whole joint can be assessed for pathological perturbations during tissue collection. It is very 
challenging to source aged human cartilage that has no OA changes, whereas this is easily 
undertaken in equine samples. Moreover, the horse has been used as a model of OA and 
there has been significant research on equine joint anatomy and pathophysiology (Goodrich 
et al., 2006a, McIlwraith et al., 2012). 
By using pathway prediction tools, such as IPA, Toppgene, Revigo and Cytoscape, I identified 
distinctive mechanisms between young intact and old OA cartilage tissues. When OA intact-
1, OA intact-2 and OA lesioned groups were compared to the young intact group, the list of 
DE miRNAs and relevant biological pathways was quite similar. These included inflammation-
related pathways, such as cytokine signalling, production and secretion of cytokines and 
defence response mechanisms. This indicated that DE miRNAs between OA groups and young 




compared the OA intact and lesioned groups to each other, I identified a different set of 
biological pathways, including ion transport, wound response, actin cytoskeleton 
organisation, blood circulation and neuronal signalling. These results suggested that 
inflammation plays a more prominent role when transitioning from normal cartilage to OA 
cartilage and perhaps during the early stages of the disease. However, once inflammation has 
been established in the joint, and OA progresses, there are little changes in inflammatory-
related pathways. This is supported by studies where they have identified inflammatory 
changes in early-stage OA (Benito et al., 2005, Sokolove et al., 2013), but not at later stages 
(Dunn et al., 2016). Indeed, our results indicate that as OA progresses, pathways related to 
mechanotransduction (ion transport), wounding, blood cell and neuron formation become 
more significant. As already discussed in Chapter 3, this is expected given that with disease 
progression, there is blood cell invasion from the subchondral bone in cartilage, and also 
innervation which is related to pain in late-stage OA. Moreover, wounding pathways are 
related to damage and degeneration as intact cartilage becomes lesioned. An interesting 
finding is the ion transport pathways identified when OA intact and OA lesioned cartilage 
were compared. Ion transport is linked to mechanotransduction and mechanical stimuli. All 
of our OA intact samples came from the lateral condyle, whereas the OA lesioned samples 
came from the medial condyles. The medial condyle is subjected to higher mechanical 
pressure than the lateral, and therefore, it is expected that DE miRNAs between OA intact 
and lesioned tissue could be involved in mechanical stimuli.   
An interesting finding from our microarray analysis, was that the majority of DE miRNAs had 
lower expression in the old OA cartilage groups compared to the young intact group. This 
could be due to disruption of the miRNA processing machinery during OA. Studies have shown 
that expression of DGCR8, which is part of the microprocessor complex, decreased with 
ageing in human MSCs, and overexpression of DGCR8 alleviated cartilage degradation in mice 
with ACL-induced OA (Deng et al., 2019a). Similarly, genetic deletion of DICER and DROSHA 
led to increased numbers of hypertrophic chondrocytes, increased chondrocyte death and 
decreased chondrocyte proliferation and OA-like symptoms in murine joints (Kobayashi et al., 
2008, Kobayashi et al., 2015). These studies suggest that changes in the cellular components 




decreased miRNA expression. This may also justify the high number of DE miRNAs in our 
microarray study.  
Following microarray analysis and pathway identification, a set of miRNAs was selected for 
qPCR validation and further experimental analysis. All selected DE miRNAs were validated 
with qPCR in the samples used for microarrays as well as in an independent cohort of cartilage 
samples. Agreement between the two techniques was confirmed, not only for DE miRNAs, 
but also for miRNAs that were not DE. To select appropriate endogenous reference genes, I 
looked at the microarray data to identify miRNAs with stable expression between the 
different groups. miR-1915-3p, -6786-5p and -6087 had stable expression in the microarrays, 
and that was also confirmed with qPCR, indicating that there was a good agreement between 
microarrays and qPCR. Of the validated DE miRNAs, four were chosen for follow up analysis: 
miR-361-5p, -379-5p, -107 and -143-3p. All four miRNAs were downregulated in human 
primary OA chondrocytes treated with IL-1β, one of the major pro-inflammatory cytokines. 
IL-1β treatment of primary chondrocytes is a common approach in miRNA research in OA. 
Microarray analyses in OA primary chondrocytes stimulated with IL-1β, revealed that most 
miRNAs which responded to the treatment were downregulated, whereas only few were 
upregulated (Akhtar et al., 2010, Rasheed et al., 2016). This is consistent with our microarray 
findings and the IL-1β treatments carried out in this thesis. I discussed previously that 
disruption of the miRNA processing machinery could lead to decreased expression of several 
miRNAs in disease. It is possible that inflammation in the joint could contribute to such 
disruption. Studies have shown that overexpression of components involved in miRNA 
biogenesis, such as DGCR8, reduced the level of inflammatory markers, such as IL-1β and IL-
6 (Deng et al., 2019a). However, it is also important to note that the duration of treatment 
can affect miRNA response. In our dataset, miR-361-5p and miR-107 showed changes in their 
expression even from the 24h timepoint, whereas miR-379-5p was unchanged after 24h of 
treatment, but showed the largest decrease after 5days of treatment. In addition, miR-143-
3p was upregulated after 24h of treatment, but was downregulated at the 5-day timepoint. 
This shows the complex regulatory mechanisms that characterise inflammatory response in 
chondrocytes. With that said, it is important to consider additional factors that contribute to 
OA, such as mechanical stress, injury, obesity, genetics, joint structure and others. Even 




does not fully represent the underlying molecular landscape of OA. As already mentioned, 
when I compared miRNA expression between OA intact and lesioned cartilage samples, I 
discovered a set of pathways related to mechanotransduction, ECM remodelling and 
wounding rather than inflammation. Therefore, it would have been useful to investigate the 
role of our selected miRNAs using alternative methods, such as subjecting chondrocytes 
under mechanical pressure to evaluate miRNA response. This could have been combined with 
chondrocytes embedded in 3D scaffolds to better represent the zonal organisation of 
chondrocytes in vivo. Even though I did not have the opportunity to carry out such 
experiments in this thesis, it would been very informative to interrogate miRNA responses 
under such conditions, given that most miRNA research in OA is being undertaken in 
monolayer cultures.  
In Chapter 5, I evaluated predicted target genes of our set of four DE miRNAs. To achieve this, 
I overexpressed and inhibited these four miRNAs using mimic and inhibitors, specific for each 
miRNA. For miR-361-5p, -379-5p and -107, I used qPCR to look at the predicted targets, 
whereas for miR-143-3p I used LC-MS/MS to investigate proteomic changes in treated 
chondrocytes. An important point to consider regarding miRNA-target interactions, is the 
complex regulation of gene expression at different levels, including post-transcriptionally and 
post-translationally. miRNAs fine tune the expression of their target genes, but they are not 
the only cellular mechanism that regulates gene expression, as other mechanisms, such as 
DNA methylation, long non-coding RNAs, transcription factor regulation, protein folding, 
contribute to regulation of gene expression. The effect of miRNA binding on their target genes 
can differ, based on the tissue/cell type, developmental stage and sequence complementarity 
amongst others (Fiannaca et al., 2018, Sood et al., 2006). In our dataset, while I was able to 
show that OA chondrocytes treated with miR-379-5p mimic and inhibitor had significantly 
higher and lower expression of TGFBR1, respectively, this interaction was not validated in 
cartilage tissues; OA cartilage tissue had lower miR-379-5p and TGFBR1 expression compared 
to young intact cartilage, suggesting that TGFBR1 was not targeted by miR-379-5p in our 
cartilage dataset. Moreover, I was not able to validate RHOA and CALM3 as targets of miR-
361-5p using qPCR. This could be due to the fact that the effect of a miRNA on its target genes 
cannot always be observed at the mRNA level. It is still unclear if the preferred way of gene 




that both mechanisms contribute to gene silencing (Cloonan, 2015). Therefore, analysis at the 
protein level, for instance with Western blotting, would have provided further evidence about 
whether RHOA and CALM3 are targeted by miR-361-5p in cartilage. In contrast, our 
experimental results support the hypothesis that miR-107 targets WNT4 and IHH in cartilage. 
OA primary chondrocytes treated with miR-107 mimic and inhibitor had lower and higher 
WNT4 and IHH expression respectively, compared to control. Moreover, I showed that WNT4 
and IHH are expressed significantly higher in OA cartilage tissue compared to young intact 
cartilage, opposite to miR-107. To further evaluate whether WNT4 and IHH are targeted by 
miR-107, I had planned to investigate their protein levels with Western blotting in treated 
chondrocytes. However, as already mentioned in Chapter 5, due to the unexpected closing of 
our laboratory facilities due to COVID-19, I was not able to carry out these experiments. 
Nonetheless, our preliminary results agree with recent studies concerning the role of miR-
107 in OA, where it was shown that miR-107 promoted chondrocyte proliferation and 
inhibited apoptosis (Qian et al., 2021, Tian et al., 2019). Excessive WNT and IHH signalling in 
OA promoted chondrocyte hypertrophy and induced expression of MMPs (Wang et al., 2019c, 
Wei et al., 2012, Zhou et al., 2014). Therefore, had I confirmed that WNT4 and IHH were 
targets of miR-107, that would have provided further evidence on the role of miR-107 in 
chondrocyte proliferation.  
One of the most promising miRNAs researched in this thesis, is miR-143-3p. Both our 
microarray analysis in Chapter 3, and our small RNA-Seq data from Chapter 6, have hinted at 
an important role for this miRNA in cartilage and OA. miR-143-3p was one of the most 
downregulated miRNAs in our microarray study. Moreover, it was downregulated in old 
equine chondrocytes compared to young. As already mentioned previously, additional work 
from our group, identified miR-143-3p as one of the miRNAs downregulated in early OA 
equine synovial fluid compared to non-OA (Castanheira et al., 2021). Our proteomics data 
from treating OA primary chondrocytes with miR-143-3p mimic and inhibitor, did not identify 
any proteins that were consistently downregulated in the mimic group and upregulated in the 
inhibitor group, that would have suggested potential targets of miR-143-3p. This could have 
been due to the detection limit of LC-MS/MS, as it can identify the most abundant proteins in 
the sample and not the total proteome. However, abundance of proteins may not always 




setup. Chondrocytes were treated for 48h before collection and lysis of cells. Changes in 
specific targets of miR-143-3p could have occurred at a prior time point, and may have no 
longer been detectable at the 48h time point. With that said, the downstream effect of those 
changes could still be detectable. Therefore, to further analyse the proteomics data, I carried 
out analysis in IPA using the list of DE proteins (p value<0.05) from the mimic vs control 
comparison and from the inhibitor vs control comparison. Analysis suggested a link between 
miR-143-3p and EIF2 signalling. EIF2 signalling is involved in protein translation and stress-
response in the cell (Wek, 2018). Reduced EIF2 signalling leads to decreased global protein 
translation and activation of specific genes important for cell survival. Bioinformatics analysis 
with IPA, predicted inhibition of EIF2 signalling in the mimic group and activation of the 
pathway in the inhibition group. This hints at a potential role of miR-143-3p in chondrocyte 
survival. In Chapter 4, I reported increased expression of miR-143-3p in chondrocytes treated 
with IL-1β for 24h, but reduced expression in chondrocytes treated for 5 days. It is possible 
that miR-143-3p is initially upregulated in chondrocytes treated with IL-1β, to aid the cells 
adapt to the effect of the cytokine, but continued treatment with IL-1β, could result in a shift 
towards apoptosis. In fact, it has been proposed that prolonged or excessive stimulus by a 
stress factor, leads to a shift in the stress response, from survival to apoptosis via 
phosphorylation of eIF2a (Bevilacqua et al., 2010). It is worth mentioning that our analysis in 
IPA, identified LARP1 as an upstream regulator of the DE expressed proteins both in the mimic 
vs control group and in the inhibitor vs control group. In fact, LARP1 was predicted to be 
activated in the mimic group, and inhibited in the inhibitor group. It is believed that LARP1 
binds and inhibits the translation of mRNA of ribosomal proteins and translation factors, 
although the data on its role are still contradictory (Fonseca et al., 2018), and there are 
currently  no data on its role in OA. However, evidence suggests that inactivation of LARP1 
leads to reduced chondrocyte proliferation and cellular growth (Berman et al., 2020). It would 
be interesting to observe future findings regarding the role of LARP1 and how these relate to 
our data which suggest a role for miR-143-3p in regulating protein translation in chondrocytes 






7.2 Future Directions 
There are several future directions for the project described in this thesis. In Chapter 5, I 
described that WNT4 and IHH could be potential targets of miR-107 in cartilage. Western 
blotting analysis could be undertaken in chondrocytes treated with miR-107 mimic and 
inhibitor to confirm targeting of WNT4 and IHH by this miRNA. Luciferase assays could also 
be carried out to confirm targeting, by using constructs that contain the 3’ UTR of these genes. 
Transfection of cells with these constructs and the miRNA mimic could further confirm 
whether these specific genes are targets of miR-107. Moreover, given that our data suggest 
the involvement of miR-107 in chondrocyte proliferation and inhibition of apoptosis, 
proliferation assays could be undertaken to measure proliferation capacity of chondrocytes 
treated with mimic and inhibitors. Another important direction that this project could follow 
is the investigation of the role of miR-143-3p in the translational capacity of chondrocytes. 
Puromycin assays in chondrocytes treated with miR-143-3p mimic and inhibitor would shed 
light on the role of this miRNA in translational capacity of chondrocytes. Ideally, treatment of 
chondrocytes with miR-143-3p mimic and inhibitors for different time points would be 
desirable. As mentioned previously, in our experiments, chondrocytes were treated for 48h 
and I measured proteomic changes for this time point. However, early changes, including 
changes in specific target genes, especially in transcription factors, may not have been 
detectable at the 48h time point. Therefore, treatment for earlier time points could assist in 
the identification of relevant miR-143-3p target genes. Moreover, investigation of LARP1 
expression in treated chondrocytes could provide more insights on its potential implication 
to our proteomics findings.  
In addition, the results described in this thesis offer the opportunity to investigate additional 
miRNAs in cartilage ageing and OA. Microarray analysis identified a high number of DE 
miRNAs between young intact cartilage from ACL donors and old OA intact and lesioned 
cartilage from patients undergoing TKA. Additional miRNAs could be selected for follow up 
analysis. It would be of interest to analyse specific miRNAs that were DE between OA intact 
and lesioned cartilage, as these would represent miRNAs involved in disease progression and 
other OA-related pathways, such as mechanotransduction. Similarly, DE miRNAs from 




identify age-related mechanisms in chondrocytes, by carrying out gain and loss of function 
experiments. 
 
7.3 Conclusion  
This thesis undertook a number of studies in human knee cartilage and human and equine 
chondrocytes, to identify aberrant expression of miRNAs in ageing and diseased cartilage, and 
to characterise the role of a specific set of miRNAs in cartilage biology. It utilised omics 
approaches to investigate transcriptomic and proteomic changes relevant to miRNA function 
and interrogate disease mechanisms in cartilage. Analyses in this thesis have pointed to the 
complex mechanistic networks that underlie cartilage pathology and have set the ground for 
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Microarray analysis between young intact cartilage from donors undergoing anterior cruciate 
ligament surgery and old osteoarthritic intact and lesioned cartilage from patients undergoing 
total knee replacement, identified sets of differentially expressed miRNAs. The full lists of 
differentially expressed miRNAs, their fold change and FDR-adjusted p values are shown here 
for the following comparisons: 
A. Old OA Intact-1 vs Young Intact 
B. Old OA Intact-2 vs Young Intact 
C. Old OA Lesioned vs Young Intact 
D. Old OA Lesioned vs Old OA Intact-1 
E. Old OA Lesioned vs Old OA Intact-2 
F. Old OA Intact-1 vs Old OA Intact-2 
 
Moreover, The IPA Core Analysis Report for comparison old OA-Lesioned vs Young Intact is 




Old OA Intact-1 vs Young Intact (Columns A, B and C) 
Old OA Intact-2 vs Young Intact (Columns D, E and F) 




Transcript ID FC Int-1 vs Y FDR Int-1 vs Y Transcript ID FC Int-2 vs Y FDR Int-2 vs Y 
hsa-miR-143-3p -7.75 9.46E-14 hsa-miR-143-3p -7.37 1.98E-14 
hsa-miR-126-3p -7.86 3.13E-13 hsa-miR-126-3p -7.08 1.86E-13 
hsa-miR-139-5p -4.14 2.03E-11 hsa-miR-139-5p -4.3 4.88E-13 
hsa-let-7c-5p -11.7 3.98E-11 hsa-miR-30c-5p -5.53 1.94E-11 
hsa-miR-148a-3p -5.17 9.36E-11 hsa-miR-148a-3p -4.87 2.03E-11 
hsa-miR-25-3p -4.56 2.83E-10 hsa-miR-379-5p -4.77 2.03E-11 
hsa-miR-30c-5p -5.45 3.21E-10 hsa-miR-25-3p -4.39 3.98E-11 
hsa-let-7b-5p -11.04 5.64E-10 hsa-miR-20a-5p -4.92 1.21E-10 
hsa-miR-379-5p -4.58 7.06E-10 hsa-miR-28-5p -4.31 3.84E-10 
hsa-miR-20a-5p -5.05 9.35E-10 hsa-miR-15a-5p -4.46 8.90E-10 
hsa-miR-125b-5p -10.76 9.35E-10 hsa-let-7g-5p -5.45 3.13E-09 
hsa-miR-628-3p -3.42 4.18E-09 hsa-miR-145-5p -8.35 4.16E-09 
hsa-miR-30a-5p -5.46 7.66E-09 hsa-miR-150-5p -3.2 4.73E-09 
hsa-miR-15a-5p -4.49 9.10E-09 hsa-miR-30a-5p -4.89 5.10E-09 
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hsa-miR-28-5p -4.1 1.17E-08 hsa-miR-628-3p -2.91 7.25E-09 
hsa-miR-10b-5p -4.81 1.44E-08 hsa-miR-10b-5p -4.37 7.79E-09 
hsa-miR-145-5p -8.85 1.45E-08 hsa-miR-432-5p -4.72 8.58E-09 
hsa-miR-432-5p -5.11 2.24E-08 hsa-miR-382-5p -4.72 9.33E-09 
hsa-miR-4454 -7.53 3.88E-08 hsa-miR-30b-5p -3.8 1.22E-08 
hsa-let-7g-5p -5.41 4.01E-08 hsa-miR-181b-5p -4.85 1.37E-08 
hsa-miR-382-5p -4.98 4.03E-08 hsa-miR-151b -4.39 2.85E-08 
hsa-miR-455-5p -4.69 5.82E-08 hsa-miR-487b-3p -3.95 2.94E-08 
hsa-miR-181b-5p -5.02 8.46E-08 hsa-miR-455-5p -4.18 4.29E-08 
hsa-miR-150-5p -3.12 8.46E-08 hsa-miR-30a-3p -2.66 1.91E-07 
hsa-miR-151b -4.68 9.60E-08 hsa-miR-409-3p -3.9 3.11E-07 
hsa-miR-409-3p -4.61 1.55E-07 hsa-miR-19b-3p -4.51 3.90E-07 
hsa-miR-30b-5p -3.7 2.41E-07 hsa-miR-106b-5p -5.5 6.61E-07 
hsa-miR-487b-3p -3.9 4.62E-07 hsa-miR-132-3p -4.69 7.36E-07 
hsa-miR-24-3p -11.54 1.03E-06 hsa-miR-4417 -4.88 1.03E-06 
hsa-miR-19b-3p -4.88 1.04E-06 hsa-miR-196a-5p -4.38 2.98E-06 
hsa-miR-106b-5p -6.1 1.06E-06 hsa-let-7f-5p -4.8 3.79E-06 
hsa-miR-26a-5p -11.26 1.20E-06 hsa-miR-378a-3p -5.12 6.68E-06 
hsa-miR-195-5p -9.55 1.37E-06 hsa-miR-17-5p -5.11 1.44E-05 
hsa-miR-132-3p -5.14 1.47E-06 hsa-miR-146a-5p -3.3 1.54E-05 
hsa-miR-23b-3p -11.31 4.16E-06 hsa-miR-106a-5p -4.61 2.03E-05 
hsa-let-7f-5p -5.37 5.24E-06 hsa-miR-28-3p -4.11 2.18E-05 
hsa-let-7i-5p -8.43 5.32E-06 hsa-miR-505-5p -2.1 2.42E-05 
hsa-miR-23a-3p -11.27 5.53E-06 hsa-miR-4253 -3.91 2.80E-05 
hsa-miR-199a-3p -9.18 5.89E-06 hsa-miR-146b-5p -3.57 2.88E-05 
hsa-miR-1281 4.3 5.89E-06 hsa-miR-654-5p -1.87 2.88E-05 
hsa-miR-4417 -4.97 7.23E-06 hsa-miR-139-3p -1.79 3.02E-05 
hsa-miR-196a-5p -4.73 7.42E-06 hsa-miR-324-5p -3.95 3.37E-05 
hsa-miR-106a-5p -5.57 8.39E-06 hsa-miR-3687 -3.64 3.40E-05 
hsa-miR-885-3p -3.4 8.80E-06 hsa-miR-27b-5p -3.33 3.55E-05 
hsa-miR-151a-5p -8.44 9.06E-06 hsa-miR-424-3p -2.3 4.01E-05 
hsa-miR-744-5p -5.33 9.37E-06 hsa-miR-24-2-5p -2.64 4.55E-05 
hsa-miR-17-5p -5.96 1.03E-05 hsa-miR-378c -3.06 6.80E-05 
hsa-miR-4750-3p 4.87 1.03E-05 hsa-miR-485-5p -2.41 8.45E-05 
hsa-miR-940 4.31 1.05E-05 hsa-miR-3907 -1.83 8.86E-05 
hsa-miR-5100 -6.96 1.08E-05 hsa-miR-196b-5p -1.88 0.000117224 
hsa-miR-378a-3p -5.65 1.08E-05 hsa-miR-331-5p -1.1 0.000118605 
hsa-let-7a-5p -10.47 1.12E-05 hsa-miR-10a-5p -1.8 0.000119464 
hsa-miR-30a-3p -2.38 1.39E-05 hsa-miR-23b-5p -3.03 0.000120825 
hsa-miR-16-5p -9.25 1.40E-05 hsa-miR-130a-3p -3.63 0.000121044 
hsa-let-7e-5p -8.43 1.44E-05 hsa-miR-93-5p -4.92 0.000128241 
hsa-miR-320c -6.15 1.45E-05 hsa-miR-3609 -3.4 0.00013218 
hsa-miR-125a-5p -7.84 1.73E-05 hsa-miR-885-3p -2.43 0.000153135 
hsa-miR-6732-5p 3.34 1.73E-05 hsa-miR-151a-3p -4.78 0.00018438 
hsa-miR-99a-5p -9.07 1.93E-05 hsa-miR-199a-3p -6.28 0.000190099 
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hsa-miR-193b-3p -7.58 2.03E-05 hsa-miR-8071 -4.17 0.000195326 
hsa-miR-103a-3p -9.37 2.57E-05 hsa-miR-6753-5p -2.09 0.000239052 
hsa-miR-107 -8.97 2.66E-05 hsa-miR-708-5p -3.32 0.000270084 
hsa-miR-146a-5p -3.62 2.83E-05 hsa-miR-181a-5p -5.37 0.000273639 
hsa-miR-181a-5p -7.26 3.08E-05 hsa-miR-181d-5p -1.76 0.0002814 
hsa-miR-152-3p -7.98 3.61E-05 hsa-miR-584-5p -1.06 0.000293246 
hsa-miR-6806-5p -2.63 3.61E-05 hsa-miR-195-3p -2.36 0.000314473 
hsa-let-7d-5p -8.92 4.26E-05 hsa-miR-378f -2.61 0.000314473 
hsa-miR-3687 -4.07 4.43E-05 hsa-miR-6846-5p -1.77 0.0003262 
hsa-miR-361-5p -7.54 4.46E-05 hsa-miR-6886-5p -1.01 0.000345523 
hsa-miR-191-5p -8.73 4.46E-05 hsa-miR-433-3p -2.4 0.000350689 
hsa-miR-320d -5.93 5.03E-05 hsa-miR-664a-5p -2.49 0.000386843 
hsa-miR-4447 -1.57 5.46E-05 hsa-miR-6875-5p -1.54 0.000462972 
hsa-miR-214-3p -6.3 6.41E-05 hsa-miR-6796-5p -1.84 0.000495271 
hsa-miR-320b -6.25 6.45E-05 hsa-miR-6807-5p -3.56 0.000509695 
hsa-miR-155-5p -6.25 6.54E-05 hsa-miR-1246 -4.27 0.000531525 
hsa-miR-28-3p -4.32 6.71E-05 hsa-miR-370-3p -2.25 0.000535333 
hsa-miR-6800-3p 4.83 6.71E-05 hsa-miR-339-5p -2.29 0.000535333 
hsa-miR-3180 -4.07 7.12E-05 hsa-miR-10b-3p -1.97 0.000546296 
hsa-miR-27b-3p -8.44 7.62E-05 hsa-miR-34a-5p -3.45 0.000576343 
hsa-miR-23b-5p -3.57 8.05E-05 hsa-miR-20b-5p -1.8 0.000576343 
hsa-miR-29a-3p -6.74 8.23E-05 hsa-miR-532-5p -3.71 0.000597097 
hsa-miR-146b-5p -3.74 8.82E-05 hsa-miR-1273h-5p -2.07 0.000608926 
hsa-miR-654-5p -1.96 8.89E-05 hsa-miR-5739 -2.51 0.00061492 
hsa-miR-134-5p -5.3 8.94E-05 hsa-miR-4462 -2.49 0.00065135 
hsa-miR-6796-3p 3.73 9.23E-05 hsa-miR-3180 -2.97 0.000655815 
hsa-miR-130a-3p -4.22 9.56E-05 hsa-miR-6746-5p -2.07 0.000656731 
hsa-miR-324-5p -4.16 9.56E-05 hsa-miR-3124-5p -1.71 0.000676276 
hsa-miR-378c -3.37 0.000102245 hsa-miR-155-5p -4.51 0.000687995 
hsa-miR-3921 3.88 0.000114082 hsa-miR-4685-5p -2.25 0.000693232 
hsa-miR-320e -5.8 0.000117224 hsa-miR-134-5p -3.91 0.000714332 
hsa-miR-6802-5p -4.1 0.000117856 hsa-miR-331-3p -1.63 0.000844346 
hsa-miR-93-5p -5.66 0.000118244 hsa-miR-3180-3p -3.92 0.0008676 
hsa-miR-331-5p -1.25 0.000118855 hsa-miR-422a -2.21 0.000905027 
hsa-miR-7112-5p -2.57 0.000121044 hsa-miR-6871-5p -1.38 0.000905027 
hsa-miR-27b-5p -3.45 0.000121075 hsa-miR-7112-5p -1.89 0.001013763 
hsa-miR-6805-3p 4.41 0.000121075 hsa-miR-135a-3p -2.13 0.00101779 
hsa-miR-150-3p -4.35 0.000122273 hsa-miR-4485 -3.06 0.001107098 
hsa-miR-151a-3p -5.62 0.000123739 hsa-miR-557 -1.68 0.001173658 
hsa-miR-100-5p -8.46 0.000132444 hsa-miR-6825-5p -2.1 0.001231898 
hsa-miR-584-5p -1.28 0.000140985 hsa-miR-6847-5p -2.92 0.001441414 
hsa-miR-664a-5p -3.08 0.000142031 hsa-miR-21-5p -3.07 0.001444229 
hsa-miR-6808-5p -3.9 0.000142444 hsa-miR-5195-3p -2.31 0.001493174 
hsa-miR-199a-5p -7.33 0.000143393 hsa-miR-6728-5p -2.04 0.001632517 
hsa-miR-1273g-3p -6.14 0.000143393 hsa-miR-6080 -1.68 0.001665757 
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hsa-miR-22-3p -8.26 0.000153322 hsa-miR-345-5p -2.82 0.001754583 
hsa-miR-30d-5p -5.68 0.00015985 hsa-miR-6768-5p -2.11 0.001845833 
hsa-miR-140-5p -6.99 0.000163318 hsa-miR-195-5p -4.9 0.001995035 
hsa-miR-548n 0.65 0.00016529 hsa-miR-1254 -1.41 0.002043351 
hsa-miR-4485 -4.08 0.000174078 hsa-miR-4284 -2.21 0.00207681 
hsa-miR-424-3p -2.34 0.000176524 hsa-miR-1273f -2.11 0.00207681 
hsa-miR-92a-3p -8.41 0.000180577 hsa-miR-30c-2-3p -1.22 0.002077768 
hsa-miR-222-3p -7.43 0.000187578 hsa-miR-3921 2.64 0.002102616 
hsa-miR-8075 3.85 0.000193438 hsa-miR-342-5p -2.48 0.002105049 













hsa-miR-6768-5p -2.88 0.000227446 hsa-miR-6808-5p -2.7 0.002136132 
hsa-miR-7641 -8.53 0.000245329 hsa-miR-199b-5p -1.67 0.002386854 
hsa-miR-3135b -4.5 0.000249544 hsa-miR-409-5p -2.01 0.002420057 
hsa-miR-6797-3p 3.98 0.000261087 hsa-miR-6797-5p -1.73 0.002420057 
hsa-miR-342-3p -6.99 0.000261215 hsa-miR-29a-3p -4.4 0.002456404 
hsa-miR-485-5p -2.5 0.000273251 hsa-miR-18a-5p -1.92 0.002534195 
hsa-miR-5739 -3.06 0.000275272 hsa-miR-196b-3p -1.47 0.002572415 













hsa-miR-4665-5p -3.44 0.000295996 hsa-miR-30e-5p -1.87 0.002854737 













hsa-miR-505-5p -1.96 0.000325312 hsa-miR-660-5p -1.85 0.002895429 
hsa-miR-320a -4.88 0.000334095 hsa-miR-3652 -1.61 0.002957094 
hsa-miR-339-5p -2.71 0.00034457 hsa-miR-152-3p -4.8 0.003051751 
hsa-miR-7111-3p 1.59 0.000345523 hsa-miR-130b-3p -3.49 0.003109917 
hsa-miR-574-3p -6.24 0.000361938 hsa-miR-6880-5p -1.98 0.003126194 
hsa-miR-185-5p -5.84 0.000386843 hsa-miR-371a-5p -1.17 0.003196903 
hsa-miR-423-5p -4.7 0.000390237 hsa-miR-1231 -3.26 0.003215076 
hsa-miR-4449 -4.51 0.000410978 hsa-miR-6515-5p -1.09 0.003488964 
hsa-miR-99b-5p -6.81 0.000417914 hsa-miR-378i -2.23 0.003543658 
hsa-miR-221-3p -6.69 0.000451063 hsa-miR-16-5p -5.11 0.003698292 
hsa-miR-497-5p -6.43 0.000462686 hsa-miR-4783-3p -1.89 0.003752725 
hsa-miR-6861-5p -3.46 0.000462686 hsa-miR-6737-5p -1.54 0.003774195 
hsa-miR-4715-5p -0.96 0.000487737 hsa-miR-487a-5p -1.51 0.00382499 
hsa-miR-4462 -2.91 0.000497922 hsa-miR-3154 -1.59 0.003858826 
hsa-miR-4728-5p -2.82 0.000535141 hsa-let-7i-5p -4.35 0.003890183 
hsa-miR-8064 -2.59 0.000566738 hsa-miR-4732-5p -1.7 0.003912236 
hsa-miR-6743-5p -2.72 0.000567477 hsa-miR-6742-5p -1.69 0.00393803 
hsa-miR-877-3p 1.76 0.000597097 hsa-miR-125a-3p -2.61 0.004162044 
hsa-miR-1228-3p 3.05 0.000605928 hsa-miR-185-5p -4.1 0.004162044 
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hsa-miR-6737-5p -2.09 0.000608926 hsa-miR-4525 -1.72 0.004258758 
hsa-miR-6845-5p -1.93 0.000614127 hsa-miR-148b-3p -1.93 0.004365419 
hsa-miR-433-3p -2.6 0.000627411 hsa-miR-6824-5p -3.31 0.004560258 
hsa-miR-3609 -3.4 0.000637676 hsa-miR-498 -1.38 0.004622029 
hsa-miR-7977 -5.32 0.000640689 hsa-miR-4760-3p 0.52 0.004654825 
hsa-miR-127-3p -6.54 0.000656731 hsa-miR-7106-3p 0.57 0.004850173 
hsa-miR-4274 3.5 0.000661762 hsa-miR-29c-3p -1.47 0.004852427 
hsa-miR-652-3p -4.28 0.000677707 hsa-miR-6881-5p -0.52 0.004852427 
hsa-miR-345-5p -3.49 0.000681972 hsa-miR-7109-5p -1.99 0.004866435 
hsa-miR-4498 -2.92 0.000710743 hsa-miR-214-5p -2.59 0.004868667 
hsa-miR-504-3p -2.57 0.000716385 hsa-miR-224-3p -1.38 0.005027193 
hsa-miR-139-3p -1.57 0.000728571 hsa-miR-6861-5p -2.41 0.00511519 
hsa-miR-3651 -5.54 0.00073299 hsa-miR-194-5p -1.63 0.005483256 
hsa-miR-6086 -2.03 0.000737983 hsa-miR-6795-5p -1.44 0.005617057 
hsa-miR-557 -1.98 0.000771848 hsa-miR-6829-5p -1.53 0.005629179 
hsa-miR-24-2-5p -2.39 0.000772999 hsa-miR-4447 -0.91 0.005749882 
hsa-miR-181d-5p -1.84 0.000772999 hsa-miR-200c-3p -1.4 0.005916613 
hsa-miR-140-3p -2.35 0.000905027 hsa-miR-3135b -2.9 0.006435194 
hsa-miR-532-5p -4.06 0.000913852 hsa-miR-4534 -1.75 0.006450207 
hsa-miR-8071 -4.15 0.000959389 hsa-miR-199a-5p -4.51 0.006489928 
hsa-miR-4688 -2.71 0.000978197 hsa-miR-330-3p -1.12 0.006531402 
hsa-miR-1231 -4.16 0.000985092 hsa-miR-504-3p -1.81 0.006779604 
hsa-miR-193b-5p -5.34 0.000989895 hsa-miR-654-3p -1.84 0.007081132 
hsa-miR-3195 -4.29 0.001044369 hsa-miR-381-3p -1.49 0.007195121 
hsa-miR-7847-3p -3.85 0.001173658 hsa-miR-3127-3p 0.68 0.007336022 
hsa-miR-3679-5p -3.03 0.001323095 hsa-miR-2467-3p -0.87 0.007741871 
hsa-miR-3907 -1.66 0.001353107 hsa-miR-99a-3p -1.3 0.00777261 
hsa-miR-4783-3p -2.39 0.001358729 hsa-miR-6806-5p -1.42 0.007789795 
hsa-miR-4685-5p -2.42 0.001379127 hsa-miR-6732-5p 1.71 0.007961221 
hsa-miR-3162-3p 2.93 0.001459343 hsa-miR-665 -2.05 0.008166454 
hsa-miR-20b-5p -1.88 0.001497287 hsa-miR-3911 -1.59 0.008274196 
hsa-miR-324-3p -3.91 0.001608828 hsa-miR-127-5p -1 0.008341602 
hsa-miR-106b-3p -3.29 0.001617047 hsa-miR-8064 -1.73 0.008341602 
hsa-miR-378f -2.58 0.001622679 hsa-miR-493-3p -1.81 0.008420047 
hsa-miR-34a-5p -3.58 0.001642706 hsa-miR-221-3p -4.38 0.008487899 
hsa-miR-370-3p -2.32 0.001679508 hsa-miR-3181 -0.86 0.008496729 
hsa-miR-224-3p -1.76 0.001720577 hsa-miR-1972 -2.15 0.008645408 
hsa-miR-331-3p -1.74 0.001744228 hsa-miR-615-3p -1.71 0.008668275 
hsa-miR-342-5p -2.88 0.001754193 hsa-miR-642b-3p -1.8 0.008864404 
hsa-miR-5572 -3.3 0.00176222 hsa-miR-362-5p -2.18 0.009060965 
hsa-miR-3154 -1.96 0.001794172 hsa-miR-339-3p -2.92 0.009110792 
hsa-miR-6742-5p -2.1 0.00180264 hsa-miR-6774-5p -1.32 0.009415942 
hsa-miR-6746-5p -2.15 0.001813198 hsa-miR-361-5p -4.04 0.009695982 
hsa-miR-4429 -4.34 0.001842869 hsa-miR-4800-3p -1.51 0.009723741 
hsa-miR-6820-5p -3.21 0.001868487 hsa-miR-5093 -2.17 0.009882725 
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hsa-miR-425-5p -4.39 0.0019177 hsa-miR-6754-3p -0.98 0.009882725 
hsa-miR-6716-5p -3.55 0.0019177 hsa-miR-1238-5p -1.33 0.010077951 
hsa-miR-6889-5p -2.8 0.001947297 hsa-miR-337-5p -1.95 0.010270926 
hsa-miR-7109-5p -2.49 0.00197038 hsa-miR-6753-3p -1.4 0.010270926 
hsa-miR-4656 -2.81 0.001988616 hsa-miR-6862-5p -0.82 0.010438325 
hsa-miR-196b-5p -1.68 0.00202093 hsa-miR-3178 -1.86 0.01061259 
hsa-miR-6807-5p -3.58 0.00204258 hsa-miR-5006-5p -2.29 0.010960124 
hsa-miR-130b-3p -4.14 0.002089534 hsa-miR-5585-3p -0.72 0.011055727 
hsa-miR-4253 -3.11 0.002089534 hsa-miR-5572 -2.37 0.01107774 













hsa-miR-494-3p -4.17 0.002155109 hsa-miR-6893-5p -1.74 0.01171248 
hsa-miR-1909-3p -3.74 0.002225003 hsa-miR-4436b-5p -1.62 0.011939261 
hsa-miR-4758-3p 1.14 0.002444246 hsa-miR-365b-5p -1.1 0.012024387 
hsa-miR-4433b-5p 1.39 0.002568336 hsa-miR-7-2-3p 0.48 0.01216102 
hsa-miR-6860 -2.04 0.002575532 hsa-miR-151a-5p -3.93 0.01279353 
hsa-miR-708-5p -3.08 0.002663473 hsa-miR-6781-5p -2.19 0.013051141 
hsa-miR-193a-5p -5.26 0.002682754 hsa-miR-8075 2.22 0.013558665 
hsa-miR-1254 -1.57 0.00269632 hsa-miR-212-3p -1.06 0.013785842 
hsa-miR-423-3p -5.39 0.002722742 hsa-miR-342-3p -4.13 0.013785842 
hsa-miR-1246 -4.19 0.002728825 hsa-miR-6762-5p -1.14 0.013954549 
hsa-miR-937-5p -2.77 0.002736254 hsa-miR-198 -1.38 0.013982956 
hsa-miR-3157-3p 3.35 0.002762931 hsa-miR-1281 1.93 0.014014488 
hsa-miR-4726-5p -1.45 0.002843541 hsa-miR-664b-5p -1.52 0.014112386 
hsa-miR-6819-3p 2.88 0.002882896 hsa-miR-6133 -1.36 0.01411325 
hsa-miR-4284 -2.42 0.003030259 hsa-miR-4257 -0.97 0.014513209 
hsa-miR-195-3p -2.17 0.003238888 hsa-miR-6830-5p -0.97 0.0147239 
hsa-miR-6886-5p -0.93 0.003274526 hsa-miR-4669 -1.68 0.014913489 
hsa-miR-4669 -2.28 0.003293414 hsa-miR-6084 -1.74 0.015110703 
hsa-miR-21-5p -3.22 0.00331709 hsa-miR-6792-5p -1.37 0.015201006 
hsa-miR-548u 0.66 0.00331709 hsa-miR-6757-5p -1.86 0.015996339 
hsa-miR-4463 -3.86 0.00331709 hsa-miR-744-3p 0.46 0.016059468 
hsa-miR-520c-3p 0.5 0.003320306 hsa-miR-425-5p -3.02 0.01618786 
hsa-miR-6728-5p -2.16 0.003321912 hsa-miR-4688 -1.75 0.016250206 
hsa-miR-498 -1.63 0.003457299 hsa-miR-3197 -3.46 0.016536143 
hsa-miR-339-3p -3.72 0.003469378 hsa-miR-93-3p -1.28 0.016850054 
hsa-miR-30e-5p -2.09 0.003472747 hsa-miR-637 -1.29 0.016951337 
hsa-miR-23a-5p -3.87 0.003479787 hsa-miR-377-5p -1.13 0.017143659 
hsa-miR-6829-5p -1.82 0.003707175 hsa-miR-6820-3p 0.69 0.017143659 
hsa-miR-6132 -3.45 0.003808028 hsa-miR-30b-3p -1.16 0.017157079 













hsa-miR-3175 -5.45 0.003858826 hsa-miR-181c-5p -1.3 0.017902095 
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hsa-miR-8089 -3.24 0.00392948 hsa-miR-376c-3p -1.64 0.01810689 
hsa-miR-500a-3p -3.91 0.00393803 hsa-miR-6819-5p -2.42 0.018281427 
hsa-miR-660-5p -2.04 0.003995135 hsa-miR-140-5p -3.82 0.018341677 
hsa-miR-4505 -3 0.004162044 hsa-miR-3162-3p 1.93 0.018552813 
hsa-miR-3124-5p -1.63 0.004260023 hsa-miR-26b-5p -0.91 0.018756299 
hsa-miR-6165 -2.78 0.004360367 hsa-miR-6877-3p -1.48 0.018867937 
hsa-miR-4436b-5p -2.07 0.004464979 hsa-miR-4750-3p 2.16 0.019552606 
hsa-miR-15b-5p -5.29 0.004514169 hsa-miR-6845-5p -1.17 0.019609517 
hsa-miR-6792-5p -1.8 0.004524906 hsa-miR-3187-3p -2.47 0.019910339 
hsa-miR-10a-5p -1.47 0.004652409 hsa-miR-1538 -1.33 0.0200721 
hsa-miR-6763-5p -2.79 0.004654825 hsa-miR-711 -0.88 0.020093343 
hsa-miR-31-5p -5.88 0.004755497 hsa-miR-625-5p -1.17 0.020127481 
hsa-miR-6080 -1.71 0.00490227 hsa-miR-1224-5p -2.2 0.02043889 
hsa-miR-591 0.55 0.004996519 hsa-miR-874-5p -0.76 0.02043889 
hsa-miR-1228-5p -3.12 0.004996519 hsa-miR-421 -1.37 0.021040138 
hsa-miR-371a-5p -1.27 0.005000899 hsa-miR-4715-5p -0.56 0.021190402 
hsa-miR-502-3p -4.24 0.005027193 hsa-miR-3917 -0.81 0.021987354 
hsa-miR-125a-3p -2.89 0.005314777 hsa-miR-26a-5p -4.33 0.02207693 
hsa-miR-548ap-5p 0.57 0.005416354 hsa-miR-1273d -1.16 0.022347306 
hsa-miR-6795-5p -1.64 0.005507729 hsa-miR-1471 -1.02 0.022578038 
hsa-miR-4324 -1.12 0.005617057 hsa-miR-4646-5p -1.71 0.022631013 
hsa-miR-6754-3p -1.2 0.005669525 hsa-miR-4271 -1.12 0.02279463 
hsa-miR-3925-5p 0.7 0.005866333 hsa-miR-920 -1.06 0.022839029 
hsa-miR-4750-5p -3.43 0.005866333 hsa-miR-652-3p -2.55 0.02306791 
hsa-miR-6749-5p -3.24 0.005916613 hsa-miR-487a-3p -1.16 0.023579731 
hsa-miR-4651 -3.29 0.006010373 hsa-miR-142-3p 0.43 0.023724432 
hsa-miR-7114-3p 2 0.00609262 hsa-miR-425-3p -1.79 0.023855959 
hsa-miR-4525 -1.89 0.006196579 hsa-miR-5001-3p -0.46 0.024136726 
hsa-miR-4534 -2 0.006196579 hsa-miR-4446-3p -0.87 0.024687865 
hsa-miR-4433b-3p -3.54 0.006196579 hsa-miR-5196-5p -2.14 0.024969322 
hsa-miR-378h 3.01 0.006274829 hsa-miR-513c-3p 0.52 0.025288878 
hsa-miR-4689 -3.54 0.006275409 hsa-miR-629-5p -1.54 0.025466238 
hsa-miR-422a -2.07 0.006407152 hsa-miR-296-3p -1.38 0.025492523 
hsa-miR-6817-3p 0.66 0.006423896 hsa-miR-6793-5p -1.06 0.025811529 
hsa-miR-194-5p -1.82 0.006587779 hsa-miR-6889-5p -1.8 0.026373888 
hsa-miR-135a-3p -2 0.006851215 hsa-miR-6865-5p -1.11 0.026450886 
hsa-miR-6798-3p 1.78 0.006854653 hsa-miR-154-5p -1.6 0.026616163 
hsa-miR-3180-3p -3.63 0.006929516 hsa-miR-4292 -0.75 0.026616163 
hsa-miR-6779-5p -2.87 0.007048073 hsa-miR-3607-5p -1.12 0.026708138 
hsa-miR-6796-5p -1.62 0.00712704 hsa-miR-4717-3p -1.39 0.026839532 













hsa-miR-3622b-5p -1.58 0.007213331 hsa-miR-3147 -1.34 0.027278639 
hsa-miR-6893-5p -2.1 0.00735397 hsa-miR-503-5p -1.31 0.027542247 
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hsa-miR-6757-5p -2.34 0.007501909 hsa-miR-548q -0.51 0.027581844 
hsa-miR-3652 -1.65 0.007510878 hsa-miR-3914 0.55 0.02799789 
hsa-miR-6727-3p 1.27 0.00756791 hsa-miR-4327 -1.31 0.028433616 
hsa-miR-6819-5p -3.09 0.007573482 hsa-miR-6782-5p -2.15 0.029095398 
hsa-miR-149-5p -1.52 0.007638362 hsa-miR-127-3p -3.75 0.029247388 
hsa-miR-1238-5p -1.57 0.007705708 hsa-miR-4725-3p -1.54 0.03016603 
hsa-miR-149-3p -2.93 0.007714749 hsa-miR-1301-3p -1.54 0.030272493 
hsa-miR-197-5p -2.77 0.00777261 hsa-miR-222-3p -3.8 0.030435319 
hsa-miR-6824-5p -3.53 0.008159633 hsa-miR-378d -1.26 0.030525108 
hsa-miR-4741 -3.59 0.008166454 hsa-miR-6785-5p -1.53 0.03054425 
hsa-miR-6090 -1.09 0.008166454 hsa-miR-551b-5p -0.88 0.031274952 
hsa-miR-4513 -1.34 0.008177907 hsa-miR-4304 -0.66 0.031826119 
hsa-miR-4538 -1.01 0.008252148 hsa-miR-4655-5p -1.71 0.032459246 
hsa-miR-877-5p -2.17 0.008287102 hsa-miR-1973 -1.5 0.032854268 
hsa-miR-3911 -1.81 0.008341602 hsa-miR-6860 -1.3 0.032854268 
hsa-miR-7114-5p -2.53 0.008674587 hsa-miR-150-3p -2.13 0.033160545 
hsa-miR-10b-3p -1.7 0.008690179 hsa-miR-887-3p -0.92 0.033234756 
hsa-miR-4430 -2.13 0.008800452 hsa-miR-3944-3p -1.14 0.033441344 
hsa-miR-6797-5p -1.71 0.009151004 hsa-miR-128-3p -1.12 0.033824674 
hsa-miR-4638-5p -1.02 0.009264268 hsa-miR-6831-5p -1.6 0.033958521 
hsa-miR-4725-5p 1.43 0.009576507 hsa-miR-6857-5p -0.5 0.035346605 
hsa-miR-4752 0.64 0.009612778 hsa-miR-6878-5p 0.36 0.03536274 
hsa-miR-92b-3p -4.25 0.009796128 hsa-miR-185-3p -1.27 0.035535417 
hsa-miR-4687-3p -2.66 0.009882725 hsa-miR-7111-5p -1.65 0.035812204 
hsa-miR-1273f -2.02 0.010103903 hsa-miR-6815-5p -1.14 0.035891018 
hsa-miR-6812-5p -2.83 0.01011316 hsa-miR-6748-5p -0.78 0.036317463 
hsa-miR-6748-5p -1.07 0.010128175 hsa-miR-500a-5p -1.57 0.036447589 
hsa-miR-6790-5p -3.92 0.010193975 hsa-miR-4750-5p -2.35 0.036452091 
hsa-miR-6752-5p -3.68 0.010483633 hsa-miR-4430 -1.53 0.036584504 
hsa-miR-6515-5p -1.09 0.010890161 hsa-miR-1287-5p -0.86 0.037522356 
hsa-miR-6851-5p -1.88 0.010933575 hsa-miR-6751-5p -0.93 0.03756757 
hsa-miR-337-5p -2.2 0.010966853 hsa-miR-31-5p -3.92 0.03765947 
hsa-miR-449c-3p 0.45 0.011229996 hsa-miR-642a-3p -1.79 0.037915098 
hsa-miR-6781-5p -2.54 0.011390111 hsa-miR-191-3p -0.97 0.03977905 
hsa-miR-5195-3p -2.1 0.011837947 hsa-miR-1324 0.53 0.03983022 
hsa-miR-4433-5p 1.53 0.012042094 hsa-miR-4726-5p -0.9 0.039906025 
hsa-miR-6831-5p -2.12 0.012042094 hsa-miR-4731-3p 0.47 0.039906025 
hsa-miR-4633-5p 0.75 0.012293318 hsa-miR-138-5p -0.94 0.04101721 
hsa-miR-6738-5p -2.14 0.01251978 hsa-miR-297 -2.99 0.042908321 
hsa-miR-214-5p -2.63 0.012817184 hsa-miR-500a-3p -2.5 0.042954705 
hsa-miR-18a-5p -1.82 0.01306157 hsa-miR-4513 -0.93 0.04347851 
hsa-miR-194-3p -1.07 0.01322058 hsa-miR-5010-5p -1.11 0.043636922 
hsa-miR-637 -1.51 0.013443792 hsa-miR-518d-3p 0.34 0.044004551 
hsa-miR-4535 -1.24 0.013525862 hsa-miR-6734-5p -1.09 0.044371063 
hsa-miR-6715a-3p 1.59 0.013871386 hsa-miR-3648 -2.41 0.044646132 
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hsa-miR-548ar-3p 0.56 0.013954549 hsa-miR-936 -1.05 0.045640594 
hsa-miR-519d-3p 0.67 0.014035875 hsa-miR-8060 -0.95 0.045883963 
hsa-miR-548x-3p 0.64 0.014035875 hsa-miR-615-5p -0.78 0.0460425 
hsa-miR-377-5p -1.32 0.014066587 hsa-miR-6851-5p -1.33 0.047192511 
hsa-miR-6089 -1.05 0.014173144 hsa-miR-6877-5p -1.1 0.047669336 
hsa-miR-4279 1.71 0.014202757 hsa-miR-29b-1-5p -0.73 0.04771584 
hsa-miR-378i -2.16 0.014422422 hsa-miR-5189-5p -1.79 0.048559286 
hsa-miR-4499 -0.66 0.014513209 hsa-miR-34c-5p -0.46 0.048585262 
hsa-miR-6793-5p -1.31 0.014534341 hsa-miR-6890-5p -0.79 0.04866001 
hsa-miR-4758-5p -2.87 0.014538588  
hsa-miR-6785-5p -1.94 0.01471883 
hsa-miR-148b-3p -1.9 0.015289263 
hsa-miR-2110 -2.99 0.01534092 
hsa-miR-29c-3p -1.45 0.015976882 
hsa-miR-4732-5p -1.64 0.016334818 
hsa-miR-579-3p 0.46 0.016364921 
hsa-miR-4484 -3.67 0.016573589 
hsa-miR-6880-5p -1.85 0.016878918 
hsa-miR-487a-5p -1.45 0.016904712 
hsa-miR-135b-5p 0.66 0.01694863 
hsa-miR-6717-5p -0.88 0.017081955 
hsa-miR-409-5p -1.82 0.017183563 
hsa-miR-4298 -2.72 0.017562998 
hsa-miR-191-3p -1.25 0.017628394 
hsa-miR-212-3p -1.16 0.018281427 
hsa-miR-6770-5p -0.66 0.018521471 
hsa-miR-1468-3p 0.51 0.018629451 
hsa-miR-526a 0.48 0.019626103 
hsa-miR-5189-5p -2.35 0.019837133 
hsa-miR-6741-5p -2.17 0.019910339 
hsa-miR-325 -0.53 0.020132941 
hsa-miR-330-3p -1.11 0.020165819 
hsa-miR-8073 -1.86 0.020186228 
hsa-miR-374a-5p 0.62 0.020193757 
hsa-miR-425-3p -2.09 0.020261839 
hsa-miR-6753-3p -1.46 0.020635601 
hsa-miR-4441 -0.72 0.020783898 
hsa-miR-4749-5p -3.45 0.020904314 
hsa-miR-493-3p -1.83 0.021175313 
hsa-miR-3151-3p 0.77 0.02180052 
hsa-miR-3117-5p -0.46 0.021882546 
hsa-miR-4539 -2.41 0.021893588 
hsa-miR-1234-3p 2.67 0.02207693 
hsa-miR-4271 -1.29 0.022105275 
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hsa-miR-760 -1.36 0.022263219 
hsa-miR-198 -1.47 0.022499945 
hsa-miR-7106-5p -1.62 0.022542405 
hsa-miR-296-3p -1.6 0.022631013 
hsa-miR-642b-3p -1.82 0.022948361 
hsa-miR-6076 -0.92 0.02313208 
hsa-miR-501-3p -2.98 0.023193618 
hsa-miR-4673 -1.18 0.02334592 
hsa-miR-663b -1.58 0.02351927 
hsa-miR-6871-5p -1.09 0.023917144 
hsa-miR-744-3p 0.49 0.024287151 
hsa-miR-4530 -2.72 0.024379332 
hsa-miR-6847-5p -2.39 0.024629893 
hsa-miR-4662a-3p 0.67 0.024912413 
hsa-miR-671-3p -0.93 0.025003838 
hsa-miR-3936 -0.74 0.02522075 
hsa-miR-4488 -1.75 0.025288878 
hsa-miR-362-5p -2.17 0.025320337 
hsa-miR-6499-3p 0.68 0.025320337 
hsa-miR-6774-5p -1.32 0.025326955 
hsa-miR-5008-5p -0.61 0.025470007 
hsa-miR-483-3p 0.66 0.02549318 







hsa-miR-6729-3p 0.96 0.025886722 
hsa-miR-421 -1.51 0.026450886 
hsa-miR-6894-5p -1.53 0.026450886 
hsa-miR-532-3p -2.6 0.026645285 
hsa-miR-6752-3p 0.99 0.026650544 
hsa-miR-4743-5p -1.69 0.027042314 
hsa-miR-665 -1.99 0.027241071 
hsa-miR-381-3p -1.42 0.027514504 
hsa-miR-4634 -2.64 0.027582678 
hsa-miR-6857-5p -0.59 0.02826417 
hsa-miR-7845-5p -2.62 0.02826417 
hsa-miR-4507 -2.54 0.028433616 
hsa-miR-6848-5p -3.22 0.02851159 
hsa-miR-197-3p -2.74 0.028943187 
hsa-miR-3147 -1.51 0.030282347 
hsa-miR-4270 -2.63 0.030862063 
hsa-miR-1266-5p -0.68 0.030868094 
hsa-miR-6134 -0.63 0.031462893 
hsa-miR-7107-5p 2.41 0.031868737 
hsa-miR-1307-3p -2.73 0.032235917 
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hsa-miR-6836-5p -3.01 0.032501419 
hsa-miR-8063 -2.73 0.032517167 
hsa-miR-200c-3p -1.27 0.032688591 
hsa-miR-7160-5p -0.96 0.032865598 
hsa-miR-1225-5p -3.07 0.032888287 
hsa-miR-5193 0.93 0.032972441 
hsa-miR-137 0.4 0.033128216 
hsa-miR-3622a-5p -1.44 0.033182605 
hsa-miR-3937 -2.93 0.033995173 
hsa-miR-30b-3p -1.2 0.034265918 
hsa-miR-4433-3p -2.9 0.034291438 
hsa-miR-1202 -3.03 0.034504385 
hsa-miR-5703 -0.86 0.034504385 
hsa-miR-6722-3p -3.25 0.035087165 
hsa-miR-4731-5p -0.65 0.035322337 
hsa-miR-6881-5p -0.45 0.035322337 
hsa-miR-6762-5p -1.13 0.035357908 
hsa-miR-4649-5p -3.23 0.035509574 
hsa-miR-376c-3p -1.69 0.036317463 
hsa-miR-4257 -0.97 0.036360381 
hsa-miR-6830-5p -0.97 0.036733345 
hsa-miR-548a-3p 3.05 0.036767885 
hsa-miR-1273d -1.22 0.036959839 
hsa-miR-3181 -0.8 0.037290482 
hsa-miR-4283 -0.57 0.037522356 
hsa-miR-196b-3p -1.2 0.037619599 
hsa-miR-1271-5p -2.99 0.037696361 
hsa-miR-4718 0.44 0.037696361 
hsa-miR-6827-5p -1.12 0.037855461 
hsa-miR-518d-3p 0.4 0.037915961 
hsa-miR-625-5p -1.21 0.037916868 
hsa-miR-23c -0.98 0.037958487 
hsa-miR-29c-5p -0.68 0.039341038 
hsa-miR-1301-3p -1.68 0.039825618 
hsa-miR-6088 -0.71 0.040551784 
hsa-miR-6858-5p -2.45 0.040815743 
hsa-miR-6878-5p 0.4 0.04101721 
hsa-miR-1182 -1.06 0.041450019 
hsa-miR-29b-2-5p -2.03 0.041450822 
hsa-miR-93-3p -1.27 0.042121201 
hsa-miR-3156-3p 0.48 0.042121201 
hsa-miR-6850-3p -0.53 0.04216548 
hsa-miR-4327 -1.41 0.042355872 
hsa-miR-575 -2.58 0.042406187 
hsa-miR-762 -1.98 0.04329673 
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hsa-miR-4491 0.59 0.043435267 
hsa-miR-98-5p -0.75 0.04347851 
hsa-miR-6784-5p -2.29 0.044371063 
hsa-miR-500a-5p -1.73 0.045096056 
hsa-miR-920 -1.08 0.045179402 
hsa-miR-29b-1-5p -0.84 0.046243573 
hsa-miR-6890-5p -0.9 0.046581809 
hsa-miR-499a-5p 0.61 0.047474071 
hsa-miR-3917 -0.81 0.04771584 
hsa-miR-6803-3p 0.65 0.04771584 
hsa-miR-548e-3p 0.46 0.047933337 
hsa-miR-1260a 0.88 0.048113067 
hsa-miR-323a-5p -0.52 0.048206137 
hsa-miR-3614-3p 0.57 0.048585262 
hsa-miR-874-5p -0.75 0.048818559 
hsa-miR-4481 -1.78 0.049081251 
hsa-miR-615-3p -1.52 0.049115816 
hsa-miR-1972 -1.91 0.049342031 
hsa-miR-6738-3p 0.56 0.049342606 
hsa-miR-642a-3p -1.96 0.04937258 








Old OA Lesioned vs Young Intact (Columns A, B and C) 
Old OA Lesioned vs Old OA Intact-1 (Columns D, E and F) 





Transcript ID FC Les vs Y FDR Les vs Y Transcript ID FC Les vs Int-1 FDR Les vs Int-1 
hsa-miR-143-3p -7.35 1.73E-15 hsa-let-7c-5p 9.03 5.10E-09 
hsa-miR-126-3p -7.36 5.92E-15 hsa-let-7b-5p 8.98 2.02E-08 
hsa-miR-139-5p -4.31 2.68E-14 hsa-miR-4454 7.09 8.46E-08 
hsa-miR-148a-3p -4.77 2.15E-12 hsa-miR-125b-5p 8.25 1.04E-07 













hsa-miR-20a-5p -4.69 2.03E-11 hsa-miR-210-3p 5.79 2.76E-05 
hsa-miR-25-3p -3.96 2.03E-11 hsa-miR-320c 5.73 3.32E-05 
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hsa-miR-28-5p -4.14 4.88E-11 hsa-miR-320d 5.63 8.34E-05 
hsa-miR-15a-5p -4.22 1.76E-10 hsa-miR-4505 4.12 9.90E-05 
hsa-miR-628-3p -2.92 5.07E-10 hsa-miR-214-3p 5.96 0.000105409 
hsa-miR-30a-5p -4.71 7.93E-10 hsa-miR-320b 5.91 0.000107991 
hsa-miR-30b-5p -3.79 9.35E-10 hsa-miR-937-5p 3.61 0.000112999 
hsa-miR-10b-5p -4.23 1.02E-09 hsa-miR-744-5p 4.31 0.000143393 
hsa-miR-432-5p -4.58 1.08E-09 hsa-miR-548n -0.64 0.000166987 
hsa-miR-150-5p -2.96 1.48E-09 hsa-miR-193b-3p 6.03 0.000325919 
hsa-miR-181b-5p -4.68 2.03E-09 hsa-miR-320a 4.75 0.000377914 
hsa-let-7g-5p -4.66 4.37E-09 hsa-miR-6796-3p -3.26 0.000386843 
hsa-miR-145-5p -7.2 4.73E-09 hsa-miR-6779-5p 3.7 0.000451063 
hsa-miR-382-5p -4.16 7.66E-09 hsa-miR-940 -3.19 0.000462686 
hsa-miR-487b-3p -3.58 1.42E-08 hsa-miR-6132 4.01 0.000647846 
hsa-miR-151b -3.9 1.93E-08 hsa-miR-6743-5p 2.63 0.000677707 
hsa-miR-409-3p -3.92 2.07E-08 hsa-miR-1180-5p -1.1 0.001185151 
hsa-miR-455-5p -3.62 4.70E-08 hsa-miR-3620-5p 1.88 0.001303606 
hsa-miR-19b-3p -4.34 5.94E-08 hsa-miR-7111-3p -1.38 0.001447619 
hsa-miR-30a-3p -2.33 1.82E-07 hsa-miR-320e 4.59 0.001516529 
hsa-miR-106b-5p -5.04 2.45E-07 hsa-miR-423-5p 4.1 0.001525621 
hsa-let-7f-5p -4.58 7.25E-07 hsa-miR-6749-5p 3.65 0.001623862 
hsa-miR-196a-5p -4.07 9.98E-07 hsa-miR-4507 3.5 0.001753448 
hsa-miR-132-3p -4.02 1.03E-06 hsa-miR-4530 3.62 0.001942065 
hsa-miR-424-3p -2.48 1.34E-06 hsa-miR-6805-3p -3.39 0.00207681 
hsa-miR-195-5p -7.3 1.37E-06 hsa-miR-7847-3p 3.53 0.002445626 
hsa-miR-654-5p -1.82 5.39E-06 hsa-miR-4651 3.48 0.003115063 
hsa-miR-146b-5p -3.45 5.78E-06 hsa-miR-4687-3p 2.94 0.003543971 
hsa-miR-106a-5p -4.32 6.72E-06 hsa-miR-4429 3.95 0.00392948 
hsa-miR-199a-3p -6.92 7.44E-06 hsa-miR-877-3p -1.43 0.004396775 
hsa-miR-130a-3p -3.83 8.22E-06 hsa-miR-149-3p 3.06 0.004622029 
hsa-miR-378c -3.03 1.08E-05 hsa-miR-1202 3.84 0.005077995 
hsa-miR-146a-5p -2.94 1.08E-05 hsa-miR-4492 3.79 0.005255682 
hsa-miR-17-5p -4.42 1.63E-05 hsa-miR-4508 2.7 0.005255682 
hsa-miR-331-5p -1.09 1.92E-05 hsa-miR-6802-5p 2.85 0.005297532 
hsa-miR-885-3p -2.42 2.66E-05 hsa-miR-24-3p 5.88 0.005360181 
hsa-miR-196b-5p -1.81 3.29E-05 hsa-miR-4463 3.59 0.005484815 
hsa-miR-24-2-5p -2.35 3.48E-05 hsa-miR-591 -0.54 0.005669525 
hsa-miR-505-5p -1.78 3.52E-05 hsa-miR-6798-3p -1.77 0.006284396 
hsa-miR-16-5p -6.62 3.71E-05 hsa-miR-1281 -2.37 0.006531402 
hsa-miR-23b-5p -2.87 4.08E-05 hsa-miR-7641 6.12 0.006813824 
hsa-miR-584-5p -1.07 4.54E-05 hsa-miR-6803-5p 0.92 0.007563374 
hsa-miR-378a-3p -3.92 4.55E-05 hsa-miR-7977 4.07 0.00777261 
hsa-miR-28-3p -3.35 5.56E-05 hsa-miR-4270 3.04 0.009882725 
hsa-miR-4417 -3.3 5.87E-05 hsa-miR-6845-5p 1.43 0.009968 
hsa-miR-10a-5p -1.65 6.08E-05 hsa-miR-6820-5p 2.62 0.010210203 
hsa-miR-139-3p -1.47 6.64E-05 hsa-miR-4718 -0.52 0.010438325 
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hsa-miR-181d-5p -1.73 6.64E-05 hsa-miR-574-3p 4.39 0.010630373 
hsa-miR-155-5p -4.77 6.66E-05 hsa-miR-520c-3p -0.43 0.01107774 













hsa-miR-331-3p -1.73 8.13E-05 hsa-miR-4758-3p -0.93 0.013085771 
hsa-miR-7112-5p -2.03 8.45E-05 hsa-miR-193a-5p 4.29 0.014008818 
hsa-miR-151a-5p -5.5 8.94E-05 hsa-miR-150-3p 2.7 0.014201627 
hsa-miR-20b-5p -1.83 8.94E-05 hsa-miR-1228-5p 2.71 0.014241987 
hsa-miR-26a-5p -6.47 9.90E-05 hsa-miR-4279 -1.69 0.014357896 
hsa-miR-27b-5p -2.68 9.94E-05 hsa-miR-6088 0.82 0.014534341 
hsa-miR-3687 -2.9 0.000112753 hsa-miR-4758-5p 2.79 0.016250206 
hsa-miR-4485 -3.2 0.000127989 hsa-miR-4689 3.09 0.016956046 
hsa-miR-485-5p -2.03 0.000129982 hsa-miR-548x-3p -0.61 0.017274059 
hsa-miR-433-3p -2.25 0.000140101 hsa-miR-4750-3p -2.45 0.018089108 
hsa-miR-30e-5p -2.12 0.000143842 hsa-miR-575 2.88 0.018281427 
hsa-miR-4253 -2.97 0.000163384 hsa-miR-6812-5p 2.58 0.018281427 
hsa-miR-708-5p -3 0.000176524 hsa-let-7a-5p 5.29 0.01841332 
hsa-miR-21-5p -3.2 0.00017822 hsa-miR-8089 2.65 0.018569716 
hsa-miR-152-3p -5.37 0.000188522 hsa-miR-7114-3p -1.7 0.019399484 
hsa-miR-370-3p -2.13 0.000195326 hsa-miR-6889-5p 2.1 0.020186228 
hsa-miR-151a-3p -4.13 0.000208347 hsa-miR-3120-3p -0.43 0.02207693 
hsa-miR-181a-5p -4.78 0.000211265 hsa-miR-3664-5p 0.39 0.02309227 
hsa-miR-224-3p -1.62 0.000211265 hsa-miR-877-5p 1.86 0.023601894 
hsa-miR-99a-5p -5.78 0.000213852 hsa-miR-26a-5p 4.79 0.024219472 
hsa-miR-8071 -3.61 0.000214268 hsa-miR-6800-3p -2.65 0.024287151 
hsa-miR-324-5p -2.97 0.000220311 hsa-miR-125a-5p 3.91 0.024379332 













hsa-miR-6846-5p -1.55 0.00031561 hsa-miR-4690-5p 2.69 0.026202577 
hsa-miR-378f -2.27 0.000334095 hsa-miR-3180 2.19 0.02826417 
hsa-miR-23b-3p -6.3 0.00033649 hsa-miR-4665-5p 2.07 0.02851159 
hsa-miR-127-5p -1.19 0.00033649 hsa-miR-23b-3p 5.01 0.02883199 
hsa-miR-664a-5p -2.19 0.000343187 hsa-miR-4728-5p 1.78 0.028977053 
hsa-miR-660-5p -1.95 0.000361938 hsa-miR-103a-3p 4.65 0.029082141 
hsa-miR-337-5p -2.35 0.000390237 hsa-miR-3151-3p -0.72 0.029091686 
hsa-miR-6807-5p -3.17 0.000392715 hsa-miR-4449 2.78 0.029924576 
hsa-miR-93-5p -3.89 0.000419735 hsa-miR-6086 1.31 0.030032856 
hsa-miR-23a-3p -6.25 0.000439315 hsa-miR-6087 0.67 0.030282347 
hsa-miR-3609 -2.65 0.000523689 hsa-miR-4256 -0.46 0.030525108 
hsa-miR-339-5p -2 0.000531525 hsa-miR-23a-3p 5.02 0.030946742 
hsa-miR-24-3p -5.66 0.000597694 hsa-miR-455-3p -1.37 0.031274952 
hsa-miR-3124-5p -1.5 0.000641191 hsa-miR-2467-3p 0.81 0.031960642 
hsa-miR-6080 -1.59 0.000662042 hsa-miR-6763-5p 2.14 0.031995581 
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hsa-miR-1254 -1.36 0.000677707 hsa-miR-3651 3.51 0.034504385 
hsa-miR-532-5p -3.17 0.000728571 hsa-miR-2355-5p -0.6 0.035322337 
hsa-miR-29a-3p -4.29 0.00073299 hsa-miR-134-5p 2.8 0.03536274 
hsa-miR-409-5p -1.94 0.000779596 hsa-miR-4488 1.63 0.035742022 
hsa-let-7e-5p -4.71 0.000798209 hsa-miR-107 4.32 0.035812204 
hsa-miR-503-5p -1.69 0.000856562 hsa-miR-6799-5p 2.94 0.037229481 
hsa-miR-18a-5p -1.84 0.000912747 hsa-miR-4725-5p -1.15 0.039092445 
hsa-miR-34a-5p -2.85 0.001050485 hsa-miR-6752-5p 2.99 0.04020963 
hsa-miR-3154 -1.57 0.00110757 hsa-miR-449c-3p -0.37 0.040815573 
hsa-miR-422a -1.87 0.001265341 hsa-miR-6819-3p -2.02 0.040815743 
hsa-miR-3135b -2.99 0.001292101 hsa-miR-5193 -0.89 0.04103568 
hsa-miR-222-3p -4.81 0.001326578 hsa-miR-23a-5p 2.76 0.041649658 
hsa-miR-194-5p -1.64 0.001334904 hsa-miR-6085 2.11 0.04192142 
hsa-miR-29c-3p -1.46 0.001416766 hsa-miR-92a-3p 4.58 0.041977162 
hsa-miR-1231 -3.07 0.001456386 hsa-miR-762 1.95 0.043348753 
hsa-miR-376c-3p -1.9 0.001492759 hsa-miR-1468-3p -0.44 0.044071792 
hsa-miR-345-5p -2.49 0.001493174 hsa-let-7d-5p 4.3 0.044254966 
hsa-miR-6742-5p -1.63 0.001497287 hsa-miR-4539 2.12 0.04432732 
hsa-miR-342-5p -2.23 0.001518563 hsa-miR-3162-5p 2.66 0.046461316 
hsa-miR-557 -1.42 0.001617047 hsa-miR-8063 2.53 0.047552766 
hsa-miR-6754-3p -1.04 0.001666376 hsa-let-7e-5p 3.72 0.048308578 
hsa-miR-6875-5p -1.2 0.001737063 hsa-miR-6513-5p 0.68 0.048323174 
hsa-miR-711 -1.01 0.001876322 hsa-miR-135b-5p -0.55 0.048818559 
hsa-miR-135a-3p -1.75 0.001957012 hsa-miR-3126-3p 0.41 0.048818559 
hsa-miR-6825-5p -1.75 0.001957012 hsa-miR-1279 -0.42 0.049007779 
hsa-miR-361-5p -4.2 0.001968107  
hsa-miR-6881-5p -0.49 0.002102616 
hsa-miR-4726-5p -1.14 0.002166785 
hsa-miR-4750-3p 2.42 0.002225163 
hsa-miR-342-3p -4.4 0.002337632 
hsa-miR-191-5p -4.76 0.002386854 
hsa-let-7a-5p -5.19 0.002505639 
hsa-miR-100-5p -5.01 0.002511593 
hsa-miR-4447 -0.86 0.002511593 
hsa-miR-4673 -1.16 0.002721069 
hsa-miR-107 -4.65 0.002746171 
hsa-miR-1273h-5p -1.57 0.002750484 
hsa-miR-30c-2-3p -1.03 0.00286679 
hsa-miR-125a-5p -3.93 0.002892642 
hsa-miR-487a-5p -1.36 0.002897906 
hsa-miR-6746-5p -1.57 0.002899101 
hsa-miR-191-3p -1.18 0.003067062 
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hsa-miR-1260a 0.96 0.003085032 
hsa-miR-6824-5p -3.01 0.003112842 
hsa-miR-10b-3p -1.44 0.003401744 
hsa-miR-221-3p -4.23 0.003401744 
hsa-miR-652-3p -2.81 0.003401744 
hsa-miR-103a-3p -4.72 0.003494151 
hsa-miR-654-3p -1.73 0.003507044 
hsa-miR-30b-3p -1.22 0.003537269 
hsa-miR-199a-5p -4.2 0.003543971 
hsa-miR-421 -1.48 0.00359403 
hsa-miR-93-3p -1.34 0.003808028 
hsa-let-7d-5p -4.62 0.003825326 
hsa-miR-185-5p -3.59 0.003991644 







hsa-miR-1281 1.93 0.004302475 
hsa-miR-27b-3p -4.5 0.004360367 
hsa-miR-4324 -0.88 0.004652409 
hsa-miR-497-5p -3.94 0.00475851 
hsa-miR-4525 -1.48 0.00475851 
hsa-miR-330-3p -1.01 0.004762611 
hsa-miR-6806-5p -1.31 0.004762611 
hsa-miR-1273d -1.22 0.004839803 
hsa-miR-199b-5p -1.35 0.004852427 
hsa-miR-1273f -1.68 0.005022798 
hsa-miR-6753-5p -1.37 0.005094831 
hsa-miR-6737-5p -1.29 0.005285477 
hsa-miR-22-3p -4.55 0.005363484 
hsa-miR-6808-5p -2.14 0.005363484 
hsa-miR-212-3p -1.03 0.005441535 
hsa-miR-4783-3p -1.58 0.005491503 
hsa-miR-663b -1.44 0.005749882 
hsa-miR-3921 2.06 0.005916613 
hsa-miR-196b-3p -1.17 0.006009435 
hsa-miR-127-3p -4.01 0.006274829 
hsa-miR-5698 -0.93 0.006332704 
hsa-miR-6865-5p -1.16 0.006470483 
hsa-miR-6768-5p -1.61 0.006509487 
hsa-let-7c-5p -2.68 0.006620239 
hsa-miR-425-5p -2.94 0.006630423 
hsa-miR-3181 -0.77 0.00686925 
hsa-miR-381-3p -1.3 0.007081132 
hsa-miR-154-5p -1.67 0.007091225 
hsa-miR-3664-5p 0.35 0.007230224 
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hsa-miR-4685-5p -1.56 0.007242272 
hsa-miR-6732-5p 1.51 0.00735397 
hsa-miR-6829-5p -1.29 0.00736005 
hsa-miR-377-5p -1.09 0.007380505 
hsa-miR-625-5p -1.16 0.00762787 
hsa-miR-5739 -1.69 0.00777261 
hsa-miR-26b-5p -0.89 0.007972968 
hsa-miR-205-3p -1.12 0.008108465 
hsa-miR-4284 -1.66 0.008144449 
hsa-miR-99a-3p -1.12 0.008541873 
hsa-miR-4535 -0.99 0.009550382 
hsa-miR-642b-3p -1.55 0.009850767 
hsa-miR-4436b-5p -1.43 0.010578176 
hsa-miR-378i -1.72 0.01061259 
hsa-miR-6780b-3p 0.75 0.010794095 
hsa-miR-6830-5p -0.88 0.011055727 
hsa-miR-106b-3p -2.03 0.011254494 
hsa-miR-23c -0.89 0.011288326 
hsa-miR-29b-1-5p -0.79 0.01138115 
hsa-miR-1246 -2.72 0.011686501 
hsa-miR-4725-3p -1.53 0.011816716 
hsa-miR-8075 1.96 0.012196033 
hsa-miR-7109-5p -1.55 0.012279843 
hsa-miR-149-5p -1.09 0.012649417 
hsa-miR-487a-3p -1.11 0.012649417 
hsa-miR-198 -1.21 0.013085771 
hsa-miR-134-5p -2.5 0.014005469 
hsa-miR-130b-3p -2.56 0.014035875 
hsa-miR-128-3p -1.11 0.014112386 
hsa-miR-493-3p -1.48 0.01411325 
hsa-miR-3652 -1.17 0.01411325 
hsa-miR-3180 -1.88 0.01411325 
hsa-miR-664b-5p -1.32 0.01437568 
hsa-miR-548av-3p 0.41 0.014513209 
hsa-miR-200c-3p -1.09 0.015110703 
hsa-miR-1973 -1.47 0.015110703 
hsa-miR-371a-5p -0.85 0.015201006 
hsa-miR-181d-3p -0.87 0.01522335 
hsa-miR-4715-5p -0.51 0.015262529 
hsa-miR-4462 -1.56 0.01534453 
hsa-miR-99b-5p -3.58 0.015745485 
hsa-miR-615-5p -0.8 0.01583846 
hsa-miR-6800-3p 2.18 0.016095452 
hsa-miR-214-5p -1.94 0.016866823 
hsa-miR-181c-5p -1.14 0.016908868 
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hsa-miR-3180-3p -2.48 0.017002329 
hsa-miR-195-3p -1.36 0.017081955 
hsa-miR-551b-5p -0.84 0.017081955 
hsa-miR-5589-5p -0.65 0.017081955 
hsa-miR-6762-5p -0.96 0.017081955 
hsa-miR-6880-5p -1.41 0.017199414 
hsa-miR-339-3p -2.35 0.017379213 
hsa-miR-17-3p -1.19 0.017588632 
hsa-miR-10a-3p 0.35 0.017664904 
hsa-miR-3130-3p -0.59 0.017675837 
hsa-miR-135a-5p 0.34 0.017973088 
hsa-miR-4316 -0.43 0.017998864 
hsa-miR-6862-5p -0.67 0.01810689 
hsa-miR-194-3p -0.78 0.018281427 
hsa-miR-29c-5p -0.59 0.018818872 
hsa-miR-378d -1.18 0.018948272 
hsa-miR-504-3p -1.38 0.019062771 
hsa-miR-27a-3p -4.06 0.019241152 
hsa-miR-3620-5p 1.08 0.019241152 
hsa-miR-125b-5p -2.51 0.019837133 
hsa-miR-7114-5p -1.73 0.020204866 
hsa-miR-6861-5p -1.77 0.020223768 
hsa-miR-486-3p -0.48 0.020709085 
hsa-miR-494-3p -2.45 0.020740883 
hsa-miR-30e-3p -1.01 0.02207693 
hsa-miR-6747-5p -0.54 0.02207693 
hsa-miR-324-3p -2.2 0.022171147 
hsa-miR-148b-5p 0.46 0.022263219 
hsa-miR-3121-3p -0.39 0.022327552 
hsa-miR-5195-3p -1.47 0.023252314 
hsa-miR-1266-5p -0.54 0.023917144 
hsa-miR-4257 -0.79 0.023917144 
hsa-miR-192-5p -0.7 0.023933082 
hsa-miR-362-5p -1.67 0.023947018 
hsa-miR-6774-5p -1.01 0.024750316 
hsa-miR-22-5p -0.78 0.02522075 
hsa-miR-4292 -0.65 0.025326955 
hsa-miR-4534 -1.27 0.025466238 
hsa-miR-325 -0.39 0.02558789 
hsa-miR-143-5p -0.71 0.025972491 
hsa-miR-92a-3p -3.83 0.026450886 
hsa-miR-6797-5p -1.13 0.026450886 
hsa-miR-6820-3p 0.56 0.02677921 
hsa-miR-6847-5p -1.8 0.02677921 









hsa-miR-1228-3p 1.53 0.027159044 
hsa-miR-6757-5p -1.5 0.027890698 
hsa-miR-6781-5p -1.7 0.028943187 
hsa-miR-3607-5p -0.96 0.029277098 
hsa-miR-4498 -1.46 0.02991739 
hsa-miR-377-3p -0.4 0.030312165 
hsa-miR-6717-5p -0.61 0.031256427 
hsa-miR-7-2-3p 0.36 0.031995581 
hsa-miR-4283 -0.45 0.032612083 
hsa-miR-6887-5p -1.09 0.033234756 
hsa-miR-6785-5p -1.32 0.033478894 
hsa-miR-4446-3p -0.72 0.033868155 
hsa-miR-4748 -0.43 0.03449092 
hsa-miR-148b-3p -1.28 0.034549781 
hsa-miR-498 -0.92 0.035322337 
hsa-miR-6515-5p -0.7 0.035551052 
hsa-miR-6721-5p -1.26 0.035791098 
hsa-miR-1914-3p -0.83 0.036800847 
hsa-miR-6890-5p -0.72 0.036885636 
hsa-miR-4786-3p -0.66 0.037517115 
hsa-miR-6753-3p -1.02 0.037517115 
hsa-miR-6819-5p -1.89 0.038062423 
hsa-miR-6084 -1.31 0.03884799 
hsa-miR-4655-5p -1.44 0.04020963 
hsa-miR-3613-5p 2.53 0.04049252 
hsa-miR-542-5p -0.72 0.041215152 
hsa-miR-548a-3p 2.29 0.041450822 
hsa-miR-500a-5p -1.34 0.041856784 
hsa-miR-34a-3p -0.5 0.042547139 
hsa-miR-4274 1.65 0.042660611 
hsa-miR-4746-3p -0.54 0.043597083 
hsa-miR-4685-3p -0.62 0.044254966 
hsa-miR-4327 -1.06 0.044815606 
hsa-miR-4732-5p -1.07 0.045208942 
hsa-miR-4430 -1.29 0.045640594 
hsa-miR-1538 -1.02 0.046232489 
hsa-miR-4278 -0.37 0.047089566 
hsa-miR-3178 -1.29 0.048886666 
hsa-miR-548y -0.38 0.049342606 
hsa-miR-3195 -2.05 0.049492783 
hsa-miR-548q -0.41 0.049581805 
hsa-miR-3622b-5p -0.92 0.049584947 
hsa-miR-6728-5p -1.16 0.049584947 
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Old OA Lesioned vs Old OA Intact-2 (Columns A, B and C) 
Old OA Intact-1 vs Old OA Intact-2 (Columns D, E and F) 









































hsa-miR-548ad 0.38 0.025821697 hsa-miR-125b-5p -9.14 8.14E-08 
hsa-miR-4666b -0.48 0.026301219 hsa-miR-5100 -9.27 2.41E-07 






























































 hsa-miR-320b -6.35 0.000128241 
hsa-miR-7977 -6.44 0.000152838 
hsa-miR-4505 -4.2 0.000229215 
hsa-miR-24-3p -8.56 0.000250603 
hsa-miR-937-5p -3.61 0.000330464 
hsa-miR-4429 -5.37 0.00037246 
hsa-miR-423-5p -5.05 0.000390237 
hsa-miR-7641 -8.81 0.000390237 
hsa-miR-320a -5.12 0.00043626 
hsa-miR-6132 -4.5 0.000471017 
hsa-miR-6796-3p 3.49 0.000490611 
hsa-miR-6743-5p -2.87 0.000677707 
hsa-let-7a-5p -8.13 0.000756652 
hsa-miR-125a-5p -6.25 0.000772999 
hsa-miR-6779-5p -3.81 0.000868949 
hsa-miR-193a-5p -6.22 0.000960541 
hsa-miR-744-5p -4 0.000978197 
hsa-let-7e-5p -6.36 0.001291066 
hsa-miR-574-3p -6.01 0.001292257 
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hsa-miR-23b-3p -7.87 0.001303606 
hsa-miR-1202 -4.8 0.001360182 
hsa-miR-591 0.66 0.001754193 
hsa-miR-92a-3p -7.41 0.00180264 
hsa-let-7d-5p -6.86 0.0022226 
hsa-miR-26a-5p -6.94 0.002234389 
hsa-miR-193b-5p -5.14 0.003157938 
hsa-miR-4507 -3.59 0.003157938 
hsa-miR-548n 0.53 0.003519406 
hsa-miR-23a-3p -7.16 0.003808028 
hsa-miR-668-3p -1.12 0.00392948 
hsa-miR-7847-3p -3.63 0.004291367 
hsa-miR-4758-3p 1.16 0.004362096 
hsa-miR-940 2.8 0.004590493 
hsa-miR-23a-5p -3.99 0.005104545 
hsa-miR-4530 -3.55 0.005214083 
hsa-miR-3620-5p -1.78 0.005248823 
hsa-miR-149-3p -3.29 0.005255682 
hsa-miR-4687-3p -3.06 0.005441535 
hsa-miR-6749-5p -3.45 0.006405887 
hsa-miR-548ad 0.56 0.007332888 
hsa-miR-191-5p -5.91 0.007533354 
hsa-miR-3688-3p 0.77 0.00777261 
hsa-miR-4651 -3.42 0.00777261 
hsa-miR-6800-3p 3.36 0.00777261 
hsa-miR-99a-5p -5.75 0.007942131 
hsa-miR-4463 -3.74 0.008166454 
hsa-miR-520c-3p 0.48 0.008875159 
hsa-miR-107 -5.57 0.011180246 
hsa-miR-103a-3p -5.79 0.011423186 
hsa-miR-4492 -3.74 0.012293318 
hsa-miR-3651 -4.45 0.01234311 
hsa-miR-6798-3p 1.78 0.01239332 
hsa-miR-1281 2.37 0.013354375 
hsa-miR-4689 -3.45 0.014113385 
hsa-miR-3925-5p 0.67 0.01487736 
hsa-miR-423-3p -4.73 0.015460671 
hsa-miR-4750-3p 2.71 0.01621448 
hsa-miR-6805-3p 2.88 0.018136072 
hsa-miR-195-5p -4.65 0.018281427 
hsa-miR-455-3p 1.61 0.018281427 
hsa-miR-4508 -2.52 0.018796817 
hsa-miR-6738-3p 0.7 0.019363363 
hsa-miR-22-3p -5.42 0.02043889 
hsa-miR-151a-5p -4.51 0.020539631 
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hsa-miR-7107-5p 2.75 0.021882546 
hsa-miR-100-5p -5.39 0.023298086 
hsa-miR-27b-3p -5.12 0.023579731 







hsa-miR-6803-5p -0.86 0.024833007 
hsa-miR-7111-3p 1.08 0.024898966 







hsa-miR-6745 0.7 0.027005534 
hsa-miR-27a-3p -5.4 0.027677414 
hsa-miR-1228-5p -2.68 0.028013555 
hsa-miR-4741 -3.24 0.029247388 
hsa-miR-4758-5p -2.78 0.029488342 
hsa-let-7i-5p -4.08 0.031252384 
hsa-miR-4693-5p 0.4 0.031868737 
hsa-miR-34c-5p 0.6 0.032336957 
hsa-miR-135b-5p 0.64 0.032974733 
hsa-miR-497-5p -4.29 0.033160545 
hsa-miR-3195 -3.07 0.033441344 
hsa-miR-1288-3p 0.49 0.035334136 
hsa-miR-4270 -2.74 0.037581379 
hsa-miR-4488 -1.76 0.039244011 
hsa-miR-3914 -0.63 0.039873533 
hsa-miR-328-3p -3.27 0.041225284 
hsa-miR-6820-5p -2.34 0.041273018 
hsa-miR-6790-5p -3.44 0.041856784 
hsa-miR-6727-3p 1.08 0.042547139 
hsa-miR-4690-5p -2.72 0.042667117 
hsa-miR-6088 -0.75 0.044646132 
hsa-miR-4274 2.29 0.045559612 
hsa-miR-3175 -4.2 0.046788181 
hsa-miR-877-3p 1.13 0.046973053 
hsa-miR-8089 -2.5 0.047257571 
hsa-miR-4728-5p -1.78 0.048818559 
hsa-miR-6499-3p 0.65 0.048818559 
hsa-miR-6732-5p 1.62 0.048818559 
hsa-miR-6866-5p 0.5 0.049392034 





Analysis Name: OA-Lesioned vs Young Intact Core Analysis 
Analysis Creation Date: 2021-02-06 
Build version: exported 


















Name p-value Overlap 
Osteoarthritis Pathway 9,23E-51 21,4 % 47/220 
Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
3,50E-40 20,4 % 38/186 
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 
2,16E-37 17,4 % 38/218 
Tumor Microenvironment Pathway 4,31E-35 19,3 % 34/176 
Experiment Metadata 
Analysis Settings 
Top Canonical Pathways 
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Hepatic Fibrosis Signaling Pathway 3,52E-28 10,1 % 38/378 
 
 
(c) 2000-2021 QIAGEN. All rights reserved.   
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Top Diseases and Bio Functions   
 





(c) 2000-2021 QIAGEN. All rights reserved.   
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Summary of Analysis - OA-Lesioned vs Young Intact Core Analysis 
 





Name p-value range # Molecules 
Cancer 1,11E-22 - 4,69E-63 188 
Organismal Injury and Abnormalities 1,69E-22 - 4,69E-63 212 
Cardiovascular Disease 5,46E-23 - 1,51E-56 139 
Inflammatory Response 2,28E-22 - 7,97E-50 155 
Connective Tissue Disorders 8,87E-23 - 2,96E-48 147 
 








Cellular Movement 9,40E-23 - 5,42E-72 157 
Cellular Development 2,13E-22 - 1,17E-69 185 
Cellular Growth and Proliferation 2,13E-22 - 3,33E-64 178 
Cell Death and Survival 1,69E-22 - 3,33E-60 162 
Cell-To-Cell Signaling and Interaction 1,81E-22 - 3,98E-56 141 
 








Embryonic Development 2,09E-22 - 6,66E-72 162 
Organismal Development 2,09E-22 - 6,66E-72 182 
Connective Tissue Development and Function 7,96E-24 - 1,17E-69 153 
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Tissue Development 2,13E-22 - 1,17E-69 188 
 
(c) 2000-2021 QIAGEN. All rights reserved.   
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Summary of Analysis - OA-Lesioned vs Young Intact Core Analysis 











Name p-value range # Molecules 
Increased Levels of Alkaline Phosphatase 4,56E-02 - 3,73E-35 27 
Increased Levels of LDH 5,33E-03 - 7,77E-07 6 
Decreased Levels of Albumin 6,33E-02 - 9,25E-07 6 
Increased Levels of ALT 1,26E-03 - 1,51E-06 6 










Cardiac Enlargement 2,23E-01 - 3,24E-42 67 
Cardiac Dysfunction 3,12E-01 - 3,10E-26 37 
Heart Failure 9,76E-02 - 1,33E-21 32 
Cardiac Infarction 1,55E-01 - 1,60E-20 29 
Cardiac Fibrosis 5,45E-02 - 5,02E-18 25 








(c) 2000-2021 QIAGEN. All rights reserved.   
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Name p-value range # Molecules 
Liver Proliferation 1,93E-01 - 6,04E-38 40 
Hepatocellular carcinoma 1,06E-01 - 2,44E-24 72 
Liver Hyperplasia/Hyperproliferation 1,63E-01 - 2,44E-24 128 
Liver Fibrosis 1,23E-01 - 7,32E-23 49 










Renal Necrosis/Cell Death 4,56E-02 - 7,35E-21 40 
Renal Damage 8,91E-02 - 1,02E-18 27 
Kidney Failure 8,91E-02 - 1,80E-18 27 
Renal Proliferation 7,20E-02 - 1,40E-16 23 
Glomerular Injury 2,86E-01 - 4,54E-15 43 
















(c) 2000-2021 QIAGEN. All rights reserved.   
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Hepatic Fibrosis 2,14E-38 13,0 % 45/346  





Cardiac Hypertrophy 1,28E-28 9,9 % 39/395  
Renal Necrosis/Cell Death 1,56E-22 6,5 % 40/613  
(c) 2000-2021 QIAGEN. All rights reserved.   
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Summary of Analysis - OA-Lesioned vs Young Intact Core Analysis 
 





































Top My Lists 
Top My Pathways 





(c) 2000-2021 QIAGEN. All rights reserved.   
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Appendix to Chapter 5 
 
 
Appendix to Chapter 5 contains the list of differentially expressed proteins (p<0.05) that were 
identified in human primary OA chondrocytes treated with miR-143-3p mimic or control and 
inhibitor or control, following liquid chromatography-tandem mass spectrometry. 
Differentially expressed proteins were identified by undertaking two-tailed paired t-tests. T- 
statistic and gene ID for each protein is indicated. Moreover, for each set of differentially 
expressed proteins, a Core Analysis was undertaken in Ingenuity Pathway Analysis (Qiagen, 
UK), to identify biological pathways of interest. The report generated for each set of proteins 
is included here. 
 
 
A. Mimic vs Control-mimic comparison 
 
Protein ID Gene Name P value T-statistic 
P11413 G6PD 0.000322 11.54044 
Q9Y678 COPG1 0.000732 -9.34029 
P50991 CCT4 0.004404 -5.79679 
Q07866 KLC1 0.005327 5.500224 
P09871 C1S 0.005463 5.461922 
P11387 TOP1 0.005622 -5.41861 
Q9Y383 LUC7L2 0.005772 -5.37924 
P08253 MMP2 0.007066 5.083034 
P02792 FTL 0.007693 4.962408 
Q96HY6 DDRGK1 0.007844 4.935131 
P21796 VDAC1 0.007911 4.92333 
Q9Y6N5 SQOR 0.009081 -4.73348 
P51659 HSD17B4 0.010273 4.568451 
O95433 AHSA1 0.01041 -4.55094 
Q15233 NONO 0.010582 -4.52944 
P17302 GJA1 0.010824 4.499773 
P14550 AKR1A1 0.011041 4.474002 
Q3SY69 ALDH1L2 0.011281 4.446105 
Q8NBJ5 COLGALT1 0.011311 -4.44265 
Q96AZ6 ISG20 0.012599 -4.3047 
Q13547 HDAC1 0.013085 -4.25698 
P68431 H3C1 0.013131 -4.25261 
Q13098 GPS1 0.013437 4.223782 
P61758 VBP1 0.014133 -4.16106 
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P49773 HINT1 0.014288 -4.1476 
P67812 SEC11A 0.014403 -4.13774 
Q9UL25 RAB21 0.015146 -4.07614 
P08174 CD55 0.015383 -4.0573 
Q96S97 MYADM 0.015659 -4.03572 
P60228 EIF3E 0.015752 -4.0286 
P14678 SNRPB 0.016904 -3.94392 
Q9UHB6 LIMA1 0.017461 -3.90541 
P62913 RPL11 0.017514 3.901823 
Q15637 SF1 0.017994 -3.86994 
Q5T9A4 ATAD3B 0.018104 -3.86282 
P29992 GNA11 0.018214 3.855679 
P17936 IGFBP3 0.019169 -3.79602 
O00622 CCN1 0.019274 -3.78969 
P00450 CP 0.019582 3.771305 
P08758 ANXA5 0.019871 3.754414 
P27348 YWHAQ 0.01995 3.749816 
P49591 SARS1 0.020372 3.725744 
Q8TCT9 HM13 0.020929 -3.69487 
P62280 RPS11 0.020939 -3.69433 
Q8IXQ6 PARP9 0.021497 -3.66441 
O95302 FKBP9 0.024072 3.537306 
P23396 RPS3 0.024587 -3.51382 
Q08257 CRYZ 0.025097 3.491142 
P39023 RPL3 0.025697 -3.46516 
Q96T51 RUFY1 0.025815 -3.4601 
P09622 DLD 0.025958 -3.45408 
Q96QK1 VPS35 0.026461 3.433089 
Q9BXJ9 NAA15 0.026874 -3.41621 
P35354 PTGS2 0.027714 -3.38277 
Q9H488 POFUT1 0.028009 -3.37136 
P07741 APRT 0.028046 -3.36992 
P43490 NAMPT 0.028548 3.350769 
P16615 ATP2A2 0.031647 -3.24089 
P18510 IL1RN 0.032101 -3.22588 
P36222 CHI3L1 0.032672 3.20734 
Q15758 SLC1A5 0.032701 3.2064 
Q9H4F8 SMOC1 0.032887 -3.20044 
Q9Y6K5 OAS3 0.033132 -3.19267 
Q9BRF8 CPPED1 0.034055 3.163939 
P0DP23 CALM1 0.034057 -3.16388 
P63104 YWHAZ 0.034853 3.139847 
P31689 DNAJA1 0.03669 -3.08676 
Q9NS69 TOMM22 0.037337 -3.06879 
P36578 RPL4 0.03775 -3.05751 
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Q13526 PIN1 0.03814 -3.04699 
Q9BTV4 TMEM43 0.039491 3.011527 
Q01469 FABP5 0.041955 -2.95034 
O95373 IPO7 0.042596 -2.9351 
Q14103 HNRNPD 0.044061 -2.90128 
Q9Y3A5 SBDS 0.044124 -2.89985 
O00410 IPO5 0.0442 -2.89816 
P60842 EIF4A1 0.044666 -2.88771 
P08754 GNAI3 0.045856 2.861581 
P25398 RPS12 0.045998 -2.85853 
Q96A26 FAM162A 0.04622 -2.85375 
Q9Y2W1 THRAP3 0.046755 -2.84238 
Q05519 SRSF11 0.046876 -2.83983 
P35268 RPL22 0.047159 -2.83388 
Q96A72 MAGOHB 0.047517 -2.82642 
E9PAV3 NACA 0.047521 2.826351 
Q4ZHG4 FNDC1 0.049184 -2.79255 
P12814 ACTN1 0.049379 2.788674 




Analysis Name: Mimic vs Control-mimic 
Analysis Creation Date: 2021-02-20 
Build version: exported 


















Name p-value Overlap 
EIF2 Signaling 1,90E-07 4,0 % 9/224 
Regulation of eIF4 and p70S6K Signaling 4,38E-04 3,0 % 5/166 
Calcium Transport I 6,34E-04 20,0 % 2/10 
IGF-1 Signaling 6,78E-04 3,8 % 4/104 
Apelin Endothelial Signaling Pathway 9,88E-04 3,5 % 4/115 
Experiment Metadata 
Analysis Settings 
Top Canonical Pathways 













Name p-value Predicted Activation 


































Diseases and Disorders 
Top Upstream Regulators 







Name p-value range # Molecules 
Cancer 3,81E-03 - 5,09E-08 85 
Organismal Injury and Abnormalities 3,81E-03 - 5,09E-08 86 
Tumor Morphology 3,32E-03 - 5,09E-08 18 
Dermatological Diseases and Conditions 3,81E-03 - 2,84E-07 23 
Reproductive System Disease 3,81E-03 - 9,90E-07 58 
 








RNA Damage and Repair 4,10E-10 - 2,66E-11 10 
Protein Synthesis 5,75E-05 - 7,57E-11 28 
Cell Death and Survival 3,81E-03 - 5,09E-08 46 
Cellular Development 3,81E-03 - 5,21E-08 37 
Cellular Growth and Proliferation 3,81E-03 - 5,21E-08 36 
 








Skeletal and Muscular System Development and Function 3,81E-03 - 1,46E-06 14 
Organ Development 3,81E-03 - 1,87E-06 13 
Tissue Development 3,81E-03 - 1,87E-06 27 
Cardiovascular System Development and Function 3,81E-03 - 5,97E-06 17 
Organismal Development 3,81E-03 - 5,97E-06 27 















Name p-value range # Molecules 
Decreased Levels of Albumin 4,48E-02 - 8,32E-03 2 
Increased Levels of Albumin 2,27E-02 - 2,27E-02 1 
Increased Levels of Creatinine 5,57E-02 - 2,27E-02 2 
Increased Levels of Hematocrit 4,64E-02 - 4,64E-02 2 










Cardiac Arrythmia 1,87E-01 - 4,18E-04 7 
Cardiac Stenosis 4,48E-02 - 9,25E-04 3 
Cardiac Dilation 2,58E-01 - 3,81E-03 5 
Cardiac Enlargement 3,39E-01 - 3,81E-03 7 




Top Tox Functions 




Name p-value range # Molecules 
Liver Hemorrhaging 5,83E-03 - 3,81E-03 2 
Hepatocellular carcinoma 3,54E-01 - 4,24E-03 16 
Liver Hyperplasia/Hyperproliferation 3,54E-01 - 4,24E-03 41 
Liver Cholestasis 2,27E-02 - 1,52E-02 1 










Renal Enlargement 2,64E-02 - 8,38E-06 4 
Renal Atrophy 3,01E-02 - 6,78E-05 3 
Renal Inflammation 2,15E-01 - 6,34E-04 5 
Renal Nephritis 2,15E-01 - 6,34E-04 5 
Renal Damage 1,22E-01 - 7,89E-04 8 










1 LARP1 Cell death of osteosarcoma cells -4,082 
Top Networks   





RNA Damage and 
Score 












4 Tissue Development, 22 
Cancer 












Name p-value Overlap 
 
Renal Necrosis/Cell Death 2,35E-03 1,3 % 8/613 
Genes associated with Chronic Allograft 
Nephropathy (Human) 
2,88E-03 9,5 % 2/21 
Cardiac Necrosis/Cell Death 6,42E-03 1,6 % 5/307 
Decreases Depolarization of Mitochondria 
and Mitochondrial Membrane 






Top Tox Lists 









3,8 % 2/52 





















Molecules Expr. Value Chart 
G6PD 11,540  
KLC1 5,500  
C1S 5,462  
MMP2 5,083  
FTL 4,962  
DDRGK1 4,935  
VDAC1 4,923  
HSD17B4 4,568  
GJA1 4,500  
AKR1A1 4,474  
 
Expr Log Ratio 
  
Top My Lists 
Top My Pathways 
Top Analysis-Ready Molecules 







Molecules Expr. Value Chart 
COPG1 -9,340  
CCT4 -5,797  
TOP1 -5,419  
LUC7L2 -5,379  
SQOR -4,733  
AHSA1 -4,551  
NONO -4,529  
COLGALT1 -4,443  
ISG20 -4,305  




B. Inhibitor vs Control-inhibitor comparison 
 
Protein ID Gene Name P value T-statistic 
Q00653 RTCB 0.000251908 12.28835438 
P83731 PSMA7 0.001065084 8.469575083 
Q9UQ35 SUCLG1 0.001108887 8.380726513 
Q92544 RPS14 0.001337117 7.979125686 
P46779 DPM3 0.001591248 7.621415253 
Q96PK6 PCNA 0.002557425 6.717220544 
P28070 RPL24 0.003801506 -6.034610437 
Q9H3P7 CZIB 0.003919213 5.984625312 
P61970 DIABLO 0.004349442 -5.816480827 
Q969V3 PPP2R1A 0.007511386 4.996052903 
Q9P2X0 FBL 0.008635439 4.802016541 
O14818 PABPC4 0.010496386 -4.540090438 
P62241 ARL3 0.010705504 4.514216211 
Q6RW13 RPS8 0.010790073 4.503925891 
Q9NTK5 PSMD10 0.013018177 4.263413144 
Q96HS1 CYFIP1 0.013899665 -4.181660869 
Q9Y3U8 COASY 0.014343976 4.142790024 
P52565 SRSF3 0.014381598 -4.139565433 
Q8NE71 RPS4X 0.014632643 4.118305436 
P53597 TAP1 0.016579706 3.967037805 
Q13057 FLOT1 0.017125741 -3.928422169 
O15372 ACBD3 0.017299555 3.916439265 
P54920 SRRM2 0.01823709 3.854204449 
P62263 AGTRAP 0.018965309 3.808454163 
Q96AE4 RPL36 0.021263801 3.676791799 
Q9Y3C8 ATP13A1 0.022939718 3.591080103 
Q7L576 NUTF2 0.023043737 3.58600809 
Q9Y3I0 PRKRA 0.02372768 3.553324049 
O75569 EIF3H 0.025360874 3.479614385 
Q14247 PSMB4 0.02560612 3.469034257 
O60784 OXSR1 0.027999361 3.371709973 
O95747 CTTN 0.029434239 3.317972057 
Q13310 S100A6 0.030412006 3.283099137 
Q03518 TOM1 0.030611964 -3.27613065 
O75955 UFC1 0.031447202 3.247593376 
Q9HD20 CSTB 0.03253923 -3.211603675 
P22087 PGAM5 0.033745974 3.17345373 
P30153 ARHGDIA 0.033859545 3.169946259 
Q9NWV4 SSBP1 0.034116629 3.162057514 
P62753 NCLN 0.035792278 3.112295836 
O75832 NAPA 0.037864224 3.054421691 




Q04837 RPS6 0.039912623 3.000745357 
P62701 FUBP1 0.040557684 2.984506937 
O43681 RBM14 0.040745867 2.979826568 
P84103 OLA1 0.042144184 2.945821145 
P12004 TM9SF4 0.04304244 2.924664305 
Q9NR28 GET3 0.043275804 -2.919252059 
P06703 ABCF1 0.046067123 2.857036148 





Analysis Name: Inhibitor vs Control-inhibitor 
Analysis Creation Date: 2021-02-20 
Build version: exported 


















Name p-value Overlap 
EIF2 Signaling 2,87E-08 3,6 % 8/224 
Regulation of eIF4 and p70S6K Signaling 1,65E-06 3,6 % 6/166 
mTOR Signaling 6,42E-06 2,9 % 6/210 
Coronavirus Pathogenesis Pathway 1,92E-05 3,3 % 5/150 
Ceramide Signaling 9,53E-04 3,4 % 3/88 
Experiment Metadata 
Analysis Settings 
Top Canonical Pathways 




















































Diseases and Disorders 
Top Upstream Regulators 







Name p-value range # Molecules 
Neurological Disease 4,33E-02 - 1,59E-04 20 
Organismal Injury and Abnormalities 4,92E-02 - 1,59E-04 50 
Psychological Disorders 2,60E-02 - 1,59E-04 12 
Skeletal and Muscular Disorders 1,31E-02 - 7,80E-04 16 
Developmental Disorder 4,92E-02 - 7,94E-04 17 
 








Protein Synthesis 3,62E-02 - 2,74E-11 20 
RNA Damage and Repair 2,23E-02 - 1,10E-10 13 
Gene Expression 1,01E-02 - 4,65E-07 12 
Cell Death and Survival 4,92E-02 - 8,49E-05 26 
Cellular Assembly and Organization 4,92E-02 - 1,68E-04 16 
 








Nervous System Development and Function 4,92E-02 - 2,56E-04 11 
Tissue Morphology 4,92E-02 - 2,56E-04 15 
Embryonic Development 4,92E-02 - 1,06E-03 13 
Cardiovascular System Development and Function 4,92E-02 - 2,19E-03 3 
Connective Tissue Development and Function 3,92E-02 - 2,19E-03 10 















Name p-value range # Molecules 
Increased Levels of Creatinine 3,24E-02 - 3,24E-02 1 










Cardiac Fibrosis 1,96E-02 - 1,96E-02 1 
Heart Failure 2,38E-02 - 2,38E-02 1 
Cardiac Dilation 6,58E-02 - 6,58E-02 1 
Cardiac Enlargement 3,59E-01 - 6,58E-02 3 










Liver Cirrhosis 1,96E-02 - 1,96E-02 1 
Liver Fibrosis 1,96E-02 - 1,96E-02 1 
Top Tox Functions 




Liver Hyperplasia/Hyperproliferation 1,00E00 - 5,34E-02 22 










Nephrosis 1,09E-02 - 2,19E-03 1 
Renal Degeneration 4,38E-03 - 4,38E-03 1 
Glomerular Injury 3,46E-01 - 6,56E-03 1 
Renal Hypoplasia 6,56E-03 - 6,56E-03 1 
Renal Dilation 1,09E-02 - 1,09E-02 1 










RNA Damage and 
Score 
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Cell Cycle, Cancer, 



























Expr Log Ratio 
Nongenotoxic Hepatocarcinogenicity 4,71E-02 4,5 % 1/22 
Decreases Depolarization of Mitochondria 6,99E-02 3,0 % 1/33 
Hepatic Stellate Cell Activation 7,40E-02 2,9 % 1/35 
Pro-Apoptosis 8,81E-02 2,4 % 1/42 
Oxidative Stress 1,18E-01 1,8 % 1/57 
 
Top Tox Lists 
Top My Lists 
Top My Pathways 
Top Analysis-Ready Molecules 




Molecules Expr. Value Chart 
NFKB2 12,288  
RPL24 8,470  
SRRM2 8,381  
TM9SF4 7,979  
RPL28 7,621  
RBM14 6,717  
ACBD3 5,985  
NCLN 4,996  
DPM3 4,802  
RPS8 4,514  
 






Molecules Expr. Value Chart 
PSMB4 -6,035  
NUTF2 -5,816  
PSMA7 -4,540  
PGAM5 -4,182  
ARHGDIA -4,140  
COASY -3,928  
TAP1 -3,276  
ATP13A1 -3,212  
DIABLO -2,919  




Appendix to Chapter 6 
 
Small RNA-Seq analysis between young healthy and old healthy equine chondrocytes 
identified a set of differentially expressed miRNAs. This dataset was coupled to 
differentially expressed mRNAs from our group’s RNA-Seq experiment in young and 
old equine cartilage (Peffers, Liu, & Clegg, 2013). miRNA-mRNA pairs were uploaded 
in IPA and Core Analysis was undertaken for identification of significant biological 
pathways. The IPA Core Analysis report generated is included here. Moreover, 
results described in Chapter 6 are included in the published research article: Small 
Non-Coding RNAome of Ageing Chondrocytes (Balaskas et al., 2020). The article is 
included at the end of this Appendix. 
 
 
Balaskas, P., Green, J. A., Haqqi, T. M., Dyer, P., Kharaz, Y. A., Fang, Y., . . . Peffers, 
M. J. (2020). Small Non-Coding RNAome of Ageing Chondrocytes. Int J Mol 
Sci, 21(16). doi:10.3390/ijms21165675 
Peffers, M., Liu, X., & Clegg, P. (2013). Transcriptomic signatures in cartilage ageing. 
Arthritis Res Ther, 15(4), R98. doi:10.1186/ar4278 
 
Analysis Name: Young vs old equine chondrocytes
Analysis Creation Date: 2020-05-23 
Build version: exported 
Content version: 51963813 (Release Date: 2020-03-11) 
Name Value 
Reference set: Ingenuity Knowledge Base (Genes Only) 
Relationship to include: Direct and Indirect 
Includes Endogenous Chemicals 
Optional Analyses: My Pathways My List 
Filter Summary: 
Consider only molecules and/or relationships where 
(species = Rat OR Human OR Uncategorized OR Mouse) AND 
(confidence = Experimentally Observed) AND 
(tissues/cell lines = Large Intestine OR A2780 OR White Matter OR INS-1 OR Melanoma Cell Lines not otherwise specified OR Myeloma Cell 
Lines not otherwise specified OR CD34+ cells OR Placenta OR Corpus Callosum OR Lymph node OR Other Dendritic cells OR Cornea OR 
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Neutrophils OR Plasma cells OR Granule cells OR Cytotoxic T cells OR Forestomach OR Th2 cells OR Vd2 Gamma-delta T cells OR Nucleus 
Accumbens OR U2OS OR Granulocytes not otherwise specified OR Striatum OR Trigeminal Ganglion OR NCI-H226 OR M14 OR Other 
Pancreatic Cancer Cell Lines OR HCT-15 OR THP-1 OR Murine NKT cells OR CCRF-CEM OR DU-145 OR Monocytes not otherwise specified 
OR T47-D OR Hep3B OR Other Immune cell lines OR Peritoneal macrophages OR Prostate Gland OR Splenocytes OR Subventricular Zone OR 
J774 OR LNCaP cells OR HOP-62 OR OVCAR-5 OR Bone marrow cells not otherwise specified OR Other Kidney Cancer Cell Lines OR 
Embryonic stem cells OR KM-12 OR Jurkat OR HUVEC cells OR Central memory helper T cells OR Esophagus OR Thymocytes OR 
Hypothalamus OR Breast Cancer Cell Lines not otherwise specified OR Olfactory Bulb OR Other Endothelial cells OR HeLa OR Keratinocytes 
OR NIH/3T3 cells OR Memory T lymphocytes not otherwise specified OR Other Smooth muscle cells OR U87MG OR SK-OV-3 OR Cervical 
cancer cell line not otherwise specified OR Other CNS Cell Lines OR Sertoli cells OR Effector memory helper T cells OR Kidney cell lines not 
otherwise specified OR Macrophage Cancer Cell Lines not otherwise specified OR Pheochromocytoma cell lines not otherwise specified OR 
Hepatocytes OR Other Tissues and Primary Cells OR RAW 264.7 OR SK-N-SH OR Skin OR Smooth muscle cells not otherwise specified OR 
Lung Cancer Cell Lines not otherwise specified OR Neurons not otherwise specified OR SNB-75 OR Organ Systems not otherwise specified OR 
Pre-B lymphocytes OR Other Osteosarcoma Cell Lines OR Spinal Cord OR HS 578T OR BT-474 OR Bone marrow-derived dendritic cells OR 
Lymphoma Cell Lines not otherwise specified OR Granule Cell Layer OR Other Ovarian Cancer Cell Lines OR Ovary OR B lymphocytes not 
otherwise specified OR Intraepithelial T lymphocytes OR Lung OR 3T3-L1 cells OR Mononuclear leukocytes not otherwise specified OR 
Adipocytes OR CD56bright NK cells OR TK-10 OR Immature monocyte-derived dendritic cells OR Ventricular Zone OR Neuroblastoma Cell 
Lines not otherwise specified OR NCI-H332M OR Cardiomyocytes OR Nervous System not otherwise specified OR Peripheral blood monocytes 
OR Brain OR Hepatoma Cell Lines not otherwise specified OR Hippocampus OR BA/F3 OR RXF-393 OR NT2/D1 OR Other Nervous System 
OR Activated CD56dim NK cells OR Activated Vd1 Gamma-delta T cells OR Other Prostate Cancer Cell Lines OR PC-12 cells OR SK-MEL-5 
OR Naive helper T cells OR NCI-H23 OR Bladder OR Other Kidney cell lines OR Beta islet cells OR Cell Line not otherwise specified OR Cos-7 
cells OR Amygdala OR Melanocytes OR Peripheral blood leukocytes not otherwise specified OR Medulla Oblongata OR Granulosa cells OR 
Lens OR Central memory cytotoxic T cells OR Monocyte-derived dendritic cells not otherwise specified OR Uterus OR 786-0 OR Macrophages 
not otherwise specified OR T lymphocytes not otherwise specified OR Other Monocyte-derived dendritic cells OR Astrocytes OR Min6 OR 
Salivary Gland OR BDCA-3+ dendritic cells OR Immune cell lines not otherwise specified OR Choroid Plexus OR Chondrocytes OR Other Cells 
OR Small Intestine OR MDA-MB-231 OR Other Bone marrow cells OR RKO OR UACC-257 OR Brainstem OR Tissues and Primary Cells not 
otherwise specified OR RBL-2H3 OR Other Peripheral blood leukocytes OR BDCA-1+ dendritic cells OR K-562 OR CAKI-1 OR Liver OR Sciatic 
Nerve OR Parietal Lobe OR Crypt OR EKVX OR MOLT-4 OR Dermis OR A375 OR Memory B cells OR Thyroid Gland OR Activated Vd2 
Gamma-delta T cells OR PC-3 OR Cerebellum OR Calvaria OR A549-ATCC OR HOP-92 OR LOX IMVI OR Cartilage Tissue OR CD4+ T- 
lymphocytes OR Natural T-regulatory cells OR Colon Cancer Cell Lines not otherwise specified OR NB4 OR MCF7 OR Myeloid dendritic cells 
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OR Pyramidal neurons OR Other Neuroblastoma Cell Lines OR Other Macrophages OR NK cells not otherwise specified OR Substantia Nigra 
OR UACC-62 OR Naive B cells OR Osteoblasts OR Mammary Gland OR CNS Cell Lines not otherwise specified OR Other Teratocarcinoma 
Cell Lines OR Other T lymphocytes OR Effector memory RA+ cytotoxic T cells OR Adrenal Gland OR MG-63 OR Ovarian Cancer Cell Lines not 
otherwise specified OR PBMCs OR RPMI-8266 OR Gray Matter OR Fibroblast cell lines not otherwise specified OR Heart OR Stem cells not 
otherwise specified OR Testis OR Other Melanoma Cell Lines OR Smooth Muscle OR MEF cells OR Eosinophils OR Other Fibroblast cell lines 
OR 293 cells OR Vd1 Gamma-delta T cells OR SF-268 OR Cortical neurons OR Megakaryocytes OR Caco2 cells OR MDA-MB-435 OR Kidney 
OR Pro-B lymphocytes OR Epithelial cells not otherwise specified OR Oocytes OR Other Lymphocytes OR Other NK cells OR SK-MEL-2 OR 
MDA-N OR Other Epithelial cells OR Other B lymphocytes OR HepG2 OR NCI-ADR-RES OR U266 OR Microvascular endothelial cells OR 
MDA-MB-468 OR Trachea OR SF-295 OR A498 OR Stomach OR Other Immune cells OR HCC-2998 OR Mesenchymal stem cells OR Effector 
T cells OR Dendritic cells not otherwise specified OR ACHN OR Other Cervical cancer cell line OR Putamen OR Teratocarcinoma Cell Lines not 
otherwise specified OR Lymphocytes not otherwise specified OR Th17 cells OR Kidney Cancer Cell Lines not otherwise specified OR 
Plasmacytoid dendritic cells OR Other Mononuclear leukocytes OR SW-620 OR Monocyte-derived macrophage OR Endothelial cells not 
otherwise specified OR Retina OR HT29 OR IGROV1 OR OVCAR-3 OR Immune cells not otherwise specified OR Other Pheochromocytoma 
cell lines OR Other Granulocytes OR Other Neurons OR Other Colon Cancer Cell Lines OR Mature monocyte-derived dendritic cells OR 
Activated CD56bright NK cells OR Langerhans cells OR Thalamus OR Other Leukemia Cell Lines OR Purkinje cells OR Spleen OR SF-539 OR 
WEHI-231 OR Leukemia Cell Lines not otherwise specified OR Other Breast Cancer Cell Lines OR Dorsal Root Ganglion OR Vascular smooth 
muscle cells OR Prostate Cancer Cell Lines not otherwise specified OR Other Memory T lymphocytes OR Cerebral Ventricles OR HMC-1 OR 
Bone marrow-derived macrophages OR OVCAR-4 OR Cerebral Cortex OR HCT-116 OR UO-31 OR OVCAR-8 OR Pancreatic Cancer Cell Lines 
not otherwise specified OR SW-480 OR Other Stem cells OR CD56dim NK cells OR Other Lymphoma Cell Lines OR SK-MEL-28 OR Caudate 
Nucleus OR Mast cells OR HuH7 OR PANC-1 OR Other Hepatoma Cell Lines OR Epidermis OR J-774A.1 OR Cells not otherwise specified OR 
Thymus OR U251 OR HL-60 OR Effector memory cytotoxic T cells OR Adipose OR Th1 cells OR SR OR Peripheral blood lymphocytes OR BT- 
549 OR Other Myeloma Cell Lines OR Microglia OR Other Lung Cancer Cell Lines OR NCI-H522 OR Pancreas OR Swiss 3T3 cells OR 
Osteosarcoma Cell Lines not otherwise specified OR Other Organ Systems OR MALME-3M OR Pituitary Gland OR Other Monocytes OR HEL 
OR Other Cell Line OR Fibroblasts OR Other Macrophage Cancer Cell Lines OR Blood platelets OR SN12C OR Activated helper T cells) AND 
(mol. types = biologic drug OR canonical pathway OR chemical - endogenous mammalian OR chemical - endogenous non-mammalian OR 
chemical - kinase inhibitor OR chemical - other OR chemical - protease inhibitor OR chemical drug OR chemical reagent OR chemical toxicant 
OR complex OR cytokine OR disease OR enzyme OR function OR fusion gene/product OR G-protein coupled receptor OR group OR growth 
factor OR ion channel OR kinase OR ligand-dependent nuclear receptor OR mature microRNA OR microRNA OR other OR peptidase OR 
phosphatase OR transcription regulator OR translation regulator OR transmembrane receptor OR transporter) AND 
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(data sources = An Open Access Database of Genome-wide Association Results OR BIND OR BioGRID OR Catalogue Of Somatic Mutations In 
Cancer (COSMIC) OR Chemical Carcinogenesis Research Information System (CCRIS) OR ClinicalTrials.gov OR ClinVar OR Cognia OR DIP 
OR DrugBank OR Gene Ontology (GO) OR GVK Biosciences OR Hazardous Substances Data Bank (HSDB) OR HumanCyc OR Ingenuity 
Expert Findings OR Ingenuity ExpertAssist Findings OR IntAct OR Interactome studies OR MIPS OR miRBase OR miRecords OR Mouse 
Genome Database (MGD) OR Obesity Gene Map Database OR Online Mendelian Inheritance in Man (OMIM) OR TarBase OR TargetScan 
Human) 
Name p-value Overlap 
Activation 
Chondrocytes in Rheumatoid Arthritis 
Upstream Regulators 





Hepatic Fibrosis / Hepatic Stellate Cell 1,15E-04 2,2 % 4/186 
Role of Osteoblasts, Osteoclasts and 2,20E-04 1,8 % 4/220 
Axonal Guidance Signaling 4,63E-04 1,0 % 5/484 
GP6 Signaling Pathway 5,67E-04 2,5 % 3/119 
Hepatic Fibrosis Signaling Pathway 1,51E-03 1,1 % 4/368 
Top Canonical Pathways 
Top Upstream Regulators 
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Top Diseases and Bio Functions 
Diseases and Disorders 
Name p-value range # Molecules 
Skeletal and Muscular Disorders 1,50E-03 - 1,22E-09 16 
Connective Tissue Disorders 1,50E-03 - 3,52E-08 16 
Organismal Injury and Abnormalities 1,50E-03 - 3,52E-08 31 
Cancer 1,49E-03 - 5,30E-07 31 
Developmental Disorder 1,37E-03 - 5,30E-07 17 
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Molecular and Cellular Functions 
Name p-value range # Molecules 
Cellular Movement 1,41E-03 - 4,23E-10 21 
Cell Morphology 1,37E-03 - 3,52E-08 16 
Cellular Development 1,42E-03 - 4,94E-07 24 
Cell Death and Survival 1,37E-03 - 1,08E-05 18 
Cell-To-Cell Signaling and Interaction 1,37E-03 - 1,88E-05 20 
Physiological System Development and Function 
Name p-value range # Molecules 
Embryonic Development 1,37E-03 - 6,19E-09 20 
Organismal Development 1,50E-03 - 6,19E-09 24 
Cardiovascular System Development and Function 1,37E-03 - 2,51E-08 13 
Connective Tissue Development and Function 1,50E-03 - 3,52E-08 15 
Skeletal and Muscular System Development and Function 1,50E-03 - 3,52E-08 15 
Top Tox Functions 
Assays: Clinical Chemistry and Hematology 
Name p-value range # Molecules 
Increased Levels of Alkaline Phosphatase 6,81E-03 - 4,34E-03 2 
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Decreased Levels of Albumin 8,16E-03 - 8,16E-03 1 
Cardiotoxicity 
Name p-value range # Molecules 
Cardiac Stenosis 1,63E-02 - 1,40E-06 4 
Cardiac Dysfunction 9,51E-02 - 8,01E-04 4 
Congenital Heart Anomaly 4,67E-02 - 4,09E-03 3 
Cardiac Transformation 5,45E-03 - 5,45E-03 1 
Cardiac Arrythmia 2,20E-01 - 1,14E-02 3 
Hepatotoxicity 
Name p-value range # Molecules 
Congestion of liver 2,73E-03 - 2,73E-03 1 
Hepatocellular carcinoma 1,02E-01 - 1,36E-02 4 
Liver Hyperplasia/Hyperproliferation 1,02E-01 - 1,36E-02 15 
Liver Inflammation/Hepatitis 1,02E-01 - 2,22E-02 3 
Liver Proliferation 2,24E-01 - 4,17E-02 2 
Nephrotoxicity 
Name p-value range # Molecules 
Renal Inflammation 1,37E-03 - 1,37E-03 1 
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Renal Nephritis 1,37E-03 - 1,37E-03 1 
Renal Necrosis/Cell Death 3,44E-01 - 4,43E-03 5 
Renal Hypoplasia 5,84E-02 - 4,70E-03 2 
Glomerular Injury 4,54E-02 - 5,45E-03 2 
Top Regulator Effect Networks 
ID Regulators Disease & Functions Consistency Score 
1 CEBPA Invasion of cells,Invasion of tissue 3,5 
2 IL4 Cell proliferation of tumor cell lines 1,789 
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Name p-value Overlap 
Renal Necrosis/Cell Death 1,04E-03 0,9 % 5/579 
VDR/RXR Activation 5,08E-03 2,6 % 2/78 
Protection from Hypoxia-induced Renal 
Ischemic Injury (Rat) 
5,45E-03 25,0 % 1/4 
Hepatic Fibrosis 1,09E-02 1,7 % 2/116 
Recovery from Ischemic Acute Renal 
Failure (Rat) 
1,89E-02 7,1 % 1/14 
Top My Lists 
Top Tox Lists 
Top My Pathways 
Top Analysis-Ready Molecules 
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Abstract: Ageing is a leading risk factor predisposing cartilage to osteoarthritis. However, little
research has been conducted on the effect of ageing on the expression of small non-coding
RNAs (sncRNAs). RNA from young and old chondrocytes from macroscopically normal equine
metacarpophalangeal joints was extracted and subjected to small RNA sequencing (RNA-seq).
Differential expression analysis was performed in R using package DESeq2. For transfer RNA
(tRNA) fragment analysis, tRNA reads were aligned to horse tRNA sequences using Bowtie2 version
2.2.5. Selected microRNA (miRNAs or miRs) and small nucleolar RNA (snoRNA) findings were
validated using real-time quantitative Polymerase Chain Reaction (qRT-PCR) in an extended cohort
of equine chondrocytes. tRNA fragments were further investigated in low- and high-grade OA
human cartilage tissue. In total, 83 sncRNAs were differentially expressed between young and old
equine chondrocytes, including miRNAs, snoRNAs, small nuclear RNAs (snRNAs), and tRNAs.
qRT-PCR analysis confirmed findings. tRNA fragment analysis revealed that tRNA halves (tiRNAs),
tiRNA-5035-GluCTC and tiRNA-5031-GluCTC-1 were reduced in both high grade OA human
cartilage and old equine chondrocytes. For the first time, we have measured the effect of ageing on
the expression of sncRNAs in equine chondrocytes. Changes were detected in a number of different
sncRNA species. This study supports a role for sncRNAs in ageing cartilage and their potential
involvement in age-related cartilage diseases.
Keywords: chondrocyte; ageing; equine; small non-coding RNA
1. Introduction
Articular cartilage is a specialised connective tissue of diarthrodial joints. Its smooth lubricated
surface assists joint movement and its mechanical properties facilitate load bearing in the joint. The
tissue harbours one cell type; the chondrocyte, and is devoid of blood vessels and nerves, receiving
nutrients from synovial fluid and subchondral bone [1]. Articular cartilage is characterised by an
extracellular matrix (ECM) consisting of mainly collagen type 2 and proteoglycans, which give the
tissue many of its properties. After reaching maturity, cartilage displays a limited repairing capacity as
indicated by low chondrocyte proliferation and low collagen turnover [2].
There are a number of factors affecting the homeostatic properties of cartilage such as genetics
and obesity [3]. However, ageing is a leading risk factor that predisposes cartilage to pathological
changes and disease, such as osteoarthritis (OA), the most common joint disease [3]. These age-related
Int. J. Mol. Sci. 2020, 21, 5675; doi:10.3390/ijms21165675 www.mdpi.com/journal/ijms
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changes affect both chondrocyte physiology and ECM properties. Aged chondrocytes display increased
senescence and higher expression of catabolic markers; features also evident in OA chondrocytes [3,4].
Moreover, in humans, aged knee cartilage is thinner compared to younger cartilage and is characterised
by increased collagen crosslinking and altered proteoglycan content. These changes affect matrix
stiffness, make cartilage susceptible to fractures and lower its ability to sense mechanical stimuli [3,5,6].
The exact mechanisms through which age can affect cartilage health remain elusive, though
it is believed to be a cumulative combination of many molecular pathways rather than a single
aetiology. Recent advances in the field have recognised epigenetics in ageing and diseased articular
cartilage as an area of growing interest [6,7]. A class of epigenetic modifications that have attracted
increasing attention are small non-coding RNAs (sncRNAs). They are short, typically <200 bp, RNA
species, which are not translated into protein but have other structural or regulatory biological roles.
These include microRNAs (miRNAs or miRs), small nuclear RNAs (snRNAs), small nucleolar RNAs
(snoRNAs), piwi-interacting RNAs and transfer RNAs (tRNAs). SncRNAs are promising candidates
for targeted therapeutics due to their small size and diverse cellular functions. By using specific
synthetic oligonucleotides, aberrant expression of sncRNAs in disease could be modified, resulting in
delay or reversal of pathological changes [8]. Furthermore, sncRNAs could be used as biomarkers to
monitor disease initiation and progression or response to treatment [9,10]. This is of high importance
in OA, as treatment is currently symptomatic and most patients with end-stage OA require joint
replacement; a procedure with a high social and economic burden for patients and the healthcare
system respectively [11].
MiRNAs, the most studied sncRNAs, regulate gene expression by binding complementary
sequences in the 3’ untranslated region of their messenger RNA (mRNA) targets, thus inhibiting mRNA
translation [8]. MiRNAs have been linked to ageing and diseased cartilage; miR-140 is important for
cartilage development and deletion of miR-140 in mice causes skeletal defects [12]. Moreover, OA
chondrocytes show decreased expression of miR-24, resulting in increased expression of the senescent
marker p16INK4a, highlighting the link between OA and senescence; a hallmark of ageing [4].
In addition to miRNAs, snoRNAs are increasingly studied in ageing and OA. Snora73 expression
increases in the joint and serum of old mice compared to young mice [9] and we have also previously
identified a catalogue of age-related snoRNAs in human knee cartilage [13]. SnoRNAs have canonical
roles in the post transcriptional modification of RNA substrates including ribosomal RNAs, and
mRNAs, but can also exhibit non-canonical functions such as miRNA-like activity [14]. Their aberrant
expression has also been associated with the development of some diseases [15]. Our previously
conducted mouse study demonstrated alterations in the snoRNA profile of young, old and OA joints
in mice when compared to healthy controls, highlighting the potential of snoRNAs to be used as
novel markers for this disease [9]. We have also identified changing snoRNA profiles in ageing and
OA human cartilage [16], synovial fluid from horses with early OA and diseased anterior cruciate
ligaments from OA joints [17].
tRNAs are adaptor molecules of ~73–90 nucleotides long consisting of a T-loop, D-loop, variable
loop, and the anticodon loop. Protein translation requires amino acids to be linked together into
polypeptides and tRNAs recruit these amino acids to the translating ribosome. Recent studies have
shown that tRNAs are a major source of sncRNAs with an active role in gene regulation [18]. tRNA
fragments result from specific processing of tRNAs. These include tRNA halves (tiRNAs), which are
28–36 nucleotide long fragments formed by Angiogenin (ANG). ANG divides the tRNA into two
halves at the anticodon loop [19] giving rise to the 3′ tiRNA and 5′ tiRNA halves. tRNAs are also
processed into smaller fragments; tRNA-derived small RNA fragments (tRFs); tRF-1, tRF-2, tRF-3 and
tRF-5, however the naming conventions of these classes is still not consistent [20]. RNase Z, or its
cytoplasmic homologue ELAC2, [21] cleaves the 3′ trailer fragment of pre-tRNAs resulting in tRF-1
formation. The enzyme responsible for the cleavage of tRF-2 fragments is still unclear. The tRF-2
fragment consists of the anticodon loop of the tRNA and has been detected in breast cancer MDA-231
cells [22]. Dicer and ANG cleave tRNAs into ~15–30 nucleotide tRF-3 and tRF-5 fragments. TRF-3
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fragments are cleaved at the T loop by Dicer [23] and ANG [24] and tRF-5 fragments are derived from
the cleavage of the D-loop by Dicer [23]. The final category of tRFs are i-tRFs, which are internal to
the respective tRNA and can straddle the anticodon loop [25]. Limited knowledge of the expression
and role of tRNA and tRFs is available in health and disease [26] with even less in musculoskeletal
biology [27,28].
In this study, we investigated the expression changes of sncRNAs in chondrocytes isolated from
healthy metacarpophalangeal joints of young and old horses. Findings for tRNAs are compared to a
human OA data set. Age-related changes may predispose cartilage to disease by altering the complex
sncRNA expression profile. This provides a sncRNA-wide insight into age-related targets for future
therapeutic approaches.
2. Materials and Methods
All reagents were from Thermo-Fisher-Scientific, Loughborough, UK unless stated.
2.1. Sample Collection and Preparation
Samples were collected from an abattoir as a by-product of the agricultural industry. Specifically,
the Animal (Scientific procedures) Act 1986, Schedule 2, does not define collection from these sources
as scientific procedures. Ethical approval was therefore not required. Full thickness equine cartilage
was removed from the entire surface of macroscopically normal metacarpophalangeal joints of young
n = 5 (age mean ± standard deviation; 4 ± 1 years) and old n = 5 (17.4 ± 1.9 years) non-Thoroughbred
horses. Scoring of the metacarpophalangeal joint was undertaken using a macroscopic grading system,
as previously described [29] and samples with no macroscopic perturbations were selected (combined
score of zero). Freshly isolated chondrocytes were removed from all 10 samples of harvested cartilage,
as previously described [30], plated to confluence and RNA extracted from two million cells per donor.
In addition to the above samples, RNA from chondrocytes from young n = 2 (age mean ±
standard deviation; 0.75 ± 0.3 years) and old n = 6 (age mean ± standard deviation; 19.3 ± 3.6 years)
non-Thoroughbred horses were used for validation.
2.2. RNA Isolation, cDNA Library Preparation, and Small RNA Sequencing (RNA-seq)
Total RNA including small RNAs was extracted, as previously described [31], and purified using
the miRNAeasy kit (Qiagen, Crawley, UK) according to manufacturer’s instructions and including an
on-column DNAse step to remove residual genomic DNA. The integrity of the RNA was assessed
on the Agilent 2100 Bioanalyser system using an RNA Pico chip (Agilent, Stockport, UK). The
NEBNext®Small RNA Library Prep Set for Illumina®was used for library preparation (New England
Biolabs, Ipswich, MA, USA) but with the addition of a Cap-Clip™ Acid Pyrophosphatase (Cell script,
Madison, WI, USA) step to remove potential 5′ caps found on some snoRNAs. Samples were amplified
for 15 cycles and size was selected. The libraries were sequenced on an Illumina MiSEq platform
(Illumina, San Diego, CA, USA) with version 2 chemistry using sequencing by synthesis technology to
generate 2 × 150 bp paired-end reads with >12 million clusters per run.
2.3. Data Processing
Sequence data were processed through a number of steps to obtain sncRNA expression values
including basecalling and de-multiplexing of indexed reads using CASAVA version 1.8.2 [32]; adapter
and quality trimming using Cutadapt version 1.2.1 [33] and Sickle version 1.200 to obtain fastq files of
trimmed reads; aligning reads to horse genome reference sequences (GCF_002863925.1) using Tophat
version 2.0.10 [34] with option “–g 1”; counting aligned reads using HTSeq-count against the annotated
features which are combined annotation information from the sources: NCBI Equus caballus 3.0 genome
annotation, miRBase horse micro RNA annotation, Rfam snoRNA annotation.
Differential expression analysis was performed in R environment using package DESeq2 [35].
The processes and technical details of the analysis included: assessing data variation and detecting
Int. J. Mol. Sci. 2020, 21, 5675 4 of 22
outlier samples through comparing variations of within and between sample groups using principle
component analysis (PCA) and correlation analysis; handling library size variation using the DESeq2
default method; formulating data variation using negative binomial distributions; modelling data using
a generalised linear model; computing log2 Fold Change (logFC) values for required contrasts based
on model fitting results through contrast fitting approach, evaluating the significance of estimated
logFC values by Wald test; adjusting the effects of multiple tests using False Discovery Rate (FDR)
approach to obtain FDR [36] adjusted P-values.
2.4. Pathway Analysis
In order to identify miRNA targets, bioinformatic analysis was performed by uploading
differentially expressed miRNA data into the MicroRNA Target Filter module within Ingenuity Pathway
Analysis software (IPA) (Qiagen Redwood City, CA, USA) along with previously identified differentially
expressed mRNAs from our ageing equine cartilage study following RNA-seq [31]. In IPA we selected
miRNA-target genes based on the direction of differential expression (for example, if a miRNA was
reduced in expression it was only matched to mRNAs that demonstrated increased expression). We
then identified the networks, functions, and canonical pathways of these miRNA-target genes.
2.5. qRT-PCR Validation
Validation of the small RNA-seq results was undertaken using real-time quantitative PCR
(qRT-PCR) analysis in the samples used for sequencing as well as additional samples. SncRNAs were
chosen based on level of differential expression. Total RNA was extracted and quantified as above.
cDNA was synthesized using 200 ng RNA and the miScript II RT Kit according to the manufacturer’s
protocol (Qiagen, Crawley, UK). qRT-PCR mastermix was prepared using the miScript SYBR Green
PCR Kit (Qiagen, Crawley, UK) and the appropriate miScript Primer Assay (Qiagen, Crawley, UK) (File
S1) using 1 ng/µL cDNA according to manufacturer’s guidelines. qRT-PCR was undertaken using a
LightCycler®96 system (Roche, Welwyn Garden City, UK). Relative expression levels were normalised
to U6 (as this was stable in the small RNA-seq data set) and calculated using the 2-∆Ct method [37].
2.6. tRNA Fragment Analysis
Following the alignment of trimmed reads to NCBI horse genome reference sequences (version
3.0) using Tophat version 2.1.0 [38], the candidate tRNA reads were extracted from the BAM files
according to whether they overlapped the ranges covered by tRNA features. The read pairs were
stitched into RNA fragments using PEAR (version 0.9.10) [39]. The output reads were aligned to horse
tRNA sequences (defined in NCBI GCF_002863925.1_EquCab3.0_genomic.gff) using Bowtie2 version
2.2.5. Only the perfectly mapped fragments were extracted and taken as tRNA fragments for further
explorations. Finally, statistical analyses were mainly focused on the fragment length and the mapping
start location, which generated the length distribution and the mapping start position distribution
of observed tRNA fragments, as well as the summary table for observed tRNA fragments and their
target tRNAs.
2.7. Novel snoRNA Analysis
Putative snoRNAs were detected from the raw pair-end reads using ShortStack 3.8.4 [40] with the
setting “–mincov 5”, which specifies that the clusters of small RNAs must have at least five alignments.
The ShortStack results were subsequently fed into SnoReport 2.0 [41], which uses RNA secondary
structure prediction combined with machine learning as the basis to identify the two main classes of
snoRNAs; the box H/ACA and the box C/D. Putative snoRNAs were annotated from our experimental
small RNA-seq data using ShortStack and SnoReport.
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2.8. Statistical Analysis
3D PCA score plots and heat maps were carried out using MetaboAnalyst 3.5 [42] (http://www.
metaboanalyst.ca) which uses the R package of statistical computing software [43].
For statistical evaluation of qRT-PCR results, following normality testing, Mann-Whitney tests
were performed using GraphPad Prism version 7.03 for Windows, (GraphPad Software, La Jolla, CA,
USA); p values are indicated.
2.9. Human Sample Collection and Preparation
De-identified human OA cartilage approved by Northeast Ohio Medical University (NEOMED)
Institutional Review Board and Summa Health Systems, Barberton, Ohio as ‘non-human subject study
under 45 CFR’ was used. Total RNA was extracted from smooth, macroscopically intact human OA
cartilage with a Mankin score of 2 or less (n = 1, female, 60 years old) and damaged OA cartilage with
a Mankin score of 4 or higher (n = 1, female, 80 years old) using MiRNeasy Kit (Qiagen, Germantown,
MD, USA). RNA was quantified using the Nanodrop 1000 Spectrophotometer (Thermo Fisher, Waltham,
MA, USA). TapeStation 4200 (Agilent Technologies, Santa Clara, CA, USA) was used to determine
RNA integrity using High Sensitivity RNA Screentape analysis kit (Agilent, Santa Clara, CA, USA).
2.10. Removal of tRF Modifications from Human Cartilage RNA
The rtStar™ tRF&tiRNA Pretreatment Kit (ArrayStar, Rockville, MD, USA) was used according
to the manufacture’s description. For cDNA qRT-PCR library construction, tRF modifications
were removed from RNA. The kit removes 3′-aminoacyl and 3′-cP for 3′ adaptor ligation,
phosphorylates 5′-OH for 5′-adaptor ligation, and demethylates m1A, m1G, and m3C for efficient
cDNA reverse transcription.
2.11. tRF 3′ and 5′ Adaptor Ligation for Human Cartilage cDNA Synthesis
The rtStar™ First-Strand cDNA Synthesis Kit (ArrayStar, Rockville, MD USA) was used according
to the manufacturer’s description. The kit sequentially ligates 3′-Adaptor with its 5′-end to the 3′-end
of the RNAs, and 5′-Adaptor with its 3′-end to the 5′-end of the RNAs. The non-ligation ends of 3′
and 5′ Adaptors were blocked by modifications. A universal priming site for reverse transcription was
contained within the 3′ adaptor. Spike-in RNA was used for monitoring the cDNA synthesis efficiency
and as a quantitative reference.
2.12. tRF and tRNA Human qPCR Arrays
The nrStar™ Human tRF and tiRNA PCR Array (ArrayStar, Rockville, MD, USA) was used
according to the manufacturers description to profile 185 tRF and tiRNA fragments, of which 101 are
derived from tRF and tiRNA database [44,45] and the other 84 from recently published papers [46–48].
RNA Spike in control and a positive PCR control were used to evaluate PCR efficiency and a genomic
DNA control was used to monitor genomic DNA contamination. To profile parent tRNAs, the nrStat
Human tRNA PCR Array (ArrayStar, Rockville, MD, USA) was used according to the manufacturer’s
protocol. This array consisted of 163 PCR-distinguishable nuclear tRNA isodecoders and 22 PCR
distinguishable mitochondrial tRNA species covering all anti-codons compiled in GtTNAdb [49,50]
and tRNAdb [51] databases. Genomic DNA and positive PCR controls were included to monitor the
quality of RNA sample.
qRT-PCR reactions were conducted using Power SYBR Green master mix (Life technologies,
Carlsband, CA, USA) on a Step One Plus (Applied Biosystems, Waltham, MA, USA) machine. U6,
SNORD43 and SNORD45 were used as endogenous controls for normalisation of tRF, tiRNA and tRNA
detection. Target tRNA, tiRNA and tRF levels were determined as fold change differences utilising the
∆∆Ct method [37].
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3. Results
3.1. Preliminary Analysis of Small RNA-seq Data
To identify differential expression of sncRNAs in ageing, Illumina MiSeq was utilised. Summaries
of raw, trimmed reads, and mapped reads to Equus caballus database can be found in File S2. Reads
mapping percentages were between 92 to 94.3%. There were 2128 sncRNAs identified. The categories
of non-coding RNAs identified are in Figure 1A and File S3 and included miRNAs, snoRNAs, novel
snoRNAs, tRNAs, snRNAs, and long non-coding RNAs (lncRNAs).
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Figure 1. Age-related differential small non-coding RNA (sncRNA) gene expression. (A) The 
categories of non-coding RNAs identified in young and old equine chondrocytes; long non-coding 
RNAs (lncRNAs), microRNAs (miRNAs or miRs), small nucleolar RNAs (snoRNAs), small nuclear 
RNAs (snRNAs), transfer RNAs (tRNAs). (B) 3D principle component analysis (PCA) plot between 
the selected principle components (PCs). The explained variances are shown in brackets. (C). 
Clustering results shown as a heatmap (distance measure using Euclidean, and clustering algorithm 
using Ward) for the top 90 molecules. 
3.2. Age-Related Differential Small Non-Coding RNA Gene Expression 
There were no overall differences in the distribution of classes of sncRNAs in ageing. The effect 
of age on the expression of sncRNAs was weak and the separation of young and old samples was not 
clear. The 3D PCA plot (Figure 1B) indicated that few, but very specific changes in the expression of 
sncRNAs were found, and samples from old donors were more variable than those from young. A 
heat map of hierarchical clusters of correlations among samples (Figure 1C) depicts that the sncRNA 
expression of young and old groups are not very different. 
There were 83 sncRNAs differentially expressed with age; six snoRNAs, 11 novel snoRNAs, 
three snRNAs, 31 lncRNAs, 27 tRNAs (p < 0.05) and five miRNAs (FDR-adjusted p < 0.05) (Table 1). 
Data is deposited on NCBI GEO, accession; E-MTAB-8112.  
  
Figure 1. Age-relat d differential small non-coding RNA (sncRNA) gene expression. (A) The categories
of non-coding RNAs identified in young a d old equine chondrocytes; long n -coding RNAs
(lncRNAs), microRNAs (miRNAs or miRs), small nucleolar RNAs (snoRNAs), small nuc ear RNAs
(sn s), transfer RNAs (tRNAs). (B) 3D principle comp nent a alysis (PCA) plot between the
selected principle components (PCs). The explain d v riances are shown in brackets. (C). Clustering
results shown as a heatmap (distance measure using Euclidea , and clustering algorithm using Ward)
for the top 90 molecules.
3.2. Age-Related Differ ntial Small Non-Coding R i
There were no overall differ nces in the distribution of classes of sncRNAs in ageing. ff t of
age on the expr ssion of sncRNAs was weak and the separation f and old samples was not
clear. The 3D PCA plot (Figure 1B) indicate t t f , t r s ecific changes in th expression of
sncRNAs were found, and samples from old donors ere ore variable than those from young. A
heat map of hierarchical clusters of correlations a ong sa ples (Figure 1C) depicts that the sncRNA
expression of young and old groups are not very different.
There were 83 sncRNAs differentially expressed with age; six snoRNAs, 11 novel snoRNAs, three
snRNAs, 31 lncRNAs, 27 tRNAs (p < 0.05) and five miRNAs (FDR-adjusted p < 0.05) (Table 1). Data is
deposited on NCBI GEO, accession; E-MTAB-8112.
Int. J. Mol. Sci. 2020, 21, 5675 8 of 22
Table 1. Differentially expressed sncRNAs in ageing chondrocytes. Log2 fold change values were
derived with young as the reference group. A positive log2 fold change equates to higher expression
in old, whereas a negative log2 fold change equates to lower expression in old. All are significant at
p < 0.05, except for miRNAs that are significant with a false-discovery rate (FDR-)adjusted p value of
p < 0.05.












ECABCGRLG0000003960 novel snoRNA −2.6
ECABCGRLG0000002980 novel snoRNA −2.5
ECABCGRLG0000006050 novel snoRNA −1.6
ECABCGRLG0000000640 novel snoRNA −1.1
ECABCGRLG0000002800 novel snoRNA −1.0
ECABCGRLG0000007680 novel snoRNA 1.8
ECABCGRLG0000008070 novel snoRNA 2.0
ECABCGRLG0000007010 novel snoRNA 2.5
ECABCGRLG0000008090 novel snoRNA 2.9
ECABCGRLG0000004470 novel snoRNA 3.0
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3.3. Age Specific miRNA Interactome
To generate an age-specific miRNA interactome of the most likely miRNA-mRNA target pairs,
analysis was performed to identify miRNA targets of the five differentially expressed miRNAs from
this study. In IPA, the five miRNAs (miR-143, miR-145, miR-181b, miR-122, miR-148a) were paired
with 351 protein coding genes differentially expressed in our previous RNA-seq study on ageing equine
cartilage [31]. In File S4, the miRNA-mRNA pairings in the correct direction (miR increase and mRNA
decrease or vice versa) are shown, including the target predictions and /or experimental validation
in the respective database. Four of the five miRNAs interacted in IPA with 31 different differentially
expressed target genes reflecting that miRNAs target many mRNAs. These mRNAs targeted by the
miRNAs were used in IPA as network-eligible molecules and overlaid onto molecular networks based
on information from the IPA Database. Networks for the four miRNAs (miR-148a, miR-122, miR-143,
and miR-181b) were generated based on connectivity (Figure 2A–D). Interesting age-related features
were determined from the gene networks inferred. Among the top canonical pathways were hepatic
fibrosis (p = 1.51 × 10−3), glycoprotein 6 (GP6) signalling (p = 5.67 × 10−4), and osteoarthritis pathway
(p = 2.93 × 10−3). The top diseases and cellular functions associated with this network are shown in
Table 2 and Figure 3. All IPA results are in File S5.
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Figure 3. Significant pathways and networks affected in cartilage ageing. IPA was used to pair 
differentially expressed mRNA and miRNA data from ageing equine cartilage and chondrocytes. 
Figure is a graphical representation between molecules identified in our data in their respective 
Figure 2. miR-mRNA interactome for differentially expressed miRs in ageing. Significantly differentially
expressed miRs were paired with differentially expressed mRNAs from our original cartilage study.
(A) miR-148a, (B) miR-122, (C) miR-143, (D) miR-181b. The legend for individual molecules is shown.
Genes in red are upregulated and green downregulated in old chondrocytes/cartilage compared to
young, and depth of colour correlates to fold expressi n change.
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expression in old group. Intensity of colour is related to higher fold-change. The key to the main
features in the networks is shown.
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Table 2. IPA mRNA target diseases and functions.
a. Top Molecular and Cellular Functions p-Value Range Number of Molecules
Cellular Movement 1.41 × 10−3–4.23 × 10−10 21
Cell Morphology 1.37 × 10−3–3.52 × 10−8 16
Cellular Development 1.42 × 10−3–4.94 × 10−7 24
Cell Death and Survival 1.37 × 10−3–1.08 × 10−5 18
Cell-To-Cell Signalling and Interaction 1.37 × 10−3–1.88 × 10−5 20
b. Top Diseases and Disorders
Skeletal and Muscular Disorders 1.50 × 10−3–1.22 × 10-9 16
Connective Tissue Disorders 1.50 × 10−3–3.52 × 10-8 16
Organismal Injury and Abnormalities 1.50 × 10−3–3.52 × 10-8 31
Cancer 1.49 × 10−3–5.30 × 10-7 31
Developmental Disorder 1.37 × 10−3–5.30 × 10-7 17
3.4. Confirmation of Differential Gene Expression Using qRT-PCR
For selected snoRNAs (snora46, snora71, snora77, and snord113) and miRNAs (miR-143, miR-145,
miR-148a, miR-122, and miR-181b) we used qRT-PCR to validate the small RNA-Seq findings in an
extended cohort of chondrocytes. Findings for snora71, snord113, miR-143, miR-145, miR-122, and
miR-181b were validated (Figure 4).
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As we identified differentially expressed tRNAs in ageing equine chondrocytes, we undertook 
additional analysis to identify tiRNAs and tRFs, as increasing experimental evidence suggests their 
Figure 4. Validation of selected sncRNAs in an extended cohort of equine young and old chondrocytes.
Real-time quantitative Polymerase Chain Reaction (qRT-PCR) was used to validate findings from the
small RNA sequencing (A) microRNAs and (B) snoRNAs, n = 5–12 per group. Statistical analysis was
undertaken using a Mann Whitney test in GraphPad Prism. Mean and standard errors are shown with
* denoting p < 0.05.
3.5. tRNA Fragment Changes in Equine Ageing
As we identified differentially expressed tRNAs in ageing equine chondrocytes, we undertook
additional analysis to i entify tiRNAs and tRFs, as increasing experimental evidence suggests their
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functional roles in OA [27]. Figure 5 shows cumulative density of tRNA fragment length, alignment
length, gene counts, and map start position. On the assessment of data variation using PCA, samples
in group “old” did not scatter very closely. Differential expression analysis of all young versus all old
did not identify any differentially expressed tRFs (FDR < 0.05). Therefore, we reanalysed the data with
the old group divided into two subgroups based on PCA findings: ‘old 1’ (samples 6, 7, 8) and ‘old 2’
(samples 9 and 10) for further differential expression analysis. There were 81 differentially expressed
tiRNAs/tRFs; 44 higher in ‘old 2’ and 37 lower in ‘old 2’ compared to young (File S6).
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Figure 6. tRNA analysis of human osteoarthritic cartilage. (A) High grade versus low grade OA
human cartilage and old versus young equine chondrocyte tRNA profiles. Heatmap of Log2 fold
change expression of 26 tRNAs detected in both human and equine samples. Human cartilage tRNAs
detected u ng a Human tRNA PCR Array. Red highlights induced tRNA expression in high grade OA
human cartilage compared to low grad and in old equine chondrocytes compared to young. Green
highlights reduced tRNA expression in high grade OA human cartilage compared to low grade and
in old equine chondrocytes compared to young. (B) High grade OA versus low grade OA human
cartilage and equine tiRNA/ RF profiles. Heatmap of Log2 foldchange expr ssion of 11 tRF/ RNA
fragme ts detected in both human nd equine samples. Human cartilage tRF/tiRNA detected using a
Human tRF&tiRNA PCR Array. Red highlights ind ced tRF/ RNA expression in human h gh grade
versus low grade OA samples and in old versus young equine samples. Green highlights e uced
tRF/tiRNA expression in human high grade versus low grade OA samples and in old versus young
equine samples.
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In both human and equine samples, the tRF-5 fragment known as tRF293/294 and 10 tiRNAs
were detected (Figure 6B). In high grade OA compared to low grade OA cartilage, seven tiRNAs and
tRF293/294 were induced and three tiRNAs were reduced. In old 1 versus young equine, five tiRNAs
and tRF293/294 were induced and five tiRNAs were reduced. In old 2 versus young equine, two
tiRNAs were induced and eight tiRNAs and tRF293/294 were reduced. Of these tRNA fragments, three
tiRNAs and tRF293/294 were induced and tiRNA-5029-GlyGCC-3 was reduced in high versus low
grade OA cartilage and in old 1 versus young equine. Two tiRNAs were induced and three tiRNAs
were reduced in high versus low grade OA cartilage and in old 2 versus young equine. In high versus
low grade OA cartilage and old 1 versus young equine tiRNA-5029-GlyGCC was reduced.
4. Discussion
Our study investigated the changing sncRNA landscape in ageing chondrocytes. Several risk
factors exist that influence cartilage health and chondrocyte homeostasis. Among them, ageing is one
of the leading risk factors contributing to cartilage-related diseases, such as OA [52]. Many studies
have shown that ageing can affect cartilage in different ways, both at cellular and molecular level.
Increased chondrocyte death, apoptosis, and a shift towards a catabolic profile have been observed
in aged chondrocytes [53]. Additional age-related changes in articular cartilage include increased
chondrocyte senescence [54], oxidative stress [55], and changes in the composition and structure of
ECM [56]. Although the underlying molecular causes of these changes are not completely understood,
it is hypothesised that aged chondrocytes respond differently to various stimuli, such as growth
factors, [53,57] and demonstrate altered molecular signatures [6].
SncRNAs are a subset of epigenetic modifiers and their role in cartilage ageing has been studied
increasingly in the last decade [6,31,58]. In the current study, we have used small RNA-seq to identify
alterations in sncRNAs between young and old equine chondrocytes. The horse is a good model
to study musculoskeletal ageing and disease as we could assess the whole joint for pathological
perturbations during tissue collection. It is very challenging to source aged human cartilage that
has no OA changes, whereas this is easily undertaken in equine samples. Moreover, the horse has
been used as a model of OA and there has been significant research on equine joint anatomy and
pathophysiology [59,60].
Within our set of differentially expressed sncRNAs, miRNAs are the best studied in musculoskeletal
ageing and cartilage. In old chondrocytes, we identified two miRNAs with higher expression; miR-122
and miR-148a, and three miRNAs with lower expression; miR-143, miR-145, and miR-181b. Of these
five miRNAs, all except miR-148a were validated in an extended cohort of young and old equine
chondrocytes with qRT-PCR. MiR-122 has been researched extensively in liver [61,62], but its role in
musculoskeletal ageing is less clear. MiR-122 was decreased in the serum and plasma of patients with
osteoporosis, the most common age-related bone disease [63], but was significantly upregulated in
senescent human fibroblasts [64] and was shown to upregulate p53 which is induced in senescence [65].
MiR-143 was downregulated in muscle satellite cells from old mice and primary myoblasts from
old humans and mice [66]. In addition, circulating miR-143 was upregulated in young individuals
following resistant exercise, but was downregulated in older individuals after resistant exercise [67].
MiR-145 was downregulated in old OA patients [68] as well as in experimental OA rat chondrocytes
treated with tumour necrosis factor (TNF) [69] and, finally, miR-181b was downregulated in skeletal
muscle of old rhesus monkeys [70].
To further investigate the potential role of the differentially expressed miRNAs identified in this
study, we used IPA to combine them with the differentially expressed mRNAs from our previous
equine cartilage study [31]. IPA miRNA ‘Target Filter and Expression Pairing’ identified 31 potential
target genes. IPA core analysis of these genes revealed canonical pathways associated with cartilage
physiology, such as role of chondrocytes in rheumatoid arthritis, OA-related pathways and bone
morphogenic protein (BMP) signalling, all of which have been reported to change with ageing [56,71,72].
Moreover, top diseases and disorders linked to these genes, as identified by IPA, included skeletal and
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muscular disorders and connective tissue disorders. Of note, follistatin (FST) which was upregulated
in old equine cartilage and was predicted by IPA as a target of the downregulated miR-143, was
overexpressed in human OA chondrocytes [73] and canine OA cartilage [74] and was induced by
telomere shortening [75], a process associated with ageing. Moreover, TNF ligand superfamily member 11
(TNFSF11), also known as receptor activator of nuclear factor kappa-B ligand (RANKL) was upregulated in
old equine cartilage and was identified as a predicted target of the downregulated miR-181b. Higher
expression of TNFSF11/RANKL, which correlated with bone loss, was reported in old C57BL/6 mice [76],
rabbits with chronic antigen-induced arthritis [77], and in human high grade OA cartilage [78]. These
results demonstrate the adverse effect of ageing on miRNA levels and their potential use as biomarkers
or therapeutic targets for age-related musculoskeletal diseases.
Six snoRNAs were identified as differentially expressed due to ageing in chondrocytes.
This conserved class of non-coding RNAs are principally characterised as guiding site-specific
post-transcriptional modifications in ribosomal RNA [79] (canonical snoRNAs), but can also modify
additional classes of RNAs including other snoRNAs, tRNAs and mRNAs; so called non-canonical
snoRNAs [80,81]. Examples of age-related snoRNAs in equine ageing chondrocytes with canonical
functions include snora71 and snord29. Novel non-canonical functions reported for snoRNAs
including the modulation of alternative splicing [82], an essential involvement in stress response
pathways [83] and the modulation of mRNA 3′ end processing [84]. Similar to miRNAs, snoRNAs are
emerging as important regulators of cellular function and disease development [15], related to their
ability to fine-tune ribosomes accommodating changing requirements for protein production during
development, normal function, and disease [85]. We have previously identified a role for snoRNAs
in cartilage ageing and OA [16] and their potential use as biomarkers for OA [9]. Interestingly there
was a reduction in snord113/114 in ageing chondrocytes which agrees with our previous findings in
equine cartilage ageing [31]. We have also previously demonstrated that SNORD113 was reduced
in ageing human knee cartilage but increased in OA [16] and increased in human anterior cruciate
ligament [17]. SNORD113/114 are located in imprinted loci and may play a role in the evolution and/or
mechanism of epigenetic imprinting. Although belonging to the C/D box class of snoRNAs which
direct site-specific 2′-O-ribose methylation of substrate RNAs, they differ from other C/D box snoRNAs
in their tissue specific expression profiles (including fibroblast, chondrocytes and osteoblasts) and the
lack of known substrate RNA complementarity. This currently classifies them as orphan snoRNAs
as they are not predicted to guide the 2′-O-ribose methylation but have novel, unknown roles [86].
Additionally, SNORD113 functions as a tumour suppressor in hepatic cell carcinoma by reducing
cell growth, and it inactivates the phosphorylation of extracellular signal-regulated kinase (ERK)
1/2 and mothers against decapentaplegic homolog (SMAD) 2/3 in mitogen-activated protein kinase
(MAPK)/ERK and transforming growth factor beta (TGF-β) pathways [87]. Together, our snoRNA
findings indicate that age-related changes in chondrocyte snoRNAs could have important implications
through both canonical and non-canonical snoRNA routes.
This is the first study to detect tRNA and tRNA fragments in equine chondrocytes and to compare
these findings with tRNA and tRNA fragments detected in human OA cartilage. For our tRNA data,
old donors clustered into two groups and further analysis was undertaken with these subgroups.
There were no apparent differences in these subgroups with regards to age or sex and scores were all
zero. The parent tRNA Cys-GCA was found to be increased in both aged equine chondrocytes and
high grade OA human cartilage samples. tRNA Cys-GCA levels have previously been reported to
be increased in human chondrocytes induced with the cytokine interleukin (IL) 1 beta resulting in
the production of the tRNA fragment tRF-3003a, a type 3-tRF produced by the cleavage of Cys-GCA.
tRF-3003a has been shown to post-transcriptionally regulate the Janus Kinase 3 (JAK3) expression
through sequence complementarity via the Argonaute (AGO) / RNA-induced silencing complex (RISC)
in human chondrocytes [27].
The Janus Kinase and Signal Transducer and Activator of Transcription (JAK-STAT) pathway
is the target of several cytokines such as interferon-γ, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, and IL-15.
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Many of these cytokines are known to play important roles in synovial inflammation during OA
pathogenesis [88,89].
The tRNA fragments detected in equine samples that matched with human samples consisted of
5′ tiRNA and tRF-5 fragments. Many of the equine fragments detected did not fall into the classical
tRF-3, tRF-5, or tiRNA size ranges and instead may likely be i-tRFs, which are internal to the respective
tRNA and can straddle the anticodon loop. 5′ tiRNA, 3′ tiRNA, tRF-3, and tRF-5 fragments were
detected in the low-grade OA cartilage and in the high grade OA cartilage. In our human studies,
base modifications found on tRNAs and tRF/tiRNA fragments that would normally block reverse
transcription were removed and this may account for some of the differences found between the equine
and human tRNA/tRF profiles.
The importance of modulation of tRNA levels and tRNA fragments in articular cartilage
homeostasis remains an unexplored area. This is the first evidence that aged equine samples
have changes in the expression of specific tRNAs and tRFs when compared to young equine samples.
We report for the first time several 5′ tiRNAs, such as tiRNA Glu-TTC and tiRNA His-GTG, were
induced in old compared to young equine chondrocytes and in high grade compared to low grade
human OA cartilage. Previous reports have shown that 5′ tiRNAs can be produced by cell stress in
mammalian cells and these 5′ tiRNA half fragments may have a role in inhibiting cell translation and
could be involved in stress granule formation [90]. Further studies are required to find the mechanism
by which these fragments are produced and whether the changes in the profile of fragments found in
old compared to young equine chondrocytes or high compared to low grade OA cartilage potentially
contribute to the development of OA.
We are aware our study has a number of limitations. The effect of ageing between young and old
equine chondrocytes was small on the differential expression of sncRNAs. However, it is likely that we
are therefore interrogating highly specific changes that are age dependent. Furthermore, we cannot rule
out changes related to the use of chondrocytes instead of cartilage tissue. Even though chondrocytes of
low passage were used, collagenase digestion and plating of cells could have affected their phenotype
and gene expression. The choice of chondrocytes over cartilage tissue was made based on RNA from
cartilage tissue is of low quality (in our hands) and heavily contaminated with proteoglycans [91],
usually making it challenging for sequencing. In our previous study interrogating snoRNAs in human
knee cartilage ageing and OA [16] we utilized cartilage tissue as opposed to chondrocytes. The old
non-OA cartilage was derived from the grossly normal condyle of OA joints. In the study we found
a number of age and OA specific snoRNAs, but we could not define the cartilage as truly normal
as it was derived from an OA joint. Nevertheless, we identified two age related, no species specific
snoRNAs that were DE in both our studies, snord113 and snord29. The use of the Illumina MiSeq
platform would have contributed to the low number of differentially expressed sncRNAs as it offers
less depth coverage compared to other platforms, such as the HiSeq platform. Finally, we have used
a relatively small number of samples per group. Given the use of primary cells and the degree of
variability observed, especially for the old group, the inclusion of five samples pre group may have
contributed to the small number of differentially expressed sncRNAs in ageing equine chondrocytes
on our study.
5. Conclusions
For the first time we have described, using unbiased methods, the effect of ageing on the expression
of sncRNAs in equine chondrocytes. We detected variable classes of sncRNAs (the small non-coding
RNAome) in young and old chondrocytes, which are differentially abundant, indicating that there are
multiple levels of epigenetic control in cartilage and chondrocyte ageing. Among them, there were
miRNAs, which are predicted to play a role in the development of the musculoskeletal system and
in skeletal disorders. In addition, the current study is one of the few studies that have investigated
tRNAs and tRNA fragments, in an attempt to uncover novel molecular signatures in aged and diseased
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chondrocytes/cartilage that could be useful in the future as therapeutic targets. Further research is
needed to elucidate the role and function of these molecules and their potential link to disease.
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